Design and synthesis of purine isosteres as inhibitors of Nek2 and CDK2 by Turner, David Michael
1 
 
Design and Synthesis of Purine 
Isosteres as Inhibitors of Nek2 
and CDK2 
This thesis is submitted to Newcastle University                                                     
for the degree of doctor of philosophy 
David Michael Turner 
 
April 2013 
 
2 
Declaration 
The research described within this document was performed between October 2009 
and October 2012 in the Medicinal Chemistry Laboratories, Bedson Building, 
Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, 
UK, NE1 7RU. This research was conducted in collaboration with scientists at the 
University of Leicester, Henry Welcome Building, Lancaster Rd, Leicester, LE1 9HN 
and the CR UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 
15 Cotswold Rd, Sutton, Surrey, UK, SM2 5NG and 237 Fulham Road, London, 
SW3 6JB. 
All research described within this thesis is original in content, and does not 
incorporate any material or ideas previously published or presented by other authors 
except where due reference is given.  
No part of this thesis has been previously submitted for a degree, diploma or any 
other qualification at any other university. 
3 
Acknowledgements 
Firstly, I would like to thank my supervisors Dr Céline Cano, Professor Roger Griffin, 
Professor Bernard Golding and Dr Ian Hardcastle for their continued support and 
guidance throughout my PhD and during the construction of my thesis. I am very 
grateful for all the opportunities that I have had whilst studying at the NICR, and feel 
that my experience has helped to shape my future career path. 
Additionally, I am very grateful to Dr Karen Haggerty and Carlo Bawn for their 
technical expertise and assistance during my PhD. I would also like to say thank you 
to all the members of the group and particularly the Nek2 team, who have made my 
time here at Newcastle University an unforgettable experience; Santosh Adhikari, 
Lauren Barrett, Dr Ruth Bawn, Annalisa Bertoli, Dr Tim Blackburn, Dr Benoit 
Carbain, Sarah Cully, Honorine Lebraud, Nicholas Martin, Dr Chris Matheson, Dr 
Elisa Meschini, Duncan Miller, Dr Stephanie Myers, Dr Sara Payne, James Pickles, 
Dr Tommy Rennison, Dr Charlotte Revill, Dr Jen Ricci, Andrew Shouksmith, Dr Kate 
Smith, Judith Unterlass, Dr Chris Wong, Bian Zhang and Dr Andrey Zaytsev. 
I would like to acknowledge all of the collaborators on the Nek2 and CDK2 projects 
including Professor Herbie Newell and Lan-Zhen Wang at the NICR and Dr Swen 
Holder and Katherine Boxall at the Institute of Cancer Research (ICR). I would also 
like to thank Dr Richard Bayliss and Dr Sharon Yeoh for their supervision and 
patience during my structural biology placement at the University of Leicester. 
I want to express my gratitude to the Engineering and Physical Sciences Research 
Council (EPSRC) and Cancer Research UK for their generous funding of my PhD, 
and on-going research at the NICR. 
Finally, I would like to thank my parents Bob and Christine Turner and my girlfriend 
Kirsty Jackson for their continued support and encouragement throughout my 
studies. 
 
 
4 
Abstract 
Nek2 and CDK2 are serine/threonine protein kinases that are implicated in cell cycle 
control and cancer. The Nek family of enzymes contains 11 known serine/threonine 
protein kinases (Nek1-11) and are involved in mitotic cell cycle control. There is 
evidence that of these 11 kinases, Nek2, Nek6, Nek7 and Nek9 play an important 
role in the regulation of mitotic events through microtubule control. Particular interest 
has been placed upon Nek2, which has been shown to have a critical role in mitosis, 
assisting centrosome disjunction. 6-Ethnyl purine 39, was identified as a sub-
micromolar irreversible inhibitor of Nek2 (IC50 = 150 nM), exhibiting good selectivity 
over other members of the Nek family. It was believed that this compound formed a 
triplet of H-bonds with the amino acids of the Nek2 ATP-binding site hinge region via 
the 2-amino N-H, the purine N3 and the imidazole N9H, allowing an initial non-
covalent binding interaction, which facilitates subsequent covalent modification. To 
validate this binding motif and to act as control compounds, N-methylated purines 
52-54 were synthesised, along with the 2-phenoxypurine 55 and the 2-benzylpurine 
56. These compounds were all essentially inactive in the Nek2 inhibition assay, 
which demonstrated that the purine 2-amino N-H group and imidazole N9H were 
essential for non-covalent binding interactions. 
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To investigate the influence of the purine heterocycle upon Nek2 inhibitory activity 
and ethynyl group reactivity, heterocyclic derivatives of 39 were synthesised. 
Deazapurines 87 and 88 were weakly active in the Nek2 inhibition assay (IC50 = 30 
µM and 24 µM, respectively), whilst pyrazolopyrimidine 89 and triazolopyrimidine 90 
had sub-micromolar activity comparable with the parent purine 39. The 5-
formylpyrimidine 101 and triazine 91 were modest inhibitors of Nek2 (IC50 = > 10 µM 
and 17 µM, respectively). By contrast, pyrimidine 95 (10% inhibition at 100 µM) 
demonstrated weak Nek2 inhibitory activity. 
 
Quantitative 1H NMR (q1H-NMR) kinetic studies were performed to model the 
reaction of ethynyl-functionalised heterocycles with Cys-22 at the Nek2 ATP-binding 
site. Compounds 54, 56, and 88-89 were reacted with N-acetylcysteine methyl ester 
in DMSO-d6 at 24 
oC under pseudo first order reaction conditions. The most reactive 
compounds were triazolopyrimidine 90 and pyrazolopyrimidine 89. The 2-
benzylpurine 56 and N-methylanilinopurine 54 had moderate reactivity, comparable 
with the parent purine 39. The least reactive compound was pyrrolopyrimidine 88, 
which was approximately 150-fold less reactive than purine 39.   
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CDK2 is a member of the cyclin-dependent kinase (CDK) family of enzymes and a 
mediator of cell cycle progression. Of the 11 known human CDKs, four (CDK1, 
CDK2 CDK4 and CDK6) have been directly implicated in cell cycle regulation. 
Mutation of genes coding for CDKs are common in a variety of cancers, making 
CDKs attractive chemotherapeutic targets. Purines 249 and 37 were identified as 
moderate (IC50 = 17 µM) and potent (IC50 = 5 nM) ATP-competitive inhibitors of 
CDK2, respectively. The focus of this research was to determine whether subtle 
changes to the core heterocycle would allow retention of CDK-inhibitory activity.  
 
CDK2 inhibitors based on the pyrazolopyrimidine and triazolopyrimidine heterocycles 
(256, 252, 257 and 253) were of comparable potency with the corresponding purines 
(249 and 37). The most potent compound was triazolopyrimidine 253 with an IC50 
value of 3 nM against CDK2. Interestingly, the pyrrolopyrimidine 255 proved only 
weakly active (IC50 > 100 µM), whereas the functionalised pyrrolopyrimidine 251 had 
potent CDK2 inhibitory activity (IC50 = 26 nM). Finally, imidazopyridine 254 exhibited 
activity comparable with purine 249; however, imidazopyridine 250 was found to be 
approximately 30-fold less potent (IC50 = 140 nM) than the parent 37, for reasons 
that remain unclear. 
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Chapter One: Cancer in Human Health and Disease 
1.1 Cancer Epidemiology 
Cancer is a disease characterised by loss of normal cell function resulting in rapid 
uncontrolled cell proliferation and growth.1 Cancer has become the major cause of 
death globally with an estimated 7.6 million fatalities attributed to cancer in 2008 
alone.2 It is predicted that this figure will continue to rise to over 13.1 million by the 
year 2030, making new cancer drug development an area of crucial interest.2 There 
are over two hundred forms of cancer, and it is known that cancer can develop in 
almost every tissue type, with the most common forms being breast, lung, colorectal 
and prostate cancer.1,3 
A normal healthy cell may become cancerous through the accumulation of genetic 
mutations resulting in loss of cell differentiation and uncontrolled proliferation. These 
mutations may be present at birth, or more commonly are the result of chronic 
exposure to genotoxic stimuli such as chemical carcinogens (e.g. asbestos and 
tobacco smoke), viruses (e.g. human papilloma virus (HPV)) or physical carcinogens 
(e.g. UV light and ionising radiation).2 The human body has evolved mechanisms to 
protect against genetic damage, and most often cells bearing these abnormalities 
are quickly destroyed or repaired. It is rare that a single mutation will result in 
malignancy, as this is usually a multistep process requiring the accumulation of 
many mutations of different genes over time. It is for this reason that 75% of all new 
cases of cancer in the UK are diagnosed in patients aged 60 and over.4 
 
1.2 Pathophysiology of Cancer 
For a cell to become malignant it must develop errors in the regulation of 
homeostasis through mutations that favour enhanced growth and proliferation.5 
These mutations may be viewed as minor changes to the DNA sequence through 
point mutations (single base substitution), or larger scale changes such as 
translocations, deletions, and amplifications which alter chromatin structure.4 
Mutations become problematic when they accumulate, causing disruption of the cell 
cycle through oncogene activation or removal of vital tumour suppressor gene 
Chapter One 
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function.4  Oncogenes (e.g. RAS and ERK) are genes that are highly and/or 
abnormally expressed in tumour tissue and are known to induce cancer in cells. 
These genes derive from proto-oncogenes through a function-altering mutation.6 
Tumour suppressor genes (e.g. p53 and BRCA1) are key regulatory genes that 
function to prevent carcinogenesis. As with all genes, there are two copies of each 
individual proto-oncogene or tumour suppressor gene present in every cell. Mutation 
of both alleles of these genes is required to alter function, which is why mutations 
that give rise to cancer are usually somatic and occur over long periods of time. 
Inherited mutations may occur when a defective gene is passed down from a parent 
to their offspring. The remaining dominant allele maintains function; however, 
individuals are at increased risk of developing cancer.1,6 
The transition of normal healthy cells to a neoplastic state is a complex process 
requiring the acquisition of a number of traits. In 2000, Hanahan and Weinberg 
proposed six acquired capabilities of cells that induce oncogenesis.7 This was 
updated in 2011 to include the traits shown in Figure 1.5 In the following section, 
each trait will be discussed to provide an overview of the events preceding 
malignancy. 
 
Figure 1 - Hallmarks of cancer as described by Hanahan and Weinberg 2011.5   
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1.2.1 Sustained Proliferative Signalling  
Cells in a dormant non-proliferative state may become active through mitogenic 
signalling. This signalling occurs via transmembrane receptors that detect growth 
factors, extracellular matrix components and cell-cell adhesion molecules. External 
signals are then transmitted across the cell membrane to promote growth and 
proliferation.5,7 In healthy cells these processes are tightly regulated and essential for 
maintaining homeostasis. In cancerous cells this control system is compromised, 
resulting in aberrant signalling to favour sustained proliferation.5  
Premalignant epithelial cells must acquire multiple mutations before malignancy 
develops. The process of tumour progression occurs over several stages and 
requires multiple growth factors. These are small polypeptide molecules that bind to 
transmembrane receptors causing activation of proliferative signalling cascades (e.g. 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI-3K)) to 
favour transcription and ultimately clonal expansion.8 The expression of growth 
factors (GFs) in normal healthy cells is a highly regulated process and functions 
through a paracrine mode of action. In cancer cells this regulation is lost, allowing 
cells to evade proliferative control and develop self-sufficiency in growth signals, 
leading to sustained proliferative signalling.7 
A method of achieving self-sufficiency is through mutations that induce GF secretion 
in neoplastic cells. By generating their own GFs, cancer cells may be stimulated to 
continually replicate through autocrine signalling.9 Alternatively, tumour cells can 
exploit the presence of ambient GFs and become hypersensitised through the 
increased expression of receptor tyrosine kinases (RTKs) (e.g. epidermal growth 
factor receptor (EGFR)) at the cell surface. This allows cancerous cells to proliferate 
in the presence of low levels of GFs that would not normally permit replication.7,10,11 
Overexpression of these receptors, or the expression of mutated receptors, has 
been implicated in ligand-independent proliferative signalling.12,13 GF-independent 
induction of cell proliferation may also occur through downstream activation of 
intrinsic signalling cascades. An example of this is the activation of B-Raf protein, 
which when mutated stimulates the Raf-mitogen-activated protein (MAP)-kinase 
pathway resulting in cell proliferation.5,14 
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1.2.2 Evading Growth Suppressors  
Negative regulation of growth and proliferation is an essential component of normal 
cell homeostasis, designed to prevent malignant transformation. It has been 
demonstrated experimentally in mice that signalling cascades that orchestrate 
growth suppression often contain established tumour suppressor genes.5 These 
suppressor genes are frequently mutated in cancers, resulting in inactivation, and 
permitting unregulated growth. Two key tumour suppressor genes that regulate cell 
proliferation and are commonly mutated in cancers are the genes coding for 
retinoblastoma-associated protein (pRb) and p53. The gene coding for pRb receives 
primarily extracellular signals, which are interpreted and combined to make the 
decision whether a cell should be allowed to grow and proliferate, or enter a state of 
senescence. pRb is an important checkpoint protein, restricting progression beyond 
the G1 stage of the cell cycle.
15,16 Cancer cells with mutated pRb lack this vital 
gatekeeper, allowing cells to enter a persistent proliferative state.5 By contrast, the 
gene coding for p53 (TP53) responds to intracellular stress and damage signalling 
pathways by monitoring the level of free nucleotide bases, glucose and oxygen, as 
well as the intensity of growth-promoting signals. If conditions are deemed sub-
optimal, TP53 forces the cell into a state of senescence until conditions are returned 
to normal. Additionally, If significant cellular damage is detected, TP53 can activate 
apoptotic signalling pathways resulting in programmed cell death.17 Somatic 
mutations of TP53 are very common in human cancer.18 
 
1.2.3 Activating Invasion and Metastasis 
Metastasis involves a series of events that allow transport of cancerous cells from a 
primary tumour to distant parts of the body, resulting in the formation of secondary 
tumours. Tumour metastasis is associated with poor prognosis and is the primary 
cause of cancer-related deaths.19-21 Surgical treatment of metastatic tumours is 
rarely attempted due to the systemic distribution of the disease. Treatment usually 
involves a combination of chemotherapy, hormone therapy and radiation; however, 
success is limited, and this treatment functions primarily as a palliative solution.22 
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The first stage in the process of metastasis is the invasion of surrounding tissue by 
neoplastic cells. To facilitate this, a change in the tumour phenotype must occur that 
causes a loss of cell adhesion through disruption of cell-cell interactions and cell-
extracellular matrix (ECM) binding (Figure 2).23,24 Proteases are recruited that cause 
degradation of the ECM, which liberates growth factors and chemokines favouring 
cell motility.22 Liberated cells are then able to enter the blood stream or lymphatic 
system via the tumour blood vessels.21 Cells are transported systemically until 
reaching the site of dissemination where they arrest through the use of specific 
adhesion factors or, more commonly, owing to size restriction in the capillaries.22 At 
this point malignant cells may extrude from the vessel (extravasation) and enter 
surrounding tissue. If these cells survive the microenvironment of the tissues in 
which they reside, secondary tumour formation may occur through cell growth and 
proliferation.19-22 
 
Figure 2 – Schematic representation of tumour metastasis (adapted from Pai et 
al.).25  
1.2.4 Enabling Replicative Immortality 
The chromosomes of normal cells contain repetitive nucleotide sequences 
(TTAGGG) known as telomers that protect against genomic instability, and hence 
malignancy, through the prevention of chromosomal degradation.26 With each 
subsequent round of the cell cycle, telomer length decreases until eventually the 
protective telomer cap is removed.27 This may cause cells to enter a non-replicative 
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state (senescence) or to proceed to a crisis phase due to end-on chromosome 
ligation, arrest of the cell cycle and activation of apoptotic signalling cascades.5 
Telomerase is a DNA polymerase that functions to increase telomer length, thus 
enhancing the replicative potential of cells. Expression of telomerase is generally low 
in somatic cells; however, telomerase is expressed at significant levels in 
approximately 90% of immortalised cells including T-lymphocytes and  tumour cells.5 
Overexpression of telomerase allows tumour cells to subvert senescence and 
apoptosis through the prevention of telomer shortening, enabling replicative 
immortality. Interestingly, recent findings have suggested that delayed telomerase 
upregulation in preneoplastic cells that allows telomer shortening, may induce 
mutations leading to malignancy. It is suggested that subsequent activation of 
telomerase stabilised these cells allowing immortality and tumour progression.5,28  
 
1.2.5 Inducing Angiogenesis 
As tumour volume expands beyond a small population of cells, there is an elevated 
demand for nutrients and oxygen as well as increased waste production.29 Up until 
this point, metabolic needs are met by passive diffusion at a rate proportional to 
tumour surface area (Figure 3, A). The level of diffusion becomes insufficient for 
further growth at a tumour size of 1-2 mm, and, as such, many tumours remain 
dormant and do not develop further.30,31 To expand beyond these biophysical 
constraints a tumour must establish its own blood supply through a process known 
as angiogenesis.5,7,31 
 
Figure 3 – Schematic representation of tumour angiogenesis (adapted from 
Siemann).32  
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At gestation, normal healthy cells undergo embryonic vasculogenesis allowing 
formation of the vascular tree. This primary network of blood vessels is adapted and 
modified to ensure suitable delivery of nutrients throughout the body.29,33 
Subsequent changes to the vascular structure are required for growth and repair and 
occur through angiogenesis. In normal tissue this process is highly regulated and 
controlled by a number of pro- and anti-angiogenic signalling cascades.34 By 
contrast, the balance of angiogenic signals in vascular tumours is disrupted to favour 
angiogenesis in a process known as an ‘angiogenic switch’.5,34 As an avascular 
tumour grows in size, angiogenesis may be activated through the release of 
angiogenic factors that bind to surrounding host blood vessels to induce capillary 
formation (Figure 3, B). These capillaries infiltrate the tumour body providing 
nutrients and oxygen to satisfy metabolic demands (Figure 3, C).29,31 Unlike normal 
angiogenesis, which is transient, tumour angiogenesis remains constantly active 
favouring rapid vascularisation and growth. Tumour vasculature appears irregular, 
convoluted and poorly formed as growth is unregulated.34 These vessels are also 
highly permeable with little basal membrane or cellular junctions when compared to 
normal blood vessels. Tumour vessels are therefore an ideal conduit for carcinoma 
cells to enter the circulatory system, possibly allowing the development of metastatic 
tumours.35  
A major inducer of tumour angiogenesis is vascular endothelial growth-factor-A 
(VEGF-A),31 and mRNA coding for VEGF-A is greatly up-regulated in the majority of 
human cancers. Similarly, elevated levels of VEGF and its partner receptor Flk-1 
have been reported in metastatic colon cancer at levels proportional to tumour 
vascularisation.36 VEGF-A is a well characterised 34-42 kDa glycoprotein that 
functions as a cytokine, binding to and activating three structurally related type III 
receptor tyrosine kinases (VEGFRs 1-3 also known as FLT1, KDR and FLT4, 
respectively).37,38 In doing so, a number of downstream effects occur via signalling 
cascades.  VEGF-A can induce angiogenesis through a number of mechanisms 
including elevated endothelial cell proliferation, increased vascular permeability, 
lattice formation, promotion of endothelial cell migration, and chemotaxis of vascular 
precursor cells.38 Elevated VEGF-A gene expression in tumours may occur as a 
consequence of oncogenic signalling and/or hypoxia-induced cellular stress.5  
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A number of factors exist to control angiogenesis by inhibiting proangiogenic 
signalling cascades. One such molecule is thrombospondin-1 (TSP-1), a 
matricellular glycoprotein known to regulate cell proliferation, migration and 
apoptosis. 5,39 These processes require the formation of cell surface multi-protein 
complexes to enable signal transduction. It is the role of TSP-1 to enable correct 
orientation and composition of these complexes by specific interaction with growth 
factors and cytokines, as well as components of the extracellular matrix and cell 
membrane. In doing so, TSP-1 can neutralise proangiogenic signals, thereby 
suppressing tumour growth.35 
A second protein critical for inhibition of tumour angiogenesis is p53, a protein 
expressed by the gene TP53. p53 is a well-established tumour suppressor gene 
essential for maintaining genomic stability.40  Among numerous additional tumour 
suppressive functions, p53 may limit angiogenesis through induction of cell-cycle 
arrest and initiation of apoptosis. Additionally, p53 is able to inhibit hypoxia-induced 
angiogenesis by preventing activation of proangiogenic growth factors such as 
VEGF.41 Mutation of genes coding for antiangiogenic ligands are a leading cause of 
the angiogenic switch, resulting in increased tumour vasculisation and growth.  
 
1.2.6 Resisting Cell Death 
Apoptosis is a method of programmed cell death employed to remove redundant, 
damaged or infected cells. This process is essential for foetal development as well 
as in homeostasis, and as a form of defence against DNA damage and pathogens in 
adult tissue.42,43 Apoptosis involves a series of interconnected biochemical events 
that enable selective caspase activation in cells labelled for destruction.44 Caspases 
are proteolytic enzymes that induce apoptosis, causing cells to shrink, undergo 
chromatin degradation, and eventually break apart into small fragments known as 
vesicles which are later phagocytosed and destroyed.43 There are two major 
pathways involved in apoptosis, the extrinsic receptor-mediated pathway and the 
intrinsic mitochondrial pathway. The extrinsic pathway is activated by extracellular 
ligands that induce assembly of the death-inducing signalling complex (DISC) and 
stimulate receptor oligomerization. The intrinsic mitochondrial pathway induces 
apoptosis through modification of pro- and anti-apoptotic signalling via the regulatory 
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B-cell lymphoma 2 (Bcl-2) family of proteins.5 This allows apoptosome formation due 
to mitochondrial release of cytochrome c, which triggers a signalling cascade 
resulting in caspase activation and ultimately apoptosis.44 The evasion of apoptosis 
in tumour cells may occur through activation of specific oncogenes with antiapoptotic 
functions (e.g. c-Myc) or disablement of pro-apoptotic tumour suppressor genes (e.g. 
Chk1/Chk2 and p53) allowing rapid expansion of the cell population.44-46 Modulation 
of apoptosis through targeting of the underlying cell death signalling pathways or 
removal of endogenous apoptotic inhibitors in tumour cells may have a therapeutic 
benefit for the treatment of cancers.17 Most therapeutic agents of this type are in the 
early stages of clinical development; however, there is substantial interest in the 
development of these compounds for use in combination with established cancer 
chemotherapeutic agents.47 
 
1.3 Small-Molecule Chemotherapeutic Agents in the Treatment of Cancer 
The treatment of cancer may consist of localised treatments such as surgery and 
radiotherapy, or systemic treatment through the use of chemotherapeutic drugs. It is 
the goal of the majority of anticancer drugs currently in development, to prevent 
tumour progression by inhibiting cell growth and division (cytostatic drugs) or killing 
tumour cells (cytotoxic drugs).4 There are two broad classes of cancer 
chemotherapeutic agents, traditional cytotoxic drugs, and targeted therapies.  
 
1.3.1 Cytotoxic Cancer Chemotherapy 
Conventional cytotoxic anticancer drugs non-specifically target enzymes and 
macromolecules (e.g. DNA) causing toxicity and ultimately cell death. Once 
administered, these compounds are distributed systemically and accumulate in cells 
with high proliferative activity. This causes greater susceptibility to drug induced 
toxicity in cancer cells as they are rapidly dividing and, as such, have high metabolic 
demands.48 However, a disadvantage of cytotoxic cancer chemotherapy is that 
compounds are indiscriminately cytotoxic, and therefore induce toxicity in all rapidly 
dividing cells including those found in the gut epithelium, bone-marrow and hair-
follicles. This gives rise to the classical toxicities associated with cancer 
chemotherapy, such as gastrointestinal disturbance, myelosuppression and 
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alopecia.48-50 These side-effects can result in substantial patient discomfort and may 
in some cases be dose-limiting.   
Table 1. shows a selection of traditional cytotoxic drugs used in the treatment of 
cancer. The choice of the correct chemotherapeutic regime is greatly dependent 
upon the type of cancer, drug resistance and side-effects of treatment. Traditional 
cytotoxic cancer chemotherapeutics remain an important part of the arsenal of 
anticancer drugs.  
Table 1. Examples of common cytotoxic agents used in the treatment of cancer 
Class Structure/Name 
DNA-alkylating 
agent 
(Nitrogen 
mustards) 
  
Platinum 
containing DNA-
cross-linking agent  
 
Mitotic inhibitor 
(taxanes and vinca 
alkaloids) 
  
Folate antagonist 
(antimetabolite) 
 
 
Topoisomerase 
inhibitor 
  
Chapter One 
26 
 
Figure 4 – Cytotoxic cancer chemotherapy.49 
Traditional cytotoxic agents work by inhibiting cell division. Figure 4 shows the 
various classes of cytotoxics. Antimetabolites (e.g. methotrexate 7 and pemetrexed 
8) prevent DNA replication by inhibiting nucleic acid formation. Topoisomerase 
inhibitors (e.g. topotecan 9 and doxorubicin 10) prevent relaxation of DNA 
supercoiling. Alkylating agents including nitrogen mustards (e.g. cyclophosphamide 
1 and chlorambucil 2) and platinum based compounds (e.g. cisplatin 3 and 
carboplatin 4) form single and double strand breaks in DNA through alkylation of 
purine bases. Finally, taxanes (e.g. paclitaxel 5) and vinca alkaloids (e.g. vincristine 
6) inhibit mitosis by disrupting microtubule function.49 
As mentioned previously, it is difficult to avoid nonspecific-cytotoxicity with traditional 
cytotoxic drugs. Also, due to systemic distribution and indiscriminate drug binding, a 
large dose of compound is often required to achieve a therapeutic concentration at 
the tumour site. To combat this and improve selectivity, several mechanistically new 
cytotoxic drug targeting approaches have been adopted to elevate drug 
accumulation in cancerous cells.51 One such approach is to target subtle differences 
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in tumour physiology such as enzyme expression, hypoxia and pH, by designing 
compounds that exploit these differences.  
 
1.4 Targeted Cancer Chemotherapy 
Over the past 20 years cancer research has advanced dramatically. A detailed 
understanding of the molecular and genetic processes responsible for oncogenesis 
has allowed the discovery of new targeted anticancer therapies. Unlike traditional 
cytotoxics, targeted chemotherapy is directed towards specific enzymes/pathways 
critical for tumour progression.52 These pathways include targets such as growth 
factors, signalling molecules, cell-cycle proteins and processes involved in apoptosis 
and angiogenesis.5,7,48 An attractive feature of targeted chemotherapy is the potential 
for low cytotoxicity in normal healthy tissue, whilst maintaining good efficacy against 
neoplastic cells leading to a broader therapeutic window.50,53 Unlike cytotoxic 
therapy, which is administered at the maximum tolerated dose, targeted therapy is 
given at the optimal biologically effective dose (OBD). This is the dose level 
designed to ‘saturate’ the target causing inactivation. In many cases this will be 
substantially lower than the maximum tolerated dose. It is unnecessary to further 
increase the dose as this may result in needless toxicity.54 Targeted therapy is often 
cytostatic as cell proliferation and/or metastasis is prevented without significant 
tumour regression.55 Long dosing regiments are often required, and, as such, orally 
active drugs with minimal chronic side-effects are most desirable.54  
 
 
Figure 5 – Comparing the dose response of cytotoxic and targeted cancer 
chemotherapeutic agents.54 
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Figure 5 shows a typical dose-response for targeted anticancer agents and 
conventional cytotoxic therapy. As described previously, a disadvantage of 
cytotoxics is dose limiting toxicity. The graph shows that the antitumour effect of 
cytotoxic drugs increases with elevated dose alongside toxicity (shown in red) until 
the maximum tolerated dose is reached. By contrast, when the dose of a targeted 
anticancer agent is increased the optimal biological dose is obtained at target 
saturation. After this point no improvement in antitumour activity is observed and 
toxicity rapidly rises.54 
 
It is possible to combine the benefits of both traditional cytotoxic therapy and 
molecular targeted therapies through a multi-agent approach. The aim of multi-agent 
cancer therapy is to resensitise drug resistant cancerous cells or enhance the activity 
of conventional drug and radiation therapies.56 A good example of this is the use of 
the poly(ADP-ribose) polymerase-1 (PARP)-1 inhibitors veliparib (ABT-888) 11 and 
rucaparib (AG-014699) 12, which have been shown to potentiate DNA damage in-
vivo when co-administered with the topoisomerase-I poison topotecan 9.57,58 
Unfortunately, the effectiveness of current PARP-1 inhibitors when used in 
combination therapy, is often limited due to high toxicity, which illustrates the 
difficulties in the design and instigation of a successful multi-agent chemotherapeutic 
regime.59  
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Chapter Two: Targeting Protein Kinases with Small-molecule 
Inhibitors 
2.1 The Role of Protein Kinases in Cell Signalling 
The sequencing of the human genome was completed in 2003, allowing 
identification of the 20-25,000 genes that make up human DNA.60 From this, a group 
of 518 genes, collectively known as the kinome, was identified that coded for human 
protein kinases.61 The kinome can be broadly divided into the protein kinase and lipid 
kinase families of enzymes based upon their catalytic specificity.20, 21 Additionally, 
protein kinases may be further subdivided into serine/threonine protein kinases and 
tyrosine kinases due to their substrate activity. However, there are instances where a 
protein kinase does not fit into a single class, an example of which are the mitogen 
activated protein kinase kinases (MAPKKs), which are dual-specificity kinases and 
interact with both threonine and tyrosine residues of their substrate proteins.62 
Kinases are located on cell membranes, within the cytoplasm and inside the nucleus 
of all cells.  
Protein kinases are essential enzymes that maintain homeostasis, allowing cells and 
tissues to respond to changes in their environment through a complex series of 
interlinked phosphorylation events. This is possible because kinases have a pivotal 
role in the control of cell physiology through many processes, including cell cycle 
regulation, cell differentiation and programmed cell death.63 These processes are 
controlled by kinase-mediated signal transduction through the transfer of γ-
phosphate from ATP to the hydroxyl groups of a serine, threonine or tyrosine 
residues of substrate proteins (Figure 6).61,62,64 Substrate specificity is maintained 
because phosphate transfer requires the correct orientation of both ATP and the 
substrate protein.65  
 
Figure 6 – Schematic representation of protein phosphorylation by a kinase 
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Mammalian protein kinases are highly conserved families of enzymes containing 
250-300 amino acid residues within the kinase domain. Recent advances in 
biophysical analysis techniques such as NMR spectroscopy and X-ray protein 
crystallography have allowed the structural elucidation of many kinases, thereby 
revealing significant structural similarities. Kinases consist of two globular 
polypeptide lobes connected by the enzyme active-site. The N-terminal lobe consists 
of a β-sheet and an α-helix, whereas the larger C-terminal lobe is composed 
primarily of α-helixes and an additional activation loop of 25-35 amino acid residues 
between the conserved residues Asp-Phe-Gly (DFG) and the less conserved Ala-
Pro-Glu (APE) motif.65 The orientation of the DFG motif is important for enzyme 
activation, and it has been suggested that the DFG aspartate residue is used to 
chelate Mg2+, which assists in ATP-binding and γ-phosphate transfer.65  At the core 
of the kinase molecule is the catalytic domain and the conserved ATP-binding 
pocket. Within this site lies the ‘hinge’ region, a peptidic backbone that forms H-
bonding interactions with the purine N1 and C6-NH2 group of ATP. Additional 
hydrophobic interactions are formed through nonpolar aliphatic groups, which further 
improve binding of ATP.65  
Kinase-mediated protein phosphorylation is essential for cell signalling. Expression 
of mutated or dysfunctional kinases as a result of genetic damage may elicit 
abnormal cell signalling leading to disease.  In the last 20 years there has been 
much interest in the role of kinases in human disease. It has been estimated that 
more than 400 human diseases are linked to modified kinase activity.66 Aberrant 
kinase activity can result in the development of poorly differentiated cells with a 
survival advantage, leading to rapid cell proliferation and eventually malignancy.63,67 
Selectively targeting kinases to modulate activity is an appealing cancer 
chemotherapeutic strategy, and has been used successfully for the inhibition of both 
tyrosine kinases and serine/threonine kinases.62  
 
2.2 ATP-Competitive Inhibition of Protein Kinases 
The design of targeted and selective inhibitors of human protein kinases is a major 
goal of chemotherapeutic research.65 As described previously, the ATP-binding 
domain is relatively highly conserved between kinase family members, and this is 
reflected in the difficulty of designing selective ATP-competitive kinase inhibitors.68  
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One of first ATP-competitive kinase inhibitors to be discovered was the natural 
product staurosporine 13. This compound was found to bind within the ATP pocket 
of kinases and demonstrated potent inhibitory activity. An important consequence of 
this was the observation that ATP-competitive ligands such as 13, could compete 
with the high cellular concentration of endogenous ATP due to increased binding 
affinity, causing enzyme inhibition.68 This was later discovered to be due to additional 
binding interactions between 13 and unoccupied sub-pockets within the kinase ATP-
binding domain. Interestingly, regardless of its bulky size, 13 was found to be a pan-
kinase inhibitor that inhibits >90% of all known kinases.69 This lack of selectivity 
made 13 a poor drug candidate due to unwanted toxicity.68 The first potent and 
selective ATP-competitive inhibitor that received clinical approval was imatinib 14 in 
2001. This drug selectively targets the BCR-Abl tyrosine kinase associated with the 
Philadelphia chromosome, and has been approved for the treatment of chronic 
myelogenous leukemia (CML) and gastrointestinal stromal tumours (GIST).70,71 
        
Figure 7 - Comparison of type I (A) and II (B) binding modes of ATP-competitive 
kinase inhibitors.72 
A) Type I B) Type II 
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There are several classes of ATP-competitive kinase inhibitors, the most common of 
which are the type I and type II inhibitors, based upon their binding mode (Figure 
7).72 Type I inhibitors make up the majority of established ATP-competitive inhibitors 
and target kinases in their active conformation. Type I ligands mimic the binding of 
ATP and contain a heterocyclic scaffold that binds to the kinase hinge region through 
H-bond interactions. This binding is assisted by additional hydrophobic interactions 
between the heterocyclic moiety and the surrounding hydrophobic regions, and does 
not require direct interactions with the DFG motif (Figure 7, A).72,73 Type II kinase 
inhibitors also occupy the ATP-binding site; however, these compounds bind to the 
inactive kinase conformation via alternative H-bonding and hydrophobic interactions. 
This is possible due to a change in the orientation of the kinase activation loop, 
resulting in a ‘DFG-out’ conformation that facilitates binding via additional 
interactions with the DFG motif. An example of this binding mode is shown for the 
binding of imatinib 14 to the tyrosine kinase BCR-Abl (Figure 7, B). Compounds that 
inhibit kinases in their inactive form are often highly potent as they prevent kinase 
activation and subsequent ATP-binding.72,73 
 
2.3 Irreversible Enzyme Inhibition  
Compounds that cause irreversible inhibition of the activity of a biological target 
through covalent modification have, until recently, been unpopular as drug 
candidates through fears of off-target toxicity.74 Early approaches to the design of 
covalent enzyme inhibitors targeted catalytic nucleophiles within the active-site. This 
can lead to selectivity problems between different enzyme classes, making this 
approach unattractive.74 A resurgence of interest in covalent irreversible inhibitors 
has occurred recently, owing to the human genome project, advances in structure 
based-design, and structural bioinformatics.74 Modern irreversible enzyme inhibitors 
(inactivators) are designed to selectively target non-catalytic residues that are poorly 
conserved between families of enzymes.75 Rational design of the ligand using 
techniques such as X-ray protein crystallography allows optimisation of the initial 
non-covalent binding interaction. The choice of electrophilic ‘warhead’ is also 
essential and reactivity must be tuned to prevent reactions with endogenous 
nucleophiles (e.g. GSH) while maintaining good target specificity. 76,77  
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2.3.1 Safety of Irreversible inhibitors 
There are inevitably reservations over the safety of inherently electrophilic drugs and 
therapeutic agents that are metabolically activated to electrophilic species. Many 
pharmaceutical companies avoid this class of compound entirely, designating 
electrophilic groups as known toxicophores.78 A major concern regarding the safety 
of these compounds is as a consequence of the potential for random or prolonged 
covalent binding of the reactive species. Whilst this may result in acute toxicity, an 
additional problem is that such compounds may bring about an immune response 
through haptenization of proteins, and a possible result of this is autoimmune 
toxicity.76,78,79 These safety concerns can be minimised through the design of weakly 
electrophilic targeted covalent inhibitors. In contrast to highly reactive electrophilic 
compounds, which are likely to target a broad spectrum of proteins, weakly 
electrophilic compounds often need to adopt an initial non-covalent binding 
interaction with the target protein prior to activation, which reduces off-target 
binding.76 
 
2.3.2 Mechanisms of Covalent Enzyme Inhibition 
Equation 1 shows a general mechanism of covalent enzyme inhibition. An initial 
reversible non-covalent interaction must first occur between the ligand (I) and 
enzyme (E). This positions the electrophilic group of the ligand in close proximity to a 
nucleophilic site within the target enzyme to give a complex (E.I). A bond forming 
reaction (k2) then occurs resulting in covalent modification to give the final covalent 
complex (E-I). For truly irreversible inhibitors, the rate of breakdown of the final 
covalent complex (k-2) will equal zero, resulting in permanent enzyme inhibition. In 
contrast, reversible or slowly reversible covalent inhibitors have a k-2 value that 
governs the off-rate of the ligand, and therefore the persistence of the enzyme 
inhibitor complex (E - I). 76  
 
Equation 1 – Schematic of irreversible enzyme inhibition (adapted from Singh et 
al.).76 
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This type of initial non-covalent enzyme-ligand interaction is referred to as 
approximation because the nucleophilic group of the enzyme and the electrophilic 
group of the ligand are placed in close proximity to one another. This lowers the 
activation energy of the reaction due to decreased enthalpy (Ho), which is caused 
by a reduction in rotational energy of the bound ligand.75 
Irreversible binding of drugs is particularly advantageous for the circumvention of 
drug-induced resistance arising by mutation of the ligand-binding site following 
treatment with a reversible inhibitor.76,80 Although mutations may affect the rate of 
formation of the initial non-covalent complex, with sufficient time and exposure to the 
irreversible inhibitor the target protein can be effectively inhibited.76  
 
2.3.3 Affinity Label Enzyme Inactivators 
Affinity label enzyme inactivators are time-dependent irreversible inhibitors that are 
often structurally similar to the enzyme’s natural substrate.75 These compounds bind 
to the enzyme active-site and form covalent bonds with amino acid side chains often 
by acylation or alkylation reactions, thus occupying the substrate-binding domain 
causing irreversible inactivation. As with all electrophilic compounds, affinity labels 
have the disadvantage of potential toxicity through reaction of the functional group 
with endogenous nucleophiles. However, although these compounds may form an 
initial non-covalent complex (E.I) with off-target enzymes and other ligands (e.g. 
GSH), covalent modification is often not possible unless a nucleophilic group is 
present and correctly orientated within the enzyme active-site. Additionally, the 
reaction of this nucleophile will occur at a far greater rate than with off-target proteins 
(typically 108 times faster) due to substrate activation, which may improve 
selectivity.75 An advantage of this is the possibility of achieving selectivity between 
families of enzymes with poorly conserved nucleophilic amino acids within the 
substrate-binding domain.  
There are three important features of compounds designed as affinity label enzyme 
inhibitors. Firstly, it is essential that the ligand forms an initial reversible binding 
interaction with the enzyme (or cofactor) binding-site. This non-covalent binding 
should be rate-limiting up until enzyme saturation, at which point increasing inhibitor 
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concentration should not increase the rate of reaction.75,81 A second important 
feature is that increasing the concentration of a reversible ligand for the target 
enzyme, such as the natural substrate or cofactor, should reduce the rate at which 
enzyme inactivation occurs. This is due to competition between inhibitor and 
substrate for access to the enzyme active-site prior to forming the final covalent 
complex. Finally, it is desirable to screen structurally unrelated compounds that 
contain an identical electrophilic functional group to the affinity label, but that do not 
form the enzyme inhibitor complex. This helps to confirm selectivity and establish 
that inhibition is a two-stage process assisted by initial non-covalent interactions, and 
not arising as a result of non-specific binding of the reactive electrophile.81 Selected 
examples of affinity labeling agents include the beta-lactam antibiotic, ampicillin (15), 
and the anti-obesity drug, orlistat (16). 
 
 
2.3.4 Mechanism-Based Inhibitors 
An alternative strategy for the design of irreversible enzyme inhibitors is to use a 
mechanism-based approach, also known as ‘suicide’ inhibition. In this situation, an 
unreactive drug serves as a substrate for the target enzyme, which causes activation 
via the normal catalytic process, for example phosphorylation. This results in the 
formation of a reactive species that behaves as an affinity label, leading to 
irreversible inactivation of the target enzyme.75 Alternatively, the reactive species 
formed may not be a covalent modifier, but instead a compound that binds much 
more strongly than the parent molecule through enhanced non-covalent interactions 
with the target enzyme, causing slowly reversible inhibition. 
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Mechanism-based inactivators have an advantage over affinity labels as there is a 
reduced risk of non-specific covalent modification and hence toxicity. This is because 
such agents remain inert until they are activated through enzyme-mediated 
activation. It is desirable that the enzyme that activates a mechanism-based inhibitor 
is also the target of inhibition as this provides high enzyme specificity and low 
toxicity. However, this is not always possible and the activated species may be 
released from the enzyme active-site allowing reaction with alternative proteins, 
which may cause toxicity.75 Examples of mechanism-based enzyme inactivators 
include the anticonvulsant drug, vigabatrin (17), and the antidepressant drug 
tranylcypromine (18).  
 
2.3.5 Differences in the Therapeutic Window of Reversible and Irreversible 
Enzyme Inhibitors 
 An ATP-competitive kinase inhibitor is only able to modify the action of its target 
enzyme when it is bound in the ATP-binding pocket. As such, the biological efficacy 
of reversible ATP-competitive kinase inhibitors is largely dependent upon the lifetime 
of the enzyme-ligand-complex (residence time) rather than ligand affinity.82 In 
addition to ADME properties, the residence time has a profound influence upon the 
half-life (t1/2) and frequency of dose required to maintain a therapeutic concentration 
of drug at the enzyme active-site. The pharmacodynamic effect of reversible 
therapeutic agents is therefore greatly influenced by pharmacokinetic factors. This is 
demonstrated in the dose-response curve shown in Figure 8, where multiple doses 
of an inhibitor may be required to achieve an effective dose. A disadvantage of this 
approach is that a high systemic level of inhibitor may be required to maintain a 
therapeutic dose, which can result in toxicity.77 
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Figure 8 – Pharmacodynamics of reversible enzyme inhibitors (adapted from Barf 
and Kaptein).77 
Irreversibly targeting enzymes through the use of agents that covalently modify the 
active-site can have a dramatic effect upon the pharmacodynamic effect of enzyme 
inhibition. For this class of inhibitor, it is the enzyme turnover (de novo synthesis) 
rather than the pharmacokinetics that drives pharmacodynamics, because the ligand 
often remains permanently bound to the enzyme active-site. As such, irreversible 
inhibitors invariably have a longer duration of action than reversible inhibitors and 
require less frequent dosing as shown (Figure 9), which may reduce systemic 
toxicity.77 A further advantage of irreversible inhibitors is that pharmacokinetic issues, 
such as rapid clearance and plasma protein binding, may be reduced because the 
pharmacodynamic action of these compounds is often retained after systemic 
removal of the drug. However, this can also be a disadvantage if transient inhibition 
or short residence times are required.74  
 
Figure 9 – Pharmacodynamics of irreversible enzyme inhibition (adapted from Barf 
and Kaptein).77 
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2.3.6 Targeting Cysteine Thiols with Electrophilic Drugs 
Cysteine (Cys) is one of the least abundant amino acid residues but also one of the 
most important. Cys residues are often found at functionally critical locations within 
proteins and, as such, mutation can often have catastrophic results that can lead to 
genetic diseases such as cancer. The roles of Cys are diverse and include structure-
stabilisation, binding of cofactors, catalytic activity and regulatory activity.83 Cys is 
distinct from other amino acids in that the thiol is able to form covalent disulfide 
bonds that are essential for protein stability and folding.84 In addition, thiol-dependent 
regulation of cellular processes is possible due to redox control. The Cys thiol, when 
subjected to oxidative stress, may be readily oxidised to a number of products 
including disulfides, sulfenic acids, sulfinic acids and sulfonic acids.85 This can result 
in upregulation of cytoprotective cellular responses such as increased cell 
proliferation or signal transduction, as well as negative responses, e.g. growth 
inhibition and cell death.86 
 
2.4 Kinase Inhibition – beyond the ATP-binding pocket 
2.4.1 Allosteric Enzyme Inhibitors 
An alternative strategy for the design of kinase inhibitors is to target sites other than 
the ATP-binding pocket with non-competitive inhibitors.87 Many enzymes contain 
additional binding domains distinct from the active-site, known as allosteric sites. 
Interaction of endogenous ligands, known as effectors, with allosteric domains 
induces conformational changes at the active-site which alters substrate affinity. 
Binding of negative effector ligands reduces substrate binding whilst binding of 
positive effector ligands enhances enzyme activity. These effectors form part of 
signalling cascades and allow the modulation of enzyme activity. Targeting allosteric 
binding sites with small-molecule inhibitors is challenging as these sites are difficult 
to characterise, and unlike active-site inhibitors there are usually no small-molecule 
natural ligands (e.g. ATP) upon which to base inhibitor design. It is for these reasons 
that the majority of known allosteric inhibitors were discovered serendipitously.88 
Despite these challenges, allosteric modulators offer the potential of compounds with 
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high selectivity and fewer side effects than active-site directed inhibitors due to 
reduced binding site similarities between kinases.89  
 
2.4.2 Targeting Protein-Protein Interactions 
An emerging area of chemotherapeutic research is the design of ligands that 
modulate protein-protein interactions (PPIs). These interactions are essential for 
almost all biological processes; however, the formation of abnormal protein 
complexes is strongly associated with cancer and other diseases. As such, there is 
much interest in the design of small-molecule inhibitors that selectively disrupt 
protein complex formation in an attempt to restore normal cellular function.90   
Until recently, protein-protein targets have been viewed as high risk owing to the 
difficulties in designing ligands that bind to this primary interaction site.91 A major 
challenge of designing small-molecule inhibitors that target PPIs is that the binding 
site is often large and featureless. Mimicking this type of interaction is therefore 
problematic as protein binding is often facilitated by a multitude of weak interactions 
over a large surface area (600-1300 Å2).92 A strategy to overcome this hurdle is to 
design inhibitors that target critical points of interaction upon the binding surface 
rather than deep pockets, of which there are few. Additionally, it has been reported 
that some PPIs are made through smaller regions of high binding energy (‘hot-
spots’), which may be targeted by small-molecule inhibitors.92 Selectivity of these 
compounds is of particular concern, as if the same interaction points appear upon 
the surface of other proteins, off-target effects and toxicity may occur.91  
The MDM2-p53 complex is an example of a PPI that is implicated in cancer and 
currently under investigation as a potential cancer therapeutic target. As described 
previously, p53 is an essential tumour suppressor protein, which is activated in 
response to cellular stress (e.g. DNA damage) and functions to prevent replication of 
cells with aberrant gene expression.93 MDM2 is a key modulator of p53 activity and 
an established oncoprotein. Binding of MDM2 to p53 causes deactivation and 
proteasomal degradation of p53, preventing p53 induced cell cycle arrest etc.93-95 It 
is possible to restore the function of p53 by disrupting the MDM2-p53 interaction with 
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small-molecule inhibitors. An example of a compound that can achieve this is nutlin-
3 19, which is currently in preclinical development as an inhibitor of MDM2-p53.96 
 
2.5 Resistance to Small-molecule Kinase Inhibitors 
Due to the rapid proliferation and genetic instability of cancer cells, it is common that 
mutations occur in response to anticancer therapy that can lead to drug resistance.97 
The speed at which these changes in drug susceptibility occur greatly influences the 
clinical efficacy of treatment. Additionally, the types of mutations that confer 
resistance are usually limited to those that conserve enzyme function.98 One method 
of acquired drug resistance is through enhanced gene expression of a target protein 
in response to cellular stress associated with treatment. This causes elevated 
expression of the target kinase, which compensates for the intracellular 
concentration of inhibitor. Alternatively, redundant pathways may be activated due to 
increased expression of downstream signalling proteins that assume the role of the 
targeted kinase.99 An example of this can be observed in the treatment of breast 
cancer with lapatinib 20, a small-molecule inhibitor of the tyrosine kinase HER2 
(ErbB2), where drug resistance typically occurs after approximately 12 months.100 
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A mutation in the amino acid sequence of the kinase ATP-binding site may result 
from selective pressure caused by drug treatment, favouring a resistant phenotype. 
One common mutation is a change in the gate-keeper residue to prevent drug 
molecules entering the ATP-binding pocket. The gate-keeper residue is an amino 
acid that controls access to a hydrophobic domain within the ATP-binding pocket 
through size exclusion.73 This hydrophobic region is often the target of small-
molecule inhibitors, which form lipophilic interactions that enhance binding affinity. 
For example, a mutation that confers resistance to imatinib 14 in CML occurs 
through substitution of Thr-315 in BCR-Abl tyrosine kinase by larger amino acid 
residues such as Ile, Asp or Asn. This causes steric clashes and loss of a vital H-
bond preventing binding of imatinib.101 Another example of a mutation in response to 
molecular targeted cancer therapy occurs following treatment with compounds that 
bind to kinases in their inactive conformation. Mutations of the amino acid sequence 
of these kinases can destabilise the DFG loop causing persistent kinase activation, 
and preventing binding of inhibitors.101 
The selective pressure of molecular targeted therapy can facilitate drug resistance.97 
A strategy to combat this is to design second generation inhibitors that target the 
mutated enzyme form or, alternatively, inhibitors with such high binding affinity for 
the wild-type target that mutation has a minimal impact upon binding. An example of 
this is dasatinib 21, a potent tyrosine kinase BCR-Abl inhibitor with 325-fold greater 
activity than imatinib 14, and used in the treatment of imatinib-resistant CML.102 
 
An alternative strategy is to target multiple kinases either through combination 
therapy or a single agent approach. This treatment strategy has the potential for 
increased potency and reduced drug resistance. However, it is often difficult to 
balance potency with off-target activity and toxicity.97   
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2.6 Functionalised Purines as Kinase Inhibitors 
The naturally occurring purines adenine and guanine have important roles in 
numerous life processes. There has been a large degree of interest in the 
modification of the purine scaffold to create chemical probes and pharmaceutical 
agents to understand and treat a multitude of conditions several of which are shown 
below (Figure 10).103 The substituents on the purine ring structure (Figure 10, R1-R7) 
can easily be modified and large libraries of modified purines have been prepared for 
high-throughput screening, allowing the discovery of potent and selective inhibitors 
of a variety of targets.  As a result of these screens, a number of purine based drug 
candidates have progressed to clinical trials for the treatment of cancer and other 
diseases. 
 
Figure 10 – Purines in the treatment of disease (adapted from Legraverend and 
Grierson).103 
As purine compounds have high natural abundance throughout the body, it is 
challenging to gain selectivity in related families of enzymes. This is emphasised by 
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the fact that an estimated 7% of all proteins expressed by genes, rely upon naturally 
occurring purines as co-factors or substrates.103  
Purine analogues are an important class of kinase inhibitors, of use for the treatment 
of diseases including cancer (Figure 10). By competing with the natural substrate 
(ATP) for the ATP-binding domain, these compounds are able to cause kinase 
inhibition, which prevents downstream phosphorylation events, thus allowing 
modulation of specific metabolic pathways.104 However, as the ATP-binding domain 
is often conserved amongst kinase family members, it may be difficult to gain good 
selectivity using inhibitors that mimic the binding of ATP. Compounds that lack 
selectivity may elicit off-target effects which could lead to toxicity. As such, it is 
important to screen kinase inhibitors against a comprehensive panel of additional 
kinases.103 Nevertheless, by modifying substituents on the purine ring to exploit non-
conserved features of the target kinase, it is possible to develop highly potent 
compounds with minimal off-target activity. This is greatly assisted by recent 
advances in X-ray crystallography, which have allowed the development of inhibitors 
using a structure based design approach.105  
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Chapter Three: Mitotic Kinases and Cell Cycle Control 
3.1 The Eukaryotic Cell Cycle 
Mitotic cell division has evolved as a series of interconnected biological events 
known collectively as the cell cycle, which facilitates DNA replication and the even 
distribution of chromosomes.106,107 Control of this cycle is achieved through 
phosphorylation-mediated signalling cascades and restriction check-points, and 
cancer may arise due to mutation of signalling genes resulting in hyperactivation. 
Similarly, mutation of genes coding for checkpoint-control proteins may prevent cell 
cycle regulation, causing genomic instability.108 As such, proteins of the cell cycle are 
attractive cancer therapeutic targets.    
 
Figure 11 - Schematic representation of the mitotic cell cycle. 
The mitotic cell cycle is divided into an ordered sequence of events known as G0, G1, 
S, G2 and M (Figure 11).  In the first stage of the cell cycle (G1), cells experience a 
period of growth during which essential proteins and enzymes (e.g. DNA 
polymerases) are synthesised for use in subsequent phases.109  G1 serves as the 
first of two restriction checkpoints that control cell cycle progression. At this point, 
cells may either progress to S-phase or enter a phase of quiescence (G0) if required. 
Cells in G0 may survive in this state for extended periods of time maintaining function 
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but remaining dormant and non-proliferative. These cells can be stimulated to re-
enter the cell cycle when required, returning to G1 through activation/silencing of key 
regulatory genes.110 After G1, the cell enters the S-phase of the cell cycle, during 
which the synthesis of DNA, centrosomes, histones and key enzymes required for 
chromosome replication takes place. The role of the S-phase is to produce two 
identical sets of chromosomes and centrosome pairs for use in mitosis. It is essential 
that both DNA replication and centrosome duplication occur only once with each 
subsequent cycle to prevent aneuploidy, the abnormal distribution of 
chromosomes.111   Following S-phase, there is a second gap phase known as G2. 
This is the final stage of the interphase component of the cell cycle, and is 
characterised by rapid growth resulting in elevated expression of the numerous 
cellular components required for mitosis. Prior to the G2/M transition, there is a 
second restriction checkpoint. At this point DNA is assessed for errors by a number 
of proteins including p53 and CDKs. If errors are found, they are either repaired or 
the cell is destroyed by apoptosis.112 The final stage of the cell cycle is the mitotic 
(M) phase, which allows chromosome segregation and cell division, resulting in the 
production of two identical daughter cells.  
 
3.2 Molecular Mechanisms of Mitosis  
Mitosis is a highly-ordered sequence of biophysical processes that facilitate 
separation and distribution of chromosome pairs in somatic cells prior to division 
(cytokinesis). Errors in mitosis are a leading cause of aneuploidy and genetic 
instability. A number of regulatory processes protect against these errors and more 
often than not abnormal cells are swiftly removed through apoptosis. Failure to 
correct these errors or eliminate affected cells can have disastrous consequences, 
leading to cancer and other diseases.111  
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Figure 12 – Stages of mitotic cell division.113 
Following completion of both the S- and G2-phases of the cell cycle, cells proceed 
into the mitotic phase (M-phase) allowing cell replication and division. The first stage 
of mitosis is prophase, during which chromosome condensation occurs (Figure 12a). 
Simultaneously, cytoplasmic organelles known as centrosomes separate and 
migrate to opposite poles of the cell, where they recruit γ-tubulin and form the 
microtubule organising centres (MTOCs) in preparation for mitotic spindle formation. 
Finally, fully condensed chromosomes begin to interact with mitotic spindle fibres 
through tubulin polymerisation, signifying the end of the prophase and the onset of 
prometaphase.114 It is essential that correct chromosome condensation occurs to 
prevent truncation and allow accurate separation of sister chromatids.115  
G2 of Interphase a - Prophase b - Prometaphase 
c - Metaphase d - Anaphase 
e – Telophase and 
Cytokinesis 
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During prometaphase, the nuclear membrane becomes hyperphosphorylated 
causing it to fragment and release the chromatid pairs from the nucleus. Three 
distinct sets of microtubule spindle fibres protrude from the MTOCs towards the cell 
cortex through microtubule polymerisation (Figure 12b).  These microtubules form 
the mitotic machinery required for chromosome segregation.116 One set of 
microtubules, the kinetochore microtubules, attach to the chromatids forming protein 
structures (kinetochores), which are essential for chromosome segregation. Each 
individual chromatid is attached to a single centrosome via these kinetochore 
microtubules ensuring correct segregation at later stages of mitosis. A second set of 
microtubules, the astral microtubules, do not connect to a kinetochore but are 
instead used to position mitotic machinery with the aid of motor proteins (dyneins). 
The third set of microtubules, known as polar microtubules, form interdigitate links 
with microtubules at the opposite pole of the cell. These microtubules are assisted by 
motor protons and help facilitate cell division.  
The cell progresses from prometaphase to metaphase when all chromosomes are 
attached to kinetochore microtubules (Figure 12c). At this point, chromosome pairs 
begin the process of chromosome ‘congression’ during which chromosomes  
translocate to the ‘equator’ of the cell and align along the metaphase plate.1,114 To 
ensure all kinetochore microtubules are correctly attached prior to mitotic 
progression, chromosomes are checked by the spindle assembly checkpoint (SAC) 
which consists of a number of cell cycle kinases including: CDK1, Aurora-B, MPS1, 
BUB1 and BUB1B.111,117 
Once the requirements of the SAC are met, the cell enters anaphase (Figure 12d) 
during which the centromere connecting sister chromatids is cleaved by the enzyme 
separin (also known as Esp1).118,119 Up until this point of the cell cycle separin is 
inhibited by the chaperone protein securin. Upon entry into anaphase, securin is 
labelled for destruction through ubiquitination by the anaphase promoting complex 
(APC/C) allowing separin activation.118,119 After cleavage of the centromere, 
chromosome segregation occurs through the actions of microtubules and motor 
proteins.114 There are two major processes that facilitate this separation, termed 
anaphase A and anaphase B. During anaphase A, kinetochore microtubules shorten, 
drawing the attached chromosomes towards opposite centrosomes. By contrast, 
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during anaphase B, centrosomes are driven apart through spindle elongation.120,121 
Finally, the kinetochore is broken down, freeing the daughter chromosomes.116 
At this point the cell enters telophase (Figure 12e). The nuclear envelope reforms 
around the condensed chromosomes from residual vesicles of the parent nuclear 
envelope, to produce two independent nuclei at opposite ends of the cell. The cell 
then initiates cytokinesis beginning with formation of the cleavage furrow. 
Simultaneously, chromosomes de-condense, and finally the cytoplasm divides 
resulting in two genetically identical daughter cells.114 The cell cycle is now complete 
and the newly produced daughter cells proceed to enter interphase in a new cell 
cycle.116 
 
Figure 13 - Schematic representation of a centrosome.122 
 
3.3 The Centrosome Cycle 
The centrosome cycle is a key component of cell physiology that functions in concert 
with the cell cycle. The role of the centrosome cycle is to facilitate the semi-
conservative replication of a cytoplasmic organelle known as the centrosome. The 
centrosome has a vital role as the major microtubule-organising centre (MTOC) of 
cells in higher-organisms.123,124 Centrosomes control microtubule dynamics allowing 
precise control of organelle transport, cell shape, polarity and motility. Centrosomes 
are particularly important for cell replication and assist mitosis through their role in 
spindle pole assembly and cytokinesis.125   
The centrosome is an organelle located within the cytoplasm near the nucleus of 
cells, which consists of two orthogonal barrel-shaped centrioles each containing nine 
microtubule triplets (Figure 13) in a 9-fold axis of symmetry.125-127 These 
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microtubules reside within the pericentriolar material – a highly organised matrix of 
proteins required for microtubule nucleation through the recruitment of γ-tubulin.126  
During the cell cycle the structure of the centrosome is precisely altered to facilitate 
centrosome duplication. These structural alterations correspond to specific events of 
the cell cycle and are collectively termed the centrosome cycle (Figure 14). Each 
centrosome cycle takes one complete cell cycle, resulting in a single replication of 
the centrosome in a semi-conserved process.127,128 
 
Figure 14 – The centrosome cycle (adapted from Crasta and Surana).127 
Figure 14 shows a schematic representation of the centrosome cycle. This 
commences at G1 with the centrosome pair consisting of a mother and daughter 
centriole. The mother centriole contains additional distil and sub-distil appendages, 
and was formed a minimum of two cycles ago. The daughter centriole was formed in 
the previous cycle and is deemed immature, as it does not yet possess these 
appendages.124,127 (a) To begin replication, the centrioles lose their orthogonal 
orientation, remaining interconnected via a flexible connector known as the 
intercentriolar linkage.127 (b) As the cell enters the S-phase of the cell cycle the 
centrioles nucleate secondary immature centrioles (procentrioles) (shown in blue) 
orthogonal to the parent centrioles. (c) The procentrioles elongate forming daughter 
centrioles (shown in blue). (d) The cell then enters G2 and the intercentriolar linkage 
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is cleaved. (e) At the G2/M transition the centrioles split and the pericentriolar 
material divides allowing the newly formed centrosome pairs to separate. (f) The 
daughter centriole from the start of the cycle then matures gaining distil and sub-distil 
appendages consisting of a range of proteins including: cenexin, ninein, CEP110 
and ε-tubulin.127 (g) At this point the cycle is complete and centrosomes migrate to 
opposite poles of the cell to form the mitotic spindle, prior to entry into mitosis. 
 
3.4 Centrosome Instability and Cancer 
Progress through the centrosome cycle is highly regulated by p53 and a number of 
cell cycle protein kinases including CDKs and aurora kinases.129 Centrosome 
stability is critical for the even distribution of chromosomes during mitosis, and it is 
essential that at the point of entry into mitosis there are exactly two centrosome pairs 
present within the cell.128  
In human cells the required number of chromosome pairs is 23. Aberrant distribution 
of these chromosomes between parent and daughter cells is a common result of 
mitotic errors, brought about through dysfunctional centrosome replication. Failures 
in centrosome replication prior to the onset of mitosis can be catastrophic. In most 
instances, cells will not divide but instead return to interphase resulting in polyploidy 
– the presence of extra chromosome pairs.130 By contrast, the presence of additional 
centrosome pairs can induce the production of a multipolar spindle, resulting in a 
myriad of daughter cells each with a randomly distributed aberrant mixture of 
chromosomes.130 In either case, genetic imbalances occur, which under normal 
circumstances prove fatal to cell survival due to intervention by apoptosis-inducing 
defence mechanisms. Cells that evade these defence mechanisms and survive may 
exhibit an altered phenotype, giving rise to aggressive growth and the invasive 
properties most often associated with cancerous cells.128 Interestingly, cells that lack 
centrosomes entirely may still engage in bipolar spindle assembly, although there is 
an increased risk of cleavage failure during mitosis.130,131  
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3.5 Targeting Mitosis in Cancer Chemotherapy 
Preventing cell cycle progression by targeting mitotic events is an effective cancer 
therapeutic strategy. Conventional cytotoxic drug classes such as taxanes and vinca 
alkaloids (see p25) target microtubules and prevent accurate spindle formation and 
chromosome alignment through stabilisation or destabilisation of tubulin, 
respectively. This causes targeted cells to remain at the spindle assembly 
checkpoint phase of mitosis, and they cannot progress into anaphase resulting in 
mitotic arrest and apoptosis.132 These therapies, although effective, are known to 
produce many side effects and toxicity due to binding of microtubules involved in 
processes required to maintain cell physiology and function.133 It is therefore 
desirable to develop modulators of mitosis that have good selectivity and do not 
interfere with tubulin function. One possible approach is to target mitotic protein 
kinases involved in tumour progression using molecular targeted therapy.  
 
3.6 Protein Kinases and Cell Cycle Progression 
Errors in cell cycle modulation can induce rapid proliferation and is often associated 
with malignant transformation. A major function of protein kinases is to monitor and 
regulate cell cycle progression, preventing errors in DNA duplication and 
chromosome segregation that would otherwise cause abnormal cell division and the 
development of cancer.117 In the following section four families of important cell cycle 
kinases will be discussed, namely CDKs, aurora kinases, Plks and the Nek family.  
 
3.7 Cyclin-Dependent Kinases (CDKs) 
The CDK family of enzymes consists of 13 serine/threonine protein kinases, many of 
which have important roles in cell cycle progression and checkpoint control.134 The 
level of CDK expression generally remains constant throughout the cell cycle; 
however, CDK activation is precisely regulated by a number of processes (Figure 
15), including binding of partner cyclins, phosphorylation, proteinogenic inhibition by 
CDKIs and ubiquitin-mediated proteolytic degradation.135-137 Monomeric CDKs are 
essentially inactive but become activated upon binding of a partner cyclin to form a 
heterodimeric protein complex. CDK activity is vastly increased due the formation of 
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targeting domains, which allow additional binding interactions and control substrate 
specificity.138,139 Mutation of genes coding for CDKs and their binding partners are 
known to cause unscheduled cell proliferation, genomic instability and aneuploidy, 
and is associated with tumour progression.137 Additionally, elevated CDK expression 
has been shown to be common in cancer. 
 
Figure 15 – Cell cycle dependent regulation of CDK activity.136 
3.7.1 CDKs in Cell Cycle Control 
At the G1 phase of the cell cycle, CDK4 or CDK6, forms a complex with D-type 
cyclins, which facilitates centrosome replication. Progression from G1 to the S phase 
is then catalysed by the CDK2/cyclin-E complex allowing chromosome replication. At 
the G2/S checkpoint, CDK2 complexes with cyclin-A, which changes its substrate 
specificity ensuring that all cellular components are correct prior to entry into mitosis 
(M). CDK1/cyclin-B then functions to facilitate the transition from G2 to M. Not all 
members of the CDK family are thought to be necessary for cell cycle progression; 
indeed the three interphase CDKs (CDK2,CDK4 and CDK6) are only required for 
proliferation of certain cell types (e.g. CDK2 for germ cells,140 CDK4 for pancreatic β-
cells141 and CDK6 for haematopoietic cells).142 Contrary to this, CDK1 has been 
shown to be essential for cell division.  Defects that induce aberrant CDK activity 
a 
b 
c 
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may give cells a proliferative advantage, and are closely linked to cancer. By 
targeting CDKs with small-molecule inhibitors it is hoped that such activity may be 
prevented through the restoration of checkpoint control, causing cell cycle arrest and 
possibly apoptosis.143 As such, CDKs have received considerable interest in the field 
of cancer therapeutics.144 
 
3.8 Aurora Kinases 
The aurora kinases are a highly conserved class of three kinases (aurora A,B and C) 
that assist mitotic spindle formation through regulation of centrosome replication, 
microtubule-kinetochore attachment, spindle checkpoint and cytokinesis.145 The 
most comprehensively studied member of this family of kinases is aurora A, which is 
located at the centrosomes, and assists mitotic spindle pole assembly and 
centrosome maturation to facilitate cell cycle progression.146,147 Aurora B is localised 
at the chromosomes and forms part of the spindle assembly checkpoint and 
chromosome passenger complex.117 The major roles of aurora B are to ensure 
correct kinetochore-microtubule attachment as well as facilitating chromosome 
segregation and cytokinesis.117,148 Inhibition of aurora B has been shown to cause 
polyploidy by removal of a critical spindle checkpoint, causing an early exit from 
mitosis without cytokinesis.149 Aurora C is not well studied but is suspected to be 
important for mitosis as it is found to accumulate at the centrosome. It has been 
suggested that the role of aurora C is highly analogous to aurora B and may in-fact 
be a redundant pathway.145 Drugs that target these kinases are thought to cause 
deregulation of microtubule dynamics, and may offer a therapeutic alternative to 
patients who do not respond to antimitotic agents.150  
 
3.9 Polo-like kinases (Plks) 
The Plk family of enzymes are serine/threonine protein kinases that have a role in 
the cell cycle and are known to be associated with cancer.151 The four members of 
the mammalian Plk family include Plk1 (Xenopus Plx1), Plk2 (serum-inducible kinase 
(Snk)), Plk3 (fibroblast growth factor inducible kinase (Fnk)/ proliferation related 
kinase (Prk)) and Plk4/Sak. Biochemical and genetic in-vivo experiments have 
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indicated the role of Plks in a number of events that occur during the cell cycle 
including: mitotic spindle formation, chromosome segregation, cytokinesis and 
numerous activation and regulatory roles. There is evidence that Plk1 is associated 
with cell proliferation linked to cancer formation. Studies with the mouse NIH3T3 cell 
line, which overexpresses murine Plk1, demonstrated a transformed phenotype with 
the presence of multinucleated cells resulting in tumour formation in nude mice. Plk1 
overexpression in human cancer has also been linked to aggressive growth and poor 
clinical outcome.151 Plk1 has therefore become a target of considerable interest and 
its inhibition may prove useful in cancer chemotherapy. The exact function of Plk2 is 
less well known, although studies in mice indicate a role in centriole duplication. Plk3 
is thought to assist G1/S progression through enhancement of cyclin E expression. 
Finally, Plk4 is known to be an essential regulator of centriole duplication.152 
 
3.10 Never in Mitosis Gene-A Related Kinases (Neks) 
Never in mitosis gene-A (NIMA), was first identified in the filamentous fungus 
Aspergillus nidulans. In this fungus the function of NIMA is to facilitate the G2/M 
transition and entry into mitosis. In humans, the closest relatives of NIMA are the 
NIMA related kinase (Nek) family of serine/threonine protein kinases, of which there 
are 11 known members (Nek1-11). Each member of the Nek family exhibits a broad 
similarity to NIMA due to possession of a highly conserved N-terminal catalytic 
domain. Contrary to this, amino acid residues found at the carboxyl terminus are 
quite different, suggesting that during the evolution of NIMA, its function has 
diversified away from G2/M progression into a more complex process.
153 This is 
further exemplified by the existence of multiple Nek kinases, many with alternative 
functions to NIMA.154 The most closely related Nek kinase member to NIMA is the 
NIMA related kinase gene 2 (Nek2), which shares a 44% amino acid homology with 
the NIMA catalytic domain. To date, none of the Nek family of enzymes have 
demonstrated a functional homologue of NIMA; however, initial characterisation 
studies have implicated Nek2 in cell cycle control and microtubule organisation.154 
Nek2 function will be reviewed in greater detail in chapter four. 
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In addition to Nek2, other members of the Nek family of enzymes may also prove to 
be viable therapeutic targets. Nek8 and Nek9 form a subfamily, as they are 
suspected to both possess the regulator of chromosome condensation domain 1 
(RCC1) and a close structural homologue at the kinase domain (Figure 16). A 
structural difference observed between Nek8 and Nek9 is that Nek9 exhibits a 
coiled-coiled domain, which is believed to allow additional protein-protein 
interactions. Additionally, Nek8/9 are structurally similar to Nek2, which suggests that 
they have a related function. Contrary to this, the Nek1/3 subfamilies appear the 
most distinct and are likely to have the greatest difference in function.153 
 
Figure 16 – Structural similarities between Nek8 and Nek9 coding domains.153 
Nek8 is thought to be associated with human cancer. The exact function of Nek8 in 
humans remains unknown, although predictions have been made using murine 
Nek8.153 In mice, mutation of the Nek8 coding gene resulted in the production of 
oversized cells with multiple nuclei. In an additional study, the expression of Nek8 
was down regulated in zebrafish embryos using anti-sense DNA, resulting in the 
formation of pronephric cysts. This suggests that Nek8 is involved in the cell cycle 
and that its disruption leads to further downstream cellular complications.155 It has 
been demonstrated that the expression of Nek8 in normal human tissue is limited, 
whereas in human breast carcinoma cells Nek8 is over-expressed.153 The result of 
this over-expression is a reduction in the concentration of endogenous actin and 
elevated CDK1/CyclinB1 levels further suggesting Nek8’s involvement at the G2/M 
transition of the cell cycle. 
As described previously, Nek9 contains a coiled-coiled domain. It has been 
demonstrated that this difference in structure to Nek8 facilitates interactions between 
Nek9 and additional binding partners, including the GTPase Ran, Nek6, Nek7 and 
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Bicd2. This suggests Nek9 may have additional roles in the regulation of 
chromosomal microtubule organisation and alignment.153 
Other members of the Nek kinases include Nek1, which has been shown to interact 
with polycystic kidney disease proteins, and may have a role in the DNA damage 
response pathway. Nek3 is believed to associate with Vav2 and modulate prolactin 
receptor signalling but is not involved in the cell cycle. Neks 4, 5 and 10 currently 
have no known function.156 Nek6 and Nek7 are closely related to each other and 
form a subfamily within the Nek kinases. It is thought that these kinases are 
activated by the C-terminal tail of Nek9, which causes phosphorylation and allosteric 
binding.157,158 Inhibition of Nek6 causes apoptosis by inducing arrest at the 
metaphase stage of mitosis.156,158 Nek11 is the most recently discovered member of 
the Nek family, and is known to be activated in response to DNA damage / stress. 
Inhibition of Nek11 by caffeine in HeLaS3 cells has been shown to minimise cell 
lethality at the S-phase, suggesting that Nek11 may help regulate the G1/S phase 
checkpoint.156,159  Aside from Nek2, Neks 6, 7 and 9 appear to have the greatest 
potential as targets for therapeutic agents.117 Each of these kinases is implicated in 
cell cycle control and has shown elevated expression in various tumour types.  
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Chapter Four: Targeting Nek2 with Small-Molecule 
Chemotherapeutic Agents 
 
4.1 Nek2 is Implicated in Chromosomal Instability and Cancer 
Genetic instability is a common characteristic of cancerous cells. It is brought about 
due to defects in DNA repair and/or changes in DNA content, through errors that 
occur during the chromosome segregation phase of mitosis.1 A common feature of 
cancer cells is missing or extra chromosomes (aneuploidy). Cells exhibiting 
aneuploid defects are at increased risk of developing chromosome instability, which 
can result in unregulated cell growth and division, causing malignant 
transformation.154,160 Cells with aberrant regulation of Nek2 activity are more likely to 
develop aneuploidy, and as such have an increased likelihood of malignant 
transformation.161 This has been reflected in studies that demonstrated a 2-5 fold 
increase in Nek2 coding gene expression in breast and cervical carcinomas as well 
as lymphomas, when compared with healthy cells.154  
 
4.2 Nek2 Induces Centrosome Splitting at the G2/M Transition  
Nek2 is a serine/threonine protein kinase that is implicated in centrosome disjunction 
and mitotic spindle formation. Nek2 is localised at the centrosomes and is expressed 
in a cell cycle-dependent manor. At G1, the level of cellular Nek2 is low; however,  
upon transition into the S-phase of the cell cycle a marked increase in Nek2 
expression is observed. The level of cellular Nek2 peaks at the G2/M transition and 
then rapidly declines upon entry into mitosis due to proteolysis.162 It is believed that 
Nek2 plays an important catalytic role in the phosphorylation of proteins involved in 
centriolar cohesion. Upon phosphorylation, centrosome segregation occurs by 
breakage of the intercentriolar linkage allowing mitotic entry (Figure 17). 
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Figure 17 - Schematic representation of Nek2 mediated centriole disjunction 
(adapted from O’Regan et al.).163 
The intercentriolar linker is a bridged structure that connects the two centrosome 
pairs (Figure 17). This structure consists of at least two proteins, including rootletin 
(shown in blue) and centrosomal Nek2 associated protein 1 (C-Nap1) (shown in red). 
C-Nap1 has been shown to locate at the end of the centriole during interphase and 
behaves as an attachment site for rootletin, which links the centrosome pairs.164  
During entry into mitosis (G2/M) Nek2 is activated following inhibition of protein 
phosphatase 1 (PP1) by inhibitor-2 protein (Inh-2), which may be assisted by CDK1 
(Figure 17). It is thought that PP1 functions to remove phosphate groups from Nek2 
and its substrate proteins which modulates Nek2 activity.123,165 Once active, Nek2 
phosphorylates C-Nap1 and rootletin causing conformational changes that favour 
centrosome splitting. After separation, the centriole pairs are transported to opposite 
poles of the mitotic cell by microtubule-based motor proteins in preparation for 
mitotic spindle formation.163 Upon entry into mitosis, Nek2 is ubiquitinated and 
rapidly undergoes proteasomal degradation by anaphase promoting complex 
(APC/C).123 
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4.3 Nek2 in the Regulation of the Centrosome Associated Protein Nlp 
In addition to the Nek2 substrates rootletin and C-Nap1 described previously, ninein-
like-protein (Nlp) has recently been identified as a substrate of Nek2. Nlp is located 
at the centrosome and functions to induce microtubule nucleation through the 
recruitment of γ-tubulin and gamma-tubulin complex component 4 (hGCP4).166 
Correct nucleation of the microtubules is essential for centrosome maturation, as 
well as accurate spindle assembly and mitotic progression.167 Overexpression of Nlp 
is known to cause the formation of aggregates around the centrosomes leading to 
mitotic defects, which has been associated with chromosome instability and 
malignant transformation.168,169 It is the role of regulatory enzymes such as Plk-1 to 
prevent aberrant Nlp activity, which is achieved by phosphorylation of Nlp causing its 
removal from the centrosome.170 In vitro and in vivo studies have demonstrated that 
Nek2 phosphorylation of Nlp occurs in a similar way to Plk1 phosphorylation, albeit 
at an alternative phosphorylation site. Interestingly, inhibition of Nek2 has been 
shown to disrupt Plk1 mediated phosphorylation of Nlp, which suggests that Nek2 
may activate Nlp allowing Plk1 binding.170 Additionally, Nlp is known to have an 
important role in cell division, as phosphorylation of Nlp by aurora-B is thought to be 
vital for cytokinesis.167  
 
4.4 Structural Features of Nek2 Kinase 
It has been established that cellular Nek2 exists as a homodimeric pair of enzymes. 
This dimerisation enables trans-autophosphorylation of serine residues at the C-
terminal region via a dimerization domain known as the leucine zipper (LZ), which 
facilitates Nek2 activation.171 Interestingly, it has been shown that this leucine zipper 
is essential for Nek2 substrate activity, and removal through deletion or mutation 
causes a reduction in centrosome splitting in U2OS cells.171 
There are two splice variants of Nek2 (Nek2A and Nek2B), the structures of which 
are shown in Figure 18. A major component of each isoform is a conserved N-
terminal kinase domain (shown in green), which is required for catalytic activity. 
Additionally both isoforms contain a leucine zipper (LZ), which allows dimerisation. 
Nek2A differs from Nek2B in that it is longer and contains a C-terminal regulatory 
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domain consisting of a protein phosphatase binding site (PP1c) alongside a coiled-
coiled domain (CC), and destruction domains (KEN-box and D-box).123 The function 
of the CC domain in Nek2A is currently unknown; however, it has been suggested 
that this site has a role in centrosome disjunction.165 
 
Figure 18 - Schematic representation of Nek2A and Nek2B (adapted from Fry).123  
Expression of Nek2A and Nek2B is cell cycle dependent but also distinct for each 
isoform. Upon entry into mitosis, Nek2A is quickly removed by APC/C following 
ubiquitination of the C-terminal domain. As this site is not present in the shorter 
Nek2B isoform, Nek2B levels remain elevated during mitosis suggesting functional 
differences.123,165 
 
4.5 Nek2 Regulation of the Spindle Assembly Checkpoint (SAC)  
The spindle assembly checkpoint (SAC) is an essential regulator of mitosis that 
ensures correct attachment of microtubules to the kinetochore of chromosomes prior 
to progression from metaphase to anaphase. Mutations that cause incorrect SAC 
regulation can induce errors in chromosome segregation, and is strongly associated 
with the development of aneuploidy and chromosome instability.172 Nek2 has been 
implicated in spindle checkpoint control through phosphorylation of the proteins 
‘highly expressed in cancer 1’ (Hec1), ‘mitotic arrest deficient 1’ (MAD1) and ‘mitotic 
arrest deficient 2’ (MAD2).173  
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Hec1 is an established oncogene and is over-expressed by a number of human 
cancers. Overexpression of Hec1 in human carcinoma has been associated with a 
poor clinical outcome, and therefore inhibition of Hec1 poses an attractive target for 
therapeutic agents. Hec1 functions to regulate mitotic spindle formation between 
kinetochores and centrosomes.174 To function correctly, Hec1 must first be activated 
through phosphorylation of Ser-165 in a cell cycle-dependent manner at the G2/M 
transition. It has been demonstrated in yeast cells using scNek2/Kin3, a Nek2 
functional homologue, that Hec1 is a substrate of Nek2 and phosphorylation at Ser-
165 is essential for Hec1 function. However, it has also been shown that this 
phosphorylation occurs in the absence of scNEk2/Kin3, suggesting a redundant 
compensatory pathway.173 Loss of Hec1 phosphorylation is known to cause errors in 
chromosome segregation ultimately resulting in reduced cell proliferation and 
increased cell death, which was demonstrated through the use of Hec1 silencing 
siRNA studies.175 A screen of approximately 24,000 compounds led to the discovery 
of the aryl thiazolylbenzamide compounds INH1 22 and INH2 23, which 
demonstrated Hec1 inhibitory activity but had low potency and aqueous solubility. 
SAR studies revealed that a central thiazolyl ring, coupled to a hydrophobic aryl ring 
and a polar arylamide were critical for activity and analogues of the two lead 
compounds focused on modification of this scaffold to improve pharmacokinetic 
properties. Although these compounds were not inhibitors of Nek2, they 
demonstrated that disruption of the downstream effects of Nek2 inhibition can induce 
chromosome misalignment leading to cell death.174 
 
Like Hec1, MAD1 and MAD2 are also mitotic checkpoint proteins that are localised 
at the kinetochore. It has been demonstrated that MAD2 is a substrate for Nek2 
phosphorylation, which is thought to allow regulation of the SAC, thus preventing 
premature entry into anaphase.176 Additional studies are required to further elucidate 
the role of Nek2 in SAC regulation.  
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4.6 Nek2 is Implicated in Chromatin Condensation 
Aside from an established role in mitosis, Nek2 has also been implicated in 
chromatin condensation during meiosis.177,178 Di Agostino observed that activation of 
the mitogen-activated protein kinase (MAPK) pathway in mouse spermatocytes, 
caused subsequent activation of p90Rsk2 and Nek2 through a kinase signalling 
cascade.177 Additional studies by Sette showed that the MAPK pathway is essential 
for efficient chromatin condensation.179 A key enzyme in this pathway is high mobility 
group AT-hook 2 (HMGA2), which has been shown to be a substrate for Nek2 by in 
vitro studies.179 HMGA2 binds to DNA at areas rich in adenine-thymine (AT) base 
pairs. The function of HMGA2 is to regulate transcription, which is achieved by 
causing conformational changes in chromatin facilitating further protein binding.180 
Upon phosphorylation, HMGA2 has a decreased affinity for DNA which may cause 
its release from chromatin allowing further condensation.177 
 
4.7 Inhibition of Nek2 Results in Decreased Tumour Cell Growth 
In vivo studies in mice have shown that Nek2 inhibition may induce a reduction in 
tumour growth. In these experiments, nude mice were inoculated with human 
cholangiocellular carcinoma cells (HuCCT1).181 Cholangiocarcinoma is a form of liver 
cancer that is rare in the western world, but is becoming increasingly common in 
southeast Asia. Four weeks after inoculation, mice bearing tumours were selected 
and treated (20 µmol/L) with either Nek2 silencing siRNA in cell matrix, a non-
silencing siRNA in cell matrix or cell matrix alone, once a week for 3 weeks (Figure 
19, a). Upon completion of treatment, tumour volumes were determined periodically, 
for 12-weeks following inoculation. Mice treated with Nek2 silencing siRNA 
experienced an approximate 50% reduction in tumour cell growth when compared 
with control mice.181 Additionally, it was shown that Nek2 inhibition in these tumours 
led to a reduction of cell division and increased cell death. To confirm that these 
results were a result of Nek2 inhibition, an immunoblot analysis was performed, 
which showed that Nek2 was effectively inhibited in treated mice by siNek2 27 (a 
Nek2 silencing siRNA) but was still active in the tumours from control mice   (Figure 
19, b).  
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Figure 19 - Inhibition of Nek2 by Nek2 silencing siRNA.181 
In vitro studies were conducted using alternative tumour cell lines including, thyroid 
hyalinising trabecular tumour (HTT) cells and the bile duct carcinoma cell line 
(TFK1). Whilst Nek2 siRNA induced cell death in TFK1 cells analogous to the 
HuCCT cell line, there was limited evidence that Nek2 inhibition reduced the viability 
of HTT cells (Figure 20). These results suggest that the therapeutic potential of Nek2 
may be limited to responsive cell lines.181 
 
Figure 20 - Effect of Nek2 inhibition on HFF, HuCCT1 and TFK1 cell lines.181 
 
 
 
 
a) b) 
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4.8 ATP-Competitive Reversible Inhibitors of Nek2 
 
Pyrazine 24 is a member of an aminopyrazine series of ATP-competitive reversible 
inhibitors that binds to an inactive form of Nek2.182 Nek2 phosphorylation, and hence 
activation, is prevented causing the enzyme to remain in an inactive state. An 
advantage of binding in this way, is that an increased window of opportunity exists 
for successful drug-target interactions, which may improve efficacy.  Whilst this 
compound was shown to have sub-micromolar Nek2 inhibitory activity (IC50 = 230 
nM) and good selectivity for Nek2 over other kinases, the pyrazine series was 
essentially inactive in cells due to poor membrane permeability.182  
Compound 25 represents a series of Nek2 inhibitors based upon the benzimidazole 
heterocycle. This compound was found to have sub-micromolar Nek2 inhibitory 
activity (IC50 = 360 nM) and good cell permeability. Unfortunately, this compound 
series was highly lipophilic and lacked good structure-activity relationships (SARs), 
preventing further advances of Nek2 inhibition.183 Additionally, this series was found 
to lack cellular activity, which was attributed to inadequate Nek2 inhibitory activity.184 
Recently, a potent selective series of Nek2 inhibitors with improved lipophilicity was 
discovered based upon a hybrid of pyrazine 24 and benzimidazole 25.184 Of this 
series, aminopyridine 26 had the highest Nek2 inhibitory activity (IC50 = 22 nM), and 
showed promising cellular activity. It is hoped that this compound will help further 
elucidate the function of Nek2 and its involvement in the cell cycle.184 
 
4.9 Oxindole Based Irreversible Inactivators of Nek2 Kinase 
The first reported irreversible inhibitor of Nek2 with cellular activity was described by 
Henise and  Taunton in 2011.185 This compound was based upon the oxindole 
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inhibitor SU11652 27, which is an ATP-competitive Nek2 inhibitor with poor kinase 
selectivity.185 The oxindole heterocycle and the pyrrole ring of 27 form a triplet of 
hydrogen bonds with the Nek2 hinge region, which is vital for potent Nek2 inhibition. 
It was determined that modifications of the 3’, 4’ and 5’ positions of the pyrrole ring 
were tolerated, and it was hoped that functionalisation of these positions would allow 
increased Nek2 selectivity due to the presence of a non-conserved cleft within the 
Nek2 ATP-binding domain, which could be occupied by small alkyl substituents. The 
6- and 7-positions of the oxindole ring form close contacts with the Nek2 methionine 
gatekeeper residue (Met-86), and therefore were unsuitable for functionalisation. 
Interestingly, the 5-chloro group of 27 was estimated to be approximately 6 Å from 
Cys-22. The close proximity of the reactive Cys residue suggested that covalent 
modification and hence irreversible Nek2 inhibition might be achievable through the 
inclusion of electrophilic groups at this position (Figure 21).  
 
Figure 21 - Design of oxindole based irreversible inhibitors of Nek2.185 
A structure-based design approach led to the synthesis of a small library of 
compounds based upon 27, with a range of electrophilic groups at the oxindole 6-
position. These included chloromethylketone 28, chloroacetamide 29, and a range of 
compounds containing Michael acceptor groups 30-34 (Figure 22). Of these, 
propyneamide 34 and chloromethylketone 28 were found to be the most potent, with 
IC50 values of 920 nM and less than 6 nM, respectively.
185 
27 
  
 
Not visible in 
structure 
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Figure 22 - First generation irreversible Nek2 inhibitors.185 
Unfortunately, these compounds were found to be non-selective and were also low-
nanomolar inhibitors of CDK1. To attempt to improve selectivity, further modifications 
were investigated leading to the discovery of alkylimidazole 35. This compound was 
found to retain Nek2 inhibitory activity (IC50 = 700 nM) and demonstrated excellent 
selectivity over CDK1 (IC50 = >20 µM), which was found to be due to the presence of 
the ethyl substituent on the imidazole ring. Covalent modification of Cys-22 within the 
Nek2 ATP-binding domain was confirmed by time-dependent inhibition studies and 
mass-spectrometry analysis of 35 bound to Nek2. Additionally, site-directed 
mutagenesis studies with the Nek2 C22V mutant (Cys-22 → Val-22), demonstrated 
a substantial reduction of Nek2 inhibitory activity of 35 compared with wild-type 
Nek2.185  
 
Finally, in vitro immunoprecipitation kinase assays in A549 lung cancer cells, showed 
that 35 inhibited cellular Nek2 (92% at 5 µM). Interestingly, it was observed that 
despite inhibition of Nek2, these cells were able to enter mitosis and form intact 
bipolar spindles. These results suggest that Nek2 is either not essential for entry into 
mitosis, or that only low levels of Nek2 are required for mitotic progression.185 
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4.10 Purines as Irreversible Inhibitors of Nek2 
The use of the purine heterocycle as a basis for Nek2 inhibitors arose from X-ray 
crystal structural analysis of the interaction between the pyrrole-indolinone 
compound SU11652 27 with the Nek2 ATP-binding site (Figure 23). SU11652 was 
designed as an ATP-competitive tyrosine kinase inhibitor; however, activity had also 
been observed for a variety of serine/threonine kinases including Nek2.186 The 
crystal structure of 27 bound to Nek2 three key H-bond interactions with the Nek2 
Hinge region (Figure 24).152 In addition to this, hydrophobic interactions are observed 
with the Met-86 gatekeeper residue. Both 27 and its fluorine derivative SU11248 36, 
demonstrated activity against Nek2 but poor kinase selectivity.152   
 
Figure 23 - H-bond interactions of 23 and 32 with Nek2 ATP-binding domain.152 
 
Figure 24 - Comparison of 27 with a purine template. 
As CDK2 and Nek2 are both members of the serine/threonine family of protein 
kinases, their ATP-binding domains have a degree of structural homology. It was 
established that that CDK2 could be inhibited by functionalised purines, which form a 
SU11652 
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H-bond triplet with amino acids of the hinge region of the ATP-binding domain, and it 
was thought that these compounds may also have Nek2-inhibitory activity.187 A 
screen of purine-based CDK2 inhibitors against Nek2, revealed NU6102 37 (see 
chapter five) as a modest inhibitor of Nek2 (IC50 = 20.9 μM) with potent CDK2 
inhibitory activity (IC50 = 5 nM). As such, 37 was selected as a hit compound with the 
aim of designing out CDK2 activity to give a potent and selective inhibitor of Nek2. 
37 was thought to act as a reversible inhibitor of Nek2 by competing for the ATP-
binding domain. In this instance, it was known that the Nek2 ATP-binding domain 
contained a cysteine residue (Cys-22) that was not present in CDK2. It was 
hypothesised that the thiol group of Cys-22 may be correctly orientated to allow 
covalent reaction with a bound purine that contained an electrophilic ethynyl group at 
the 6-position. The conjugate addition of sulfur containing nucleophiles to 6-ethynyl 
purines had been demonstrated previously by Hocek.188 However, to our knowledge 
this approach to irreversible enzyme inhibition had not been reported previously. To 
synthesise an irreversible inhibitor of Nek2 it was necessary to design a compound 
that could covalently modify the Nek2 ATP-binding domain, thus permanently 
preventing binding of the natural substrate. As the crystal structures of both CDK2 
and Nek2 had already been determined it was possible to utilise a structure-based 
approach for the design of an irreversible inhibitor of Nek2 with selectivity over 
CDK2. Traditional drug design has often adopted a random approach involving the 
screening of numerous compounds. By contrast, an intelligent design approach uses 
structural biology to identify key structural features within the binding site of the 
target enzyme or receptor. Ligands can then be designed with the assistance of 
bioinformatics and molecular modelling to contain functional groups correctly 
positioned to interact with these motifs with the aim of producing a potent selective 
inhibitor.189 This approach led to the discovery of the 6-ethynylpurine 40 (see chapter 
five), which is a potent Nek2 inhibitor (IC50 = 56 nM) with excellent selectivity over 
CDK2 (IC50 = 11.8 µM). 
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Chapter Five: Synthesis of Purine Isosteres as Inhibitors of Nek2  
5.1 Development of Purine-Based Irreversible Inhibitors of Nek2 
 
Figure 25 - Development of purine based Nek2 inhibitors at the NICR. 
A medium-throughput screen of approximately 250 compounds identified 6-
alkoxypurines as modest inhibitors of Nek2. Purine 37, a potent CDK2 inhibitor (IC50 
= 5.0 nM), demonstrated Nek2 inhibitory activity in the micromolar range (IC50 = 20.9 
µM). Investigations into modification of the 2-arylamino and 6-alkoxy groups led to 
the identification of 38. This compound was a potent inhibitor of Nek2 (IC50 = 140 
nM) with 6-fold selectivity over CDK2. Interestingly, 38 exhibited a time-dependent 
Nek2 inhibition profile characteristic of irreversible enzyme inhibition. However, 38 
was essentially inactive in cells due to poor physicochemical properties. Removal of 
the sulfonamide functionality gave 39, which was a potent Nek2 inhibitor (IC50 = 150 
nM) with selectivity over CDK2 and displayed growth inhibitory activity in vitro (GI50; 
SKBR3 cells = 0.33 µM). This compound was taken forward as an early hit, assayed 
in the ‘Dundee Kinase Screen’ against a panel of 121 kinases, and found to be 
remarkably selective for Nek2. Unfortunately, 39 had sub-optimal cellular properties 
including high lipophilicity (cLogP = 2.93) and poor aqueous solubility. A structure-
based design approach led to the discovery of 40 a potent and selective irreversible 
Nek2 inhibitor with good cellular growth-inhibitory activity (GI50; SKBR3 cells = 2.2 
µM) and acceptable drug-like properties. The additional acetamide functional group 
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possibly serves to make H-bond interactions with Ser-96 and Asp-93 within the Nek2 
ATP-binding domain (Figure 26).  
 
Figure 26  X-ray crystal structure showing irreversible covalent modification of Cys-
22 within the Nek2 ATP-binding domain by 40. 
 
5.2 Nek2 Putative Binding Mechanism 
 
Figure 27 – Mechanism of Nek2 inactivation by 6-ethynylpurines. 
The 6-ethynylpurine series has been shown to irreversibly inhibit Nek2 through 
covalent modification of Cys-22 within the Nek2 ATP-binding domain. An initial 
reversible ATP-competitive binding interaction between the ligand and the Nek2 
hinge region occurs via a triplet of H-bonds (Figure 27). The resulting enzyme-
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inhibitor complex is believed to position the electrophilic 6-ethynyl group at ca. 120o 
relative to Cys-22, which is the optimum angle of nucleophilic attack.190 ‘Partial 
protonation’ of the purine N3 via a H-bond may also facilitate covalent 
modification.191 The covalently bound ligand occupies the Nek2 ATP-binding domain 
causing irreversible inactivation of Nek2. 
 
5.3 Reversibility of the Nek2-Cys-22 Covalent Complex 
Rather than being true irreversible inhibitors of Nek2 it has been suggested that 6-
ethynylpurines such as 39 may form an initial covalent complex that is slowly 
hydrolysed to give the aldehyde 46 (Figure 28). Indeed, preliminary studies have 
identified a compound with a mass suggesting the presence of 46; however, further 
work is required to confirm this. 
  
Figure 28 - Putative mechanism for the hydrolysis of the Nek2-inhibitor complex. 
An example of this type of enzyme inhibition occurs with physostigmine 47, a 
carbamate-based reversible acetylcholinesterase (AChE) inhibitor.192 The 
mechanism of action of this drug is shown in Figure 29. A reversible enzyme-inhibitor 
complex forms, which is followed by carbamylation of the serine hydroxyl group of 
AChE causing irreversible enzyme inhibition. The covalently bond between the 
enzyme and the inhibitor is then hydrolysed to give the active enzyme, methylamine 
and CO2.
193 
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Figure 29 - Inhibition of AChE by physostigmine. 
Additionally, early work by Pritchard et al. showed that it was possible to react N-
butanethiol with 2-cyanoacrylates at physiological pH via an addition-elimination 
reaction.194 However, attempts to isolate or characterise products proved 
unsuccessful, possibly due to the reaction being rapidly reversible.194,195 Recently, 
this has been further investigated through the design of reversible covalent inhibitors 
of p90 ribosomal protein S6 kinase (RSK2) using acrylamide-based 
pyrrolopyrimidines (48-51).195 
 
A benefit of ‘reversibly’ targeting enzymes with electrophiles is that the advantages 
of irreversible inhibitors are often retained, e.g. high selectivity and long residence 
times, whilst disadvantages such as toxicity associated with covalent modification 
may be reduced.77,195  
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5.4 Structure-Activity Relationship Studies with 6-Ethynyl-2-
Phenylaminopurine (39) 
A series of 2-arylaminopurine derivatives was synthesised to further evaluate the 
importance of H-bond interactions in the initial non-covalent binding interaction with 
Nek2. The first compounds to be synthesised were the N7- and N9-methylpurines 52 
and 53, which allowed investigations into the N9H---O=C (Glu-87) H-bond. The role 
of the 2-NH---O=C (Cys-89) H-bond was evaluated through the synthesis of the 2-N-
methyl- (54), 2-phenoxy- (55) and 2-benzyl- (56) purine derivatives respectively 
(Figure 30). 
 
Figure 30 – SAR studies of purine 39.  
5.4.1 Synthesis of N7- and N9-Methyl-2-Phenylaminopurines (52) and (53) 
The N7- and N9-methyl derivatives of 39 were synthesised to further investigate the 
binding mode of this series of compounds, and provided inactive control compounds 
for further biological evaluation. Methylation at the N7- or N9-position removes a 
crucial H-bond between the purine and the hinge region of the Nek2 ATP-binding 
domain (Figure 31). This bond is likely critical for Nek2 inhibition as it positions the 
substrate in an orientation that facilitates attack of Cys-22 on the 6-ethynyl group. 
This approach was used previously within the group during the design of CDK2 
inhibitors.196  
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Figure 31 -  Methylation of 39 a removes crucial hydrogen bond.  
 
 
Reagents and conditions: i) NaNO2, HBF4, 0 
o
C – RT, 18 h; ii) MeI, K2CO3, DMF, RT, 18 h. 
Scheme 1. 
 
The Balz-Schiemann reaction allows the conversion of aromatic amines into the 
respective fluoro derivative via a diazonium intermediate.197 Traditionally this 
reaction is performed in a two-step procedure, with isolation of the diazonium 
intermediate as the tetrafluoroborate salt, followed by heating to induce 
fluorodediazoniation.198 Whilst this method can facilitate the preparation of aryl 
fluorides in good yield, the hazards associated with heating large quantities of a 
diazonium salt and the poor yields obtained with thermally sensitive substrates made 
this method unsuitable for the conversion of 57 to 58. Instead, a one-pot approach 
using NaNO2 in HBF4(aq) was used, allowing the preparation of 58 in 67% yield.
198  
Direct N-methylation of fluorochloropurine 58 using methyl iodide in basic conditions, 
gave an inseparable mixture of the N7- and N9-methylpurines 59 and 60 in a ratio of 
1:2, respectively (observed by 1H-NMR spectroscopy). The mixture of 59 and 60 was 
used in the Sonogashira cross coupling of TIPS-acetylene, which allowed separation 
of regioisomers 61 and 62 with an overall yield of 76%.  
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Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 
18 h. 
Scheme 2. 
 
The Sonogashira reaction allows the coupling of terminal acetylenes with aryl 
halides. The reaction involves the application of a palladium (0) (Pd0) complex which 
can be used directly or generated in situ through oxidation of palladium (II) (PdII). 
Copper (I) iodide (CuI) is added as a co-catalyst, together with an organic base such 
as Et3N to quench acidic side-products and generate the active palladium species 
(Pd0).199 An inert N2 atmosphere is maintained throughout to stabilise the 
intermediate metal complex and prevent oxidation.  
The Sonogashira reaction proceeds through two separate catalytic cycles (Scheme 
3). Copper iodide coordinates to the acetylene (a) which is then deprotonated by 
Et3N allowing generation of the alkynyl copper species and removal of the hydrogen 
halide side-product (b). Simultaneously, Pd(0) oxidatively inserts into the aryl-halide 
species forming the Pd(II) intermediate (c). A transmetalation reaction occurs 
between alkynyl-copper and the newly formed Pd(II) complex  resulting in 
transmetallation and regeneration of copper (I) iodide (d). Finally, reductive 
elimination results in product formation and regeneration of the palladium catalyst 
(e).199 
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Scheme 3 - Sonogashira cross-coupling mechanism. 
 
Reagents and conditions: i) PhNH2, TFA, TFE, 75 
o
C, 18 h; ii) TBAF, THF, RT, 30 min. 
Scheme 4. 
An acid-catalysed SNAr reaction allowed coupling of aniline to 61 and 62, giving 2-
arylaminopurines 63 and 64 in moderate (55%) to excellent (74%) yield, respectively. 
The use of TFE as a solvent in this reaction is advantageous as it is thought to allow 
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solvation of fluoride, resulting in increased reactivity.200,201 It was determined that 2.5 
equivalents of TFA was optimum to catalyse the reaction, and this quantity of TFA 
allows protonation of purine N1 or N3 (pKa = 2.5) with minimal protonation of the less 
basic aniline NH2 (pKa = 4.6). The final stage of this synthesis was deprotection of 
the terminal acetylene from 63 and 64. The TIPS protecting group can be readily 
removed with fluoride and a convenient source of fluoride is TBAF, which has 
advantages over other sources of fluoride such as HF and KF in terms of safety and 
solubility. An interesting finding was that yields for reactions of N7-methylpurines 61 
and 63 were lower than those observed in the synthesis of the N9-methylpurine 53, 
which is likely due to reduced stability for reasons that remain unclear. 
 
5.4.2 Synthesis of N-Methylanilinopurine (54) 
The N-methyanilinopurine derivative 54 was synthesised to address the role of the 2-
arylamino NH of parent purine 39, which forms a H-bond interaction with Cys-89 of 
the Nek2 ATP-binding domain. If this H-bond was found to be unnecessary for 
inhibitor binding, the possibility of further modification at this position was to be 
investigated.  
  
Reagents and conditions: i) N-Methylaniline, TFA, TFE, 75 
o
C, 18 h. 
Scheme 5. 
Coupling of N-methylaniline with purine 65 under standard conditions (Scheme 5) 
proved unsuccessful owing to multiple side-products, the most prominent of which 
was the TFE ether 67.  
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Reagents and conditions: i) N-Methylaniline, TFA, Toluene, MW 160 
o
C, 4 h. 
Scheme 6. 
Replacement of TFE by toluene proved an effective solution to this problem as it is 
non-nucleophilic and has a comparable boiling point (111 oC). It was also found that 
this reaction benefitted from microwave heating, allowing formation of 64 in a yield of 
68% (Scheme 6). 
 
5.4.3 Synthesis of 2-Phenoxypurine (55) 
To further investigate the role of the purine C2-NH in the binding interaction, the 2-
phenoxypurine derivative 55 was synthesised. In this compound, the donor aniline 
NH is replaced by an acceptor oxygen. The phenoxy moiety was also predicted to 
attenuate reactivity of the ethynyl group via electron donation to the purine. By 
making the ethynyl group less reactive it was hoped that selectivity for Nek2 would 
be improved. 
 
Reagents and conditions: i) Phenol, TFA, TFE, 85 
o
C, 18 h; ii) Phenol, TFA, Toluene MW 160 
o
C, 4 
h; iii) Phenol, MW 180 
o
C, 1 h; iv) Phenol, NaH, THF, 80 
o
C, 30 min. 
Scheme 7. 
Initial attempts to couple phenol directly with purine 65 were unsuccessful, resulting 
in little if any product formation alongside a multitude of side-products. The standard 
TFA/TFE coupling conditions that worked well for reactions with anilines, failed when 
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phenol was the substrate, owing to displacement of fluoride by trifluoroethanol to 
give 67. Using toluene in place of TFE resulted in no observed reaction, even with 
prolonged heating at high temperatures (160 oC, 8 h). In addition, modifying the 
number of equivalents of TFA used to catalyse the reaction was investigated. 
However, even with 20-equivalents of TFA no product formation (68) was observed. 
An alternate approach was to generate phenoxide using a base, thus enhancing 
nucleophilicity. Literature examples using this method are reportedly high yielding 
and rapid, but in this case only degradation was observed, possibly due to instability 
of the TIPS protecting group of 65. 
As phenol was too unreactive for an acid-mediated coupling reaction and base 
catalysed reactions led to degradation, a mild Pd catalysed approach was 
investigated.  
 
Reagents and Conditions: i) PMBCl, K2CO3, DMF, 65 
o
C, 18 h; ii) TIPS-acetylene, Pd(PPh3)Cl2 (5 
mol%), CuI (5 mol%), Et3N, THF, RT, 18 h; iii) Benzyltriethylammonium nitrite, TMSCl, DCM; iv) 
Phenol, K3PO4, Pd(OAc)2 (2 mol%),  XPhos (3 mol%), Toluene, 100 
o
C, 1 h; v) TFA, 75 
o
C, 3 h; vi) 
TBAF, THF, RT, 2 h. 
Scheme 8. 
The 9-position of 2-amino-6-chloropurine 69 was protected as the PMB derivative 70 
using standard conditions.202 This resulted in an inseparable mixture of PMB-
regioisomers of the N7- and N9-products in a 1:9 ratio, respectively, (observed by 1H-
NMR spectroscopy).  This mixture was taken forward into the Sonogashira reaction, 
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which did not reach completion even after additional catalyst and further equivalents 
of TIPS-acetylene were added. It was interesting to note that only a single product 
71 was isolated, suggesting that the N7-PMB regioisomer was unreactive owing to 
the proximity of the bulky protecting group to the 6-chloro substituent of 67. A 
modified Sandmeyer reaction was then performed using benzyltriethylammonium 
nitrite (BTEA.NO2), which gave 2-chloropurine 72.
203 
 
Scheme 9 - Generation of nitrosyl chloride from benzyltriethylammonium nitrite 
There is much debate over the mechanism of the copper-free Sandmeyer reaction, 
although the reaction is thought to be initiated through the generation of nitrosyl 
chloride, which in this case may be formed from the reaction of 
benzyltriethylammonium nitrite with TMSCl (Scheme 9).204 
Scheme 10 - Chlorodediazotisation reaction mechanism 
A diazotisation reaction occurs by reaction of 2-aminopurine 71 with nitrosyl chloride. 
This results in the charged species 74, which is deprotonated by TMSO- to form 
nitrosamine 75, and tautomerizes to give 76. A protonation occurs followed by loss of 
water to form diazonium 78. Finally an SNAr reaction with endogenous chloride 
causes loss of dinitrogen and formation of 2-chloropurine 72.204 This method of 
chlorodediazotisation is particularly suited to substrates such as 71, due to the mild 
reaction conditions, which allowed preparation of 72 in 72% yield.  
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A Buchwald-Hartwig etherification205 of 72 allowed rapid coupling of phenol in a yield 
of 72%, and the PMB protecting group of 73 was then removed with TFA. Finally, the 
TIPS protecting group of 68 was removed with TBAF to give 6-ethynylpurine 55 in 
near quantitative yield (99%). 
5.4.4 Synthesis of 2-Benzylpurine (56) 
The final modification at the C2 position to be investigated was the replacement of 
the aniline NH of 39 with a methylene group to give 2-benzylpurine 56. It was hoped 
that the non-conjugated benzyl group would potentiate the reactivity of the 6-ethynyl 
group towards electrophiles. Additionally, removal of the aniline NH renders this 
compound an excellent probe molecule to further investigate the importance of the 
aniline H-bond interaction. 
Reagents and Conditions: i) Phenylacetic acid, EDC.HCl, DMAP, Pyridine/DMF, 70 
o
C, 18 h; ii) 
NaOH (2 M), 100 
o
C, 1 h; iii) SOCl2, DMF, CHCl3, 65 
o
C, 2 h; iv) Boc2O, DMAP, DCM, RT, 1 h; v) 
TIPS-acetylene, Pd(PPh3)Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 4 h; vi) TFE, 85 
o
C, 3 h; vii) 
TBAF, THF, RT, 15 min. 
Scheme 11. 
The reaction scheme was designed to allow rapid synthesis of 56 in high yield using 
a modification of an established synthetic route.196,206  
 
Reagents and conditions: i) Phenylacetic acid, EDC.HCl, DMAP, DMF, Pyridine, 70 
o
C, 18 h; ii) 2 M 
NaOH, 100 
o
C, 30 min.  
Scheme 12. 
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The first stage of the reaction scheme was the formation of the purine heterocycle 
using a modified literature procedure.206 EDC was chosen as the coupling agent due 
to the aqueous solubility of the starting material and by-product, which simplified 
purification.  
 
Reagents and conditions: i) POCl3, 110 
o
C, 3h. 
Scheme 13. 
An initial attempt to chlorinate the purine 6-position of 81 was made using standard 
conditions employing POCl3. A small amount of 2-benzylpurine 82 was observed by 
LC-MS and TLC; however, the major reaction product was the homodimeric 
compound 85. After aqueous workup, none of the desired product 82 remained in 
the reaction mixture and the homodimeric product 85 was isolated in 46% yield. It is 
likely that the acidic conditions of the reaction, and subsequent aqueous work-up, 
catalyse formation of 85 via protonation of the purine N1- or N3-positions.  
 
Reagents and conditions: i) SOCl2, DMF, CHCl3, 65 
o
C, 90 min; ii) Boc2O, DMAP, DCM, RT, 18 h. 
Scheme 14. 
Milder reaction conditions were achieved using SOCl2 and DMF in chloroform.
206 
The reaction proceeds through the in situ generation of the Vilsmeier reagent and 
resulted in 80% of 82 with no observable formation of the undesired homodimeric 
product 85. However, a disadvantage of using DMF in a chlorination reaction such 
as this is that dimethylcarbamoyl chloride (DMCC) is formed, which is a potential 
human carcinogen.207  
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Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 4 
h; ii) TFE, 85 
o
C, 3 h; iii) TBAF, THF, RT, 15 min. 
Scheme 15. 
The purine N9-position of 83 was then protected as the Boc carbamate in 76% yield. 
A Sonogashira reaction using standard conditions coupled the TIPS-ethynyl group to 
give 84. The Boc protecting group was removed through thermolytic cleavage using 
TFE as a solvent. An advantage of this deprotection method was that all unwanted 
by-products are volatile and were thus removed by evaporation to give 2-
benzylpurine 86 in 91% yield.208 The final stage of this reaction scheme was removal 
of the TIPS protecting group using TBAF in THF to furnish 56 in almost quantitative 
yield. 
 
5.5 Synthesis of Purine Isosteres 
A major aim of this project was to investigate alternative heterocycles to the purine 
as irreversible inhibitors of Nek2. These compounds allow entry into novel patent 
space, and in many cases provide new vectors which can be further functionalised. 
These include the C6-position of imidazopyridine 87, the C5- and C6-positions of 
pyrrolopyrimidine 88, and C3-position of pyrazolopyrimidine 89 (indicated in red), 
which may lead to more potent inhibitors. It was hoped that by altering the number of 
nitrogen atoms in the heterocycle it would also be possible to modulate the reactivity 
of the electrophilic ethynyl group, to balance Nek2 reactivity with selectivity over 
endogenous thiol containing proteins. A further consequence of changing the 
heterocycle was that physicochemical properties such as LogP and topological polar 
surface area (tPSA) could be modified without significantly altering the overall shape 
of the ligand. This may allow discovery of a potent Nek2 inhibitor with improved 
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pharmacokinetics, and hence more favourable drug-like properties than the parent 
purine 39. 
 
Figure 32 – Alternative heterocycles as inhibitors of Nek2. 
 
5.5.1 Synthesis of Imidazo[4,5-b]pyridine (87)  
 
Removal of the purine N1 nitrogen to give the imidazopyridine core heterocycle alters 
the electronic character of the ring system by increasing electron density. A direct 
consequence of this should be attenuation in reactivity of the conjugated electrophilic 
ethynyl group towards nucleophiles. This can be useful in the design of electrophilic 
irreversible inhibitors, and allows the potential to fine-tune reactivity away from 
endogenous nucleophiles such as GSH whilst maintaining target activity. 
Additionally, by exchanging the pyrimidine ring for a pyridine the C6 position is 
Chapter Five 
 
85 
available for further functionalisation. It is interesting to note the difference in 
calculated tPSA and cLogP between the more lipophilic imidazopyridine 87 and the 
parent purine 39 (Figure 33). 
 
Figure 33 - Comparison of the calculated physicochemical properties of purine 39 
and imidazopyridine 87. 
Little literature precedent exists for the synthesis of 5,7-bifunctionalised 
imidazopyridines, and a literature search revealed no compounds that contain an 
ethynyl functionality at the 7-position. The difficulties encountered during the 
synthesis of compound 87 perhaps help to explain why this heterocycle is less 
studied than the corresponding purine. 
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Reagents and Conditions: i) (EtO3)CH, TFA, TFE, MW 140 
o
C, 15 min; ii) mCPBA, CHCl3, RT, 18 h; 
iii) POCl3, MW 140 
o
C, 15 min; iv) Boc2O, DMAP, THF, RT, 3 h; v) TBAN, TFAA, DCM, 0 
o
C, 1 h; vi) 
RaNi, H-cube (40 
o
C, 1 mL/min), 0.05 M solution in DCM; vii) NaNO2, HBF4, 0 
o
C-RT, 1 h; viii) DHP, 
CSA, EtOAc, 60 
o
C, 18 h; ix) TIPS-acetylene, Cs2CO3, PdCl2(MeCN)2 (10 mol%), XPhos (30 mol%), 
MeCN, 80 
o
C, 2 h; x) TFA, IPA, H2O, 100 
o
C, 18 h; xi) PhNH2.HCl, TFE, 100 
o
C, 7 days; xii) TBAF, 
THF, RT, 5 min. 
Scheme 16. 
A synthetic strategy was developed for the preparation of imidazopyridine 87 based 
upon syntheses developed by Schelling et al. and Deghati et al.209,210 The first stage 
of this reaction scheme entails formation of the imidazo[4,5-b]pyridine core 
heterocycle. Several attempts were made using literature procedures (Scheme 17), 
none of which produced satisfactory results and often lead to multiple side-products 
and difficult isolation.211 
 
Reagents and conditions: i) (EtO)3CH, 150 
o
C, 3 h; ii) (EtO)3CH, 3 Å molecular sieves, DMF,  220 
o
C, 1 h; iii) 2-(ethoxymethylene)malononitrile, AcOH, 120 
o
C, 1 h. 
Scheme 17. 
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Reagents and conditions: i) (EtO)3CH, TFA, TFE, MW 140 
o
C, 15 min. 
Scheme 18. 
By using triethyl orthoformate 114 in TFE with a catalytic amount of TFA (5 mol%) it 
was possible to prepare imidazopyridine 103 in almost quantitative yield. Although 
this reaction proceeds well using conventional heating, it was found that with 
microwave assisted heating the reaction was accelerated and produced less of the 
imine intermediate 119 observed as a side-product (Scheme 19). 
Scheme 19 – Formation of imidazo[4,5-b]pyridine heterocycle. 
The reaction is initiated by loss of EtOH from 114 to give the reactive oxonium 
species 115. One of the exocyclic amine groups from pyridine 102 then attacks via a 
nucleophilic addition to form hemiacetal 117. The hemiacetal is protonated by TFA 
followed by E2 elimination of EtOH to form iminium 119. An intramolecular cyclisation 
occurs, followed by proton transfer to furnish tetrahedral intermediate 121. Finally, an 
elimination of ethanol gives imidazopyridine 103. 
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Reagents and conditions: i) mCPBA, CHCl3, RT, 18 h; ii) POCl3, MW 140 
o
C, 15 min; iii) Boc2O, 
DMAP, THF, RT, 3 h. 
Scheme 20. 
To allow functionalisation, the imidazopyridine N-oxide 104 was prepared by reaction 
of imidazopyridine 103 with mCPBA.212 The N-oxide 104 is a dipolar species and the 
electrons of the oxygen atom are delocalised into the pyridine ring system (Scheme 
21). The overall result of this is activation of the ortho- and para-positions of the 
pyridine ring to electrophilic attack.  
 
Scheme 21 - Imidazopyridine N-oxide resonance structures (adapted from Ochi).213 
Treatment of imidazopyridine N-oxide 104 with POCl3 gave a 2:1 mixture of the para- 
and ortho-chloroimidazopyridines, respectively, which were separated by selective 
precipitation resulting in imidazopyridine 105 in 41% yield.211 The imidazole nitrogen 
was then protected as the carbamate to furnish 106 in good yield (80%). 
 
Reagents and conditions: i) TBAN, TFAA, DCM, 0 
o
C, 1 h. 
Scheme 22. 
Mild regioselective nitration of 106 with tetra-N-butylammonium nitrate (TBAN) and 
trifluoroacetic anhydride (TFAA)  gave nitro compound 107.210 Interestingly, when 
the N3 position was protected with THP rather than Boc no reaction was observed, 
suggesting the electron-withdrawing carbamate group may facilitate nitration. 
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Scheme 23 – Radical mediated nitration of imidazopyridine 106.214 
It was originally speculated that the reaction was initiated by the homolytic cleavage 
of trifluoroacetyl nitrate formed during the TBAN/TFAA reaction, resulting in the 
generation of nitro and a trifluoroacetyl radicals.210 However, more recent studies 
revealed that trifluoroacetyl nitrate reacts directly with 106 forming the 7-nitramine 
intermediate 124 (Scheme 23).214 124 undergoes homolytic cleavage, resulting in 
formation of .NO2 and the aryl radical 125, which react through a radical termination 
to form tetrahedral intermediate 126. Interestingly, the nitration of 106 is selective for 
the 2-position due to stabilisation of the aryl radical by the para-chloro 
substituent.210,214 The final step of this reaction mechanism is liberation of TFA from 
the unstable intermediate 126 to give the desired product 107. 
 
Reagents and conditions: i) RaNi, H-cube (40 
o
C, 1 mL/min), 0.05 M solution in DCM; ii) NaNO2. 
HBF4(aq), 0 
o
C – RT, 1 h. 
Scheme 24. 
The nitro group of 107 was reduced to the respective amine using an H-cube® 
continuous flow hydrogenation unit. 7-Chloro-5-fluoroimidazopyridine 108 was 
prepared in a reasonable overall yield of 44% through a one-pot tandem carbamate 
deprotection and fluorodediazotisation sequence using Balz-Schiemann conditions.   
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Reagents and conditions: i) DHP, CSA, EtOAc, 60 
o
C, 18 h; ii) TIPS-acetylene, Cs2CO3, 
PdCl2(MeCN)2 (10 mol%), XPhos (30 mol%), MeCN, 80 
o
C, 2 h. 
Scheme 25. 
The imidazopyridine NH of 109 was protected as the THP-derivative 110. A 
Sonogashira reaction of 110 was attempted unsuccessfully using standard 
Pd(PPh3)Cl2 / CuI conditions. It is possible that failure of this reaction was due to the 
electron rich nature of the imidazopyridine ring system of 110, which prevents 
palladium insertion. It has been suggested that the rate determining step of the 
Sonogashira reaction is initial oxidative addition of the Pd0 into the Ar-halogen 
bond.215 An end-on ligation of the halogen to the palladium is believed to precede 
this and could be viewed as electron donation. Therefore electron-rich substrates are 
likely to form a more stable Pd complex, requiring greater activation energy to 
proceed to the subsequent oxidative addition stage of the cycle. The reaction was 
heated, but this led to decomposition of the starting material (110). 
Alternative conditions were sought, and a copper-free method developed by 
Buchwald et al. for coupling terminal acetylenes and electron rich heteroarenes 
proved a suitable alternative, allowing the synthesis of 111 in near quantitative 
yield.215 A disadvantage of the copper based Sonogashira reaction is the potential 
for Glaser oxidative dimerization of terminal acetylenes.216 Replacement of CuI with 
a suitable ligand eliminates this side reaction. 
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Scheme 26 - Copper free Sonogashira coupling of terminal acetylenes with aryl 
halides.217 
The mechanism for the copper-free Sonogashira reaction of terminal acetylenes 
compounds with aryl halides (Scheme 26) is likely to proceed via a mechanism 
similar to the traditional Sonogashira reaction. The reaction is initiated by oxidative 
addition of Pd0 into the aryl halide (a) followed by a reversible coordination of the 
alkyne -system to the palladium complex (b) resulting in an alkyne-Pd(II) complex. 
The now acidic, acetylene proton is removal by a base, for example Et3N, allowing 
ligand coordination (c). A cis/trans isomerisation occurs (d) followed by reductive 
elimination (e), which reforms the active Pd0 species and releases the newly formed 
arylethynyl product.  
  
Reagents and conditions: i) TFA, IPA, H2O, 100 
o
C, 18 h; ii) PhNH2.HCl, TFE, 100 
o
C, 7 days; iii) 
TBAF, THF, RT, 5 min. 
Scheme 27. 
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Removal of the THP protecting group from 111 was achieved in 92% yield.218 
Displacement of the 5-fluoro group of 112 with aniline using standard TFA/TFE 
conditions was unsuccessful, and gave no observable product formation. However, 
reaction of 112 with aniline hydrochloride in TFE was successful, albeit slow, 
resulting in 113 in 78% yield.  
The final stage of this reaction scheme was the TBAF-mediated deprotection of 113 
to give imidazopyridine 87. The reaction was successful; however, after purification 
1H-NMR spectroscopy confirmed TBAF contamination of the product. Residual TBAF 
was removed using a calcium sulfonate scavenger resin, which had been developed 
previously to address this problem.219 It is likely that residual TBAF from the reaction 
mixture coordinates to either the ethynyl group or a heterocyclic nitrogen atom of 87. 
Addition of the scavenger resin removes TBAF from the reaction mixture by forming 
calcium fluoride and polymeric tetrabutylammonium sulfonate (Scheme 28), which 
are removed by filtration.219,220 
 
Scheme 28 - Removal of TBAF contamination with calcium sulfonate resin.220 
 
5.5.2 Synthesis of 7H-Pyrrolo[2,3-d]pyrimidines (88) and (231) 
 
The second deazapurine compound to be investigated was the pyrrolopyrimidine 88. 
In this compound, the role of the purine N7 was investigated. Compared with the 
imidazopyridine 87, removal of this nitrogen should lead to attenuation of ethynyl 
reactivity due to increased electron density. However, it was unclear if this nitrogen 
was essential for Nek2-inhibitory activity. Calculated tPSA and cLogP values (Figure 
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34) are almost identical to those obtained for imidazopyridine 87, showing the 
increased lipophilicity of pyrrolopyrimidine 88 compared with the parent purine 39. 
 
Figure 34 - Comparison of the calculated physicochemical properties of purine 39 
and pyrrolopyrimidine 88. 
Reagents and Conditions: i) HCl(aq), 90 
o
C, 30 min; ii) 133, NaOAc, 100 
o
C, 5 h; iii) PhPOCl2, 220 
o
C, 5 h; iv) TsCl, DMAP, Et3N, DCM, RT, 1 h; v) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 
mol%), Et3N, THF, RT, 48 h; vi) PhNH2, TMSCl, n-BuOH, 116 
o
C, 72 h; vii) Cs2CO3, MeOH, THF, 0 
o
C, 18 h; viii)  TBAF, THF, RT, 15 min. 
Scheme 29. 
Bromoacetaldehyde was prepared in situ through hydrolysis of bromoacetaldehyde 
diethylacetal 127 using aqueous HCl. 2-Aminouracil 133 was then added to give 
pyrrolopyrimidine 128 in 67% yield. A proposed reaction mechanism is shown in 
Scheme 30. In the first stage of this reaction an electrophilic aromatic substitution of 
133 with bromoacetaldehyde occurs, followed by intramolecular cyclisation and loss 
of water gave imine 139, which tautomerizes to the more stable 2-
hydroxypyrrolopyrimidine 128.221 
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Scheme 30 – Formation of 7H-pyrrolo[2,3-d]pyrimidine (128) 
An alternative mechanism for this reaction could be for the exocyclic NH2 of 133 to 
attack the CHO of bromoacetaldehyde first, followed by an intramolecular SN2 
reaction. It would be interesting to monitor this reaction in situ using 1H-NMR 
spectroscopy, to gain a detailed understanding of the reaction mechanism through 
the identification of key intermediates.  
 
Reagents and Conditions: i) PhPOCl2, 220 
o
C, 5 h. 
Scheme 31. 
The next stage of the reaction scheme involved chlorination of pyrrolopyrimidine 128. 
This reaction was attempted using phosphorus oxychloride (POCl3) as a chlorinating 
agent, but there were multiple side-products and low product formation was 
observed. Refluxing in POCl3 is one of the most common methods for performing 
chlorodehydroxylation reactions. This method is useful but limited by the somewhat 
low boiling point of POCl3 (107 
oC) which can be insufficient for some reactions. A 
solution to this problem is to heat the reaction mixture in a sealed vessel, or more 
recently through microwave irradiation. Both methods allow higher temperatures, but 
the hazards and impracticalities involved in the scale-up of such techniques limited 
their usefulness for this particular reaction. An alternative to POCl3 is phosphorus 
pentachloride (PCl5), which has a much higher boiling point (180 
oC) but this reagent 
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can also act as an oxidative chlorinating agent through displacement of aromatic 
protons. Using phenylphosphonic dichloride (PhPOCl2) solves both problems as it is 
a non-oxidative chlorinating agent that boils at 258 oC.222 In this reaction PhPOCl2 
was used successfully to synthesise the dichloropyrrolopyrimidine 129 from 128 in 
53% yield.  
Reagents and conditions: i) TsCl, DMAP, Et3N, DCM, RT, 1 h; ii) TIPS-acetylene, Pd(PPh3)2Cl2 (5 
mol%), CuI (5 mol%), Et3N, THF, RT, 48 h; iii) PhNH2, TMSCl, n-BuOH, 116 
o
C, 72 h. 
Scheme 32. 
THP protection of the pyrrolopyrimidine 7-NH was unsuccessful; however, tosyl 
protection proved a suitable alternative to give 130 in 88% yield. The next stage of 
the reaction scheme was the regioselective Sonogashira coupling of TIPS acetylene 
to 130. Initial concerns over selectivity between coupling at the desired 4-position 
and undesired 2-position of 130 were unfounded. It is likely that this selectivity is due 
to increased electrophilicity of the 4-position making palladium insertion more 
energetically favourable.223 Using standard Sonogashira cross-coupling conditions, 
131 was formed in 85% yield with no observable side-products. Aniline was coupled 
to 131 through an acid catalysed SNAr reaction. A literature procedure using 
trimethylsilyl chloride (TMSCl) in butanol, to generate anhydrous HCl, worked well, 
resulting in 132 in 89% yield, with no observable cleavage of the tosyl or TIPS 
protecting groups.  
 
Reagents and conditions: i) Cs2CO3, MeOH, THF, 0 
o
C, 18 h; ii) TBAF, THF, RT, 15 min. 
Scheme 33. 
The final stages of the reaction scheme entailed removal of the tosyl and TIPS 
protecting groups from 132 and 140, respectively. It was important to remove the 
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tosyl protecting group first to prevent side reactions with the ethynyl group. Standard 
tosyl deprotection methods require harsh conditions, e.g. NaOH in alcohol-based 
solvents at high temperatures, nucleophiles such as Gilman’s reagent (PhMe2SiLi), 
reducing agents including Red-Al or dissolving metal reductions with lithium or 
sodium in ammonia or methanol.224 The presence of the TIPS ethynyl moiety of 132 
makes these methods unsuitable in this case. A mild selective deprotection method 
was achieved using Cs2CO3 in a mixture of MeOH and THF. Methoxide generated in 
situ attacks the sulfonyl group resulting in cleavage of the tosyl protecting group. The 
by-product of this reaction methyl p-toluenesulfonate (MeOTs), reacts further to form 
tosic acid and dimethyl ether.224 Using literature conditions (RT, 15 min) the reaction 
proceeded rapidly, but in modest yield (39%), due to multiple side-products owing to 
TIPS deprotection. By cooling the mixture to 0 oC the reaction progressed more 
slowly (18 h vs. 15 min) but no side-products were observed, and an almost 
quantitative yield of 140 was achieved. Finally the TIPS protecting group was 
removed with TBAF to give 88 in 78% yield. There was concern that the TIPS-
ethynyl group of 88 may have been introduced at the 2-position during the 
Sonogashira reaction (Scheme 32) rather than at the required 4-position. However, 
the X-ray crystal structure of 88 (Figure 35) confirmed that the proposed structure of 
88 was correct. It is interesting to note the H-bond interactions between molecules of 
88 via the pyrrolopyrimidine N1 and N7 positions. 
                      
Figure 35 - X-ray crystal structure of pyrrolopyrimidine 88. 
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Reagents and conditions: i) 290, TMSCl, n-BuOH, 116 
o
C, 72 h. 
Scheme 34. 
Synthesis of the functionalised derivative 141 proved problematic. It was found that 
the SNAr coupling conditions that worked well in the synthesis of 132, resulted in no 
observable product formation even with prolonged reaction times and microwave 
assisted heating (140 oC, 6 h). TFA/TFE coupling conditions were attempted but also 
failed.  
 
Reagents and conditions: i) 290, Pd2(dba)3 (4 mol%), XPhos (4 mol%), K2CO3, MeCN, 80 
o
C, 2 h. 
Scheme 35. 
Buchwald-Hartwig coupling was employed successfully to give a separable mixture 
of the desired product 141 (35%) and the undesired acetamide coupled product 142 
(10%). A literature review of coupling conditions revealed that the choice of ligand 
and Pd source are critical in selectivity during Buchwald-Hartwig type aminations.225 
With further optimisation and careful choice of ligand/catalyst, it is likely that 
selectivity and yield could have been improved substantially. However, as there was 
sufficient material to complete the reaction scheme, this was not investigated further. 
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5.5.3 Synthesis of 1H-Pyrazolo[3,4-d]pyrimidines (89) and (154)  
 
The 1H-pyrazolo[3,4-d]pyrimidine heterocycle has found application as an important 
scaffold in many fields of drug discovery, including oncology, antibacterial research 
and in compounds used to promote histamine release.226 Pyrazolo[3,4-d]pyrimidines 
can in many cases mimic the purine scaffold whilst subtly changing the overall 
electronic character of the heterocycle.227 The C3-position of the pyrazolopyrimidine 
also offers a synthetic ‘handle’ which may be functionalised providing access to 
areas of chemical space previously unavailable. In addition, replacement of the 
imidazole of the purine by a pyrazole may facilitate alternative H-bond interactions. 
Interestingly, calculated tPSA and cLogP values (Figure 36) are very similar to those 
obtained for the parent purine 39 suggesting similar physicochemical properties. It 
was unclear if any difference in reactivity would be observed between the 
pyrazolopyrimidine and purine ethynyl groups, and whether this would impact upon 
Nek2-inhibitory activity.  
 
Figure 36 - Comparison of the calculated physicochemical properties of purine 39 
and pyrazolopyrimidine 89. 
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Reagents and Conditions: i) POCl3, DMF, 110 
o
C, 4 h; ii) N2H4.H2O, MeOH, -30 
o
C, 6 h; iii) DHP, 
CSA, EtOAc, 55 
o
C, 16 h; iv) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 
18 h; v) TFA, TFE, H2O, 100 
o
C, 6 h; vi) PhNH2, TFA, TFE, 100 
o
C, 18 h; vii) TBAF, THF, RT, 15 min.  
Scheme 36. 
Barbituric acid 143 was reacted with freshly prepared Vilsmeier reagent, generated 
in situ reaction of POCl3 and DMF, resulting in formylation of the C
5 position. Further 
heating gave the desired 2,4,6-trichloropyrimidine-5-carbaldehyde 144 (55%).228 
 
Scheme 37 – Formation of the pyrazolopyrimidine heterocycle. 
Cyclisation of 144 with hydrazine hydrate in MeOH was used to generate 
pyrazolopyrimidine 145.228 It is unclear whether the hydrazine first attacks the C5-
formyl group to form the hydrazone intermediate 150 (as shown in Scheme 37), or if 
an SNAr reaction precedes this due to the reactive 4/6 chlorine atoms of the 
pyrimidine ring system. However, as both synthetic routes inevitably lead to 
pyrazolopyrimidin 145, this was not further investigated. 
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Reagents and conditions: i) TsCl, Et3N, DMAP, DCM; ii) TsNHNH2, MeOH, -30 
o
C, 6 h. 
Scheme 38.  
Initial attempts to protect the pyrazole ring NH of 145 as the tosyl derivative 152 
were unsuccessful due to decomposition of both starting materials and product. An 
alternative approach using tosylhydrazide (TsNHNH2) in place of hydrazine hydrate 
at the cyclisation step was also attempted with pyrimidine 144, in an effort to 
introduce the tosyl protecting group. However, this reaction also proved 
unsuccessful.  
 
Reagents and conditions: i) DHP, CSA, EtOAc, 55 
o
C, 16 h. 
Scheme 39. 
THP protection of pyrazolopyrimidine 145 using standard conditions proved a 
suitable alternative to tosyl protection, allowing the preparation of 146 in 79% yield. 
 
Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), Cs2CO3, DMF, 
MW 45 
o
C, 10 min. 
Scheme 40. 
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A literature review for Sonogashira cross-coupling conditions of pyrazolopyrimidines 
with terminal acetylenes, identified a mild and selective microwave-assisted method 
to couple the TIPS ethynyl group at the desired C4-position of 146. The reaction was 
performed in DMF, which efficiently absorbs microwave radiation, and Cs2CO3 was 
used as base. An advantage of microwave over conventional heating is that 
localised superheating of the catalyst can occur, often leading to increased reaction 
rates and catalytic turnover. These conditions worked well for small scale reactions 
(ca. 50 mg) resulting in a 69% yield of pyrazolopyrimidine 147. However, larger scale 
reactions (>100 mg) were found to be capricious and low yielding (<30%). 
 
Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 
18 h. 
Scheme 41. 
Fortunately, the Sonogashira conditions previously developed for the purine system 
were a suitable alternative, allowing the synthesis of 147 in 69% yield. 1D NOE 1H-
NMR spectroscopic analysis of 147 was attempted to determine whether the correct 
regioisomer had been obtained, as it was hoped that an interaction between the C3- 
pyrazole proton and a methyl proton of the TIPS group of 147 would be detectable. A 
very faint signal was observed, but it was unclear whether this was significant. 
Attempts were made to grow crystals of 147 for X-ray crystallography using a variety 
of conditions, none of which were successful. It was decided to persevere with the 
synthesis of pyrazolopyrimidine 89 in the hope that it would be possible to grow 
crystals of a subsequent synthetic product.  
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Reagents and conditions: i) TFA, TFE, H2O, 100 
o
C, 6 h. 
Scheme 42. 
Removal of the THP protecting group from 133 was unsuccessful when 2-propanol 
(IPA) was used as a solvent, as the reaction would only proceed to ca. 50% 
completion (observed by LC-MS analysis). When IPA was replaced by TFE, the 
reaction proceeded to completion due possibly to the higher acidity of TFE. In the 
remaining steps the aniline side chain was coupled using standard TFA/TFE 
conditions, followed by removal of the TIPS group. In each case yields and reaction 
times were comparable with the parent purine. 
 
Figure 37 - X-ray crystal structure of pyrazolopyrimidine 154. 
A small-molecule X-ray crystal structure was successfully solved for 
pyrazolopyrimidine 154 following crystallisation from THF (Figure 37). This confirmed 
that the product was the correct regioisomer.  
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5.5.4 Synthesis of 3-Methyl-1H-pyrazolo[3,4-d]pyrimidine (165) 
As the pyrazolopyrimidine derivative 89 was found to have Nek2 inhibitory activity 
comparable with the purine 39 (IC50 values of 430 nM vs. 150 nM respectively), it 
was decided to investigate modification of the C3 position of 89. The initial objective 
was to synthesize the C3 methyl derivative 165 as the simplest modification, to 
determine whether further elaboration at this position would be tolerated. 
 
Reagents and conditions: i) NBS, MeCN, 100 
o
C, 15 min; ii) DHP, CSA, EtOAc, 65 
o
C, 18 h; iii) 
Trimethylboroxine, Pd(PPh3)3 (10 mol%), Cs2CO3, Toluene, MW 140 
o
C, 1 h. 
Scheme 43. 
The 3-bromo derivative 165 was prepared by electrophilic aromatic substitution of 
145 with NBS. This compound 155 was unstable, and was used directly in the THP 
protection step to give the stable THP-amine 156 (55%). It was hoped that palladium 
insertion would favour the 3-bromo position of 156 over the chloro substituents, thus 
allowing selective alkylation. However, attempts at Suzuki couplings using 
trimethylboroxine and a variety of bases and palladium catalysts were unsuccessful, 
leading to no observable product (157) formation.   
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Reagents and Conditions: i) POCl3, DMF, 110 
o
C, 4 h; ii) MeMgBr, THF, 0 
o
C – RT, 1 h; iii) DMP, 
DCM, RT, 2 h; iv) N2H4.H2O, MeOH, -15 
o
C, 6 h; v) DHP, CSA, EtOAc; vi) TIPS-acetylene, 
Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 18 h; vii) TFA, TFE, H2O, 100 
o
C, 18 h; viii) 
PhNH2, TFA, TFE, 85 
o
C, 18 h; ix) TBAF, THF, RT, 15 min. 
Scheme 44. 
As such, an alternative synthetic route to 165 was devised by incorporating the 
methyl group into the pyrazolopyrimidine scaffold early in the synthesis using 
Grignard chemistry (Scheme 44). An advantage of this approach was that all of the 
subsequent chemistry had been previously optimised during the synthesis of 
pyrazolopyrimidine 89.  
 
Reagents and conditions: i) MeMgBr, THF, 0 
o
C – RT, 1 h; ii) DMP, DCM, RT, 2 h. 
Scheme 45. 
Reaction of 2,4,6-trichloropyrimidine-5-carbaldehyde 144 with methylmagnesium 
bromide (MeMgBr)  resulted in a rapid and clean conversion into the respective 
alcohol 158 in 74% yield. The wide range of commercially available Grignard 
reagents renders this method an attractive approach to introduce a variety of alkyl 
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groups at the 3-position. The newly formed alcohol 158 required oxidation to the 
ketone 159 prior to cyclisation with hydrazine. Many methods are available to 
perform this reaction, including Swern oxidation or the use of chromium based 
oxidising agents, but due to concerns as to the stability of 158, a much milder 
approach was needed. To date, hypervalent iodine reagents have proven useful for 
the oxidation of primary and secondary alcohols to their respective aldehydes and 
ketones. These reagents facilitate mild chemoselective oxidation, without the need 
for highly toxic heavy metal oxidising agents such as the chromium (VI) based 
oxidising agents (e.g. pyridinium chlorochromate (PCC)).229 The most commonly 
used hypervalent iodine reagents are 2-iodoxybenzoic acid (IBX, 166) and Dess-
Martin periodinane (DMP, 167). IBX has been reported as explosive which may limit 
its use for large scale reactions.229,230 However, Dess and Martin have suggested 
that residual potassium bromate (KBrO3), or another impurity from the synthesis of 
this compound, may be responsible for its potentially explosive nature and that pure 
IBX should be relatively stable.229,230 
 
A major disadvantage of 166 is that it has very poor solubility in most common 
organic solvents, which can reduce rates of reactions.230 By contrast 167, the 
triacetoxy derivative of 166, has far greater solubility increasing its usefulness as an 
oxidising agent. In this reaction, 167 was used successfully to convert alcohol 158 
into ketone 159 in excellent yield (97%). 
 
Reagents and conditions: i) N2H4.H2O, MeOH, -15 
o
C, 6 h 
Scheme 46. 
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Cyclisation of 159 with hydrazine to form pyrazolopyrimidine 160 was initially 
attempted using the conditions established previously (-30 oC, 18 h); however, it was 
found that the reaction could not be driven to completion. It was interesting to note 
that the arylhydrazine intermediate 168 was observed (by LC-MS), suggesting that 
the 4-chloro position is more reactive than the 5-acetyl moiety of 159. 
 
The reaction mixture was warmed to -15 oC resulting in consumption of the starting 
material 159 and intermediate 168. The yield was lower than for the reaction of the 
formyl derivative 144 with hydrazine (55% vs. 80%), which was attributed to 
formation of a number of uncharacterised side-products arising as a result of the 
increased temperature and decreased reactivity of the carbonyl group of 168. 
The subsequent reaction steps proceeded in yields similar to those for the synthesis 
of pyrazolopyrimidine 89, to give the target compound 165.   
 
5.5.5 3H-[1,2,3]Triazolo[4,5-d]pyrimidines (90) and (232) 
 
In the 3H-[1,2,3]triazolo[4,5-d]pyrimidine scaffold, C8 of the purine imidazole has 
been replaced by nitrogen to form an azapurine. It was thought that this would elicit a 
significant electron-withdrawing effect, thus potentiating the reactivity of the 7-ethynyl 
group. Whilst this could lead to enhancement of Nek2-inhibitory activity, there was 
also a possibility that this might lead to significant off-target activity. Additionally, 
there were concerns as to the stability of this heterocycle, although examples of 
clinical candidates based upon this heterocycle are reported, e.g. 169 (Ticagrelor), a 
triazolopyrimidine-based inhibitor of ADP-induced platelet aggregation developed by 
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AstraZeneca. This compound was recently approved for the treatment of acute 
coronary syndromes.231  
 
A comparison of the tPSA and cLogP values of 90 with 39 (Figure 38) suggested a 
reduction in lipophilicity and an increase in polar surface area compared with the 
parent purine.  
 
Figure 38 - Comparison of the calculated physicochemical properties of parent 
purine 39 and triazolopyrimidine 90. 
 
The synthesis of triazolopyrimidine 90 was particularly challenging owing to the 
inherent instability of this heterocycle. This required the development of mild 
conditions for each step of the reaction sequence. 
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Reagents and Conditions: i) NaNO2, HCl(aq), H2O, 0 
o
C, 30 min; ii) 177, AcOH, NaOAc, H2O, 0 
o
C – 
RT, 18 h; iii) Zn, AcOH, THF, RT, 15 min; iv) NaNO2, AcOH, H2O, 0 
o
C – RT, 1 h; v) Boc2O, DMAP, 
THF; vi) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), DIPEA, THF, RT, 18 h; vii) TFE, 75 
o
C, 1 h; viii) Benzyltriethylammonium nitrite, TMSCl, DCM, 0 
o
C – RT, 1 h; ix) PhNH2, DMSO, 70 
o
C, 
96 h; x) TBAF, THF, 0 
o
C, 1 h.  
Scheme 47. 
A solution of the diazonium salt of p-chloroaniline was prepared by reaction of 170 
with NaNO2 in aqueous HCl at 0 
oC, and added to 4-chloro-2,6-diaminopyrimidine 
(177) to give the azo compound 171, which was isolated and reduced to 
triaminopyrimidine 172.232,233 Pyrimidine 172 was found to be unstable and 
prolonged storage resulted in formation of a dark purple side-product, possibly 
through N-oxidation. This derivative was therefore stored at reduced temperature 
under nitrogen or used immediately in the reaction with NaNO2 to form 
triazolopyrimidine 173.   
 
Reagents and conditions: i) NaNO2, HBF4(aq), 0 
o
C – RT.  
Scheme 48. 
Introduction of the 2-fluoro group in 173 using Balz-Schiemann conditions (Scheme 
48) proved unsuccessful, resulting in very little formation of 177, and the production 
of numerous side-products of which the major product was 
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dihydroxytriazolopyrimidine 178. It is likely that fluoro compound 177 was unstable to 
the harsh reaction conditions and so an alternative synthetic route was developed. 
 
Reagents and conditions: i) Boc2O, DMAP, THF, RT, 18 h. 
Scheme 49. 
The TIPS-ethynyl group was introduced to 174 prior to addition of the aniline to 
reduce stability issues. THP protection of the triazole ring of 173 was attempted, but 
led to a mixture of triazole regioisomers making purification difficult. Regioselective 
Boc protection of 173 gave 174 in 74% yield. The X-ray crystal structure of 174 
confirmed the Boc group was added regioselectively to 173 at the 3-position (Figure 
39). Triazolopyrimidine 174 was unstable in the presence of solvents such as MeOH, 
and decomposition was found to occur when stored in air at RT. It was therefore 
important that 174 was stored under nitrogen at reduced temperature prior to use. 
 
Figure 39 - X-ray crystal structure of 174 confirms regioselective protection of the 
triazolopyrimidine N3 as the Boc carbamate.  
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Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), DIPEA, THF, 
RT, 18 h; ii) TFE, 75 
o
C, 1 h 
Scheme 50. 
The TIPS-ethynyl group was introduced at the 7-position of 174 under Sonogashira 
conditions. The reaction proceeded optimally when DIPEA was used as a base, as 
this minimised side-product formation, and the Boc protecting group was removed 
quantitatively from 179 by refluxing in TFE. A variety of copper-mediated Sandmeyer 
type reaction conditions were attempted to replace the amino group of 175 by chloro-
, bromo- or iodo-substituents, but all were unsuccessful owing to decomposition of 
175. 
 
Reagents and conditions: i) SOCl2, LiCl, isoamyl nitrite, DMA, 0 
o
C – RT, 1 h. 
Scheme 51. 
A copper-free modified Sandmeyer chlorination reaction was attempted on amine 
175 using SOCl2, LiCl and isoamyl nitrite in DMA to form the 5-chloro compound 180 
(Scheme 51).234 It is believed that this reaction is initiated through in situ formation of 
nitrosyl chloride followed by chlorodediazotisation analogous to the 
benyzltriethylammonium nitrite-mediated cholorodediazotisation strategy described 
previously (Scheme 9). Although this reaction was successful, it was found to be 
unreliable and low yielding (16%). Hydroxy derivative 181 was also observed as a 
major side-product due to adventitious water. Purification of 180 was difficult as the 
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compound was found to be unstable to liquid chromatography conditions. The 
multitude of side-products made it impractical to use the crude product 180 directly 
for the next reaction step. 
 
Reagents and conditions: i) Benzyltriethylammonium nitrite, TMSCl, DCM, 0 
o
C – RT, 1 h; ii) 
PhNH2, DMSO, 70 
o
C, 96 h; iii) TBAF, THF, 0 
o
C, 1 h. 
Scheme 52. 
The benzyltriethylammonium nitrite-mediated method (Scheme 10) of chlorination 
was found to be a suitable alternative for the preparation of 180, proceeding 
smoothly and with no observable side-products.200 An aqueous work up removed 
residual benzyltriethylammonium nitrite and hydrolysed TMSCl to TMSOH, which 
was removed by evaporation. Silica based MPLC was attempted, but again it was 
found that compound 180 was unstable, and so the crude product 180 was used 
directly for the reaction with aniline without further purification. Initial attempts at this 
reaction using TFE as a solvent, with the addition of TFA, resulted in rapid formation 
of 176 (30 min), together with several by-products including the TFE ether derivative 
182. Reaction at lower temperature and in the absence of TFA was investigated, but 
no improvements were observed. This problem was resolved by performing the 
reaction in a 1 M solution of aniline in DMSO. Finally, the TIPS protecting group was 
removed from 176 using TBAF in THF. The reaction was performed at reduced 
temperature (0 oC) due to concerns over the stability of 90. 
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5.5.6 Synthesis of 1,3,5-Triazine-based Nek2 inhibitors (91-94) 
 
A rapid, concise and high yielding synthesis of trifunctionalised 1,3,5-triazines was 
developed. The rationale for synthesising this heterocycle was to investigate the 
importance of the imidazole ring for potency. It was hoped that the electron-deficient 
triazine heterocycle would increase the reactivity of the conjugated acetylene 
towards Cys-22 within the Nek2-ATP-binding domain leading to increased Nek2 
inhibitory activity. A small library of alkylamines (91-94) was synthesised to 
investigate structure-activity relationships. 
 
Reagents and Conditions: i) PhNH2, K2CO3, THF, 0 
o
C – RT, 1 h; ii) TIPS-acetylene, Pd(PPh3)2Cl2 
(5 mol%), CuI (5 mol%), DIPEA, THF, RT, 18 h; iii) RNH2, THF, RT, 3 h; iv) TBAF, THF. 
Scheme 53. 
A thermally controlled SNAr reaction of cyanuric chloride 183 with aniline gave 
dichlorotriazine 184 exclusively in 73% yield.235 Standard Sonogashira conditions 
were attempted to couple TIPS-acetylene with triazine 184 (Scheme 54); however, in 
addition to coupling of the TIPS ethynyl group to furnish 185, a side reaction with 
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triethylamine led to the quaternary ammonium species 189 as the major product 
(observed by LC-MS analysis). 
 
Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), Et3N, THF, RT, 
18 h. 
Scheme 54. 
Zinc acetylide 190 was prepared from TIPS-acetylene and used in a Negishi 
coupling reaction with triazine 184 (Scheme 55). Anilinotriazine 185 was obtained in 
low yield (12%) together with multiple side-products, as such, an alternative route 
was developed.236  
 
Reagents and conditions: i) TIPS-acetylene, n-BuLi, THF, -78 
o
C, 30 min.; ii) ZnCl2; iii) 190, 
Pd(PPh3)4 (30 mol%), THF, -78 
o
C – RT, 1 h. 
Scheme 55. 
Sonogashira coupling of triazine 184 with TIPS-acetylene in the presence of DIPEA 
gave triazine 185 in 64% yield, with a 14% yield of the undesired disubstituted 
compound 191 (Scheme 56), which was separable from 185 by RP-MPLC. 
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Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), DIPEA, THF, 
RT, 18 h. 
Scheme 56. 
A range of alkylamines were then coupled to 184 including MeNH2, EtNH2 and 
PMBNH2 in high yield (80-96%). Synthesis of the parent amine derivative 91 was 
achieved by TFA-mediated PMB deprotection of 188. Finally, the TIPS protecting 
group was removed with TBAF to give the target triazines 91-94 in 91-98% yield.  
 
5.5.7 Synthesis of Pyrimidine-Based Nek2 Inhibitors 
Pyrimidines are able to participate in a number of unique reactions due to their 
electronic structure. For example, the carbon atoms at the 2-,4- and 6-positions are 
activated to SNAr type reactions due to electron deficiencies in the system caused 
by localisation of electrons at N1/3. This is further enhanced as the ring nitrogens are 
positioned meta with respect to one another, resulting in a cumulative effect. 
Additionally, the electron rich ‘semi-aromatic’ 5-position may participate in 
electrophilic aromatic substitution reactions with suitable electrophiles (e.g. N-
bromosuccinimide).237 
 
To further investigate the potential application of 6-membered ring heterocycles as 
inhibitors of Nek2, a small library of pyrimidine derivatives was synthesised. As for 
the triazine series, it was essential to maintain the triplet of H-bonds with the Nek2 
hinge region. It was also important that the 6-ethynyl and 2-anilino groups were 
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present in target molecules analogous to purine 39. A range of amines was 
investigated at the pyrimidine 4-position as well as several 5-halogenated derivatives 
(Figure 40). It was unclear how Nek2 inhibitory activity would compare to the parent 
purine 39 or triazines 91-94. However, due to the increased electron density of the 
pyrimidine series it was suspected that an attenuation of ethynyl group reactivity 
would be observed.  
 
Figure 40 – Pyrimidine-based Nek2 inhibitors. 
An initial synthetic route based upon that of the 1,3,5-triazines was attempted 
starting from 2,4,6-trichloropyrimidine 201. However, this strategy was found to be 
unsuitable due to poor regioselectivity (Scheme 57) 
 
Reagents and conditions: i) PMBNH2, K2CO3, THF, 0 
o
C – RT, 15 min. 
Scheme 57.  
A synthetic route  was devised that incorporated the aniline side chain at the start of 
the synthesis (Scheme 58), thus preventing regioselectivity issues. A further 
advantage of this approach was that final derivatization occurs towards the end of 
the scheme, aiding library synthesis. 
Chapter Five 
 
116 
 
Reagents and Conditions: i) Cyanamide, HNO3, EtOH, 100 
o
C, 16 h; ii) Diethyl malonate, NaOMe, 
MeOH, RT, 18 h; iii) POCl3, MW 140 
o
C, 20 min; iv) RNH2, THF, RT, 18 h; v) 216, Pd(PPh3)4 (10 
mol%), Cs2CO3, Dioxane, MW 140 
o
C, 2 h; vi) TBAF, THF, RT, 15 min. 
Scheme 58. 
 
Aniline was reacted with cyanamide in the presence of nitric acid to form 
phenylguanidine nitrate 205.238 A Pinner pyrimidine synthesis gave the pyrimidine 
206 which was treated with POCl3 to give dichloropyrimidine 207.
239 
 
Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (10 mol%), Et3N, CuI, THF, RT, 18 h. 
Scheme 59. 
Sonogashira coupling of the TIPS ethynyl group with 207 was successful; however, 
upon coupling of the ethynyl group, all attempted amine additions failed. It is likely 
that the exchange of the electron-withdrawing chloro group of 207 for an electron-
donating acetylene reduced the reactivity of pyrimidine 214. A variety of conditions 
were attempted to facilitate this reaction, including microwave irradiation of a solution 
of 214 in neat PMBNH2 and deprotonation of the amine with NaH to increase 
nucleophilicity. Unfortunately, in each case no reaction was observed. A copper-
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based Ullmann coupling reaction of 214 with MeNH2 was also attempted but led to 
decomposition. A number of palladium-mediated Buchwald amination conditions 
were attempted, but again decomposition of 214 was observed. 
 
Reagents and conditions: i) RNH2, THF, RT, 18 h 
Scheme 60. 
It was decided to attempt to couple the amine functional group to pyrimidine 207 
prior to the Sonogashira reaction, in the hope that the increased electron deficiency, 
due to the presence of two chloro substituents in pyrimidine 207, would facilitate the 
reaction (Scheme 60). Interestingly, after a single addition of amine no further 
reaction took place. It was therefore possible to use multiple equivalents of amine, 
which reduced the reaction time and negated the need for an additional base.  
 
Reagents and conditions: i) TIPS-acetylene, Pd(PPh3)2Cl2 (5 mol%), Et3N, CuI (5 mol%), THF, RT, 
18 h. 
Scheme 61. 
Unfortunately, after introduction of the amino group the subsequent Sonogashira 
reaction became disfavoured (Scheme 61). It is possible that the increased electron 
density of pyrimidine 208 stabilises the intermediate Pd complex preventing oxidative 
addition.215 Attempts at heating the reaction resulted in decomposition, as did the 
reaction using Buchwald’s copper free Sonogashira method.225 
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Reagents and conditions: i) 216, Pd(PPh3)4 (10 mol%), Cs2CO3, dioxane, MW 140 
o
C, 2 h. 
Scheme 62. 
A key step in this reaction scheme was the Suzuki coupling of the TBDMS acetylene 
pinacolborane 216 to 6-chloropyrimidines 208-210 (Scheme 62). Early experiments 
using the highly active ‘Pd-118’ 217 and moderately active Pd(dppf)Cl2 218 catalysts 
resulted in modest product formation, and a number of side-products including 
dehalogenated pyrimidines. Pd(PPh3)4 218 was found to be better suited for this 
reaction and resulted in clean conversion to the pyrimidine 213. Unfortunately, the 
reaction could not be driven to completion even with prolonged heating, 
stoichiometric amounts of catalyst and 3 equivalents of 216. This problem was 
resolved through the use of microwave-assisted heating. Reactions were conducted 
at 140 oC for 2 h, and optimised to require 0.1 equivalent of Pd(PPh3)4 and 1.5 
equivalents of 216. Yields of 211-213 were variable, ranging from 64-88%, albeit with 
minimal side-product formation. 
 
To obtain the aminopyrimidine 95, the PMB protected derivative 213 was refluxed in 
TFA, resulting in clean deprotection to afford pyrimidine 220. In the final stage, the 
TBDMS group was removed from pyrimidines 211-213 and 220 with TBAF in THF in 
a method analogous to that employed for TIPS group deprotection.  
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5.5.8 Synthesis of 5-Halopyrimidines 
A series of 5-halopyrimidines was investigated based upon aminopyrimidine 95. It 
was hoped that inclusion of electron-withdrawing halogen groups such as fluoro, 
chloro and bromo would enhance the reactivity of the ethynyl group and increase 
Nek2 inhibitory activity. In addition, these halogen groups could be used in future 
chemistry to further investigate the effect of modifications at the pyrimidine 5-position 
on Nek2 inhibition. 
 
Reagents and conditions: i) NCS, MeCN, MW 100 
o
C, 30 min; ii) NBS, MeCN, MW 100 
o
C, 30 min. 
Scheme 63. 
Electrophilic aromatic substitution of the pyrimidine 5-position of 220 was achieved 
using N-chlorosuccinimide (NCS) or N-bromosuccinimide (NBS) to afford the 2-
chloro- and 2-bromopyrimidine derivatives 221 and 222, respectively. Electrophilic 
halogenating agents such as NCS and NBS are convenient, easy to handle, and 
allow selective halogenation of the pyrimidine ring in good yield. 
The final 5-halopyrimidine derivative to be synthesised was the 5-fluoro pyrimidine. 
The inclusion of fluorine in chemotherapeutic compounds is increasingly common, 
and can have a profound effect upon toxicity and potency.240 Compounds containing 
a fluoride atom may behave as antimetabolites as the C-F bond can mimic C-H, 
whilst preventing metabolism. An example is 5-fluorouracil 197, which is a 
mechanism-based irreversible inhibitor of thymidylate synthase used in cancer 
chemotherapy. Additionally, inclusion of fluoride into the structure of corticosteroids 
can greatly increase the half-life by enhancing the lipid-water solubility ratio. An 
example of this is the corticosteroid triamcinolone 224, which is known for its long 
duration of action.241  
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Several attempts were made to synthesise the 5-fluoropyrimidine 223 using N-F 
based electrophilic fluorinating agents (Scheme 64).240 Regrettably, none of the 
attempted fluorinations were successful due to decomposition of pyrimidine 220, and 
it was decided to attempt to introduce the fluorine atom at an earlier stage in the 
synthetic scheme. 
 
Reagents and conditions: i) Selectfluor™, MeCN, MW 100 
o
C, 4 h; ii) 1-Fluoropyridinium 
tetrafluoroborate, MeCN, MW 100 
o
C, 4 h; iii) 1-Fluoro-2,4,6-trimethylpyridinium tetrafluoroborate 
MeCN, MW 100 
o
C, 4 h. 
Scheme 64. 
Dihydroxypyrimidine 206 was chosen as the starting material, as this compound 
should have has increased reactivity towards electrophiles due to higher electron 
density. However, this compound failed to react with any of the fluorinating agents 
even with prolonged heating at elevated temperatures (140 oC, 6 h) (Scheme 64). 
The decision was therefore made to abandon the synthesis of 5-fluoropyrimidine 224 
in favour of more synthetically accessible targets.   
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Reagents and conditions: i) Selectfluor™, MeCN, MW 100 
o
C, 4 h; ii) 1-Fluoropyridinium 
tetrafluoroborate, MeCN, MW 100 
o
C, 4 h; iii) 1-Fluoro-2,4,6-trimethylpyridinium tetrafluoroborate 
MeCN, MW 100 
o
C, 4 h. 
Scheme 65. 
 
5.5.9 Synthesis of 5-Formylpyrimidine (101)  
The final pyrimidine compound synthesised was the 5-formylpyrimidine 101. 
Previous work by Marchetti et al demonstrated that 225 is a potent inhibitor of CDK2. 
An intramolecular H-bond between the amino N-H and formyl oxygen forms a 
pseudocycle. The remaining N-H, is thereby orientated towards the hinge region 
resulting in a ‘purine-mimetic’ structure with enhanced competitive binding at the 
CDK2 ATP-binding domain.242  It was hoped that the pseudocyclic conformation of 
225 would be retained in the 6-ethynyl compound 101, resulting in an increase in 
potency (Figure 41). It is likely that the electron-withdrawing effect of the formyl 
group would also enhance reactivity of the terminal 6-ethynyl group of 101, assisting 
attack of Cys-22 within the Nek2 ATP-binding domain. 
 
Figure 41 - 5-Formylpyrimidines as purine mimetics. 
 
An initial strategy for introduction of the 5-formyl group was to conduct a Vilsmeier-
Haack reaction on compound 220. Standard conditions with DMF in POCl3 led to 
decomposition of pyrimidine 220, and a milder method was attempted using the 
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isolated (chloromethylene)dimethyliminium chloride (Vilsmeier salt) in MeCN. At 
room temperature no reaction occurred so the reaction mixture was heated (100 oC, 
30 min), which resulted in a small amount of the desired formyl product 226 together 
with di-aldehyde side-product 227 (Scheme 66).  
 
Reagents and conditions i) Vilsmeier salt, MeCN, RT - 100 
o
C, 4 h. 
Scheme 66. 
 
Reagents and Conditions: i) POCl3, DMF, 0 
o
C – 110 
o
C, 3 h; ii) PMBNH2, DIPEA, THF, RT, 1 h; iii) 
216, Pd(PPh3)4 (10 mol%), Cs2CO3, dioxane, MW 140 
o
C, 2 h; iv) TFA, 80 
o
C, 18 h; v) TBAF, THF, 
RT, 15 min. 
Scheme 67. 
To improve selectivity, the formyl group was introduced at an earlier stage of the 
synthesis (Scheme 67), which allowed selective 5-formylation of pyrimidine 228. It 
was important to maintain the temperature at 0 oC and to use a single equivalent of 
DMF in the reaction to ensure regioselectivity and monoformylation of 206. 
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Reagents and conditions: i) PMBNH2, DIPEA, THF, RT, 1 h. 
Scheme 68. 
The next stage in the reaction was the coupling of PMBNH2 to pyrimidine 228 
(Scheme 68), which adds the 4-amino group. It was interesting to note the increased 
reactivity of the formyl compound (288) when compared to the unsubstituted 
pyrimidine 207. Using multiple equivalents of PMBNH2 led to displacement of both 
chloro groups from pyrimidine 228. By contrast, using a single equivalent of PMBNH2 
resulted in a slow reaction, which did not reach completion presumably due to HCl 
liberated during the reaction. By adding 1 equivalent of DIPEA, this problem was 
resolved, allowing rapid preparation of pyrimidine 229 in 85% yield. The remaining 
steps including the Suzuki reaction, PMB deprotection and TBDMS deprotection, 
proceeded in similar yields to those for the non-formylated series. 
 
 2D-COSY 1H-NMR spectroscopic analysis was performed on 5-formylpyrimidine 
101 to confirm the presence of the desired intramolecular H-bond between the 5-
formyl oxygen and the 4-amino NH (Figure 42). The data clearly showed that the two 
amino protons (a) and (b) had distinct chemical environments and coupled with one 
another, strongly suggesting that an intramolecular H-bond was present in the 
molecule.  
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Figure 42 – 2D-COSY 1H-NMR analysis of 101.   
 
 
Figure 43 - The X-ray crystal structure of 101 confirmed the presence of an 
intramolecular H-bond between the carbonyl oxygen and the 4-amino NH. 
(a) 
(a) 
(b) 
(a) (b) 
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Crystals of 101 were prepared by dissolution in EtOAc followed by gradual solvent 
evaporation. The small-molecule X-ray crystal structure of 101 was solved (Figure 
43), which confirmed the presence of the expected intramolecular hydrogen bond 
between the 5-formyl oxygen and the 4-amino NH. 
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Chapter Six: Biological Evaluation of Nek2 Inhibitors 
 
6.1 Structure-Activity Relationship Studies for 6-Ethynyl-2-Phenylaminopurine 
(39) 
6.1.1 N7- and N9-Methylpurines (52) and (53) 
 
Figure 44. 
Compounds 52 and 53 were evaluated for Nek2 inhibitory activity. Methylation of 
either imidazole nitrogen greatly reduced potency due to loss of a critical H-bond. 
Interestingly, the N9-methyl compound 53 was found to retain some activity (Nek2; 
IC50 = 28.3 µM). This suggests that the N
9H H-bond interaction with the hinge is not 
essential for Nek2 inhibitory activity, although it is important for an in initial non-
covalent binding interaction. By contrast, compound 52 was essentially inactive 
(Nek2; 15% inhibition at 50 µM). A consequence of methylation of the N7-position is 
that the N9-nitrogen becomes an H-bond acceptor rather than a donor. This could 
potentially produce a repulsive effect with the amino acids of the Nek2 hinge region 
within the ATP-binding domain.  Compounds 52 and 53 were also found to be 
essentially inactive in the CDK2 counter-screen. 
In vitro time dependent-inhibition studies of Nek2 were performed using compounds 
52 and 53. Figure 45 shows the percentage of Nek2 inhibition over a range of 
concentrations and times. Compound 53 was an irreversible inhibitor of Nek2 as 
demonstrated by the increase in potency relative to incubation time (Figure 45, a). 
By contrast, the level of Nek2 inhibition by compound 52 was not time dependent 
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Figure 45, b), suggesting that this compound has little/no irreversible inhibitory 
activity at the observed pre-incubation times and concentrations. 
 
 
Figure 45 - in vitro Nek2 inhibition studies with N-methylpurines 53 and 52, 
performed at the NICR. 
To ascertain whether compounds 52 and 53 were control compounds for the parent 
purine 39 they were screened in a number of cancer cell lines known to have 
elevated Nek2 expression (Table 2). These cell lines included: human breast cancer 
cell lines MDAMB231 and SKBR3, human osteosarcoma cell line (U2OS) and the 
transformed cell line human embryonic kidney 293 (HEK293). If growth inhibition 
was due to inhibition of Nek2 these compounds would be expected to have poor 
cellular potency and hence a high GI50 value. Compounds 52 and 53 possessed 
cellular activity comparable with the parent purine 39 in all cell lines assayed, with 
the exception of HEK293. In this cell line the N7-methypurine 52 was found to be 12-
a) 
b) 
N-Methylpurine (53) Time 
Dependent Inhibition Studies 
N-Methylpurine (52) Time 
Dependent Inhibition Studies 
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fold less active than the parent 39. Interestingly, the N9-methypurine 53 was found to 
have growth-inhibitory activity comparable with the parent purine 39. Cellular activity 
in the absence of Nek2 inhibitory activity suggests that growth inhibition may be due 
to an off-target effect rather than as a result of Nek2 inhibition. 
Table 2 – Growth inhibition studies with N-Methylpurines 52 and 53, performed at 
the NICR.a 
a
 Compounds 52 and 53 are weak inhibitors of Nek2 but demonstrated cellular 
growth inhibitory activity comparable to the parent purine 39. 
C-Nap1 is a substrate for Nek2 phosphorylation and a component of the 
intercentriolar linkage.  Depletion of cellular Nek2 through irreversible inhibition 
causes a reduction in phospho-C-Nap1 (pC-Nap1) concentration.123,163 In vitro 
phospho-C-Nap-1 (pC-Nap1) assays with N-methylpurines 52 and 53 were 
performed in U2OS cells, allowing a comparison of cellular Nek2 inhibitory activity 
and growth inhibition with the parent purine 39 (Figure 46). 
 
Figure 46 – In vitro pC-Nap1 assay with N-methylpurines (53, 52, 39), performed at 
the NICR.  
Assay/Cell Line 
GI50 or IC50 
(μM) 
   
Nek2 15% inhibition at 50  μM 28.3 0.15 
MDAMB231 1.7 0.9 1.1 
U2OS 1.4 1.4 1.8 
HEK293 1.2 >0.05 0.1 
SKBR3 0.31 0.22 0.33  
53 52 39 
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In the pC-Nap1 assay, U2OS cells were synchronized for 16 h, washed, and 
incubated in the presence of the desired compound for 4 h. The cells were then 
stained to visualize γ-tubulin and pC-Nap1, which allows pC-Nap1 co-localised with 
the centrosomes to be counted. Each compound was titrated at varying multiples of 
the GI50 until no change of pC-Nap1 was observed. The results from the pC-Nap1 
assays (Figure 46) demonstrate that the N9-methylpurine 53 showed dose-
dependent inhibition when titrated at greater than 1.25x its GI50. By contrast, the N
7-
methylpurine 52 did not inhibit Nek2 even at 5x the GI50. The parent purine 39 also 
produced a dose response but at lower concentrations than compound 53. Studies 
at 5x the GI50 of 39 failed to cause further reduction in pC-Nap1 levels, suggesting 
that a compensatory pathway may be in place permitting C-Nap1 phosphorylation in 
the absence of Nek2.  
Figure 47 shows a direct comparison of growth-inhibitory activity between parent 
purine 39 and N-methylpurines 52 and 53 in SKBR3, cells over a range of 
concentrations. The cellular potency of all three compounds follows a very similar 
trend independent of Nek2 inhibitory activity. These findings increase the likelihood 
that growth inhibition is due to off-target activity, rather than as a result of Nek2-
inhibitory activity. 
 
Figure 47 - SKBR3 Growth Inhibition Assays of N-Methylpurines 52 and 53, 
performed at the NICR. 
N-Methylpurines 52 and 53 were screened against a panel of 121 kinases (single 
point determination at 1 µM) to assess kinase selectivity. Nek2-inhibitory activity was 
53 -1 
53 -2 
53 -3 
52 -1 
52 -2 
52 -3 
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observed to be higher for both compounds 52 and 53 (29% and 64% inhibition at 1 
µM respectively) than for the Caliper assay (15% inhibition at 50 µM and 28 µM, 
respectively). This is likely because these compounds exhibit time-dependent 
inhibition kinetics and, as such, the incubation time of the assay affects the observed 
potency. In addition to Nek2 inhibition, compounds 52 and 53 showed inhibitory 
activity of greater than 30% at 1 µM in Bruton's tyrosine kinase (BTK) and aurora 
kinase A (AK-A). 
BTK is a Tec family kinase involved in B-lymphocyte development, differentiation 
and cell signalling. There is evidence to suggest that BTK is a mediator of 
proinflammatory signals which has led to interest in the development of selective 
BTK inhibitors for the treatment of autoimmune diseases (e.g. rheumatoid arthritis) 
and B-cell malignancies.243-246 BTK contains a non-conserved Cys residue (Cys-481) 
within the ATP-binding domain which may be targeted by electrophiles. Ibrutinib 
(PCI-32765) 230 is an example of an orally active irreversible BTK inhibitor that is 
currently in phase II clinical trials for the treatment of B-cell non-Hodgkin 
lymphoma.243-246  
 
In addition to BTK inhibitory activity, N7-methylpurine 52 was found to have moderate 
aurora kinase A (AK-A) (34% at 1 µM) activity. As mentioned previously (chapter 3), 
AK-A is a cell cycle kinase that facilitates mitotic spindle assembly. It is possible that 
inhibition of AK-A could cause cell cycle arrest and growth inhibition. 
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6.1.2 Investigating the Requirement of the 2-Amino H-Bond of Purine (39) for 
Nek2 Inhibitory Activity 
 
Figure 48. 
Evaluation of 54 in Nek2 and CDK2 inhibition assays revealed that methylation of the 
2-aryamino group was not tolerated resulting in a large reduction in both Nek2 and 
CDK2 activity compared with the parent purine 39. However, it was unclear if this 
loss of potency was due to a reduction in binding affinity as a result of removal of a 
critical H-bond interaction, or simply a steric clash arising from the methyl group. To 
address this, additional modifications of the purine 2-position were investigated. 
Replacement of the aniline NH in 39 by oxygen in 55 caused a substantial reduction 
of potency in both the Nek2 and CDK2 assays. This suggests that H-bond acceptor 
groups at the C2-position are not tolerated and, as such, this series was abandoned.  
2-Benzylpurine 56 showed reduced inhibitory activity against both Nek2 and CDK2 
compared with the parent purine 39, which is likely due to loss of the 2-NH hydrogen 
bond interaction with Cys-89 of the Nek2-ATP-binding domain. In combination with 
the results from the 2-methylanilinopurine 54 and the 2-phenoxypurine 55 this 
indicates that the aniline NH of the parent purine 39 is required for potent Nek2 
inhibitory activity and likely enhances the initial non-covalent ATP-competitive 
binding interaction.  
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6.2 Ethynyl-Substituted Heterocyclic Derivatives of Purine (39) as Irreversible 
Nek2 Inhibitors 
6.2.1 Imidazo[4,5-b]pyridine (87) 
 
Figure 49. 
A 200-fold reduction in Nek2 activity was observed for 87 compared with 39 
alongside a slight gain in CDK2 inhibitory activity. It is possible that the increased 
electron density of the imidazopyridine heterocycle may attenuate ethynyl reactivity 
preventing covalent modification by Cys-22 at the Nek2 ATP-binding domain. 
Additionally, the increased electron density relative to purine 39 may also raise the 
pka of the aniline side chain NH causing it to become less acidic. This could reduce 
the H-bond interactions between the ligand and the Nek2 hinge region. These results 
suggest that the purine N1 nitrogen is important for Nek2 inhibitory activity. 
 
6.2.2 7H-Pyrrolo[2,3-d]pyrimidines (88) and (231) 
 
Figure 50 – Comparison of potency between pyrrolopyrimidine and purine 
heterocycles. 
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Pyrrolopyrimidines 88 and 231 had substantially lower Nek2 inhibitory activity than 
the parent purines 39 and 40. Similar to imidazopyridine 87, it was likely that the 
increased electron density due to loss of a nitrogen atom from the heterocycle 
compared with the purine reduces the reactivity of the ethynyl group towards 
nucleophilic attack. A slight increase in CDK2 inhibitory activity was observed for 
both compounds, although this increase was highest in pyrrolopyrimidine 88. 
 
Figure 51 – X-ray crystal structure of 231 in complex with Nek2. Electron density 
(grey wire mesh) was observed suggesting 231 bound within the Nek2 ATP-binding 
domain; however, there was insufficient electron density to confirm covalent 
modification of Cys-22. Note: ene-sulfide bond was modelled to show its predicted 
position, but was not observed. 
The Nek2 X-ray co-crystal structure (Figure 51) showed compound 231 bound within 
the Nek2 ATP-binding domain. The triplet of hydrogen bonds between the ligand and 
the Nek2 hinge region was maintained through the pyrrolopyrimidine N1 and N7 as 
well as the aniline amino NH group. However, this compound did not appear to be 
covalently bound to Cys-22, since electron density between the ligand and Cys-22 
was not visible (Figure 51). It is likely that 231 is therefore a reversible inhibitor of 
Nek2 and did not covalently modify Nek2 during the crystal soak. To further 
2.8 Å 
Hinge 
Cys-22 
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investigate this possibility, in-vitro Nek2 time-dependent inhibition studies should be 
performed using compound 231.  
 
Figure 52. 
Pyrrolopyrimidine 231 was evaluated for growth inhibitory activity in SKBR3 cells, 
and although essentially inactive in the Nek2 assay, 231 had sub-micromolar growth 
inhibitory activity. This supports the suggestion that growth inhibitory activity may be 
independent of Nek2 activity and due to off-target effects. 
 
6.2.3 1H-Pyrazolo[3,4-d]pyrimidines (89) and (154) 
 
Figure 53 – Comparison of potency between pyrazolopyrimidine and purine 
heterocycles. 
Biological evaluation revealed that the unsubstituted aniline derivative 89 was a sub-
micromolar Nek2 inhibitor (430 nM) with good selectivity over CDK2. A 3-fold loss in 
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Nek2 inhibitory activity was observed when compared with the parent purine 39 (IC50 
= 150 nM) but this was deemed negligible.  Interestingly, the acetamide derivative 
154 was found to have modest Nek2 inhibitory activity (8.5 µM) and CDK2 activity 
(6.7 µM) compared with the parent purine 40, and a 150-fold loss in activity was 
observed. It was unclear why the unsubstituted pyrazolopyrimidine 89 retained 
activity when the functionalise pyrazolopyrimidine 154 did not. Both compounds 89 
and 154 were analysed in Nek2 co-crystallisation studies to determine whether an 
alternative binding mode was possible in either case.  
 
 Figure 54 - X-ray crystal structure of 89 in complex with Nek2 suggested covalent 
modification of Cys-22. Note: further refinement is required to confirm ene-sulfide 
bond geometry. 
The Nek2 X-ray co-crystal structure (Figure 54) showed that pyrazolopyrimidine 89 
clearly covalently bound to Cys-22, with a triplet of H-bonds arising with the hinge 
region of the ATP-binding domain. This is the expected binding motif that is shared 
with the parent purine 39.  
Hinge 
Cys-22 
2.75 Å 
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Figure 55 - X-ray crystal structure of 154 in complex with Nek2 suggested covalent 
modification of Cys-22. Note: further refinement is required to confirm ene-sulfide 
bond geometry. 
Pyrazolopyrimidine 154 was seen to bind to Nek2 in a very similar way to the 
unsubstituted pyrazolopyrimidine 89 (Figure 55), and it is unclear why there is a 
difference in potency between the two compounds 89 and 154. One possibility is that 
a slight steric clash is observed between the pyrazole nitrogen of the functionalised 
pyrazolopyrimidine 154 and Met-86 gatekeeper residue, reducing non-covalent 
binding. Indeed, a small degree of unusual electron density was observed around 
Met-86 and the model was adjusted to accommodate both conformations of Met-86; 
however, it remains unclear if a steric clash is responsible for the reduction in 
potency.  
 
Figure 56. 
Pyrazolopyrimidine 89 demonstrated growth inhibitory activity comparable with the 
parent purine 39; however, it is uncertain whether if this activity was due to Nek2 
Met-86 
Hinge 
Cys-22 
2.8 Å 
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inhibition or an off-target effect. Further biological screening of 89 is therefore 
required to address this. 
 
6.2.4 3-Methyl-1H-Pyrazolo[3,4-d]pyrimidine (165) 
 
Figure 57. 
It was determined that the methyl group at the 3-position of 165 was not tolerated 
and resulted in a 7-fold reduction in Nek2 inhibitory activity when compared with the 
parent pyrazolopyrimidine 89. To identify why this simple modification resulted in 
such a loss in potency this compound was analysed in Nek2 X-ray co-crystal studies. 
Additionally, CDK2 inhibitory activity was also reduced from 5.4 µM to 27.5 µM. 
 
Figure 58 - The X-ray crystal structure of 165 in complex with Nek2 suggested 
covalent modification. A steric clash with the C3-methyl group of 165 causes the side 
chain of the Met-86 gatekeeper residuce to flip, resulting in reduced binding 
efficiency. Note: further refinement is required to confirm ene-sulfide bond geometry. 
2.2 Å 
Met-86 
Hinge 
Cys-22 
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The Nek2 crystal structure (Figure 58) showed that compound 165 covalently 
modified Cys-22 of Nek2 and bound in a similar orientation to the parent 
pyrazolopyrimidine 89. However, one clear observed difference was the orientation 
of the Nek2 gatekeeper residue Met-86, which was flipped when compared with the 
conventional binding motif. It is likely that a steric clash with the 3-methyl group of 
165 forces the methionine side-chain to realign in order to accommodate the ligand. 
This causes an energetic penalty, and is likely responsible for the reduction in 
activity when compared with the unsubstituted compound 89. In light of this 
observation, it was decided that there would be no benefit in investigating further 
substituents at the 3-position (e.g. Et, i-Pr, halogens etc.). 
 
6.2.5 3H-[1,2,3]Triazolo[4,5-d]pyrimidines (90) and (232) 
 
Figure 59 – Comparison of potency between triazolopyrimidine and purine 
heterocycles. 
Triazolopyrimidine 90 possessed similar Nek2 inhibitory activity to the parent purine 
39 and was weakly active against CDK2. The functionalised aniline derivative 232 
showed a 4-fold reduction in Nek2 inhibitory activity when compared to purine 40, 
and was also poorly active in the CDK2 assay. Cell based assays in the SKBR3 cell 
line showed that 90 had similar cellular potency to the parent purine 39. By contrast, 
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the cellular activity of triazolopyrimidine 232 was found to be considerably higher 
than the parent purine 39 (14.8 µM vs. 2.2 µM, respectively). It is possible that 
triazolopyrimidine 232 had weak growth inhibitory activity due to its high calculated 
polar surface area of 116.6 (tPSA purine = 104.2) and low cLogP value of 0.54 
(cLogP purine = 1.24) (Figure 60), which may prevent 232 from crossing cell 
membranes. 
 
Figure 60. 
 
Figure 61 - X-ray crystal structure of 232 in complex with Nek2. Covalent 
modification of Cys-22 was clearly visible; however, further refinement is required to 
confirm presence of the ene-sulfide bond. 
Triazolopyrimdine 232 covalently modified Cys-22 of the Nek2 ATP-binding domain, 
which provides evidence that 232 is an irreversible Nek2 inhibitor (Figure 61). The 
binding orientation of 232 was very similar to the parent purine 40, as 
2.8 Å 
Hinge 
Cys-22 
Ser-96 
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triazolopyrimidine 232 made H-bond interactions with Cys-89 and Glu-87 of the Nek2 
hinge region via the triazolopyrimidine heterocycle and the 5-amino NH group. The 
acetamide side chain was poorly resolved due to flexibility and rotation of this group. 
However, there was a small degree of electron density in the vicinity of the 
triazolopyrimidine side chain, which suggested that the acetamide functional group 
was orientated towards the hydroxyl group of Ser-96, indicating the presence of a 
possible H-bond interaction.   
 
Figure 62 – Kinase selectivity screen of triazolopyrimidine 232 showing percentage 
inhibition (single point determination 1 µM). 
Triazolopyrimidine 232 was screened against a panel of 121 kinases to assess 
kinase selectivity (Figure 62). Nek2 inhibition of 92% was observed, alongside 
significant inhibition of only 6 other kinases indicating good selectivity. As for the N-
methylpurines 48 and 49, triazolopyrimidine 232 was an inhibitor of BTK (47% 
inhibition at 1 µM), which was possibly due to covalent modification of Cys-481 within 
the BTK ATP-binding domain. A second Cys containing kinase that was inhibited by 
232 was glycogen synthase kinase 3β (GSK-3β) (52% inhibition at 1 µM). GSK-3β is 
a Ser/Thr protein kinase involved in numerous physiological processes including 
glycogen metabolism and gene transcription.247 There has been much interest in the 
development of small-molecule inhibitors of GSK-3β for the treatment of diabetes 
mellitus, due to its role in glycogen metabolism.248 Additionally, GSK-3β contains a 
non-conserved Cys residue (Cys-199) located within the ATP-binding domain that is 
susceptible to covalent modification by electrophiles. Recently, halomethylketones 
(Figure 63) have been identified as irreversible inactivators of GSK-3β that function 
through alkylation of Cys-199.249,250 It is not unreasonable to suggest that 
triazolopyrimidine 232 binds in a similar orientation to these ligands and covalently 
modifies Cys-199 within the GSK-3β ATP-binding domain. 
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Figure 63 – Halomethylketones that covalently modify Cys-199 of GSK-3β. 
Additionally, the serine/threonine protein kinases Chk1 and Chk2 were inhibited by 
69% and 61%, respectively. The function of Chk1/2 is to regulate checkpoint 
signalling during the cell cycle, particularly in response to DNA damage. 
Interestingly, both Chk1 and Chk2 have been implicated in cancer and there is 
currently growing interest in the development of small-molecule inhibitors that target 
these kinases.46 Triazolopyrimidine 232 was also found to be a low-micromolar 
inhibitor of protein kinase B (PKBb) (48% inhibition at 1 µM). PKBb (also known as 
Akt) is a signalling protein that has a role in metabolism, cell cycle control and 
apoptosis.251 PKBb has been described as an attractive cancer chemotherapeutic 
target due to its influence on the proliferation and survival of tumour cells.252,253 
Finally, aurora kinase B (AK-B) inhibitory activity of 51% was observed, which is 
similar to the value obtained for N-methylpurine 48 (30% inhibition at 1 µM).  
 
6.2.6 1,3,5-Triazine Based Nek2 Inhibitors 
 
Figure 64 – Comparison of potency between triazines 91-94 and parent purine 39. 
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Biological evaluation of the triazine series revealed that the unsubstituted amine 
derivative 91 and N-methylamine 93 were modest inhibitors of Nek2 with 17 µM and 
16 µM Nek2 inhibitory activity, respectively. Extension of the N-alkyl chain was not 
tolerated as demonstrated by the reduction in potency of the N-ethylamine derivative 
93 (Nek2; IC50 = 43 µM) and N-PMB-amine 94 (Nek2; 13% inhibition at 50 µM). This 
is likely due to a steric clash with the Met-86 gatekeeper residue of the Nek2 ATP-
binding domain. All compounds were found to be essentially inactive in the CDK2 
inhibition assay. 
 
Figure 65. 
Growth inhibition studies of compound 91 in SKBR3 cells gave a GI50 value of 0.51 ± 
0.1 µM. Due to the poor Nek2 inhibitory activity (Nek2; IC50 = 17 µM) it is unlikely that 
growth inhibition is due to Nek2 inhibition, but rather, as a result of off-target activity. 
Further screening of this compound would be required to confirm this. 
6.2.7 Pyrimidine Based Nek2 Inhibitors 
 
Figure 66 – Comparison of potency between pyrimidine series and parent purine 39. 
Chapter Six 
 
143 
The pyrimidine series were found to be very weak inhibitors of Nek2, with IC50 values 
in excess of 100 µM observed for all compounds. It was suspected that the 
pyrimidine 4-amino group of this series cannot effectively mimic the purine N9 H-
bond interaction between 39 and the Nek2 hinge region, which reduces the initial 
ATP-competitive binding.  
 
Figure 67. 
Interestingly, pyrimidine 95 demonstrated moderate growth inhibitory activity in 
SKBR3 cells (GI50 = 4.9 ± 0.6 µM) despite exhibiting poor Nek2 inhibitory activity. To 
determine if off-target binding of pyrimidine 95 is responsible for this growth inhibition 
it would be useful to perform a selectivity screen against a broad panel of kinases.  
 
6.2.8 5-Formylpyrimidine (101) 
 
Figure 68 – 5-Formylpyrimidine 101 has increased potency compared with 
pyrimidine 95 but lower Nek2 inhibitory activity than the parent purine 39. 
The formylpyrimidine compound 101 was assayed for Nek2- and CDK2-inhibitory 
activity. A 70-fold reduction in Nek2 inhibitory activity of 101 was observed when 
compared with the parent purine 39. However, compound 101 was 40-fold more 
potent than pyrimidine 95. A reduction in CDK2 inhibitory activity was also observed. 
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It is interesting to note that the 5-formylpyrimidine 101 was found to be 10-fold more 
potent in cells (GI50; SKBR3 = 0.47 ± 0.15 µM) than the non-formylated pyrimidine 95 
(GI50; SKBR3 = 4.9 ± 0.6 µM) although it is unclear if this is due to Nek2 inhibition or 
an off-target effect. 
 
Figure 69 - X-ray crystal structure of 101 in complex with Nek2 suggested covalent 
modification of Cys-22. The side chain of the Met-86 gatekeeper residue was found 
to be present in both the conventional and flipped orientations. Note: further 
refinement is required to confirm ene-sulfide bond geometry. 
Figure 69 showed covalent modification of Cys-22 by the pyrimidine 6-ethynyl group 
of 101. The ligand binding was similar to that of the parent purine and the hinge H-
bond interaction was clearly visible. The Met-86 gatekeeper residue was modelled in 
both the conventional and flipped orientation as the electron density suggested both 
conformers were present. A steric clash with Met-86 could therefore possibly explain 
the reduction in potency versus the parent purine 39.  
 
2.2 Å 
Met-86 
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Chapter Seven: 1H-qNMR Kinetic Experiments of Irreversible Nek2 
Inhibitors 
7.1 Introduction to Quantitative 1H NMR (qNMR) Spectroscopy 
NMR spectroscopy is commonly used as a primary method of measurement to allow 
structural elucidation of molecules.254 The first reported use of qNMR was by Hollis 
in 1963 for pharmaceutical analysis of commercial analgesics consisting of aspirin, 
phenacetin and caffeine.255 qNMR is now established as a vitally important technique 
in a range of fields, and is routinely used to characterise the composition of a variety 
of analytes including pharmaceutical preparations, natural products, peptides, 
agrochemicals, food products and biofluids (metabolomics).254 qNMR is a non-
destructive method of analysis which has low uncertainty in quantification.256 
Alternative approaches to quantification include high performance liquid 
chromatography (HPLC) and gas chromatography (GC). These analytical methods 
are commonly used for quantitative sample analysis, particularly within the 
pharmaceutical industry. However, as these techniques rely upon the 
physicochemical differences of analytes rather than structural complexity, good 
chromatographic properties are required for accurate analysis. Additionally, mixtures 
of polar compounds with low molecular weights and poor chromophores can be 
particularly problematic, and often require high levels of optimisation to obtain good 
chromatographic separation and accurate quantification. By comparison, qNMR 
analysis of these types of compounds is often relatively straightforward.257 A further 
advantage of qNMR over chromatographic analysis techniques is the ease of sample 
preparation. qNMR can be used to rapidly analyse complex mixtures such as urine 
or plasma, often with minimal sample preparation.256 
 
7.2 Prerequisites for Successful qNMR Analysis 
There are a number of prerequisites for accurate quantitative NMR analysis. The first 
of these is the choice of analysis peak. The signal intensity (I) observed after an 
NMR experiment directly relates to the number of nuclei (N) responsible for said 
signal multiplied by the spectrometer constant (Ks), as shown in the equation 
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(      ). To allow accurate qNMR measurement of peak intensity, it is essential 
that this peak be distinct from others around it in order to prevent overlap. This is 
known as “purity of the NMR signal”.254  
Early NMR instruments suffered from low sensitivity and precision of quantification, 
which made qNMR experiments disfavoured. This is not an issue for modern 
instruments as there are a number of methods for maximising sensitivity, including 
high-field strength (>400 MHz instrument), gradient shimming techniques for 
improved spectra quality, and specialised probes. To optimise the accuracy of 
integration it is essential that the baseline noise is minimal to allow the maximum 
signal-to-noise ratio. A way of doing this is by using inverse- or cryo-probes which 
can increase the signal-to-noise by more than ten-fold. However, these probes are 
expensive and can make this approach cost-prohibitive. A simpler and more 
economical solution to improve the signal-to-noise ratio is to increase the 
concentration of analyte by reducing the volume of solvent, although this is limited by 
the solubility of the analyte in the chosen solvent. Finally, increasing the number of 
scans can be used to enhance the signal-to-noise ratio.254 This may not be 
appropriate for kinetic experiments as the ratio of reactants and products is dynamic, 
which may result in inaccurate data collection.  
A problem often encountered during qNMR experiments is the presence of spinning 
side bands caused by variations in the magnetic field. These peaks appear either 
side of a genuine signal at a distance directly proportional to the frequency of 
rotation. In standard qNMR experiments these are avoided by simply preventing 
sample rotation.254 This is not possible in the case of a kinetic experiment where 
sample homogenisation is important. In our experiments spinning side bands were 
not a problem owing to the high field strength (500 MHz) of the instrument used, and 
the nature of the peak being investigated (ethynyl C-H).258  
A further consideration is the presence of 13C satellite peaks. These interfering peaks 
appear at the sides of a genuine peak and arise from 1H/13C coupling between 
adjacent nuclei. 13C satellites can be avoided through heteronuclear decoupled 
experiments or, as our experiments, by using an instrument of high field strength 
(>400 MHz).254,258 
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7.3 Optimisation of Relaxation Time - Inversion Recovery Experiment  
 
 
Figure 70 - NMR inversion recovery pulse sequence (adapted from Claridge).259 
It is important to calculate the longitudinal relaxation time (Τ1) of nuclear spin in-order 
to guarantee the best possible signal. The maximal theoretical recovery of 
magnetisation (99.33%) after a 90o rf pulse is obtained after a period of at least 5Τ1. 
One may determine the value of Τ1 in seconds (Τ1s) through inversion recovery 
sequence experiments (Figure 70). A 180o rf pulse is used to disrupt the nuclear spin 
from its thermal equilibrium causing inversion of the spin population from z+ to z-, 
which results in a negative signal (Figure 71, A – B). The system responds to offset 
this change and re-establish equilibrium, through the loss of energy in the form of 
heat. As the spin populations precess from -z towards the x-y intercept the signal is 
reduced to zero and then recovers to +z (Figure 71, B – C). Magnetisation along the 
z plane is unobservable, so after a period of time ( ) a second pulse of 90o is used to 
return the vector to the x-y plane (Figure 71, C – D).259 
 
Figure 71 - Inversion recovery sequence (adapted from Claridge).259 
If   = 0, there is no recovery of spin population, and thus the magnetisation vector 
remains at -z (Figure 72, A – B). A 90o pulse is then used causing the spin 
x y 
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x y 
z 
x y 
z 
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z 
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population to precess from -z to -y with the maximum possible signal intensity (Figure 
72, B – C). This results in a negative or ‘inverted’ spectrum. 
 
Figure 72. 
By contrast, gradually increasing the value of   to the point where   ∞ > 5Τ1 allows 
complete relaxation to occur, resulting in the maximum positive signal at +y (Figure 
73, A – C).259 
 
Figure 73. 
Accurate calculation of Τ1 in most cases is both time consuming and unnecessary 
due to the variety of nuclei and Τ1s values observable within the analyte. It is 
possible to quickly estimate Τ1 by monitoring the disappearance of signals during the 
recovery of spin population.  
The Bloch theory of NMR (Equation 2) states that recovery of +z magnetisation (Mz) 
is exponential and can be described using Equation 2. 
   
  
  
       
  
 
Therefore: 
          
       
Equation 2 - Bloch Equation (adapted from Claridge).259 
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M0 represents the magnetisation at thermal equilibrium. The time taken for this 
process to occur is represented by the constant Τ1.  This equation can be modified to 
calculate the intensity of magnetisation (Mt) as shown in Equation 3. 
           
       
Equation 3. 
When the longitudinal magnetisation reaches the x-y intercept (at time      ) the 
population difference equals zero, resulting in an Mt value also of zero. The above 
equation can therefore be rearranged to give: 
             
Therefore: 
   
     
   
            
Equation 4. 
An inversion recovery experiment was used to determine the optimum relaxation 
time for the ethynyl C-H of purine 56 (Figure 74). The experiment was run using the 
pulse program shown in Figure 70, whilst incrementally increasing the recovery time 
( ) between pulses until a positive signal for the ethynyl C-H was observed. An initial 
recovery time of zero (   = 0) (shown in black) was used to obtain the maximum 
negative signal. The recovery time ( ) was gradually increased until the signal for the 
ethynyl C-H proton was no longer visible (     ), which occurred at a time of 4 s 
(shown in orange). For this compound a relaxation time (    of 5.8 s was obtained 
using Equation 4. To obtain the maximum theoretical recovery of magnetisation, and 
obtain the strongest possible signal, this value was multiplied by 5 to give an 
optimum relaxation time of 28.9 s.  
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Figure 74 - 1H-NMR inversion recovery experiment for purine 56. 
7.4 qNMR Kinetic Analysis of Irreversible Nek2 Inhibitors 
Before commencing the qNMR experiment, there were a number of considerations 
necessary for the design of the reaction. Firstly, the choice of deuterated solvent is of 
importance. Initial attempts were made using D2O as the reaction solvent to mimic 
physiological conditions. Unfortunately, D2O was found to be unsuitable for use in 
this reaction due to the poor solubility of reagents.260 DMSO-d6 proved a suitable 
alternative as it provided excellent solubility, and the residual solvent peak is at 2.50 
ppm (1H NMR) which does not interfere with analysis. Sample concentration was 
another important factor that needed to be addressed. As stated previously, to 
improve the signal-to-noise ratio, sample concentration may be increased, but 
factors such as solubility and availability of starting materials limit the achievable 
concentration.254 A concentration of 6 mmol/L was found to provide a good balance 
between these two factors, and so this concentration was chosen for all experiments. 
CH 
CH 
CH 
CH 
CH 
CH 
CH 
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Finally, the temperature at which the reaction is performed is closely related to the 
overall rate of reaction. It was determined that a temperature of 24 oC allowed 
analysis of 6-ethynylpurine 39 over a period of 4-5 h, providing multiple analysis 
points that were ideal for accurate rate measurement.260  
N-Acetylcysteine methyl ester 239 was chosen as a suitable nucleophile for this 
reaction due to the similar reactivity of its thiol group to that of Cys-22 within the 
Nek2 ATP-binding domain. A 10-fold excess of 239 relative to the ethynyl compound 
was used to ensure that pseudo-first-order kinetics were maintained. A pseudo-first-
order reaction is a second-order reaction that utilises a large excess of one reagent 
(>10-fold). In doing so, no appreciable change in the concentration of this reagent is 
observed, which greatly simplifies calculation of the apparent rate constant k’ from 
the equation: rate         .261 
1,4-Diazabicyclo[2.2.2]octane (DABCO) was chosen as a base owing to its simple 
NMR profile and good solubility in DMSO-d6. 0.30 mole equivalents of DABCO were 
sufficient to catalyse the reaction of 6-ethynylpurine 56 and thiol 239 at an 
observable rate.260 It is thought that DABCO deprotonates 239 to form the thiolate, 
which is approximately 100-fold more reactive than the parent thiol.260 Although the 
uncatalysed reaction still proceeds, the DABCO-catalysed reaction is more 
kinetically favoured, resulting in rate enhancement without alteration of reaction 
order.262  
An appropriate internal standard is vital for successful qNMR analysis. The NMR 
signal from the internal standard must appear in a distinct region of the NMR spectra 
for accurate quantification. The standard should also have good solubility in the 
chosen solvent, be chemically inert, and have low volatility so that the concentration 
remains constant throughout the experiment.256 DMF fulfilled all of these criteria and 
was chosen as the internal standard. One mole equivalent of DMF was used, which 
allowed baseline-correction based upon the formyl proton at 7.95 ppm (1H NMR, 
DMSO-d6). Reaction progress was observed by monitoring the change in intensity 
over time of the terminal ethynyl C-H of the electrophiles 54, 56, 88, 89, and 90 
relative to the DMF internal standard.  
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7.5 qNMR Kinetic Analysis – Results  
7.5.1 Reaction of 2-Benzylpurine (56) with N-Acetylcysteine Methyl Ester (239) 
 
Reagents and Conditions: i) 239, DABCO, DMF, DMSO-d6, 24 
o
C, analysed every 10 min. 
Scheme 69. 
The first compound to be investigated was the 2-benzylpurine derivative 56. It was 
predicted that replacement of the electron-donating aniline conjugated to the purine 
for 39, by the non-conjugated benzyl group 56 might increase reactivity of the 6-
ethynyl group to nucleophilic attack. Using the conditions previously established for 
6-ethynypurine 39, 56 was successfully reacted with 239. The reaction reached 
completion after approximately 2 h and obeyed pseudo-first-order kinetics as shown 
by the linear relationship observed between ln[56] and time (Figure 75). 
 
Figure 75 - 1H-NMR spectrum (500 MHz) stacked plot showing consumption of 56.  
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Figure 76 – Consumption of benzylpurine 56 following reaction with N-acetylcysteine 
methyl ester (239). The reaction was performed in triplicate (A-C) and was monitored 
through the dissaperance of the ethynyl proton at δ 4.94 using 1H-NMR (500 MHz, 
DMSO). 
Table 3 - Apparent rate constants (k’) and half-life (s) for the reaction of 56 with 239. 
Using these data the average value of k’ was determined as 4.90 x 10-4 s-1 with a 
standard deviation (SD) of 1.0 x 10-5 s-1. Interestingly, despite predictions of a 
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marked increase in the rate of reaction when compared to parent purine 39 (k’ = 4.6 
x 10-4 s-1), no significant gain in reactivity was observed with 56. The average half-life 
(t1/2) was determined as 1415 ± 29 s. The coefficient of determination (R
2) ranged 
from 0.9203-0.9832, indicating a good fit for the data.  
7.5.2 Reaction of 2-Methylanilinopurine (54) with Thiol (239) 
Reagents and Conditions: i) 239, DABCO, DMF, DMSO-d6, 24 
o
C, analysed every 10 min. 
Scheme 70. 
The conditions used previously (0.30 mole equivalents DABCO) were employed for 
the reaction of the 2-methylanilino-6-ethynylpurine 54 with thiol 239. The reaction 
proceeded more slowly than for the parent purine 39 and did not reach completion 
after 5 h. Data analysis was thus limited to the first 160 minutes of the reaction as no 
useful information was obtained after this time-point. This compound obeyed 
pseudo-first-order kinetics as shown through the linear relationship between ln[(54)] 
and time (Figure 78).  
 
Figure 77 - 1H-NMR spectrum (500 MHz) stacked plot showing consumption of 54.  
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Figure 78 – Consumption of N-methylanilinopurine 54 following reaction with N-
acetylcysteine methyl ester (239). The reaction was performed in triplicate (A-C) and 
was monitored through the dissaperance of the ethynyl proton at δ 4.75 using 1H-
NMR (500 MHz, DMSO). 
Table 4 - Apparent rate constants (k’) and half-life for the reaction of 54 with 239. 
The average k’ value was 1.40 x 10-4 s-1 with an SD of 1.2 x 10-5 s-1. This value is 4-
fold lower than the k’ value obtained for 56. It is possible that the electron-donating 
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character of the conjugated side chain of 54 increases the overall electron density of 
the purine core, reducing the electrophilicity of the 6-ethynyl group and hence 
reactivity towards thiol 239. The average t1/2 was determined as 5072 ± 410 s. The 
relatively high SD value indicates a lack of consistency between datasets, and 
additional repeat reactions would likely lower this value leading to a more accurate 
dataset. The R2 values range from 0.8869 – 0.9895 indicating a good data fit. 
7.5.3 Reaction of Pyrrolopyrimidine (88) with Thiol (239) 
Reagents and Conditions: i) 239, DABCO, DMF, DMSO-d6, 24 
o
C, analysed every 10 min. 
Scheme 71. 
The first of the alternative heterocycles to be investigated was pyrrolopyrimidine 88. 
This compound had shown modest Nek2-inhibitory activity (IC50 = 24 µM) which was 
attributed to the low electrophilicity of the ethynyl group due to increased electron 
density relative to the parent purine 39. This compound proved particularly 
unreactive, and after 5 h the reaction had reached approximately 50% conversion of 
pyrrolopyrimidine 88 to the E and Z alkenes 242 and 243. Pseudo-first-order kinetics 
was observed as indicated by the linear relationship between ln[88] and time (Figure 
80). 
 
Figure 79 - 1H-NMR spectrum (500 MHz) stacked plot showing consumption of 88.  
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Figure 80 – Consumption of pyrrolopyrimidine 88 following reaction with N-
acetylcysteine methyl ester (239). The reaction was performed in triplicate (A-C) and 
was monitored through the dissaperance of the ethynyl proton at δ 4.71 using 1H-
NMR (500 MHz, DMSO). 
Table 5 - Apparent rate constants (k’) and half-life for the reaction of 88 with 239. 
Pyrrolopyrimidine 88 was the least reactive compound investigated. An average k’ 
value of 3.0 x 10-6 s-1 was obtained with an SD of 1.5 x 10-6 s-1. This compound was 
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150-fold less reactive than the parent purine 39 (k’ = 4.46 × 10-4 s-1) and had a t1/2 of 
6.5 ± 0.34 h.260 The R2 values range from 0.9187 – 0.9951 indicating a good data fit. 
These results demonstrate the need for an electron deficient heterocycle to maintain 
ethynyl reactivity towards electrophilic thiols. 
 
7.5.4 Reaction of Pyrazolopyrimidine (89) with Thiol (239) 
Reagents and Conditions: i) 239, DABCO, DMF, DMSO-d6, 24 
o
C, analysed every 10 min. 
Scheme 72. 
The second alternative heterocycle to be investigated was pyrazolopyrimidine 89. 
This compound had potent irreversible Nek2-inhibitory activity (IC50 = 430 nM) 
comparable with the parent purine 39 (IC50 = 150 nM). Initial reaction attempts using 
0.30 mole equivalents of DABCO resulted in consumption of pyrazolopyrimidine 89 
at a rate too fast for accurate observation. By reducing the concentration of DABCO 
to 0.03 mole equivalents the reaction proceeded at a slower rate, allowing monitoring 
over a period of 2 h. Due to insufficient availability of 89 it was only possible to 
perform a single repeat reaction rather than two repeats, as is convention.  
 
Figure 81 - 1H-NMR spectrum (500 MHz) stacked plot showing consumption of 89.  
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Figure 82 – Consumption of pyrazolopyrimidine 89 following reaction with N-
acetylcysteine methyl ester (239). The reaction was performed in duplicate (A and B) 
and was monitored through the dissaperance of the ethynyl proton at δ 4.98 using 
1H-NMR (500 MHz, DMSO). 
Table 6 - Apparent rate constants (k’) and half-life for the reaction of 89 with 239. 
The average k’ value of 89 was determined as 5.49 x 10-4 s-1 (SD of 2.82 x 10 -5 s-1) 
demonstrating a high rate of reaction with thiol 239. Compound 89 obeyed pseudo-
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first order kinetics and had an average t1/2 of 1263 ± 65 s. The R
2 values of the 
dataset ranged from 0.9408-0.9937 indicating a good data fit.  
7.5.5 Reaction of Triazolopyrimidine (90) with Thiol (239) 
Reagents and Conditions: i) 239, DABCO, DMF, DMSO-d6, 24 
o
C, analysed every 10 min. 
Scheme 73. 
The final heterocycle to be investigated was the triazolopyrimidine derivative 90. This 
compound was found to be a potent irreversible inhibitor of Nek2 (IC50 = 130 nM), 
and this was attributed to the electron-deficient heterocycle enhancing ethynyl 
reactivity towards thiol nucleophiles. Early reactions using 0.03 mole equivalents of 
DABCO proceeded very rapidly, and the reaction was complete within 30 minutes. 
Standard qNMR methodology was inadequate as only 3 data points were collected 
per experiment which was insufficient for accurate analysis. The solution to this 
problem was to reduce the number of scans from 8 to 4, which shortened the overall 
experiment time and increased the number of data points collected. 
 
Figure 83 - 1H-NMR spectrum (500 MHz) stacked plot showing consumption of 90.  
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Figure 84 – Consumption of triazolopyrimidine 90 following reaction with N-
acetylcysteine methyl ester (239).The reaction was performed in triplicate (A-C) and 
was monitored through the dissaperance of the ethynyl proton at δ 5.19 using 1H-
NMR (500 MHz, DMSO). 
Table 7 - Apparent rate constants (k’) and half-life for the reaction of 90 with 239. 
Triazolopyrimidine 90 was more than 3-fold more reactive than pyrazolopyrimidine 
89 and had an average k’ value of 17.4 x 10-4 s-1 (SD = 1.42 x 10-4 s-1). The average 
t1/2 was only 401 ± 31 s and the R
2 value ranged from 0.8291 - 0.8882 indicating 
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acceptable fit. Quality of data could possibly be improved by further increasing the 
number of data points and discounting data after 1600 s. However, this was not 
possible with the instrumentation available. 
7.6 Discussion 
 
1H-qNMR spectroscopy was successfully used to investigate the influence of 
modifications at the purine 2-position upon conjugate addition of thiol 239 to 6-
ethynyl purines 54 and 56. It was discovered that methylation of the 2-amino group 
resulted in a 4-fold reduction in the rate of the Michael addition of thiol 239 when 
compared with the parent purine 39. By contrast, replacement of the 2-anilino group 
of 39 by a benzyl group 56 resulted in no significant change in reactivity. These 
results suggest that the reduction in Nek2 inhibitory activity observed for 54 and 56 
(IC50 > 10 µM) when compared with parent purine 39 (IC50 = 150 nM) is not due to 
attenuation of ethynyl reactivity. 
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A number of heterocyclic derivatives of 6-ethynyl purine 39 were also investigated. 
Pyrrolopyrimidine 88 was the least reactive compound examined and was 
approximately 150-fold less reactive than the parent purine 39. The low reactivity of 
the ethynyl group of 88 may explain why this compound was such a poor inhibitor of 
Nek2 (IC50 = 24.3 µM). The pyrazolopyrimidine and triazolopyrimidine compounds 89 
and 90, respectively, had the highest rates of reactivity with thiol 239 and required 
only 0.03 equivalents of the DABCO catalyst. The most reactive compound was the 
triazolopyrimidine 90, which is likely due to the high electron deficiency of this 
heterocycle. Interestingly, 90 had similar Nek2 inhibitory activity to the parent purine 
39 (IC50 = 130 nM and 150 nM, respectively) despite a large increase in the reactivity 
of the ethynyl group of 90.  
 
7.7 Future qNMR Studies to Investigate the Reaction of Ethynyl-Functionalised 
Heterocycles with N-Acetylcysteine Methyl Ester (239) 
 
Figure 85. 
To further investigate the influence of the conjugated heterocycle upon ethynyl 
reactivity it would be interesting to perform qNMR experiments using imidazopyridine 
87, pyrimidine 95, and triazine 91 as substrates for reaction with thiol 239. 
Additionally, studies of functionalised purine derivatives with electron 
withdrawing/donating groups positioned around the aniline ring (248) should be 
attempted to help understand the importance of the aniline side chain for good 
ethynyl reactivity. In combination with Nek2 IC50 values, qNMR could prove a 
valuable tool in the screening of future electrophilic Nek2 inhibitors. 
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Chapter Eight: Synthesis of Purine Isosteres as Inhibitors of CDK2 
8.1 The Role of CDK2 in Cell Cycle Regulation 
CDK2 is a serine/threonine protein kinase that functions principally at the G1/S phase 
of the cell cycle.263 CDK2 has two partner cyclins – cyclin E and cyclin A, which 
regulate CDK2 function. The CDK2/cyclin-E complex is at its highest level during the 
G1/S transitions and it was initially thought that CDK2 and cyclin-E were essential for 
cell cycle progression through inhibition of the retinoblastoma protein (pRb).140 pRb 
is a tumour suppressor protein that arrests cells at G1/S preventing cell cycle 
progression. This is achieved as pRb causes inactivation of E2F family members, 
which in-turn prevents DNA transcription. Inactivation of pRb by 
hyperphosphorylation causes the release of transcription factors, which favour cell 
cycle progression.264 
Upon progression into the S-phase of the cell cycle, CDK2/cyclin-E induces cyclin-E 
autophosphorylation. The newly formed phosphorylated cyclin-E is ubiquitinated, 
which enables proteasomal degradation by F-box protein FBW7.140,265 CDK2 then 
binds cyclin-A, which changes its substrate specificity. The resulting CDK2/cyclin-A 
complex phosphorylates the protein cell division cycle 6 (Cdc6), causing Cdc6 to 
translocate to the cytoplasm of the cell, which may prevent further DNA 
replication.266 Additionally, CDK2/cyclin-A has been implicated in mitotic progression 
due to its ability to phosphorylate endogenous Cdh1, which allows the accumulation 
of cyclin-B in preparation for the G2/M transition.
267 
A further cell cycle dependent role of CDK2 is in the control of centrosome 
duplication. As described previously (Chapter 3), the duplication of centrosomes for 
mitosis is a highly ordered process and is achieved via the centrosome cycle.125 
Studies show that CDK2, together with partner cyclins E and A, may facilitate 
centrosome replication through the phosphorylation of proteins involved in the 
centrosome cycle.128,268,269 
 
 
Chapter Eight 
 
165 
8.2 Cell Cycle-Independent Functions of CDK2 
In addition to facilitating cell cycle progression, it has been established that CDK2 
has a number of secondary roles that are independent of the cell cycle. One such 
role is in the DNA damage response pathway, which enables DNA repair. In 
response to DNA damage, cell cycle progression is prevented due to cells not 
meeting the criteria of checkpoint controls at G1, S, or G2/M. This allows time to 
repair DNA damage or activate apoptosis in-order to prevent errors in mitosis.270 In 
response to DNA damage, p21Cip1/Waf1 is activated by the tumour suppressor p53.
271 
Binding of p21 to CDK2/cyclin-E causes CDK2 inhibition and induces cell cycle 
arrest at the G1/S checkpoint, which prevents replication of damaged DNA.
270 
Interestingly, it has been demonstrated in CDK2 depleted cells that CDK1/cyclin-B 
was also a substrate for p21 and compensates for CDK2 inactivation at the G1/S 
transition.272 However, CDK1 was not able to faithfully repair DNA to the extent that 
CDK2 can resulting in delayed DNA replication.270 These findings suggest CDK2 
may have an important role in the DNA repair pathway through the binding of 
additional substrates.  
 
8.3 CDK2 as a Target for Cancer Chemotherapy 
Early in vitro cellular studies using a dominant negative (DN) CDK2 construct, 
demonstrated that in the absence of CDK2, cell cycle progression was halted at the 
G1/S transition.
273 This observation suggested CDK2 is essential for the initiation of 
DNA synthesis in higher eukaryotes, which made CDK2 a priority target. However, 
later research cast doubt upon the viability of CDK2 as a cancer chemotherapeutic 
target due to its non-essential role in cell proliferation.140,274,275 CDK2 inhibitory 
studies using antisense oligonucleotides or CDK2 siRNA showed sustained cell 
proliferation in the absence of CDK2.274 Additionally, CDK2 knockout mice were 
found to be viable, indicating that CDK2 is not essential. However, it was found that 
these mice were sterile indicating the importance of CDK2 in mouse germ cell 
maturation and meiosis.140,275 A possible explanation for the apparent viability of cells 
in the absence of CDK2, was that a redundant pathway was in place, which 
compensates for CDK2 inactivation. This was later confirmed in studies that 
demonstrated that in the absence of CDK2, CDK1 is able to compensate and 
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maintain cell cycle progression through the binding of cyclin-A.276 Interestingly, 
inhibition of both CDK1 and CDK2 caused cells to arrest in G2. Despite the apparent 
non-essential role of CDK2 in cell proliferation, inhibitors of CDK2 may still be of use 
as targeted anticancer agents particularly in patients with specific tumour genotypes 
that give rise to predisposed drug sensitivity.134 Additionally, due to the secondary 
functions of CDK2 in the control of DNA damage repair pathways and centrosome 
duplication CDK2 remains an interesting target for the treatment of cancer.270 
 
8.4 SAR Studies with ATP-Competitive Heterocyclic CDK2 Inhibitors  
 
Figure 86. 
It was of interest to note the differences in CDK2-inhibitory activity observed between 
the parent purine 39 and the heterocycle derivatives 87-90. The imidazopyridine 87, 
pyrrolopyrimidine 88 and pyrazolopyrimidine 89 derivatives were found to have 
increased potency compared with the parent 6-ethynylpurine 39 whereas 
triazolopyrimidine 90 was essentially inactive as a CDK2 inhibitor. To investigate this 
further the corresponding heterocyclic derivatives of NU6102 37, a potent CDK2 
inhibitor (IC50 = 5.4 nM), were synthesised. Derivatives of NU2058 249, a modest 
CDK2 inhibitor (IC50 = 17 µM) known to potentiate cisplatin cytotoxicity, were also 
synthesised and evaluated for both CDK2 inhibitory activity and their ability to 
enhance cisplatin cytotoxicity. 
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Figure 87. 
The optimum substituent at the purine 6-position was previously identified as 
cyclohexylmethoxy, which makes hydrophobic interactions within the ribose pocket 
of the CDK2 ATP-binding domain (Figure 88).277 Non-covalent binding to the 
backbone of Glu-81 and Leu-83 within the CDK2 hinge region is facilitated by a 
triplet of H-bonds with the 2-amino group and N3- and N9-positions of purine 249. 
This hydrogen bonding motif has been shown previously to be essential for CDK2-
inhibitory activity.277 
 
Figure 88 - Binding interactions of 249 within the CDK2 ATP-binding domain.277 
A structure based design approach based upon 249, led to the discovery of 37 (IC50 
= 5 nM), a potent and selective CDK2 inhibitor. The 2-arylamino group of 37 
occupies a hydrophobic region and forms π-stacking interactions with the kinase 
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surface.277 The para-sulfonamide substituent further improves binding by making 
additional H-bond interactions with the side chain oxygen and backbone nitrogen of 
Asp-86 at the specificity surface (Figure 89).277 
 
Figure 89 – X-ray crystal structure of purine 37 in complex with CDK2.277  
 
8.5 Synthesis of Heterocyclic Derivatives of (249) and (37) 
Synthetic strategies were developed for the preparation of imidazo[4,5-b]pyridine, 
7H-pyrrolo[2,3-d]pyrimidine, 1H-Pyrazolo[3,4-d]pyrimidine and 3H-[1,2,3]Triazolo[4,5-
d]pyrimidine derivatives of 249 and 37 (Figure 90). Unlike the Nek2 inhibitors which 
contained an electrophilic ethynyl group at the purine 6-position, these compounds 
were designed to be ATP-competitive CDK2 inhibitors. Variations in the potency of 
these compounds may therefore reflect changes in H-bond interactions at the CDK2 
ATP-binding domain leading to subtle differences in the binding mode, which would 
help to further establish SAR and may allow the discovery of a new potent and 
selective series of CDK2 inhibitors. 
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Figure 90 - Heterocyclic derivatives of purines 249 and 37. 
 
8.5.1 Synthesis of Imidazo[4,5-b]pyridines (254) and (250) 
A synthetic strategy was developed for the preparation of imidazopyridines 249 and 
37 based upon the synthesis of ethynylimidazopyridine 87 (Scheme 16). Unlike the 
ethynyl series, which used an SNAr reaction to couple the aniline side chain, this 
synthesis was designed to include a Buchwald amination step, which was hoped to 
improve the yield and shorten reaction times. 
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Reagents and Conditions: i) TFE, 85 
o
C, 1 h; ii) Fe, AcOH:H2O:EtOH (1:5:15) 90 
o
C, 1 h; iii) PMBCl, 
K2CO3, DMF, 60 
o
C, 18 h; iv) Sodium cyclohexylmethoxide, DMSO, MW 100 
o
C, 2 h; v) 
Diiodomethane,  isoamyl nitrite, CuI, THF, 80 
o
C, 4 h; vi) Sulfanilamide 264, Pd2(dba)3 (4 mol%), 
XPhos (4 mol%), K2CO3, MeCN, 85 
o
C, 6 h; vii) TFA, 85 
o
C, 4 h. 
Scheme 74. 
Imidazopyridine 107 was prepared as described previously (Scheme 16). The Boc 
protecting group was removed by heating to reflux in TFE, which gave 258 in near 
quantitative yield.208 It was not possible to reduce the nitro group of 258 using the 
conditions previously employed due to low solubility of both starting material and 
product. However, an alternative approach using 2.2 equivalents of iron powder in a 
mixture of EtOH, water and AcOH (15:5:1) selectively reduced of the nitro group to 
furnish 259 in 87% yield.  
 
Reagents and conditions: i) Sodium cyclohexylmethoxide, DMSO, 0 
o
C - 100 
o
C, 1 h. 
Scheme 75. 
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An initial attempt to couple cyclohexylmethoxide (prepared by treatment of 
cyclohexymethanol with NaH) with imidazopyridine 259 was made using a literature 
procedure that was utilised for the synthesis of the purine 249 (Scheme 77).278 No 
reaction was observed at room temperature (48 h) and so the temperature was 
gradually increased (0 oC – 100 oC) resulting in decomposition of 259 and the 
formation of multiple side-products. 
 
Reagents and conditions: i) DABCO, DMSO, RT – 60 
o
C, 48 h; ii) sodium cyclohexylmethoxide, 
DMSO, RT - 100 
o
C, 48 h. 
Scheme 76. 
An alternative approach was to form the ‘DABCO-imidazopyridine’ salt 265, which 
could be used in the reaction with cyclohexylmethoxide to form imidazopyridine 254. 
It was reported that the relative rate of reaction for purines was increased ca. 10-fold 
for the displacement of the DABCO salt, when compared with the purine derivative 
259.279 The reaction of DABCO with imidazopyridine 259 resulted in no reaction so 
heating was attempted but this led to degradation of 259 and the formation of a 
multitude of side-products. It is likely that the electron-rich -system of 
imidazopyridine 259 makes SNAr reactions difficult. However, there are literature 
examples of successful SNAr reactions between 259 and primary amines.
209 In an 
attempt to prevent side-product formation it was decided to protect the N3 position of 
259 as the PMB derivative 260 (Scheme 77). 
 
Reagents and conditions: i) PMBCl, K2CO3, DMF, 60 
o
C, 18 h; ii) sodium cyclohexylmethoxide, 
DMSO, MW 100 
o
C, 2 h. 
Scheme 77. 
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Imidazopyridine 259 was successfully protected as the PMB amine 260 in moderate 
yield (42%). The PMB derivative 260 was then treated with cyclohexylmethoxide in 
DMSO. After stirring overnight at RT a small amount of product 261 was observed by 
LC-MS analysis. Microwave irradiation of the reaction mixture (100 oC, 2 h) resulted 
in consumption of the starting material with minimal side-product formation, to give 
261 in 75% yield. The PMB group of 261 was readily removed with TFA to provide 
254 in 70% yield (Scheme 78). 
 
Reagents and conditions: i) TFA, 75 
o
C, 2 h. 
Scheme 78. 
To allow further functionalisation at the 5-position, the iodo-species 262 was formed 
from imidazopyridine 261 through a Sandmeyer type reaction with diiodomethane, 
isoamyl nitrite and CuI in THF.280 This was followed by a Buchwald-Hartwig 
amination of 262 to couple the sulfanilyl side chain, furnishing 263 in 43% yield. 
 
Reagents and conditions: i) Diiodomethane, isoamyl nitrite, CuI, THF, 80 
o
C, 4 h; ii) Sulfanilamide 
264, Pd2(dba)3 (4 mol%), XPhos (4 mol%), K2CO3, MeCN, 85 
o
C, 6 h. 
Scheme 79. 
Final PMB deprotection was achieved by treatment of 263 with TFA to give 250 in 
excellent yield (99%) (scheme 80). 
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Reagents and conditions: i) TFA, 85 
o
C, 4 h. 
Scheme 80. 
 
8.5.2 Synthesis of 7H-Pyrrolo[2,3-d]pyrimidines (251) and (255) 
The synthesis of pyrrolopyrimidine derivatives 251 and 255 was developed starting 
from 2,6-diaminopyrimidin-4(3H)-one (266). Cyclisation of 266 with 
bromoacetaldehyde formed pyrrolopyrimidinone 264 in 63% yield. Chlorination was 
achieved by heating 264 in POCl3, which gave 4-chloro derivative 265 (44% yield). 
The coupling of cyclohexylmethoxide with 265 proved particularly problematic and no 
observable reaction occurred at room temperature. However, using microwave 
assisted heating (170 oC, 5 h) it was possible to synthesise 255 in a 17% isolated 
yield together with a number of uncharacterised side-products. 
Reagents and Conditions: i) HCl(aq), 90 
o
C, 30 min; ii) 266, NaOAc, H2O, 80 
o
C, 3 h; iii) POCl3, 110 
o
C, 5 h; iv) Sodium cyclohexylmethoxide, DMSO, MW 170 
o
C, 5 h.  
Scheme 81. 
 
Purification of 255 was difficult and scale-up to more than 100 mg was equally 
problematic. It was hoped that protection of the pyrrolopyrimidine N7-position of 265 
would improve the yield by preventing side reactions. 
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Table 8 - Protection of the pyrrolopyrimidine N7-position of 265 
 
Protecting 
Group 
(X) 
Protection 
Conditions 
Yield 
Deprotection 
Conditions 
Stable During Coupling 
of Cyclohexylmethoxide 
Ts 
TsCl, Et3N, THF 
RT, 18 h 
85% 
NaOH/MeOH 
Gilman Reagent 
Na/NH3 
No 
TIPS 
TIPSCl, NaH, THF 
-78 
o
C – RT, 18 h 
71% 
TFA 
TBAF 
No 
t-Boc 
Boc2O, DMAP, THF 
0 
o
C – RT, 2 h 
80% TFA No 
PMB 
PMBCl, NaH, DMF 
-78 
o
C – RT, 18 h 
49% TFA Yes
o-NB 
o-NBBr, NaH, DMF 
-78 
o
C – RT, 18 h 
63% UV irradiation No 
SEM 
SEMCl, NaH, 
MeCN 
-30 
o
C – RT, 18 h 
74% 
TFA 
TBAF 
Yes 
 
The tosyl-, trimethylsilyl- and t-Boc-protected derivatives of 265 were synthesised, 
and in each case protection of the pyrrolopyrimidine 7-position was selective and 
high yielding (71-85%). Unfortunately, none of these protecting groups withstood the 
conditions used during subsequent coupling of the cyclohexylmethoxide at the 4-
position.  
 
Reagents and conditions: i) PMBCl, NaH, DMF, 0 
o
C - RT, 18 h; ii) sodium cyclohexylmethoxide, 
THF, 0 
o
C - RT, 18 h; iii) isoamyl nitrite, SOCl2, LiCl, THF, RT, 3 h; iv) sulfanilamide 264, Pd2(dba)3 (4 
mol%), XPhos (4 mol%), K2CO3, MeCN, 80 
o
C, 4 h. 
Scheme 82. 
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The next protecting group investigated for the protection of 265 was PMB. This 
group was coupled in a reasonable yield of 49% (Scheme 82), which enabled 
attachment of the cyclohexylmethoxy group to 266 using standard conditions, 
furnishing 267 in 77% yield. A modified Sandmeyer chlorodediazotisation type 
reaction gave the chloro compound 268, which was used in the Buchwald-Hartwig 
coupling of sulfanilamide 264 to give 269 in excellent yield (85%). The final reaction 
step entailed removal of the PMB protecting group from 269. Regrettably, after 
several failed attempts using a range of conditions (Figure 91) this group could not 
be removed and this approach was abandoned. 
Figure 91 – Attempted removal of the PMB protecting group from 269. 
An alternative protecting group investigated for the protection of 265 was ortho-
nitrobenzyl (o-NB), a photolabile protecting group which can be removed easily using 
UV radiation. The likely mechanism of this deprotection has been extensively 
studied, both experimentally and theoretically, and is shown in Scheme 83.281,282 
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Scheme 83 - Photolytic cleavage of the o-NB protecting group from 
pyrrolopyrimidines (Adapted from Il'ichevet al.).282  
A photoreaction induces a proton transfer and tautomerization of the 2-nitrobenzyl 
group of 270 resulting in nitro tautomer 271. A cyclisation then forms the acetal 
intermediate 272, which ring opens to give the hemiacetal 273. The hemiacetal 273 
is then hydrolysed resulting in removal of the protecting group to give the 
unprotected pyrrolopyrimidine and 2-nitrosobenzaldehyde 274. 
 
Reagents and conditions: i) o-NBBr, NaH, DMF, 0 
o
C - RT, 18 h; ii) sodium cyclohexylmethoxide, 
THF, 0 
o
C - RT, 18 h. 
Scheme 84. 
Protection of pyrrolopyrimidine 265 at the N7-position with o-NB proceeded in 63% 
yield. However, when the coupling of the cyclohexylmethoxide group was attempted 
the   o-NB group was removed with no observable product (276) formation. A 
possible explanation for this finding is that the benzylic proton of 270 is sufficiently 
acidic to be removed by the strongly basic sodium cyclohexylmethoxide (Scheme 
84). The resulting carbanion may then tautomerise to the intermediate 277 resulting 
in removal of the o-NB group analogous to the photodeprotection mechanism 
(Scheme 85). 
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Scheme 85. 
The final protecting group to be investigated was 2-(trimethylsilyl)ethoxymethyl 
(SEM). Previous work within the research group demonstrated that SEM could be 
successfully used for the protection of N-pyrrole groups.283 There was also limited 
literature precedent for the use of SEM as a protecting group for 
pyrrolopyrimidines.284   
 
Reagents and conditions: i) SEMCl, NaH, MeCN, RT, 18 h. 
Scheme 86. 
SEM protection of pyrrolopyrimidine 265 was attempted. Initially this reaction was 
performed at RT resulting in a mixture of regioisomers 278 and 279 in a 1:1 ratio 
(Scheme 86). By cooling the reaction mixture to 0 oC formation of the unwanted 
regioisomer 279 was avoided, allowing the isolation of 278 in 74% yield (Scheme 
87). 
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Reagents and Conditions: i) SEMCl, NaH, MeCN, 0 
o
C – RT, 18 h; ii) Sodium cyclohexylmethoxide, 
THF, 0 
o
C – RT, 18 h; iii) Isoamyl nitrite, SOCl2, LiCl, THF, RT, 3 h; iv) Sulfanilamide 264, Pd2(dba)3 (4 
mol%), XPhos (4 mol%), K2CO3, MeCN, 80 
o
C, 4 h; v) TFA, RT, 18 h; vi) NH4OH, MeCN, H2O, RT,    
1 h. 
Scheme 87. 
Following SEM protection of 265, the cyclohexylmethoxy group was introduced to 
give 278 in 79% yield. This was followed by a modified Sandmeyer 
chlorodediazotization and finally a Buchwald-Hartwig amination with sulfanilamide 
264 to give pyrrolopyrimidine 282.  
Reagents and conditions: i) TFA, RT, 18 h; ii) NH4OH, MeCN, H2O, RT, 1 h. 
Scheme 88. 
Attempted final removal of the SEM protecting group from 282 by stirring with TBAF 
in THF at room temperature resulted in no reaction. The reaction mixture was 
gradually heated to reflux (70 oC, 24 h) but without success. A literature example of 
pyrrolopyrimidine SEM deprotection using this method has been reported, and it was 
unclear why the reaction was unsuccessful with 282.284 However, treatment of 282 
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with TFA resulted in the formation of hemiacetal 283 which was fully deprotected 
with aqueous ammonia in MeCN, to give the target pyrrolopyrimidine derivative 251. 
 
8.5.3 Synthesis of 1H-Pyrazolo[3,4-d]pyrimidines (252) and (256) 
A concise synthesis of pyrazolopyrimidines 252 and 256 was developed based upon 
a literature procedure (Scheme 89).228 
 
Reagents and Conditions: i) POCl3, DMF, 110 
o
C, 3 h; ii) N2H4.H2O, Et3N, THF, H2O, 50 
o
C, 1 h; iii) 
Sodium cyclohexylmethoxide, DMSO, 100 
o
C, 30 min; iv) Isoamyl nitrite, LiCl, SOCl2, DMA, 0 
o
C – 
RT, 6 h; v) Sulfanilamide 264, TFA, TFE, 80 
o
C, 48 h. 
Scheme 89. 
A tandem Vilsmeier-Haack/chlorodehydroxylation reaction of 284 gave 
dichloropyrimidine 285 in moderate yield (59%). Cyclisation with hydrazine hydrate 
gave pyrazolopyrimidine 286, which was reacted with cyclohexylmethoxide to give 
derivative 256 in 37% yield. A modified Sandmeyer chlorodediazotization reaction 
was then used which furnished 6-chloro derivative 287 in 43% yield. Finally, an acid 
catalysed SNAr reaction with sulfanilamide 264 was used to give the target 
pyrazolopyrimidine 252 in 32% yield. 
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8.5.4 Synthesis of 3H-[1,2,3]Triazolo[4,5-d]pyrimidines (253) and (257)  
A synthetic route to triazolopyrimidines 253 and 257 was developed starting from 
173, which was prepared as summarised in Scheme 90. 
 
Reagents and Conditions: i) Sodium cyclohexylmethoxide, DMSO, RT, 18 h; ii) Isoamyl nitrite, LiCl, 
SOCl2, DMA, 0 
o
C – RT, 6 h; iii) Sulfanilamide 264, TFA, TFE, 80 
o
C, 2h. 
Scheme 90. 
Triazolopyrimidine 173 was reacted with cyclohexylmethoxide in DMSO to give 
derivative 257 in 70% yield. Sandmeyer chlorodehydroxylation gave 288, which was 
unstable to chromatography and used directly in the next reaction without further 
purification. The final step was an acid-catalysed SNAr reaction of 288 with 
sulfanilamide 264 to give derivative 253 in 35% yield. It is likely that had the starting 
material been pure, this reaction would have been much higher yielding as no 
significant side-products were observed. 
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8.6 CDK2-Inhibitory Activity for Isosteres of 2-Amino-6-
Cyclohexylmethoxypurine 
 
Figure 92. 
Biological evaluation of the heterocyclic derivatives of purine 249 revealed 
compounds 254, 256 and 257 demonstrated CDK2-inhibitory activity comparable 
with the parent purine 249, whereas pyrrolopyrimidine 255 was essentially inactive 
for reasons that remain elusive. One possible explanation is that the purine 249 
makes an interaction within the CDK2 active-site by virtue of the N7, which is lost in 
the pyrrolopyrimidine derivative 255. Another possibility is that the H-bond made by 
the pyrrolopyrimidine NH may be weaker than that of the corresponding nitrogen of 
the other heterocyclic derivatives, which could lead to an alternative binding 
orientation. To further elucidate this, it would be interesting to compare the co-crystal 
structures of these compounds in complex with CDK2. Additionally, it would be 
interesting to investigate modifications of the alkoxy-group for each heterocyclic 
series to determine if trends in CDK2 inhibitory activity were heterocycle dependent. 
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8.7 CDK2 IC50 Determination of Alternative Heterocycles Based on Purine (37) 
A range of heterocyclic derivatives of the potent CDK2 inhibitor NU6102 (37) (IC50 = 
5 nM) were synthesised and evaluated for CDK2-inhibitory activity (Figure 93). 
These compounds were designed to serve as pharmacological probes to further 
evaluate CDK2 as a prospective cancer chemotherapeutic target. 
 
Figure 93. 
Imidazopyridine 250 was found to be 28-fold less active than the parent purine 37, 
whereas pyrrolopyrimidine 251 was 5-fold less active. This result was surprising 
considering that the NU2058 (249) derivative 255 was essentially inactive, which 
demonstrates the importance of the additional sulfanilamide H-bond interactions of 
these compounds. A possible explanation for the reduction in potency of 250 and 
251 when compared with purine 37 could be reduced H-bonding between the 
heterocycle and amino acids or water molecules present at the CDK2 ATP-binding 
domain caused by removal of the purine N1 or N7 nitrogen from these heterocycles. 
As such, it would be interesting to compare the X-ray co-crystal structures of these 
compounds bound to CDK2 with that of purine 37. Pyrazolopyrimidine 252 had 
similar CDK2 inhibitory activity (IC50 = 18 nM) to the purine 37. The most potent 
compound was triazolopyrimidine 253 (IC50 = 3 nM) which was equipotent with the 
parent purine 37. 
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Future work would include growth inhibition assays to determine if potency towards 
CDK2 translates into cellular activity. Screening of these compounds against a panel 
of kinases would allow observation of differences in the kinase selectivity profile for 
each compound. 
 
8.8 Potentiation of Cisplatin Cytotoxicity by NU2058 (249) and Analogues 
Cisplatin (3) is a member of a family of platinum containing drugs that have found 
widespread use in the treatment of cancer.285 Although cisplatin is effective in many 
tumour types, it is particularly effective for the treatment of testicular cancer with 
curative rates in excess of 90%.286 The mechanism of cisplatin uptake into cells is 
not fully understood, although it is believed that the drug can cross cell membranes 
through a combination of active transport and passive diffusion.286  Once inside the 
nucleus of the cell, cisplatin forms DNA adducts by covalent modification of purine 
bases predominantly at the N7-position. A second covalent modification results in a 
1,2- or 1,3-intrastrand crosslink, or in some instances interstrand crosslinks (Figure 
94).286 A consequence of this may be DNA damage due to impaired cell replication, 
inhibition of transcription, cell-cycle arrest, activation of DNA repair pathways and 
apoptosis.286  
 
Figure 94 - Cisplatin causes cell death through the formation of DNA adducts 
(adapted from Wang).286 
3 
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Cisplatin has been shown to be an effective treatment for some tumour types but has 
limited clinical use in others. In addition, previously responsive cancers may develop 
resistance due to changes in cell signalling causing increased DNA repair, altered 
cellular transport and enhanced drug efflux.285 Another limiting factor in the treatment 
of cancers with platinum containing compounds is the propensity for toxicity. 
Cisplatin and derivatives are known to have numerous side-effects including 
nephrotoxicity, emetogenesis and neurotoxicity.286,287 An effective strategy to combat 
both drug resistance and toxicity is to target the pathways involved in these 
processes. By doing so it may possible to increase drug potency whilst minimising 
toxicity. Similarly, by targeting pathways involved in cisplatin induced resistance it 
may be possible to render an otherwise ineffective drug active.285   
Previous studies have demonstrated that NU2058 (249), a modest CDK2 inhibitor 
(IC50 = 17 µM) can potentiate cisplatin-induced cytotoxicity in vitro.
288 It was initially 
hypothesised that increased cytotoxicity was as a result of CDK2 inhibition, but this 
was later disproved by comparative studies with NU6230 (289), a structurally related 
CDK2 inhibitor with similar potency (IC50 = 18 µM), and NU6102 (37), a potent and 
selective CDK2 inhibitor (IC50 = 5 nM) (Figure 95).
285 
 
 
Figure 95 - 249 and 37 potentiate cisplatin cytotoxicity in vitro (adapted from 
Harrison).285 
 Vehicle (0.1% (v/v) DMSO) 
249 (100 µM) 
289 (100 µM) 
37   (100 µM) 
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Head and neck squamous carcinoma cells (SQ20b) were treated with the 
appropriate purines for 2 h at 100 µM, followed by exposure to cisplatin for an 
additional 2 h. All compounds were found to be non-toxic when administered in the 
absence of cisplatin. LC50 values (the concentration of drug required to reduce 
plating efficiency by 50%) were determined and compared with a vehicle control of 
cisplatin alone.285 The dose modification factor (DMF) (ratio of vehicle control and 
combined treated LC50 value) was determined for each compound. It was revealed 
that 249 potentiated cisplatin cytotoxicity with a DMF value of 3.1. Similarly, NU6102 
37 enhanced cisplatin cytotoxicity with a DMF value of 2.3. Interestingly, this 
compound was substantially more potent than 249 as a CDK2 inhibitor but had 
similar activity in the cisplatin combination cytotoxicity assay. Cells treated with 289 
and cisplatin showed no significant increase in cytotoxicity. Cellular assays 
confirmed that 289 had similar cellular CDK2 inhibitory activity to 249, suggesting 
that cisplatin potentiation is independent of CDK2 inhibition.285 
The mechanism for the potentiation of cisplatin cytotoxicity by 249 remains unknown. 
It has been suggested that 249 may attenuate cellular transport of cisplatin, causing 
accumulation and thus resulting in an increase in the number of DNA adducts. A 
second possibility is that 249 modulates DNA repair pathways through interactions 
with an as of yet unidentified target resulting in enhanced cytotoxicity.285 A similar 
assay was used to evaluate the ability of derivatives 255, 256 and 257 to potentiate 
cisplatin cytotoxicity (Figure 96). 
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Figure 96 - Cisplatin combination cytotoxicity assay. 
Figure 96 shows the results from the cisplatin combined cytotoxicity assay. Whereas 
triazolopyrimidine 257 and pyrrolopyrimidine 255 did not potentiate cisplatin 
cytotoxicity, treatment with pyrazolopyrimidine 256 led to an increase in cisplatin 
cytotoxicity comparable with the parent purine 249 (DMF values = 2.3 and 3.0, 
respectively). The fact that pyrazolopyrimidine 256 and triazolopyrimidine 257 have 
similar CDK2 inhibitory activity, yet different cytotoxicity when co-administrated with 
cisplatin, suggests that the observed synergistic effects are independent of CDK2 
inhibition, which supports the previous results.285  
Future studies including CDK2 cell-based assays of all inhibitors will determine if 
these compounds inhibit CDK2 in cells. Furthermore, an investigation into the 
mechanism by which pyrazolopyrimidine 256 causes potentiation of cisplatin 
cytotoxicity, and a comparison of this compound with purine 249 would be of interest. 
Finally, imidazopyridine 254, which has similar CDK2 inhibitory activity to NU2058 
(26 µM vs. 17 µM, respectively), remains to be investigated for potentiation of 
cisplatin cytotoxicity. 
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Chapter Nine: Conclusions and Future Work 
9.1 Design and Synthesis of Irreversible Inactivators of Nek2 
6-Ethynylpurine 39 was identified as a sub-micromolar ATP-competitive irreversible 
inhibitor of Nek2 with growth-inhibitory activity in cells. This compound forms a non-
covalent binding interaction with the Nek2 hinge region at the ATP-binding domain 
via a triplet of H-bonds, which is thought to facilitate covalent modification of the 6-
ethynyl group by Cys-22. A series of derivatives of 39 were synthesised (Figure 97) 
for structure activity studies of the N9 and 2-amino H-bond donor groups. N-
methylated derivatives 52-54, phenoxypurine 55, and benzylpurine 56 were 
significantly less potent (IC50 > 10 µM) than 39 (IC50 = 150 nM), due to loss of an 
essential H-bond interaction with the Nek2 hinge region. 
 
Figure 97 – Purine based derivatives of 39 for Nek2 structure activity studies. 
Growth inhibition studies were performed upon the weakly active Nek2 inhibitors 52 
(GI50; SKBR3 = 0.31 µM) and 53 (GI50; SKBR3 = 0.22 µM), which revealed that 
these compounds had similar cellular potency as the parent purine 39 (GI50; SKBR3 
= 0.33 µM) despite poor Nek2 inhibitory activity. These findings suggested that the 
cytotoxicity of 52 and 53 was independent of Nek2 inhibition and possibly due to 
binding of an as yet undetermined target. 
A series of structurally similar heterocyclic derivatives of purine 39 (Figure 98) were 
synthesised to investigate the influence of the conjugated heterocycle upon ethynyl 
reactivity and hence irreversible Nek2 inhibitory activity. These compounds were 
designed to mimic the triplet of H-bond interactions between 39 and the Nek2 hinge 
region, which is essential for Nek2 inactivation by 6-ethynyl purines.  
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Figure 98 – Heterocyclic derivatives of purine 39. 
Deazapurines 87 and 88 were significantly less potent (IC50 = 30 µM and 24.3 µM, 
respectively) than purine 39 (IC50 = 150 nM), which was attributed to attenuation of 
ethynyl reactivity due to the increased electron density of these heterocycles. It was 
unclear whether 87 and 88 were irreversible inactivators of Nek2 or ATP-competitive 
reversible inhibitors, as such, future work should include time-dependent inhibition 
studies. By contrast, Pyrazolopyrimidine 89 and triazolopyrimidine 90 were sub-
micromolar (IC50 = 430 nM and 130 nM, respectively) irreversible inactivators of 
Nek2 with growth inhibitory activity comparable with 39. These two series may prove 
a viable alternative to the purine heterocycle and should be investigated further 
through the synthesis of a small library of substituted aniline derivatives of 89 and 90 
for use in comparative studies. 
Finally, a series of 6-membered heterocycles based upon 39 was investigated, which 
included triazine 91, pyrimidine 95, and 5-formylpyrimidine 101. Pyrimidine 95 was 
found to be weakly active (IC50 > 100 µM), whilst triazine 91 and 5-formylpyrimidine 
101 were modest Nek2 inhibitors (IC50 = 17 µM and > 10 µM, respectively). These 
findings, in addition to the limited patent space of both triazines and pyrimidines, led 
to these series being abandoned in favour of more appealing targets. 
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Future work should include the synthesis and biological evaluation of triazolopyridine 
295, imidazopyridine 296, and triazolopyridine 297, which were not synthesised due 
to time-constraints. Synthesis of triazolopyridine 295 would allow further investigation 
into the role of the pyrimidine N1 of purine 39 whilst retaining the electron-deficiency 
of the heterocycle. This compound may demonstrate greater potency than 
imidazopyridine 87 due to increased ethynyl reactivity, which could lead to the 
discovery of a new series of Nek2 inhibitors. Compounds 296 and 297 allow 
investigation into the role of the N3-position of 39, which is thought to be partially 
protonated via a H-bond with Cys-89 of the Nek2 hinge region, which is thought to 
facilitate covalent modification of the ethynyl group (Figure 27, p70). Additionally, it 
would be interesting to observe the difference in potency between 296 and 297, 
which has increased electron-deficiency. 
 
9.2 qNMR Kinetic Analysis of Irreversible Nek2 Inhibitors 
1H-qNMR studies of irreversible Nek2 inhibitors 54, 56 and 88-90 (Figure 99) was 
performed at 24 oC using N-acetylcysteine methyl ester (239) in DMSO-d6 with a 
catalytic amount of DABCO. Analysis of purines 54 and 56 revealed that modification 
of the 2-position through N-methylation or replacement of the 2-amino group with a 
benzyl group, did not significantly alter ethynyl reactivity, which confirmed that the 
reduced Nek2 inhibitory activity observed for 54 and 56 relative to purine 39 was due 
to loss of the 2-amino H-bond. Additional experiments with the heterocyclic 
derivatives 88, 89 and 90 revealed that the pyrrolopyrimidine was substantially less 
reactive than 39, whereas pyrazolopyrimidine 89 and triazolopyrimidine 90 had 
increased reactivity and required 0.03 equivalents of DABCO rather than 0.30 
equivalents, which was used in previous experiments.  
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Figure 99 - 1H-qNMR spectroscopy of selected ethynyl-compounds. 
1H-qNMR spectroscopy proved a valuable tool for the evaluation of ethynyl reactivity 
towards thiol 239. However, a limitation of this analysis technique is the requirement 
of DABCO as a base, which would not be present in a biological system. A possible 
alternative approach that should be investigated is to use an acidic catalyst, which 
could accelerate the reaction through protonation of the heterocyclic nitrogen atoms. 
It is hoped that this would more closely mimic the H-bond mediated partial-
protonation of purine 39, which is believed to facilitate covalent modification of Cys-
22 within the Nek2 ATP-binding domain (Figure 27). 
 
9.3 Design and Synthesis of ATP-Competitive CDK2 Inhibitors 
It was discovered that the heterocyclic Nek2 inhibitors 87-89 had enhanced CDK2 
inhibitory activity when compared with 39, whereas triazolopyrimidine 90 was 
essentially inactive in the CDK2 assay (IC50 > 100 µM). To further investigate this, 
heterocyclic derivatives of known purine based CDK2 inhibitors 249 (IC50 = 17 µM) 
and 37 (IC50 = 5 nM) were prepared and evaluated for CDK2 inhibitory activity 
(Figure 100). 
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Figure 100 – Heterocyclic derivatives of purines 249 and 37. 
CDK2 inhibitors based on the pyrazolopyrimidine and triazolopyrimidine heterocycles 
(256, 252, 257 and 253) had similar potency to purines 249 and 37, with the most 
potent compound being triazolopyrimidine 253 (IC50 = 3 nM). There was a significant 
difference in the potency of the functionalised imidazopyridine 250 (IC50 = 140 nM) 
and purine 37 (IC50 = 5 nM); however, imidazopyridine 254 (IC50 = 18 µM) was of 
similar potency as purine 249 (IC50 = 17 µM). Additionally, the pyrrolopyrimidine 255 
was only weakly active (IC50 > 100 µM), whereas the functionalised pyrrolopyrimidine 
251 had potent CDK2 inhibitory activity (IC50 = 26 nM). Cisplatin combined 
cytotoxicity studies of the non-functionalised heterocycles (255-257) revealed 
pyrazolopyrimidine 256 increased cisplatin cytotoxicity, comparable to purine 249, 
whereas pyrrolopyrimidine 255 and triazolopyrimidine 257 did not, for reasons that 
remain unclear. 
Future work includes kinase selectivity screens and biological testing of heterocyclic 
derivatives 250-253 to further evaluate CDK2 as a target of cancer therapeutic 
interest. Additionally, the mechanism of cisplatin potentiation by pyrazolopyrimidine 
256 and purine 249 should be further investigated through additional biological 
studies. 
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Chapter Ten: Experimental Section 
10.1 Solvents and Reagents 
All reagents used were purchased from Sigma-Aldrich, Apollo Scientific or Alfa-
Aesar and were in excess of 95% purity unless stated otherwise. Solvents were 
purchased from Fisher-scientific. Solvents stated as dry or anhydrous were stored in 
sealed glass bottles containing a SureSealTM or AcroSeal(R) septum. When required, 
solvent was removed from these bottles under dry nitrogen gas and used 
immediately. Deuterated solvent for NMR analyses were purchased from Sigma-
Aldrich. 
 
10.2 Equipment and Analysis 
10.2.1 Analytical Techniques 
1H- and 13C-NMR spectra were obtained from samples dissolved in deuterated 
solvents; chloroform (CDCl3), dimethylsulfoxide (DMSO-d6) or CD3OD using a Bruker 
Avance III 500 MHz Spectrometer (125 MHz for 13C). Chemical shift values (δ) are 
reported in parts per million (ppm) with splitting patterns abbreviated to: s (singlet), br 
s (broad singlet), d (doublet), t (triplet) and m (multiplet). The coupling constant (J) is 
given in Hz and was calculated using the software package TopspinTM developed by 
Bruker Biospin. When 13C values have not been quoted it is due to inability to 
visualise quaternary carbons. Attempts were made using high concentrations of 
analyte and increased scan times however in most cases signals for these carbons 
remained elusive. 
Fourier Transform Infrared (FTIR) spectra were obtained using a Bio-Rad FTS 
3000mx diamond attenuated total reflectance spectrometer on purified samples with 
no further preparation. Ultraviolet (UV) analysis was performed in EtOH using a 
Hitachi UV U2800A spectrophometer with an analysis range of 800-200 nm. 
LC-MS analysis was performed using a Micromass Platform LC electrospray mass 
spectrometer in positive ionisation mode (ES+) with a PDA 240-400 nm UV detector 
and a Waters Symmetry Shield RP18 3 µm, 4.6 x 20 mm column at a flow rate of 3 
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mL/min or a Waters Acquity UPLC system with PDA and ELSD employing both 
positive and negative ionisation modes and an Acquity UPLC BEH C18 1.7µm 2.1 x 
50 mm column. The mobile phase consisted of 0.1% v/v formic acid(aq) / MeCN. 
Samples analysed by high-resolution mass spectrometry (HRMS) were submitted to 
the EPSRC national mass spectrometry service centre in Swansea.  
Melting points were determined using either a Stuart Scientific SMP3 or Stuart 
SMP40 automatic melting point apparatus and were observed manually. 
cLogP and tPSA values were determined using CS ChemDrawTM Ultra 12.0 
 
10.2.2 Microwave Reactions 
Microwave assisted synthesis was performed in sealed Biotage microwave vials, 
using the Biotage Initiator Sixty microwave system.  
 
10.2.3 Chromatography 
Medium pressure automated flash chromatography (MPLC) was performed using a 
Biotage SP4 or a Varian IntelliFlash 310 flash chromatography system  with a 
solvent gradient calculated from TLC Rf values. MPLC performed on these systems 
used prepacked columns (KP-Sil, KP-NH or KP-C18). Thin layer chromatography 
(TLC) was performed using Merck TLC silica gel 60 F254 or NH2F254s plates on 
aluminium and were visualised under UV light at 245 nm. 
 
10.2.4 Analytical High Performance Liquid Chromatography 
All compounds submitted for biological evaluation were in excess of 95% purity 
which was determined using a Waters XTerra RP18, 5 µm (4.6 x 150 mm) column at 
1 mL/min in both basic (0.1% aqueous ammonia and acetonitrile) and acidic (0.1% 
formic acid and acetonitrile) conditions with a gradient of 5-100% over 15 min. 
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10.2.5 Small-Molecule X-ray Crystallography 
X-ray crystal structures were obtained by Dr. Ross W. Harrington at X-ray, 
Crystallography, School of Chemistry, Bedson Building, Newcastle University, 
Newcastle upon Tyne, NE1 7RU.  
 
10.3 Biological Evaluation of Nek2 and CDK2 inhibitors260  
Synthesised inhibitors were evaluated for Nek2 inhibitory activity and counter-
screened by Kathy Boxall, Sam Burns, Yvette Newblatt and Maura Westlake under 
the supervision of Dr. Wynne Aherne in the Analytical Screening and Technology 
Laboratory of the CR UK Centre for Cancer Therapeutics, The Institute for Cancer 
Research, Sutton, Surrey, UK, SM2 5NG. The determined inhibitory concentrations 
are reported as inhibition coefficients for 50% inhibition (IC50) or percentage inhibition 
as appropriate.  
Evaluation of inhibitors for CDK2/cyclin A3 inhibitory activity was conducted by Lan-
Zhen Wang at The Northern Institute for Cancer Research, Paul O’Gorman Building, 
Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, 
NE2 4HH.  
 
10.3.1    Nek2 Biochemical Assay  
Nek2 inhibitory activities were determined using a Caliper EZ Reader II instrument 
with either a 4 or 12 sipper microfluidic chip (Caliper Life Sciences Ltd, Runcorn, 
UK). The assay format employs an electrophoretic method which separates a 
phosphorylated peptide substrate of Nek2 from the non-phosphorylated substrate 
after incubation in the assay medium for a defined time in the presence of a chemical 
inhibitor. The separation is based on charge, with the negatively charged 
phosphopeptide migrating more rapidly towards a positively charged terminal. The 
extent of phosphorylation is proportional to the extent of functional Nek2 enzymatic 
activity in the assay solution and its ability to bind ATP to phosphorylate the peptide 
substrate. The Caliper instrument readout gives an estimate of the proportion of 
peptide substrate which is phosphorylated by uninhibited Nek2. Therefore, the 
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greater the affinity of an inhibitor for Nek2, the lower the proportion of 
phosphopeptide as detected by a fluorescence sensor. 
The assay was conducted by 1:4 dilution of a 10 mM stock solution of an inhibitor in 
DMSO by taking 15 µL of inhibitor solution and adding this to 45 µL of DMSO in the 
first row of a 384 well polypropylene assay plate (Greiner). Seven further successive 
1:3 dilutions were performed by taking 20 µL of the inhibitor solution and adding this 
to 60 µL of 100% DMSO in the well directly below, to give a 250 µM top 
concentration in DMSO. The 100% DMSO solutions were each diluted 20-fold by 
adding 2.5 µL of each well to 47.5 µL of a stock kinase buffer (25 mL, consisting of: 
stock Cisbio buffer (5 mL), 1,4-dithiothreitol (25 µL, 1 mM), MgCl2 (125 µL, 5 mM 
solution in water), Tween20 (25 µL, 0.1%) and HPLC grade water (20 mL)) to give a 
top concentration of 125 µM in 5% DMSO. To a second 384 well assay plate was 
added 4 µL of 5% DMSO solution from each well of the first assay plate to give a top 
concentration of 50 µM in 2% DMSO after a 1:2.5 dilution. To each well was added 
Nek2 enzyme (2 µL of 0.28 mg/mL aqueous solution, giving a 4 nM final 
concentration, PV3360 Invitrogen), substrate ‘peptide-11’ (5-FAM-KKLNRTLSVA-
COOH, 2 µL of 1.5 mM aqueous solution, giving a 1 µM final concentration, #760355 
Caliper Life Sciences) and finally ATP (2 µL aqueous 10 mM solution, giving a 30 µM 
final concentration) was added to initiate the reaction. The plate was immediately 
sealed and centrifuged for 1 minute to mix all of the reagents before incubation at 
room temperature for 60 min. 
The reaction was stopped after the required time by addition of 90 µL of separation 
buffer (#760367 Caliper Life Sciences). The amount of peptide 11 phosphorylation 
was then determined using the Caliper EZ Reader II instrument (1.5 psi, 1750 ΔV). 
The percentage conversion of substrate protein was measured and the percentage 
inhibition was thus calculated relative to blank wells, which contained no enzyme and 
2% DMSO, and totals wells which contained all reagents and 2% DMSO replacing 
the inhibitor.  
IC50 values were determined in duplicate over a range of 8 concentrations using 
GraphPad Prism 5, employing a non-linear regression fit of log[inhibitor] versus 
response (% inhibition) with a variable slope equation. It is noteworthy that IC50 
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values presented for the irreversible inhibitor series are the values obtained as 
above, after 60 minute incubation of the inhibitor with Nek2. 
 
10.3.2 CellTiter-Blue Assay for Cell Growth Inhibition 
U2OS human osteosarcoma cells (American Type Culture Collection, Manassas, 
Virginia, United States) were grown in McCoy’s 5A medium supplemented with 1.5 
mM L-glutamine, 25 mM HEPES, 2% penicillin/streptomycin (Invitrogen, Paisley, 
United Kingdom) and 10% foetal bovine serum (Biosera, Ringmer, East Sussex, 
United Kingdom).  MDA-MB-231 human breast cancer cells (American Type Culture 
Collection, Manassas, Virginia, United States) were grown in RPMI 1640 medium 
(Invitrogen) supplemented with 2 mM L-glutamine, 25 mM HEPES, 2% 
penicillin/streptomycin and 10% foetal bovine serum.  HeLa cells were grown in 
Dulbecco′s Modified Eagle Medium (D-MEM) (Invitrogen) supplemented with 2% 
penicillin/streptomycin and 10% foetal bovine serum.  All three cell lines were 
maintained in a humidified atmosphere of 5% CO2 at 37°C.  The medium was 
aspirated and the cells were washed with PBS (Invitrogen), trypsinized (Internal 
supply, 0.25% versene trypsin with EDTA), neutralised and counted.  Cells were 
seeded into 384-well clear tissue culture treated microtiter plates (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) at 200 cells per well in a 45 µL volume of 
the respective media.  Columns 1 and 24 had no cells added and were plated with 45 
µL of media alone.  Cells were incubated at 37°C / 5% CO2.  At 24 hours after plating, 
compounds were three-fold serially diluted in large volume V-shape 384-well 
microplates (Greiner Bio-One, Stonehouse, Gloucestershire, United Kingdom) using 
an Evolution plate handling system (PerkinElmer Life Sciences, Waltham, 
Massachusetts, USA).  Then 5 µL of diluted test compounds, Etoposide as positive 
control (Sigma-Aldrich, Gillingham, Dorset, United Kingdom), or DMSO at 1% v/v final 
concentration (Fisher Scientific, Loughborough, Leicestershire, United Kingdom) 
were added to the wells using a MiniTrack V plate handling system (PerkinElmer Life 
Sciences).  There were four replicates of each compound concentration, 32 replicates 
of DMSO wells, and 32 replicates of wells containing no cells.  Test compounds were 
screened at final concentrations of 100 µM, 33.33 µM, 11.11 µM, 3.70 µM, 1.23 µM, 
0.41 µM, 0.14 µM, and 0.05 µM.  Etoposide was screened at final concentrations of 
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10 µM, 3.33 µM, 1.11 µM, 0.37 µM, 0.12 µM, 0.041 µM, 0.014 µM, and 0.005 µM.  
After 92 hours, 5 µL of CellTiter-Blue Reagent (Promega, Southampton, United 
Kingdom) was added to the cells using a Multidrop dispenser (Thermo Electron, 
Basingstoke, Hants, United Kingdom) and incubated for 4 hours in a humidified 
atmosphere of 5% CO2 at 37°C.  After the incubation, the plates were placed at room 
temperature for 40 minutes before fluorescence was recorded (560Ex/590Em) on an 
EnVision 2103 plate reader (PerkinElmer Life Sciences).  Data were plotted as 
percentage of DMSO control against compound concentration using GraphPad Prism 
5 Software. The 50% growth inhibition (GI50) was calculated as the compound 
concentration required to reduce the cell number by 50% compared with the DMSO 
control.   
 
10.3.3    CDK2/Cyclin A3 Biochemical Assay  
Inhibition of human CDK2/Cyclin A3 was assayed as previously described187 using 
recombinant CDK2/cyclin A3 (10 µL) with 1 mg/mL histone H1 (150 µL, Sigma type 
III-S), in the presence of [gamma-32P] ATP (1-5 µL, 3000 Ci/mmol, Cat number 
NEG002A Perkin Elmer) and cold ATP (13.13 µL, 1 mM) in a final volume of 30 µl. 
The assay buffer (500 µL total volume) contained Tris-HCl pH 7.5 (50 mM) and 
MgCl2 (5 mM). The final DMSO concentration in the assay was 1% (V/V), after 
inhibitors stocks in 100% DMSO were diluted 1:10 in the appropriate assay buffer (3 
µl + 27 µl buffer), followed by addition of 3 µl of 10% inhibitor solution to a total assay 
volume of 30 µl. Therefore, the final DMSO concentration was 1%, final inhibitor 
concentration was 1/100 of the original stock solution and the final ATP 
concentration in the assay was 12.5 µM. After incubation for 10 min at 30 oC, 25 µl 
aliquots were spotted onto 2.5 cm × 3 cm pieces of Whatman P81 phosphocellulose 
paper, and after 20 s, the filters were washed five times (> 5 min each time) in 1% 
phosphoric acid. The dry filters were transferred into 6 ml plastic scintillation vials, 
5ml scintillation fluid (Amersham) was added, and the radioactivity was measured 
using a scintillation counter. 
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10.3.4 Nek2 Protein Crystallography 
Nek2 purine co-crystal structures were solved by Dr Richard Bayliss and Dr Corine 
Mas-Droux at the Section of Structural Biology, The Institute for Cancer Research, 
237 Fulham Road, London, SW3 6JB. Crystal structures of novel ethynyl 
heterocycles were solved as part of a 4-week placement under the supervision of Dr 
Richard Bayliss and Dr Sharon Yeoh at the University of Leicester, Henry Welcome  
Building, Lancaster Rd, Leicester, LE1 9HN. 
 
10.4 Index of Synthesised Compounds 
 
6-Chloro-2-fluoro-9H-purine (58) 
 
6-Chloro-2-fluoro-9-methyl-9H-purine (60) and 6-chloro-2-fluoro-7-methyl-7H-purine (59) 
 
2-Fluoro-9-methyl-6-((triisopropylsilyl)ethynyl)-9H-purine (62) and 2-fluoro-7-methyl-6-
((triisopropylsilyl)ethynyl)-7H-purine (61) 
 
9-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (64) 
 
7-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (63) 
 
6-Ethynyl-9-methyl-N-phenyl-9H-purin-2-amine (53) 
 
6-Ethynyl-7-methyl-N-phenyl-7H-purin-2-amine (52) 
 
1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (128) 
 
2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine (129) 
 
2,4-Dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (130) 
 
2-Chloro-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidine (131) 
 
N-Phenyl-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (132) 
 
N-Phenyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (140) 
 
4-Ethynyl-N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine (88) 
 
2-(3-Aminophenyl)acetamide (290) 
 
2-(3-((7-Tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl) 
amino)phenyl)acetamide (141) 
 
2-(3-((4-((Triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino) phenyl)acetamide 
(291) 
 
2-(3-((4-Ethynyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acetamide (231) 
 
3H-Imidazo[4,5-b]pyridine (103) 
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3H-Imidazo[4,5-b]pyridine 4-oxide (104) 
 
7-Chloro-3H-imidazo[4,5-b]pyridine (105) 
 
tert-Butyl 7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (106) 
 
tert-Butyl 7-chloro-5-nitro-3H-imidazo[4,5-b]pyridine-3-carboxylate (107) 
 
tert-Butyl 5-amino-7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (108) 
 
7-Chloro-5-fluoro-3H-imidazo[4,5-b]pyridine (109) 
 
Chloro-5-fluoro-3-(tetrahydro-2H-pyran-2-yl)-3H-imidazo[4,5-b]pyridine (110) 
 
5-Fluoro-3-(tetrahydro-2H-pyran-2-yl)-7-((triisopropylsilyl)ethynyl)-3H-imidazo [4,5-
b]pyridine (111)  
 
5-Fluoro-7-((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridine (112) 
 
N-Phenyl-7-((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridin-5-amine (113) 
 
7-Ethynyl-N-phenyl-3H-imidazo[4,5-b]pyridin-5-amine (87) 
 
2,4,6-Trichloropyrimidine-5-carbaldehyde (144) 
 
4,6-Dichloro-1H-pyrazolo[3,4-d]pyrimidine (145) 
 
4,6-Dichloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (146) 
 
6-Chloro-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-
d]pyrimidine (147) 
 
6-Chloro-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (148) 
 
N-Phenyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (149) 
 
4-Ethynyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine (89) 
 
1-(2,4,6-Trichloropyrimidin-5-yl)ethanol (158) 
 
1-(2,4,6-Trichloropyrimidin-5-yl)ethanone (159) 
 
4,6-Dichloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (160) 
 
4,6-Dichloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d] pyrimidine (161) 
 
6-Chloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-
pyrazolo[3,4-d]pyrimidine (162) 
 
6-Chloro-3-methyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (163) 
 
3-Methyl-N-phenyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (164) 
 
4-Ethynyl-3-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine (165) 
 
6-Chloro-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine (171) 
 
6-Chloropyrimidine-2,4,5-triamine (172) 
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7-Chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (173) 
 
tert-Butyl 5-amino-7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-carboxylate (174) 
 
tert-Butyl 5-amino-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine-3-
carboxylate (179) 
 
7-((Triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (175) 
 
2-(3-((7-((Triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl) amino)phenyl) 
acetamide (292) 
 
2-(3-((7-Ethynyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)amino)phenyl) acetamide (232) 
 
4,6-Dichloro-N-phenyl-1,3,5-triazin-2-amine (184) 
 
4-Chloro-N-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-amine (185) 
 
N
2
-Methyl-N
4
-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (186) 
 
N
2
-Ethyl-N
4
-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (187) 
 
N
2
-(4-Methoxybenzyl)-N
4
-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine 
(188) 
 
6-Ethynyl-N
2
-methyl-N
4
-phenyl-1,3,5-triazine-2,4-diamine (92) 
 
6-Ethynyl-N
2
-ethyl-N
4
-phenyl-1,3,5-triazine-2,4-diamine (93) 
 
6-Ethynyl-N
2
-(4-methoxybenzyl)-N
4
-phenyl-1,3,5-triazine-2,4-diamine (94) 
 
N
2
-Phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (293) 
 
6-Ethynyl-N
2
-phenyl-1,3,5-triazine-2,4-diamine (91) 
 
Phenylguanidine nitrate (204) 
 
6-Hydroxy-2-(phenylamino)pyrimidin-4(1H)-one (206) 
 
4,6-Dichloro-N-phenylpyrimidin-2-amine (207) 
 
6-Chloro-N
4
-methyl-N
2
-phenylpyrimidine-2,4-diamine (208) 
 
6-Chloro-N
4
-ethyl-N
2
-phenylpyrimidine-2,4-diamine (209) 
 
6-Chloro-N
4
-(4-methoxybenzyl)-N
2
-phenylpyrimidine-2,4-diamine (210) 
 
6-((tert-Butyldimethylsilyl)ethynyl)-N
4
-methyl-N
2
-phenylpyrimidine-2,4-diamine (211) 
 
6-((tert-Butyldimethylsilyl)ethynyl)-N
4
-ethyl-N
2
-phenylpyrimidine-2,4-diamine (212) 
 
6-((tert-Butyldimethylsilyl)ethynyl)-N
4
-(4-methoxybenzyl)-N
2
-phenylpyrimidine-2,4-diamine 
(213) 
 
6-((tert-Butyldimethylsilyl)ethynyl)-N
2
-phenylpyrimidine-2,4-diamine (220) 
 
5-Bromo-6-((tert-butyldimethylsilyl)ethynyl)-N
2
-phenylpyrimidine-2,4-diamine (222) 
 
6-((tert-Butyldimethylsilyl)ethynyl)-5-chloro-N
2
-phenylpyrimidine-2,4-diamine (221) 
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6-Ethynyl-N
4
-methyl-N
2
-phenylpyrimidine-2,4-diamine (96) 
 
N
4
-Ethyl-6-ethynyl-N
2
-phenylpyrimidine-2,4-diamine (67) 
 
6-Ethynyl-N
4
-(4-methoxybenzyl)-N
2
-phenylpyrimidine-2,4-diamine (98) 
 
6-Ethynyl-N
2
-phenylpyrimidine-2,4-diamine (95) 
 
5-Bromo-6-ethynyl-N
2
-phenylpyrimidine-2,4-diamine (100) 
 
5-Chloro-6-ethynyl-N
2
-phenylpyrimidine-2,4-diamine (99) 
 
7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (257) 
 
4-((7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)amino) 
benzenesulfonamide (253) 
 
2-Amino-4,6-dichloropyrimidine-5-carbaldehyde (285) 
 
4-Chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (286) 
 
4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (256) 
 
6-Chloro-4-(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (287) 
 
4-((4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6yl)amino)benzene sulfonamide 
(252) 
 
2-Amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (264) 
 
4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine (265) 
 
4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (255) 
 
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (279) 
 
4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
amine (280) 
 
2-Chloro-4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidine (281) 
 
4-((4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
yl)amino)benzenesulfonamide (282) 
 
4-((4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino) benzenesulfonamide 
(251) 
 
N-Phenyl-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (176) 
 
7-Ethynyl-N-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (90) 
 
2-Benzyl-1H-purin-6(9H)-one (81) 
 
2-Benzyl-6-chloro-9H-purine (82) 
 
tert-Butyl 2-benzyl-6-chloro-9H-purine-9-carboxylate (83) 
 
tert-Butyl 2-benzyl-6-((triisopropylsilyl)ethynyl)-9H-purine-9-carboxylate (82) 
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2-Benzyl-6-((triisopropylsilyl)ethynyl)-9H-purine (85) 
 
2-Benzyl-6-ethynyl-9H-purine (56) 
 
N-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (66) 
 
6-Ethynyl-N-methyl-N-phenyl-9H-purin-2-amine (54) 
 
6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine (70) 
 
9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (71) 
 
2-Chloro-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (72) 
 
9-(4-Methoxybenzyl)-2-phenoxy-6-((triisopropylsilyl)ethynyl)-9H-purine (73) 
 
2-Phenoxy-6-((triisopropylsilyl)ethynyl)-9H-purine (68) 
 
6-Ethynyl-2-phenoxy-9H-purine (55) 
 
N-Benzyltriethylammonium nitrite (294) 
 
4,6-Dichloro-2-(phenylamino)pyrimidine-5-carbaldehyde (228) 
 
4-Chloro-6-((4-methoxybenzyl)amino)-2-(phenylamino)pyrimidine-5-carbaldehyde (229) 
 
4-((tert-Butyldimethylsilyl)ethynyl)-6-((4-methoxybenzyl)amino)-2-(phenylamino)pyrimidine-
5-carbaldehyde (230) 
 
4-Amino-6-((tert-butyldimethylsilyl)ethynyl)-2-(phenylamino)pyrimidine-5-carbaldehyde 
(226) 
 
4-Amino-6-ethynyl-2-(phenylamino)pyrimidine-5-carbaldehyde (101) 
 
7-Chloro-5-nitro-3H-imidazo[4,5-b]pyridine (258) 
 
7-Chloro-3H-imidazo[4,5-b]pyridin-5-amine (259) 
 
7-Chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (260) 
 
7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (261) 
 
7-(Cyclohexylmethoxy)-5-iodo-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (262) 
 
4-((7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-yl) 
amino)benzenesulfonamide (263) 
 
4-((7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-yl)amino) benzenesulfonamide (250) 
 
7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-amine (254) 
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10.5 General Procedures 
 
10.5.1 General Procedure A: TBAF Mediated Silyl Deprotection of Terminal 
Acetylenes 
To a solution of the appropriate silyl protected acetylene in THF (50 mL/g) was 
added TBAF solution (1 M in THF, 1.1 equiv.). The reaction mixture was stirred (RT, 
15 min) then TBAF scavenger beads were added (10 equiv. by weight). The reaction 
mixture was stirred overnight, filtered then the solvent was removed in vacuo. The 
crude product was redissolved (EtOAc) then dry loaded onto silica and purified as 
indicated. 
 
10.5.2 General Procedure B: Nucleophilic Aromatic Substitution of 4-Chloro-N-
Phenyl-6-((Triisopropylsilyl)ethynyl)-1,3,5-Triazin-2-Amine (185) 
To a stirred solution of 4-chloro-N-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-
amine (20 mg, 0.052 mmol) in THF (50 mL/g) was added the appropriate amine (3 
equiv.). The resulting mixture was stirred (RT, 1 h). The solvent was removed in 
vacuo and the crude product redissolved in EtOAc (15 mL). The resulting solution 
was washed with water (3 x 15 mL) then dried (Na2SO4). The crude product was dry 
loaded onto silica and purified as indicated. 
 
10.5.3 General Procedure C: Nucleophilic Aromatic Substitution of 4,6-
Dichloro-N-Phenylpyrimidin-2-Amine (207) 
To a stirred solution of 4,6-dichloro-N-phenylpyrimidin-2-amine (200 mg, 0.83 mmol) 
in THF (15 mL/g) was added the appropriate amine (2 equiv.) followed by KHCO3 
(100 mg, 1.0 mmol). The resulting mixture was heated (80 oC, 6 h) resulting in 
consumption of the starting material. The reaction mixture was acidified with 
aqueous HCl(aq) (1 M) (30 mL) then extracted with EtOAc (3 x 30 mL). The combined 
organic layers were washed with NaHCO3(aq) (45 mL) and water (2 x 45 mL) then 
dried (Na2SO4). The crude product was dry loaded onto silica and purified as 
indicated. 
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10.5.4 General Procedure D: Suzuki Coupling of tert-Butyldimethylsilyl 
Acetylene Boronic Acid Pinacol Ester to Functionalised Pyrimidines 
To a solution of the appropriate chloro pyrimidine (1 equiv.) in anhydrous dioxane 
(40 mL/g) was added tert-butyldimethylsilyl acetylene boronic acid pinacol ester (1.5 
equiv.), Cs2CO3 (1.5 equiv.) and tetrakis(triphenylphosphine)palladium(0) 
(Pd(PPh3)4) (0.1 equiv.). The reaction mixture was degassed (N2, 30 min) then 
heated under microwave irradiation (2 h, 140 oC). The reaction mixture was filtered 
through Celite and EtOAc (100 mL/g) was added. The resulting solution was washed 
with water (3 x 50 mL/g), dried (Na2SO4) and dry loaded onto silica and purified as 
indicated.  
 
10.5.5 General Procedure E: TFA Catalysed Coupling of Aromatic Amines with 
Halogenated Heterocycles 
To a solution of the appropriate fluoro or chloro heterocycle (1 equiv.) in TFE (10 
mL/g) was added the aromatic amine (3 equiv.) and TFA (2.5 equiv.). The resulting 
solution was heated (110 oC, 18h) then cooled (RT) and added to NaHCO3(aq) (100 
mL/g). The aqueous mixture was extracted with EtOAc (3 x 100 mL/g) and the 
combined organic layers were washed with water (2 x 150 mL/g), dried (Na2SO4) 
and purified as indicated. 
 
10.5.6 General Procedure F: 1H-qNMR Studies260 
The ethynyl heterocycle (690 µL from a stock solution in DMSO-d6 containing 4.2 
µmol of compound) was added to a 10-fold excess of N-acetylcysteine methyl ester 
239 (7.48 mg, 42 µmol). The solution temperature was maintained at approximately 
24 °C (water-bath) before addition of a DMSO-d6 solution (10 µL) containing DABCO 
(0.14 mg, 1.26 µmol) and DMF (0.33 µL, 4.2 µmol) to afford a final ethynyl 
substituted compound in a concentration of 6 mM in a total volume of 700 µL. The 
NMR tube containing the reagents was inverted several times to aid mixing and 
dissolution of reagents. The thoroughly mixed solution was inserted into the NMR 
machine cavity and the acquisition of quantitative 1H NMR data was immediately 
initiated. The time between the addition of the DABCO/DMF-solution and the 
completion of the first 1H-qNMR experiment was monitored and subsequent time 
intervals between experiments were calculated based on the defined parameters.  
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6-Chloro-2-fluoro-9H-purine (58) 
 
A polytetrafluoroethylene (PFTE) conical flask was charged with tetrafluoroboric acid 
(180 mL) and 2-amino-6-chloro purine (9.0 g, 53.1 mmol). The resulting mixture was 
cooled to 0 oC and an aqueous solution of sodium nitrite (7.3 g, 0.106 mol) was 
introduced dropwise with stirring over a period of 75 min. The reaction mixture was 
then warmed (RT) and stirred for an additional 20 min before being cooled to -15 oC 
and neutralised (NaOH). The resulting aqueous solution was extracted with EtOAc (2 
x 500 mL) and the solvent removed under vacuum to give the title compound (54) as 
a pale yellow solid (6.0 g, 0.035 mol, 66%) which was used in the next reaction 
without any further purification.  
Rf = 0.41 (1:9 MeOH/DCM); m.p. 169-173 
oC; UV λmax (EtOH/nm) 270.0; IR ѵmax/cm
-
1: 3488, 2961, 2802, 2569, 2155,1584; 1H NMR (500 MHz, DMSO-d6) δ 8.62 (1H, s, 
C8-H), 14.01 (1H, br s, N9-H); 13C NMR (125 MHz, DMSO-d6) δ 128.1 (Ar-C), 147.5 
(Ar-C), 148.6 (Ar-C), 156.0 (C-Cl), 162.3 (C-F); 19F NMR (500 MHz, DMSO-d6) δ -
52.8; LRMS (ES+) m/z 173.1 [M+H]+.  
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6-Chloro-2-fluoro-9-methyl-9H-purine (60) and 6-chloro-2-fluoro-7-methyl-7H-
purine (59) 
 
To a solution of chloro-2-fluoro-9H-purine (58) (1.00 g, 6.37 mmol) in anhydrous 
DMF (14 mL) was added K2CO3 (0.88 g, 6.37 mmol). The reaction mixture was 
stirred (RT, 5 min) then iodomethane (435 μL, 6.37 mmol) was added dropwise to 
the reaction mixture and the vessel sealed. The reaction mixture was stirred at RT 
for 18 h. The iodomethane was removed by vacuum distillation into a rotary 
evaporator containing a 3:1 mixture of MeOH/NH4OH(32%), and residual DMF was 
removed under high vacuum. The crude product was redissolved in EtOAc (30 mL), 
dry loaded onto silica and purified by MPLC on silica (2:98 MeOH/DCM) to give a 
mixture of non-separable regioisomers (60) and (59) (ratio of  2:1 respectively 
(NMR)) as an off-white crystalline solid (0.81 g, 4.32 mmol, 75%). 
N9-Methylated compound (60) 
Rf 0.45 (5:95 MeOH/DCM); 
1H NMR (500 MHz, DMSO-d6) δ 3.82 (3H, s, CH3), 8.66 
(1H, s, C8-H); LRMS (ES+) m/z 187.1 [M+H]+. 
 
N7-Methylated compound (59) 
Rf 0.45 (5:95 MeOH/DCM); 
1H NMR (500 MHz, DMSO-d6) δ 4.13 (3H, s, CH3), 8.87 
(1H, s, C8-H); 19F NMR (500 MHz, DMSO-d6) δ -52.9, -52.4 
 
Note: Compound was not fully characterised due to inseparable mixture of 
regioisomers. 
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2-Fluoro-9-methyl-6-((triisopropylsilyl)ethynyl)-9H-purine (62) and 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine (61) 
 
The inseparable mixture of 6-chloro-2-fluoro-9-methyl-9H-purine (60) and 6-chloro-2-
fluoro-7-methyl-7H-purine (59) (0.74 g, 3.97 mmol) was dissolved in anhydrous THF 
(16 mL). (Triisopropylsilyl)acetylene (996 μL, 4.44 mmol) was added followed by 
Pd(PPh3)2Cl2 (56 mg, 0.08 mmol), CuI (15 mg, 0.08 mmol) and triethylamine (1.38 
mL, 9.92 mmol). The reaction mixture was degassed (20 min, N2) and shielded from 
light. The reaction mixture was then stirred (RT, 18 h) resulting in a colour change 
from yellow to brown. The crude product was filtered over a pad of Celite then dry 
loaded onto silica. 2-Fluoro-9-methyl-6-((triisopropylsilyl)ethynyl)-9H-purine (62) was 
purified by MPLC (3:2 EtOAc/petrol) as a yellow solid (624 mg, 1.87 mmol, 47%). 
Rf = 0.43 (3:2 EtOAc/petrol); m.p. 114-115 
oC; UV λmax (EtOH/nm) 301.0; IR 
ѵmax/cm
-1: 2944, 2866, 1581, 1509; 1H NMR (500 MHz, CDCl3) δ 1.11-1.20 (21H, m, 
SiCH and CH3), 3.85 (3H, s, CH3), 8.06 (1H, s, C
8-H); 13C NMR (125 MHz, CDCl3) δ 
11.3 ((Si(CH(CH3)2)3), 18.7 ((Si(CH(CH3)2)3), 30.1 (N
9CH3), 99.9 (C≡C-Si), 105.3 
(C≡C-Si), 133.7 (Ar-C), 133.8 (Ar-C), 143.0 (Ar-C), 143.2 (Ar-C), 146.6 (Ar-C), 157.8 
(C8-C), 159.5 (C-F); 19F NMR (500 MHz, DMSO-d6) δ -52.4; LRMS (ES+) m/z 333.1 
[M+H]+.  
 
2-Fluoro-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purine (61) was purified by 
preparative TLC (1:1 EtOAc/petrol) and obtained as a yellow solid (385 mg, 1.16 
mmol, 29%). 
Rf = 0.18 (3:2 EtOAc/petrol); m.p. 98-99 
oC; UV λmax (EtOH/nm) 298.0; IR ѵmax/cm
-1: 
3101, 3077, 2943, 2924, 2866; 1H NMR (500 MHz, CDCl3) δ 1.10-1.16 (21H, m, 
SiCH and CH3), 3.95 (3H, s, CH3), 7.96 (1H, s, C
8-H); 13C NMR (125 MHz, CDCl3) δ 
Chapter Ten 
 
208 
11.5 ((Si(CH(CH3)2)3), 19.7 ((Si(CH(CH3)2)3), 30.4 (N
7CH3), 100.1 (C≡C-Si), 104.2 
(C≡C-Si), 134.2 (Ar-C), 135.0 (Ar-C), 141.0 (Ar-C), 142.6 (Ar-C), 148.0 (Ar-C), 160.1 
(Ar-C), 161.2 (C-F); 19F NMR (500 MHz, DMSO-d6) δ -52.58; LRMS (ES+) m/z 333.1 
[M+H]+.  
 
9-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (64) 
 
The title compound was prepared following general procedure E using: 2-fluoro-9-
methyl-6-((triisopropylsilyl)ethynyl)-9H-purine (62) (300 mg, 0.911 mmol), aniline 
(166 μL, 1.82 mmol) and TFA (351 μL, 4.56 mmol) in TFE (10 mL). The resulting 
dark orange oil was purified by MPLC on silica (2:3 EtOAc/petrol) to give the title 
compound (64) as a yellow oil (270 mg, 0.67 mmol, 74%). 
Rf = 0.27 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 276.0; IR ѵmax/cm
-1: 2944, 2866, 
1581, 1509; 1H NMR (500 MHz, CDCl3) δ 1.13-1.28 (21H, m, SiCH and CH3), 3.80 
(3H, s, CH3), 7.03 (1H, tt, J = 7.4 and 1.1 Hz, C
1-H), 7.32 (2H, app. t, J = 8.0 Hz, C2-
H), 7.38 (1H, br s, ArNHAr), 7.70 (1H, d, J = 7.3 Hz, C3-H), 7.82 (1H, s, C4-H); 13C 
NMR (125 MHz, CDCl3) δ 11.4 ((Si(CH(CH3)2)3), 18.8 ((Si(CH(CH3)2)3), 29.6 
(N9CH3), 101.1 (C≡C-Si), 101.2 (C≡C-Si), 118.6 (Ar-C), 122.2 (Ar-C), 129.0 (Ar-C), 
129.6 (Ar-C), 140.0 (Ar-C), 142.1 (Ar-C), 143.6 (Ar-C), 153.5 (Ar-C), 156.4 (Ar-C); 
LRMS (ES+) m/z 406.3 [M+H]+.  
 
 
 
 
Chapter Ten 
 
209 
7-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (63) 
 
The title compound was prepared following general procedure E using: 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine (61) (385 mg, 1.16 mmol), aniline (211 
μL, 2.32 mmol) and TFA (446 μL, 5.79 mmol) in TFE (10 mL). The resulting dark 
orange oil was purified by MPLC on silica (2:3 EtOAc/petrol) to give the title 
compound (63) as a yellow oil (233 mg, 0.58 mmol, 50%). 
Rf = 0.18 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 268.0; IR ѵmax/cm
-1: 2946, 
2868,1579; 1H NMR (500 MHz, DMSO-d6) δ 1.13-1.27 (21H, m), 4.09 (3H, s, CH3), 
7.00 (1H, tt, J = 7.4 and 1.1 Hz, C1-H), 7.28 (1H, br s, ArNHAr), 7.32 (2H, dd, J = 8.4 
and 7.4 Hz, C2-H), 7.77 (1H, d, J = 7.6, C3-H), 7.96 (1H, s, C4-H); 13C NMR (125 
MHz, DMSO-d6) δ 10.5 ((Si(CH(CH3)2)3), 20.1 ((Si(CH(CH3)2)3), 31.7 (N
7CH3), 104.2 
(C≡C-Si), 105.1 (C≡C-Si), 120.6 (Ar-C), 124.2 (Ar-C), 131.0 (Ar-C), 132.4 (Ar-C), 
141.1 (Ar-C), 143.2 (Ar-C), 145.1 (Ar-C), 155.4 (Ar-C), 157.9 (Ar-C); LRMS (ES+) 
m/z 406.3 [M+H]+.  
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6-Ethynyl-9-methyl-N-phenyl-9H-purin-2-amine (53) 
 
 
 
The title compound was prepared following general procedure A using: 9-methyl-N-
phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (64) (273 mg, 0.67 mmol) and 
TBAF (1 M in THF (1.00 mL, 1.00 mmol) in THF (15 mL). The crude product was 
purified by MPLC on silica (4:1 EtOAc/petrol) to give the title compound (53) as a 
yellow solid (165 mg, 0.66 mmol, 98%). 
Rf = 0.27 (2:3 EtOAc/petrol); m.p. 200 
oC (dec.); UV λmax (EtOH/nm) 261.0; IR 
ѵmax/cm
-1: 3302, 3263, 3188, 3111, 3083, 3047, 2866, 2115, 1791; 1H NMR (500 
MHz, CDCl3) δ 3.64 (1H, s, CH ethynyl), 3.85 (1H, s, CH3), 7.05 (1H, tt, J = 7.1 and 
1.1 Hz, C1-H), 7.31 (1H, br s, ArNHAr), 7.36 (2H, dd, J = 8.4 and 7.4 Hz, C2-H), 7.70 
(2H, d, J = 7.6 Hz), 7.84 (1H, s, C4-H); 13C NMR (125 MHz, DMSO-d6) δ 29.3 
(N9CH3), 78.9 (C≡C-H), 87.2 (C≡C), 118.3 (Ar-C), 121.1 (Ar-C), 128.5 (Ar-C), 128.9 
(Ar-C), 145.3 (Ar-C), 153.4 (Ar-C), 156.1 (Ar-C); HRMS calcd for C14H12N5O [M+H]
+  
250.1087, Found 250.1087. 
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6-Ethynyl-7-methyl-N-phenyl-7H-purin-2-amine (52) 
 
 
The title compound was prepared following general procedure A using: 7-methyl-N-
phenyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (63) (223 mg, 0.55 mmol) and 
TBAF (1 M in THF (825 μL, 0.825 mmol) in THF (15 mL). The crude product was 
purified by MPLC on silica (4:1 EtOAc/petrol) to give the title compound (52) as a 
yellow solid (64 mg, 0.26 mmol, 47%). 
Rf = 0.27 (2:3 EtOAc/petrol); m.p. 240 
oC (dec.); UV λmax (EtOH/nm) 271.0; IR 
ѵmax/cm
-1: 3302, 3263, 3188, 3111, 3083, 3047, 2866, 2115, 1791; 1H NMR (500 
MHz, DMSO-d6) δ 3.99 (3H, s, CH3), 5.00 (1H, s, CH ethynyl), 6.91 (1H, tt, J = 7.3 
and 1.1 Hz, C1-H), 7.28 (2H, dd, J = 8.5 and 7.9 Hz, C2-H), 7.81 (2H, d, J = 7.70 Hz, 
C3-H), 8.45 (1H, s, C4-H), 9.62 (1H, br s, ArNHAr); 13C NMR (125 MHz, DMSO-d6) δ 
32.8 (N7CH3), 78.2 (C≡C-H), 87.5 (C≡C), 118.0 (Ar-C), 120.4 (Ar-C), 120.7 (Ar-C), 
128.4 (Ar-C), 133.1 (Ar-C), 141.0 (Ar-C), 150.3 (Ar-C), 156.4 (Ar-C), 162.5 (Ar-C); 
HRMS calcd for C14H12N5O [M+H]
+  250.1087,  Found 250.1087. 
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1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (128)289,290 
 
To a mixture of bromoacetaldehyde diethyl acetal (596 µL, 4.0mmol) and water (1.75 
mL) was added HCl(aq) (2 M) (450 µL, 0.91 mmol). The biphasic mixture rapidly 
stirred with heating until a homogenous solution was formed (90 oC, 30 min). The 
solution was cooled (RT) and NaOAc (338 mg, 4.12 mmol) was added. In a separate 
flask a suspension of 6-aminouracil (503 mg, 4.0 mmol) and NaOAc (175 mg, 2.13 
mmol) in water (3.75 mL) was stirred (RT). The freshly prepared bromoacetaldehyde 
solution was added in a single portion and the reaction was heated (80 oC, 4h) 
resulting in a light brown precipitate. The reaction mixture was cooled to 0 oC for 90 
min resulting in further precipitation which was collected by filtration. The solid was 
washed with cold water (2 x 25 mL) and acetone (25 mL) to give the title compound 
(128) as a light brown solid (403 mg, 2.7 mmol, 67%) which was used in the next 
reaction without further purification. 
m.p. 280 oC (dec.) (Lit > 250 oC); 1H NMR (500 MHz, DMSO-d6) δ 6.22 (1H, dd, J = 
2.0 and 2.1 Hz, C1-H), 6.56 (1H, dd, J = 2.0 and 2.1 Hz, C2-H), 10.47 (1H, br s, NH), 
11.09 (1H, br s, NH), 11.44 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 98.6 
(C5H), 102.8 (Ar-C), 116.5 (Ar-C), 138.8 (C6H), 151.0 (Ar-C), 159.9 (Ar-C); LRMS 
(ES+) m/z = 152.1 [M+H]+ 
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2,4-Dichloro-7H-pyrrolo[2,3-d]pyrimidine (129) 184,291 
 
A suspension of 1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (128) (77 mg, 0.51 
mmol) in phenylphosphoic dichloride (713 μL, 5.1 mmol) was and heated using 
microwave irradiation (185 oC, 30 min). The resulting dark brown oil was added 
dropwise to a rapidly stirred beaker of ice-water (50 ml) which was then neutralised 
(NaOH) and extracted with EtOAc (3 x 50 mL). The combined organic layers were 
dried (MgSO4) and dry loaded onto silica. The crude product was purified by MPLC 
(3:7 EtOAc/petrol) to give the title compound (129) as an off-white solid (48 mg, 0.26 
mmol, 50%). 
Rf = 0.40 (3:7 EtOAc/petrol); m.p. 248 
oC (Lit 247-249 oC); 1H NMR (500 MHz, 
DMSO-d6) δ 6.67 (1H, d, J = 3.6 Hz, C
1-H), 7.74 (1H, d, J = 3.6 Hz, C2-H), 12.78 (1H, 
br s, NH); LRMS (ES+) m/z = 188.0 [M+H]+. 
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2,4-Dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (130)292,293 
 
To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (129) (146 mg, 0.78 mmol) 
and p-toluenesulfonyl chloride (296 mg, 0.93 mmol) in DCM (1.5ml) was added 
triethylamine (215 μL, 1.55 mmol) and 4-dimethylaminopyridine (DMAP) (2.5 mg, 
2.02 x 10-2 mmol). The resulting solution was stirred (RT, 1h) then diluted with DCM 
(40 mL). The reaction mixture was washed with HCl(aq) (1 M) (40 mL) and 
NaHCO3(aq) (2 x 40 mL) then dried (MgSO4) and dry loaded onto silica. The title 
compound (130) was purified by MPLC on silica (3:7 EtOAc/petrol) and obtained as 
an off-white crystalline solid (235 mg, 0.69 mmol, 88%). 
Rf = 0.60 (3:7 EtOAc/petrol); m.p. 127-130 
oC; UV λmax (EtOH/nm) 229; IR ѵmax/cm
-
1: 3142, 2979, 2940, 2869, 2410, 2027, 1934, 1818, 1624, 1596, 1578, 1539; 1H 
NMR (500 MHz, DMSO-d6) δ 6.99 (1H, d, J = 4.1 Hz, C
1-H), 7.50 (2H, d, J = 8.0 Hz, 
C4-H), 8.03 (2H, d, J = 8.0 Hz, C3-H), 8.12 (1H, d, J = 4.1 Hz, C2-H); LRMS (ES+) 
m/z = 342.0 [M+H]+. 
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2-Chloro-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidine (131) 
 
To a suspension of 2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (130) (50 mg, 
0.15 mmol) copper(I) iodide (0.6 mg, 2.9 x 10-3 mmol) and Pd(PPh3)2Cl2 (2.1 mg, 2.9 
x 10-3 mmol) in anhydrous THF (1 mL) was added triisopropylsilyl acetylene (37 μL, 
0.17 mmol) followed by triethylamine (128 μL, 0.92 mmol). The vessel was capped 
and degassed (15 min, N2) then shielded from light and stirred (RT, 18 h). The 
reaction mixture was filtered through Celite, dried (MgSO4) and dry loaded onto 
silica. The crude mixture was purified by MPLC (15:85 EtOAc/petrol) to give the title 
compound (131) as a clear yellow oil (45 mg, 0.09 mmol, 63%). 
Rf = 0.53 (15:85 EtOAc/petrol); UV λmax (EtOH/nm) 269; IR ѵmax/cm
-1: 2944, 2865, 
1766, 1556, 1505, 1461; 1H NMR (500 MHz, CDCl3) δ 1.07-1.27 (21H, m, CH2CH3), 
2.41 (3H, s, CH3), 6.65 (1H, d, J = 4.1, C
1-H), 7.34 (2H, d, J = 8.0, C4-H), 7.71 (1H, 
d, J = 3.9, C2-H), 8.09 (2H, d, J = 8.0, C3-H); 13C NMR (125 MHz, CDCl3) δ 11.1 
((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 103.6 (C≡C-Si), 127.7 (Ar-C), 128.6 (Ar-C), 
130.0 (Ar-C), 146.5 (Ar-C), 184.7; HRMS Calcd for C24H30ClN3O2SSi m/z = 488.1560 
[M+H]+, Found m/z = 488.1574 [M+H]+. 
Note: Not all carbon atoms were visible 
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 N-Phenyl-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
amine (132) 
 
To a solution of 2-chloro-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-
d]pyrimidine (131) (110 mg, 0.23 mmol) in n-BuOH (2.5 mL) was added trimethylsilyl 
chloride (TMSCl) (58 μL, 0.45 mmol). Aniline (41 μL, 0.45 mmol) was added in one 
portion and vessel was capped. The reaction mixture was heated (116 oC, 72 h) 
resulting in consumption of the starting material (TLC). The reaction mixture was 
diluted with EtOAc (40 mL) then washed sequentially with HCl(aq) (1 M) (40 mL), 
NaHCO3(aq) (40 mL) and brine (40 mL). The crude product was dried (MgSO4), dry 
loaded onto silica and purified by MPLC on silica (15:85 EtOAc/petrol) to give 
compound (132) as a yellow oil (110 mg, 0.20 mmol, 89%). 
Rf = 0.37 (15:85 EtOAc/petrol); UV λmax (EtOH/nm) 271; IR ѵmax/cm
-1: 3258, 2942, 
2864, 1568, 1540, 1508; 1H NMR (500 MHz, CDCl3) δ 1.08-1.27 (21H, m, CH2CH3), 
2.33 (3H, s, CH3), 6.55 (1H, d, J = 4.0 Hz, C
1-H), 7.11 (1H, tt, J = 7.4 and 1.1 Hz,  
C5-H), 7.17 (2H, d, J = 8.5, C6-H), 7.41 (2H, app. t, J = 7.4 Hz, C7-H), 7.46 (1H, d, J = 
4.0 Hz, C2-H), 7.76 (2H, d, J = 8.0 Hz, C4-H), 7.97 (2H, d, J = 8.4 Hz, C3-H).; 13C 
NMR (125 MHz, CDCl3) δ 11.1 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 33.6 Ar-CH3), 
128.1 (Ar-C), 184.7 (Ar-C); HRMS Calcd for C30H37N4O2SSi m/z = 545.2401 [M+H]
+, 
Found m/z = 545.2385 [M+H]+. 
Note: Not all carbon atoms observed 
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N-Phenyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (140) 
 
A solution of N-phenyl-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-
2-amine (19) (100 mg, 0.18 mmol) in anhydrous THF (800 μL) was cooled to 0 oC. 
Anhydrous MeOH (400 μL) was added followed by Cs2CO3 (120 mg, 0.37 mmol). 
The reaction vessel was flushed with nitrogen and stirred (0 oC, 18 h) after which no 
starting material remained (LC-MS). The reaction mixture was added to HCl(aq) (1 M) 
(15 mL) which was then extracted with DCM (3 x 15 mL). The organic layers were 
pooled and washed with NaHCO3(aq) (45 mL) then dried (phase separator) and dry 
loaded onto silica. The title compound (20) was purified by MPLC on silica (5:95 
MeOH/DCM) and obtained as a yellow crystalline solid (66 mg, 0.17 mmol, 96%). 
Rf = 0.33 (1:3 EtOAc/petrol); m.p. 170 
oC; UV λmax (EtOH/nm) 255; IR ѵmax/cm
-1: 
3228, 2943, 2863, 2167, 1600, 1573, 1535; 1H NMR (500 MHz, CDCl3) δ 1.08-1.27 
(21H, m, CH2CH3), 6.51 (1H, d, J = 3.6 Hz, C
4-H), 7.06 (3H, m, C1-H and NH), 7.30-
7.38 (3H, m, C2-H and C5-H), 7.64 (2H, d, J = 8.5 Hz, C3-H), 8.73 (1H, br s, NH 
pyrrolopyrimidine); 13C NMR (125 MHz, CDCl3) δ 11.2 ((Si(CH(CH3)2)3), 18.7 
((Si(CH(CH3)2)3), 68.8 (C≡C-Si), 129.0 (Ar-C), 160.2 (Ar-C); HRMS Calcd for 
C23H31N4Si m/z = 391.2313 [M+H]
+, Found m/z = 391.2309 [M+H]+. 
Note: not all carbon atoms were visible 
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4-Ethynyl-N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine (88) 
 
The title compound was prepared following general procedure A using: N-phenyl-4-
((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (20) (30 mg, 7.69 x 10-2 
mmol) and TBAF (1 M in THF) (77 µL, 7.69 x 10-2 mmol) in THF (3 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(21) as a yellow solid (14 mg, 5.98 x 10-2 mmol, 78%). 
Rf = 0.30 (5:95 MeOH/DCM); m.p. 230 
oC (dec.); UV λmax (EtOH/nm) 277; IR 
ѵmax/cm
-1: 3569, 3278, 2188, 2149, 2031, 1972, 1611, 1575, 1536; 1H NMR (500 
MHz, DMSO-d6) δ 4.71 (1H, s, CH ethynyl), 6.39 (1H, d, J = 3.3 Hz, C
1-H), 6.88-6.95 
(1H, m, C1-H), 7.26 (2H, dd, J = 7.6 and J = 7.7 Hz, C2-H), 7.27 (1H, d, J = 3.3 Hz, 
C5-H), 7.81 (2H, d, J = 7.7 Hz, C3-H), 9.47 (1H, br s, NH), 11.75 (1H, br s, NH); 13C 
NMR (125 MHz, CDCl3) δ 68.3 (C-H), 84.7 (Ar-C≡C), 118.1 (Ar-C), 128.4 (Ar-C); 
LRMS (ES+) m/z = 234.95 [M+H]+; HRMS Calcd for C14H11N4 m/z = 235.0978 
[M+H]+, Found m/z = 235.0984 [M+H]+.
  
 
Note: Not all carbon atoms observed 
 
 
 
 
 
 
 
Chapter Ten 
 
219 
2-(3-Aminophenyl)acetamide (290) 
 
A solution of 3-aminophenylacetic acid (700 mg, 4.63 mmol) in MeOH (10 mL) was 
cooled to -10 oC. SOCl2 (673 µL, 9.26 mmol) was then added dropwise with stirring. 
The reaction mixture was heated to reflux (90 oC, 120 min) then cooled (RT). The 
solvent was removed in vacuo and aqueous ammonia (32%) (10 mL) was added. 
The reaction mixture was stirred (RT, 18 h) and the solvent was removed in vacuo. 
The crude product was redissolved in MeOH (20 mL) and the resulting solution was 
dry loaded onto silica then purified by MPLC (2:8 MeOH/DCM) to give the title 
compound (290) as an off-white crystalline solid (483 mg, 3.2 mmol, 70%). 
Rf = 0.53 (2:8 MeOH/DCM); m.p. 157-158 
oC; UV λmax (EtOH/nm) 238; IR ѵmax/cm
-1: 
3410, 3304, 3176, 2567, 2160, 2029, 1976, 1666, 1607; 1H NMR (500 MHz, DMSO-
d6) δ 3.19 (2H, s, CH2), 5.00 (2H, br s, NH2), 6.40-6.42 (2H, m, C
2-H and C4-H), 6.47 
(1H, s, C1-H), 6.81 (1H, br s, NH2), 6.92 (1H, app. t, J  = 7.7 Hz, C
3-H), 7.34 (1H, br 
s, NH2); 
13C NMR (125 MHz, DMSO-d6) δ 42.6 (CH2), 112.0 (Ar-C), 114.6 (Ar-C), 
116.6 (Ar-C), 128.6 (Ar-C), 136.9 (Ar-C), 148.4 (ArC-NH2), 172.4 (H2NCOCH2); 
LRMS (ES+) m/z = 151.1 [M+H]+; HRMS Calcd for C8H11N2O m/z = 151.0866 
[M+H]+, Found m/z = 151.0863 [M+H]+. 
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2-(3-((7-Tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl) 
amino)phenyl)acetamide (141) 
 
To a solution of 2-chloro-7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-
d]pyrimidine (131) (500 mg, 1.03 mmol) in anhydrous MeCN (15 mL) was added 2-
(3-aminophenyl)acetamide (290) (170 mg, 1.1 mmol), anhydrous K2CO3 (284 mg, 
2.1 mmol), Pd2(dba)3 (38 mg, 4.1 x 10
-2 mmol) and XPhos (20 mg,  4.1 x 10-2 mmol). 
The reaction mixture was capped and degassed (N2, 30 min) then heated (80 
oC, 2 
h). The reaction mixture was cooled (RT) and filtered (Celite) then diluted with EtOAc 
(50 mL). The resulting organic solution was washed sequentially with HCl(aq) (1 M) 
(30 mL), NaHCO3 (30 mL) and brine (30 mL) then  dried (Na2SO4) and dry loaded 
onto silica. The title compound (141) was purified by MPLC (8:2 EtOAc/petrol) and 
obtained as a yellow crystalline solid (215 mg, 0.36 mmol, 35%). 
Rf = 0.35 (8:2 EtOAc/petrol); m.p. 200-201 
oC; UV λmax (EtOH/nm) 240.0 and 281.5; 
IR ѵmax/cm
-1: 3476, 3269, 3206, 3150, 3062, 2952, 2864, 1665, 1625, 1578; 1H NMR 
(500 MHz,CDCl3) δ 1.08-1.22 (21H, m, SiCH and CH3), 2.39 (3H, s, Ar-CH3), 3.72 
(1H, br s, NH Amide), 4.00 (2H, s, CH2), 6.59 (1H, d, J = 4.0 Hz, C
5-H), 6.61 (1H, d, 
J = 7.6 Hz, C2-H), 6.70 (1H, br s, Ar-NH-Ar,), 6.75 (1H, d, J = 7.4 Hz, C4-H), 7.14 
(1H, t, J = 7.6 Hz, C3-H), 7.29 (2H, d, J = 8.2 Hz, C7-H), 7.61 (1H, d, J = 4.1 Hz, C6-
H), 8.01 (1H, br s, NH Amide 8.18 (2H, d, J = 8.2 Hz, C8-H); 13C NMR (125 MHz, 
CDCl3) δ 11.1 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 21.7 (Ar-CH3), 43.9 
(COCH2Ar), 60.4 (C≡C-Si), 101.3 (C
5), 101.7 (C≡C), 103.6 (Ar-C), 114.2 (Ar-C), 
116.2 (Ar-C), 118.9 (Ar-C), 119.9 (Ar-C), 126.3 (C6), 128.8 (Ar-C), 129.9 (Ar-C), 
134.3 (Ar-C), 135.2 (Ar-C), 143.6 (Ar-C), 146.0 (Ar-C), 146.9 (Ar-C), 151.9 (Ar-C), 
153.0 (Ar-C), 173.3 (C=O); HRMS Calcd for C32H40N5O3SSi m/z = 602.2616 [M+H]
+, 
Found m/z = 602.2601 [M+H]+. 
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2-(3-((4-((Triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino) 
phenyl)acetamide (291) 
 
A solution of 2-(3-((7-tosyl-4-((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
yl)amino)phenyl)acetamide (141) (204 mg, 0.34 mmol) in anhydrous THF (2 mL) was 
cooled to 0 oC. Anhydrous MeOH (1 mL) was added followed by Cs2CO3 (220 mg, 
0.68 mmol). The reaction vessel was flushed with nitrogen and stirred (0 oC, 18 h) 
after which no starting material remained (LC-MS). The reaction mixture was added 
to HCl(aq) (1 M) (20 mL) and then extracted with DCM (3 x 20 mL). The combined 
organic layers were washed with NaHCO3(aq) (30 mL) then dried (phase separator) 
and dry loaded onto silica. The title compound (291) was purified by MPLC on silica 
(5:95 MeOH/DCM) and obtained as a yellow solid (116 mg, 0.26 mmol, 75%). 
Rf = 0.57 (5:95 MeOH/DCM); m.p. 212-213 
oC; UV λmax (EtOH/nm) 279.0; IR 
ѵmax/cm
-1: 3214, 3174, 3073, 3020, 2941, 2890, 2864, 2360, 2339, 1660, 1608, 
1594; 1H NMR (500 MHz, CDCl3) δ 1.13-1.23 (21H, m, SiCH and CH3), 3.57 (2H, s, 
CH2), 5.51 (1H, br s, NH Amide), 6.33 (1H, br s, NH pyrrolopyrimidine), 6.49 (1H, dd, 
J = 3.6 and 2.0 Hz, C5-H), 6.87 (1H, d, J = 7.7 Hz, C2-H), 7.03 (1H, dd, J = 3.6 and 
2.2 Hz, C6-H), 7.26 (1H, t, J = 7.8 Hz, C3-H), 7.37 (1H, d, J = 8.10 Hz, C4-H) 7.42 
(1H, br s, ArNHAr), 7.67 (1H, s, C1-H), 9.79 (1H br s, NH Amide). 13C NMR (125 
MHz, DMSO-d6) δ 10.6 ((Si(CH(CH3)2)3), 18.5 ((Si(CH(CH3)2)3), 30.4 (Ar-CH3), 42.5 
(COCH2Ar), 95.5 (C≡C-Si), 98.9 (C
5), 103.3 (C≡C), 113.8 (Ar-C), 116.2 (Ar-C), 119.1 
(Ar-C), 121.4 (Ar-C), 125.0 (C6), 128.1 (Ar-C), 136.5 (Ar-C), 140.9 (Ar-C), 141.0 (Ar-
C), 153.1 (Ar-C), 156.0 (Ar-C), 172.2 (C=O); HRMS Calcd for C25H34N5O3SSi m/z = 
448.2527 [M+H]+, Found m/z = 448.2518 [M+H]+. 
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2-(3-((4-Ethynyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acetamide (231) 
 
The title compound was prepared following general procedure A using: 2-(3-((4-
((triisopropylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)acetamide 
(24) (58 mg, 0.13 mmol) and TBAF (1 M in THF) (142 µL, 1.42 mmol) in THF (6 mL). 
The crude product was purified by MPLC on silica (1:9 MeOH/DCM) to give the title 
compound (25) as a yellow solid (29 mg, 0.10 mmol, 77%). 
Rf = 0.48 (1:9 MeOH/DCM); m.p. 227 
oC (dec.); UV λmax (EtOH/nm) 277.5; IR 
ѵmax/cm
-1: 3376, 3266, 3109, 2360, 2337, 2114, 1663, 1604, 1575, 1538, 1471, 
1391; 1H NMR (500 MHz, DMSO-d6) 3.32 (2H, s, CH2), 4.70 (1H, s, CH Ethynyl), 
6.39 (1H, d, J = 3.5 Hz, C5-H), 6.82 (1H, d, J = 7.6 Hz, C2-H), 6.87 (1H, br s, 
ArNHAr), 7.20 (1H, t, J = 7.6 Hz, C3-H), 7.27 (1H, d, J = 3.5 Hz, C6-H), 7.40 (1H, br 
s, NH pyrrolopyrimidine), 7.52 (1H, s, C1-H), 7.80 (1H, d, J = 7.6 Hz, C4-H), 9.42 (1H, 
br s, NH Amide), 11.72 (1H, br s, NH Amide); 13C NMR (125 MHz, DMSO-d6) δ 42.5 
(CH2), 80.4 (C≡C-H), 84.7(C≡C), 99.1,(C
5), 113.8 (Ar-C), 116.3 (Ar-C), 119.2 (Ar-C), 
121.5 (Ar-C), 125.0 (C6), 128.1 (Ar-C), 136.5 (Ar-C), 140.7 (Ar-C), 141.0 (Ar-C), 
153.1 (Ar-C), 155.9 (Ar-C), 172.2 (H2NCOCH2); HRMS Calcd for C16H14N5O m/z = 
292.1198 [M+H]+, Found m/z = 292.1198 [M+H]+. 
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3H-Imidazo[4,5-b]pyridine (103)294,295 
 
To a solution of 2,3-diaminopyridine (2.00 g, 18.3 mmol) in TFE (15 mL) was added 
triethylorthoformate (3.66 mL, 22 mmol). TFA (71 μL, 0.915 mmol) was added and 
the reaction mixture was heated via microwave irradiation (140 oC, 15 min) after 
which no starting material remained (TLC). The solvent was removed in vacuo and 
the crude product was redissolved in EtOAc (50 mL) then washed sequentially with 
NaHCO3 (1 x 50 mL) and brine (2 x 50 mL) then dried (Na2SO4). The crude product 
was dry loaded onto silica and purified by MPLC (3:7 MeOH/EtOAc) to give the title 
compound (103) as an orange crystalline solid (2.13 g, 17.8 mmol, 97%). 
Rf = 0.50 (3:7 MeOH/EtOAc); m.p. 148-150 
oC (Lit 148-151 oC); UV λmax (EtOH/nm) 
281.0; IR ѵmax/cm
-1: 3062, 3022, 2980, 2921, 2851, 2807, 2769, 2711; 1H NMR (500 
MHz, DMSO-d6) δ 7.23 (1H, dd, J = 8.0 and 4.7 Hz, C
2-H), 8.02 (1H, d, J = 7.6, C3-
H), 8.35 (1H, d, J = 2, C1-H), 8.42 (1H, s, C4-H), 12.90 (1H, br s, NH 
imidazopyridine); LRMS (ES+) m/z 120.04 [M+H]+. 
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3H-Imidazo[4,5-b]pyridine 4-oxide (104)296 
 
To a suspension of 3H-imidazo[4,5-b]pyridine (103) (1.60 g, 13.4 mmol) in 
chloroform (30 mL) was added 3-chloroperbenzoic acid* (mCPBA) (62%) (4.45 g, 
18.7 mmol). A slight exotherm was observed alongside dissolution of the starting 
material. The mixture was stirred (RT, 18 h) resulting in a light yellow precipitate 
which was removed by filtration then washed with DCM (30 mL) to leave the crude 
product. The title compound was purified by recrystallisation from acetic acid (20 mL) 
to give the title compound (104) as pale yellow crystals (1.47 g, 11.9 mmol, 81%). 
*mCPBA purity determined by titration against sodium thiosulfate  
m.p. 262-263 oC (AcOH) (Lit 252 oC MeOH); UV λmax (EtOH/nm) 299.0; IR ѵmax/cm
-
1: 3163, 3128, 3084, 2877, 2783, 2740, 2559, 1227 (N-oxide); 1H NMR (500 MHz, 
DMSO-d6) δ 7.21 (1H, dd, J = 8.3 and 6.4 Hz, C
2-H), 7.60 (1H, d, J = 7.9 Hz, C3-H), 
8.19 (1H, d, J = 6.3 Hz, C1-H), 8.41 (1H, s, C4-H), 13.25 (1H, br s, N3-H); LRMS 
(ES+) m/z 136.03 [M+H]+. 
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7-Chloro-3H-imidazo[4,5-b]pyridine (105)297 
 
A suspension of 3H-imidazo[4,5-b]pyridine 4-oxide (104) (500 mg, 3.70 mmol) in 
POCl3 (3.73 mL, 40.7 mmol) was heated via microwave irradiation (140 
oC, 15 min) 
after which the starting material had been consumed (TLC). The reaction was 
repeated seven times and the crude products were combined. Residual POCl3 was 
neutralised by dropwise addition of the reaction mixture to rapidly stirring ice water. 
The resulting solution was cooled (0 oC) and the pH adjusted to 7 (NaOH). The 
aqueous solution was extracted with EtOAc (3 x 300 mL) and the organic layers 
were combined and dried (Na2SO4) to give the crude product as a mixture of both 
the ortho- and the desired para-chloro regioisomers (1:3 respectively). The crude 
product was dry loaded onto NH silica and purified by NH MPLC on silica (7:1 
EtOAc/MeOH) to give the title compound (105) as a white solid (1.64 g, 10.7 mmol, 
41%).  
Rf = 0.18 (NH silica 1:7 MeOH/EtOAc); m.p. 176-177 
oC (Lit 178 oC); UV λmax 
(EtOH/nm) 278.0; IR ѵmax/cm
-1: 3203, 3117, 3075, 3053, 2965, 2914, 2821, 2755, 
2479, 2410, 2163; 1H NMR (500 MHz, DMSO-d6) δ 7.38 (1H, d, J = 5.3 Hz, C
2-H), 
8.29 (1H, d, J = 5.3 Hz, C1-H), 8.51 (1H, s, C3-H), 13.41 (1H, br s, NH 
imidazopyridine); LRMS (ES+) m/z 120.04 [M+H]+. 
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tert-Butyl 7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (106)297 
 
 
To a solution of 7-chloro-3H-imidazo[4,5-b]pyridine (105) (1.64 g, 10.7 mmol) in 
anhydrous THF (100 mL) was added di-tert-butyl dicarbonate (Boc2O) (3.27 g, 15.0 
mmol). 4-Dimethylaminopyridine (DMAP) (13 mg, 0.11 mmol) was then added and 
the resulting mixture was stirred (RT, 3 h) resulting in consumption of the starting 
material (LC-MS). The solvent was removed in vacuo and the residual yellow oil was 
redissolved in EtOAc (50 mL), washed with brine (3 x 50 mL) then dried (Na2SO4) 
and dry loaded onto silica. The title compound (106) was purified by MPLC on silica 
(7:3 petrol/EtOAc) and obtained as a colourless oil (2.31 g, 9.12 mmol, 85 %). 
Rf = 0.44 (3:7 EtOAc/Hexane); m.p. 184 
oC (Lit 184 oC); 1H NMR (500 MHz, CDCl3) δ 
1.71 (9H, s, CH3), 7.38 (1H, d, J = 5.3 Hz, C
2-H), 8.45 (1H, d, J = 5.3 Hz, C1-H), 8.52 
(1H, s, C3-H); LRMS (ES+) m/z 154.07 (Boc removed) [M+H]+;  
 
 
 
 
 
 
 
 
 
Chapter Ten 
 
227 
tert-Butyl 7-chloro-5-nitro-3H-imidazo[4,5-b]pyridine-3-carboxylate (107)297 
 
 
A solution of tert-butyl 7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (106) (337 
mg, 1.33 mmol) in DCM (6 mL) was cooled to 0 oC. In a separate flask the nitration 
mixture was prepared by addition of tetrabutylammonium nitrate (1.21 g, 4.00 mmol) 
to a stirred solution of trifluoroacetic anhydride (554 μL, 4.00 mmol) in DCM (6 mL) at 
0 oC. The nitration mixture was stirred for 10 min, before being added dropwise to 
the solution of tert-butyl 7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (106). 
Upon addition the mixture immediately turned yellow and after 15 min the starting 
material had been consumed (LC-MS). The reaction mixture was washed with 
NaHCO3(aq) (1 x 20 mL) and water (2 x 20 mL), dried (Na2SO4) then dry loaded onto 
silica. The title product (107) was purified by MPLC (3:7 EtOAc/petrol) and obtained 
as a pale yellow crystalline solid (280 mg, 0.94 mmol, 71%). 
Rf = 0.60 (3:7 EtOAc/Hexane); m.p. 131-132 
oC (Lit 288.2 - 290 oC); UV λmax 
(EtOH/nm) 287.0; IR ѵmax/cm
-1: 3197, 3116, 3001, 2983 2945, 1751 (C=O stretch), 
1545 (Asym NO2 stretch), 1369 (sym NO2 stretch), 1154 (nitro C-N); 
1H NMR (500 
MHz, CDCl3) δ 1.75 (9H, s, CH3), 8.39 (1H, s, C
2-H), 8.81 (1H, s, C1-H); LRMS (ES+) 
m/z 199.05 (Boc removed) [M+H]+. 
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tert-Butyl 5-amino-7-chloro-3H-imidazo[4,5-b]pyridine-3-carboxylate (108) 
 
A 0.05 M solution of tert-butyl 7-chloro-5-nitro-3H-imidazo[4,5-b]pyridine-3-
carboxylate (107) (250 mg, 0.84 mmol) in DCM (17 mL) was reduced using an H-
Cube® continuous flow reactor (Thalesnano Inc.) with a Raney Nickel CatCart (40 
oC, 1 mL/min). After 3 cycles LC-MS confirmed complete conversion of starting 
material to the title product. The solvent was removed in vacuo to give the title 
compound (108) as a colourless oil (188 mg, 0.70 mmol, 84%). 
Rf = 0.45 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 279; IR ѵmax/cm
-1: 3491 (asym 
NH2), 3315 (sym NH2), 3194, 3157, 3049, 3006, 2978, 1769 (C=O stretch); 
1H NMR 
(500 MHz, DMSO-d6) δ 1.60 (9H, s, CH3), 6.45 (2H, br s, NH2), 6.56 (1H, s, C
1-H), 
8.31 (1H, s, C2-H); 13C NMR (125 MHz, DMSO-d6) δ 27.5 (CH3), 84.8 (OC(CH3)3), 
105.0 (Ar-C), 124.9 (Ar-C), 134.9 (Ar-C), 139.0 (Ar-C), 145.5 (Ar-C), 145.9 (Ar-C), 
158.4 (C=O); LRMS (ES+) m/z 269.07 (Boc removed) [M+H]+; HRMS Calcd for 
C11H14ClN4O2 m/z = 269.0800 [M+H]
+, Found m/z = 269.0805 [M+H]+. 
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7-Chloro-5-fluoro-3H-imidazo[4,5-b]pyridine (109) 
 
A polytetrafluoroethylene (PFTE) conical flask was charged with tetrafluoroboric acid 
(1 mL, 15.7 mmol) and tert-butyl-5-amino-7-chloro-3H-imidazo[4,5-b]pyridine-3-
carboxylate (108) (78 mg, 0.29 mmol). The reaction mixture was cooled to 0 oC and 
an aqueous solution of sodium nitrite (40 mg, 0.58 mmol) was introduced dropwise 
over a period of 10 min. The resulting mixture was stirred (2h, 0 oC) then allowed to 
warm (RT, 20 min). The reaction mixture was cooled to -15 oC, neutralised with 
aqueous NaOH (2 M) and extracted with EtOAc (3 x 30 mL). The combined organic 
layers were dried (Na2SO4), dry loaded onto silica and purified by MPLC on silica 
(3:2 EtOAc/petrol) to give the title compound (109) as a pale yellow solid (22 mg, 
0.13 mmol, 44%).  
Rf = 0.40 (3:2 EtOAc/petrol); m.p. 210 
oC; UV λmax (EtOH/nm) 281; IR ѵmax/cm
-1: 
3117, 3083, 3024, 2895, 2772, 2703, 2631, 2501, 2462, 2387, 1034 (C-F stretch); 1H 
NMR (500 MHz, DMSO-d6) δ 7.23 (1H, s, C
1-H), 8.51 (1H, s, C2-H), 13.58 (1H, br s, 
NH); 13C NMR (125 MHz, DMSO-d6) δ 103.5 (Ar-C), 103.9 (Ar-C), 144.8 (Ar-C), 
158.1 (Ar-C), 160.0 (Ar-C); 19F NMR (470 MHz, DMSO-d6) δ -73.69; LRMS (ES+) 
m/z 171 [M+H]+; HRMS Calcd for C6H4ClFN3 m/z = 172.0071 [M+H]
+, Found m/z = 
172.0071 [M+H]+.  
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Chloro-5-fluoro-3-(tetrahydro-2H-pyran-2-yl)-3H-imidazo[4,5-b]pyridine (110)  
 
To a solution of 7-chloro-5-fluoro-3H-imidazo[4,5-b]pyridine (109) (76 mg, 0.44 
mmol) in anhydrous EtOAc (15 mL) was added (Rac)-camphor sulfonic acid (3.5 mg, 
1.5 x 10-2 mmol). The reaction mixture was heated to 60 oC at which point 3,4-
dihydro-2H-pyran (44 µL, 0.49 mmol) was added. The reaction mixture was heated 
for a further 18 h then cooled to RT and neutralised (NH4OH(aq) (32%)). The reaction 
mixture was washed with brine (15 mL) and water (2 x 15 mL) then dried (Na2SO4) 
and dry loaded onto silica. The title compound (110) was purified by MPLC (2:3 
EtOAc/petrol) and obtained as a colourless oil (106 mg, 0.42 mmol, 94%). 
Rf = 0.31 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 265; IR ѵmax/cm
-1: 3115, 2874, 
2415, 2318, 1035 (C-F stretch); 1H NMR (500 MHz, CDCl3) δ 1.5-2.2 (6H, m, 3 x 
CH2), 3.75-3.81 (1H, td, J = 5.9 and 2.6 Hz, CH2), 4.15-4.20 (1H, td, J = 11.8 and 
2.1, CH2), 5.72 (1H, dd, J = 10.6 and 2.4, CH), 6.97 (1H, s, C
1-H), 8.28 (1H, s, C2-H); 
13C NMR (125 MHz, DMSO-d6) δ 22.9 (CH2), 24.7 (CH2), 30.1 (CH2), 68.2 (OCH2), 
97.5 (ArCH-O-CH2), 101.9 (Ar-C), 110.2 (Ar-C), 122.5 (Ar-C), 138.1 (Ar-C), 159.1 
(Ar-C), 160.2 (Ar-C); 19F NMR (470 MHz, DMSO-d6) δ -72.97; HRMS Calcd for 
C11H12ClFN3O m/z = 256.0647 [M+H]
+, Found m/z = 256.0651 [M+H]+. 
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5-Fluoro-3-(tetrahydro-2H-pyran-2-yl)-7-((triisopropylsilyl)ethynyl)-3H-imidazo 
[4,5-b]pyridine (111)  
 
A suspension of caesium carbonate (159 mg, 0.49 mmol), triisopropylsilyl acetylene 
(38 μL, 0.25 mmol), 2-dicyclohexylphosphion-2,4,6-triisopropylbiphenyl (XPhos) (2.8 
mg, 5.9 x 10-3 mmol) and PdCl2(CH3CN)2 (0.5 mg, 2.0 x 10
-3 mmol) was prepared in 
anhydrous acetonitrile (1 mL). A solution of 7-chloro-5-fluoro-3-(tetrahydro-2H-pyran-
2-yl)-3H-imidazo[4,5-b]pyridine (110) (50 mg, 0.20 mmol) in anhydrous acetonitrile (1 
mL) was added to the reaction mixture. The vial was capped and the reaction 
mixture was degassed (20 min, N2) then heated (80 
oC, 2 h) resulting in a colour 
change from yellow to dark red. The reaction mixture was cooled and filtered through 
Celite before being diluted with EtOAc (10 mL) and washed with water (3 x 10 mL). 
The resulting solution was dried (MgSO4) then dry loaded onto silica and purified by 
MPLC on silica (3:7 EtOAc/ petrol 3:7) to give compound (111) as a colourless oil 
(53 mg, 0.13 mmol, 67%). 
Rf = 0.68 (3:7 EtOAc/petrol); UV λmax (EtOH/nm) 271; IR ѵmax/cm
-1: 3124, 2915, 
2792, 2162, 1651; 1H NMR (500 MHz, CDCl3) δ 1.14-1.19 (21H, m, CH2CH3), 1.59-
2.21 (6H, m, 3 x CH2), 3.75-3.81 (1H, td, J = 11.9 and 2.6 Hz, CH2), 4.12-4.19 (1H, 
m, CH2), 5.72 (1H, dd, J = 10.4 and 2.3 Hz, CH), 6.95 (1H, s, C
1-H), 8.26 (1H, s, C2-
H); 13C NMR (125 MHz, DMSO-d6) δ 11.1 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3),  
22.1 (CH2), 24.4 (CH2) 31.5 (CH2) 68.1 (OCH2) 95.1 (ArCH-O-CH2), 95.2 (C≡C-Si), 
101.3 (C≡C), 101.7 (Ar-C), 110.2 (Ar-C), 116.1 (Ar-C), 119.4 (Ar-C), 126.7 (Ar-C), 
141.8 (Ar-C), 162.2 (Ar-C);  HRMS Calcd for C22H33FN3OSi m/z = 402.2371 [M+H]
+, 
Found m/z = 402.2368 [M+H]+. 
 
 
Chapter Ten 
 
232 
5-Fluoro-7-((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridine (112) 
 
5-Fluoro-7-((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridine (111) (20 mg, 0.05 
mmol) was dissolved in 2-propanol (0.5 mL). Trifluoroacetic acid (77 μL, 1 mmol) 
was added followed by water (77 μL). The reaction mixture was heated (100 oC, 2 h), 
cooled to RT and diluted in EtOAc (10 mL). The resulting solution was washed 
sequentially with NaHCO3(aq) (10 mL) and water (3 x 10 mL) then dried (MgSO4) and 
dry loaded onto NH silica. The title compound (112) was purified by MPLC (NH 
silica; 5:95 MeOH/DCM) and obtained as a yellow oil (14.6 mg, 4.6 x 10-2 mmol, 
92%). 
Rf = 0.40 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 279; IR ѵmax/cm
-1: 2944, 2891, 
2866, 2798, 2712, 2639, 2362, 2166, 1616, 1602, 1590, 1574, 1494, 1463, 1350; 1H 
NMR (500 MHz, MeOD) δ 1.16-1.24 (21H, m, (Si(CH(CH3)2)3), 7.00 (1H, s, C
1-H), 
8.38 (1H, s, C2-H); 13C NMR (125 MHz, DMSO-d6) δ 10.6 ((Si(CH(CH3)2)3), 18.5 
((Si(CH(CH3)2)3), 158.2 (Ar-C); 
19F NMR (500 MHz, CDCl3) δ -71.71 and -74.17 
(imidazole isomers); HRMS Calcd for C17H25FN3Si m/z = 318.1796 [M+H]
+, Found 
m/z = 318.1796 [M+H]+. 
 
Note: not all carbon atoms were visible 
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N-Phenyl-7-((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridin-5-amine (113) 
 
Aniline hydrochloride (114 mg, 0.88 mmol) was added to a solution of 5-fluoro-7-
((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridine (112) (70 mg, 0.22 mmol) in 
trifluoroethanol (1 mL). The reaction mixture was heated (78 oC, 7 days) after which 
it had neared completion (TLC). The solvent was removed in vacuo and DCM (25 
mL) was added. The resulting solution was washed with HCl(aq) (1 M) (10 mL) and 
NaHCO3(aq) (1 x 25 mL) then dried (phase separator) and dry loaded onto NH silica. 
The crude product was purified by MPLC (NH silica; 5:95 MeOH/DCM 5:95) to give 
(113) as a yellow oil (67 mg, 0.17 mmol, 78%). 
Rf = 0.50 (NH silica 5:95 MeOH/DCM); UV λmax (EtOH/nm) 268; IR ѵmax/cm
-1: 3105, 
3046, 2942, 2864, 2562, 2249, 2159, 2024, 2021, 1714, 1613, 1597; 1H NMR (500 
MHz, MeOD) δ 1.16-1.24 (21H, m, CH3CH), 6.86 (1H, s, C
4-H), 6.91 (1H, tt, J = 7.4 
and 1.1 Hz, C1-H), 7.22-7.28 (2H, app. t, J = 7.4 Hz, C2-H), 7.71 (2H, d, J = 7.8 Hz, 
C3-H) 8.02 (1H, s, C5-H); 13C NMR (125 MHz, DMSO-d6) δ 10.7 ((Si(CH(CH3)2)3), 
18.5 ((Si(CH(CH3)2)3), 96.6 (C≡C-Si), 102.5 (C≡C), 109.6 (Ar-C), 117.6 (Ar-C), 120.3 
(Ar-C), 122.3 (Ar-C), 127.6 (Ar-C), 128.6 (Ar-C), 139.9 (Ar-C), 141.7 (Ar-C), 146.0 
(Ar-C), 152.1 (Ar-C);  HRMS Calcd for C23H30N4Si m/z = 391.2313 [M+H]
+, Found 
m/z = 391.2317 [M+H]+. 
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7-Ethynyl-N-phenyl-3H-imidazo[4,5-b]pyridin-5-amine (87) 
 
The title compound was prepared following general procedure A using: N-phenyl-7-
((triisopropylsilyl)ethynyl)-3H-imidazo[4,5-b]pyridin-5-amine (113) (29 mg, 7.42 x 10-2 
mmol) and TBAF (1 M in THF) (111 µL, 0.11 mmol) in THF (3mL). The crude product 
was purified by NH MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(87) as a yellow solid (12 mg, 5.12 x 10-2 mmol, 69%). 
Rf = 0.24 (5:95 MeOH/DCM); m.p. 200 
oC (dec.); UV λmax (EtOH/nm) 260; IR 
ѵmax/cm
-1: 3407, 3283, 3117, 3051, 2856, 2577, 2357, 2344, 2265, 2201, 2161, 
1979, 1597, 1580, 1495, 1438, 1380; 1H NMR (500 MHz, MeOD) δ 4.63 (1H, br s, 
Ethynyl CH), 6.82 (1H, s, C4-H), 6.89 (1H, tt, J = 7.4 and 1.2 Hz, C1-H), 7.26 (2H, 
app. t, J = 7.4 Hz, C2-H), 7.73 (2H, d, J = 7.9 Hz, C3-H), 8.09 (1H, s, C5-H), 9.11 (1H, 
br s, ArNHAr), 12.82 (1H, br s, NH imidazopyridine); LRMS (ES+) m/z = 235.2 
[M+H]+; HRMS Calcd for C14H11N4 m/z = 235.0978 [M+H]
+, Found m/z = 235.0980 
[M+H]+ 
Note: insufficient sample for 13C NMR analysis 
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2,4,6-Trichloropyrimidine-5-carbaldehyde (144)298 
 
To a flask containing anhydrous DMF (733 µL, 9.5 mmol) cooled to 0 oC was added 
POCl3 (7 mL, 76 mmol) dropwise with stirring (0 
oC 30 min). Barbituric acid (1 g, 7.8 
mmol) was added and the resulting suspension was stirred (RT, 60 min). The 
reaction mixture was heated to reflux (110 oC, 4 h) after which half of the POCl3 was 
removed via vacuum distillation. The remaining solution was neutralised by drop 
wise addition over rapidly stirred ice water. A yellow precipitate formed and was 
collected by filtration, washed with water (50 mL) and dissolved in DCM (25 mL). The 
resulting yellow solution was washed with NaHCO3(aq) (50 mL) and water (50 mL) 
then dried (phase separator) and the solvent was removed in vacuo to leave an 
orange solid. The crude product was purified by triturating with hot 2-propanol (3 x 
50 mL) to give the title compound (144) as a light yellow crystalline solid (907 mg, 
4.3 mmol, 55%). 
Rf = 0.62 (DCM); m.p. 128-131 
oC (Lit 130-132 oC); UV λmax (EtOH/nm) 251; 1H 
NMR (500 MHz, CDCl3) δ 10.42 (1H, s, CHO); IR ѵmax/cm
-1: 1704 (CO), 1521, 1495, 
1414, 1314, 1296, 1201, 1116; LRMS (ES+) m/z = 211.8 [M+H]+ 
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 4,6-Dichloro-1H-pyrazolo[3,4-d]pyrimidine (145)299,300 
 
A solution of 2,4,6-trichloropyrimidine-5-carbaldehyde (144) (3 g, 14.2 mmol) in 
MeOH (75 mL) was cooled to -30 oC. In solution of hydrazine hydrate (710 µL, 14.6 
mmol) in MeOH (18 mL) at -30 oC was prepared added dropwise followed by a 
solution of triethylamine (2.1 mL, 14.2 mmol) in MeOH (18 mL) at -30 oC. The 
reaction mixture was stirred (-30 oC, 6 hours) and the solvent was removed in vacuo 
to leave a crude brown deposit. The solid was heated to reflux in 2-propanol (100 
mL) and filtered whilst hot. The filtrate was evaporated to dryness, redissolved in 
EtOAc (100 mL) then dry loaded onto silica. The crude product was purified by 
MPLC on silica (5:95 MeOH/DCM) to give the title compound (145) as an 
orange/yellow solid (2.15 g, 11.4 mmol, 80%). 
Rf = 0.40 (5:95 MeOH/DCM); m.p. 320 
oC (dec.) (Lit 145 oC dec.); UV λmax 
(EtOH/nm) 270; IR ѵmax/cm
-1: 3254, 3211, 3188, 2828, 2392, 2296, 2266, 2216, 
2176, 2131, 1989, 1865, 1686, 1596; 1H NMR (500 MHz, DMSO-d6) δ 8.52 (1H, s, 
CH), 14.65 (1H, br s, NH). 
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4,6-Dichloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (146)299 
 
To a solution of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (145) (50 mg, 0.27 mmol) 
in EtOAc (2 mL) was added (Rac)-camphor sulfonic acid (2.1 mg, 9.0 x 10-3 mmol). 
The reaction mixture was heated to 60 oC and 3,4-dihydro-2H-pyran (26 µL, 0.29 
mmol) was added. The resulting solution was heated (60 oC, 18 h) then cooled to RT 
and washed with NaHCO3(aq). EtOAc (15 mL) was added and the resulting organic 
solution was washed with brine (15 mL) and water (2 x 15 mL) then dried (Na2SO4) 
and dry loaded onto silica. The title compound (146) was purified by MPLC on silica 
(DCM) as a white solid (57 mg, 0.21 mmol, 79%). 
Rf = 0.49 (DCM); m.p. 64-66 
oC; UV λmax (EtOH/nm) 214; IR ѵmax/cm
-1: 3098, 2956, 
2931, 2870, 2426, 2158, 2035, 1973, 1770, 1591, 1542, 1476; 1H NMR (500 MHz, 
CDCl3) δ 1.59-2.56 (6H, m, 3 x CH2), 3.81 (1H, m, CH), 4.12 (1H, m, CH), 6.00 (1H, 
dd, J = 10.4 and 2.5 Hz, CH), 8.19 (1H, s, pyrazolopyrimidine CH); 13C NMR (125 
MHz, CDCl3) δ 22.7 (CH2), 24.8 (CH2), 29.4 (CH2), 68.5 (CH2), 83.0 (N-CH), 113.3 
(C3-H); HRMS Calcd for C10H11Cl2N4O m/z = 273.0310 [M+H]
+, Found m/z = 
273.0309 [M+H]+. 
 
Note: not all carbon atoms visible 
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6-Chloro-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-
pyrazolo[3,4-d]pyrimidine (147) 
 
4,6-Dichloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (146) (50 mg, 
0.18 mmol), caesium carbonate (119 mg, 0.37 mmol), Pd(PPh3)2Cl2 (2.8 mg, 4.02 x 
10-3 mmol) and CuI (1.5 mg, 8.04 x 10-3 mmol) were added to a flask. Anhydrous 
DMF (1 mL) was then added followed by triisopropylsilyl acetylene (45 µL, 0.20 
mmol). The reaction vessel was capped and degassed (15 min, N2) then heated via 
microwave irradiation (45 oC, 10 min). The reaction mixture was diluted with EtOAc 
(50 mL) then filtered through Celite, washed with water (3 x 50 mL) and dried 
(MgSO4). The crude product was dry loaded onto silica and purified by MPLC on 
silica (15:85 EtOAc/petrol) to give compound (147) as a colourless oil (53 mg, 0.13 
mmol, 69%). 
Rf = 0.52 (15:85 EtOAc/petrol); UV λmax (EtOH/nm) 217; IR ѵmax/cm
-1: 2943, 2892, 
2865, 2165, 1559, 1464, 1440, 1381; 1H NMR (500 MHz, CDCl3) δ 1.10-1.26 (21H, 
m, CH2CH3), 1.59-2.56 (6H, m, 3 x CH2), 3.80 (1H, m, CH), 4.12 (1H, m, CH), 6.00 
(1H, dd, J = 10.4 and 2.5 Hz, CH), 8.16 (1H, s, CH pyrazolopyrimidine); 13C NMR 
(125 MHz, CDCl3) δ 10.9 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 22.4 (CH2), 24.7 
(CH2), 29.3 (CH2), 68.5 (OCH2), 83.0 (Ar-CH-O), 113.3 (C
3-H),  HRMS Calcd for 
C21H32ClN4OSi m/z = 419.2028 [M+H]
+, Found m/z = 419.2029 [M+H]+.  
 
Note: not all carbon atoms visible 
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6-Chloro-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (148) 
 
To a solution of 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl)ethynyl)-
1H-pyrazolo[3,4-d]pyrimidine (147) (170 mg, 0.41 mmol) in TFE (8 mL) was added 
TFA (156 μL, 2.03 mmol) and water (156 μL).  The reaction mixture was heated (100 
oC, 4 h) then diluted with NaHCO3(aq) (50 mL) and extracted with DCM (2 x 50 mL). 
The DCM layers were combined then washed with water (2 x 50 mL) and dried 
(phase separator). The crude product was dry loaded onto silica and purified by 
MPLC on silica (15:85 EtOAc/petrol) to give the compound (148) as a white solid 
(101 mg, 0.30 mmol, 75%). 
Rf = 0.40 (15:85 EtOAc/petrol); m.p. 108-111 
oC; UV λmax (EtOH/nm) 216; IR 
ѵmax/cm
-1: 3192, 3131, 3111, 3016, 2943, 2865, 2892, 2808, 2728, 2360, 2168, 
1701, 1565, 1461; 1H NMR (500 MHz, CDCl3) δ 1.08-1.29 (21H, m, CH2CH3), 8.19 
(1H, s, CH pyrazolopyrimidine), 10.67 (1H, br s, NH pyrazolopyrimidine); 13C NMR 
(125 MHz, CDCl3) 11.1 ((Si(CH(CH3)2)3), 18.6 (Si(CH(CH3)2)3), 100.6 (C≡C-Si), 
106.0 (C≡C-Si), 134.7 (C3H), 146.7 (Ar-C). HRMS Calcd for C16H24ClN4Si m/z = 
335.1453 [M+H]+, Found m/z = 335.1458 [M+H]+. 
Note: Not all carbon atoms were visible 
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N-Phenyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine 
(149) 
 
The title compound was prepared following general procedure E using: 6-chloro-4-
((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (148) (105 mg, 0.31 mmol), 
aniline (86 μL, 0.94 mmol) and TFA (60 µL, 0.79 mmol) in TFE (6 mL). The crude 
product was dry loaded onto silica and purified by MPLC on silica (15:85 
EtOAc/petrol) to give (149) as a light yellow solid (90 mg, 0.23 mmol, 73%). 
Rf = 0.55 (15:85 EtOAc/petrol); m.p. 153-156 
oC; UV λmax (EtOH/nm) 214; IR 
ѵmax/cm
-1: 3125, 3027, 2943, 2864, 2794, 2726, 2388, 2279, 2242, 1967, 1933, 
1596, 1572, 1532, 1487; 1H NMR (500 MHz, CDCl3) δ 1.1-1.3 (21H, m, CH2CH3), 
7.09 (1H, tt, J = 7.4 and 1.1 Hz, C1-H), 7.37 (2H, app. t, J = 7.37 Hz, C2-H), 7.41 (1H, 
br s, ArNHAr), 7.66 (2H, d, J = 7.6, C3-H), 7.91 (1H, s, C4-H), 10.05 (1H, br s, NH 
pyrazolopyrimidine); 13C NMR (125 MHz, CDCl3) δ 18.7 (Si(CH(CH3)2)3), 36.5 
(Si(CH(CH3)2)3), 99.1 (C≡C-Si), 110.2 (C≡C), 116.9 (Ar-H), 122.5 (Ar-H), 129.3 (Ar-
H), 134.1 (C4-H); HRMS Calcd for C22H30N5Si m/z = 392.2265 [M+H]
+, Found m/z = 
392.2265 [M+H]+. 
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4-Ethynyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine (89) 
 
The title compound was prepared following general procedure A using: N-phenyl-4-
((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (149) (45 mg, 0.12 
mmol) and TBAF (1 M in THF) (172 µL, 0.17 mmol) in THF (3 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(89) as an orange solid (17 mg, 7.23 x 10-2 mmol, 63%). 
Rf = 0.70 (5:95 MeOH/DCM); m.p. 240 
oC (dec.); UV λmax (EtOH/nm) 269; IR 
ѵmax/cm
-1: 3289, 2119, 2030, 1593, 1556, 1497, 1448, 1413, 1310, 1286, 1239; 1H 
NMR (500 MHz, DMSO-d6) δ 4.98 (1H, s, CH ethynyl), 6.98 (2H, m, C
1-H), 7.31 (2H, 
app. t, J = 7.5 Hz, C2-H), 7.83 (2H, d, J = 7.7 Hz, C3-H), 8.08 (1H, s, C4-H), 9.99 (1H, 
br s, ArNHAr), 13.54 (1H, br s, NH pyrazolopyrimidine); 13C NMR (125 MHz, DMSO-
d6) δ 74.1 (C≡C-H), 85.9 (C≡C-Ar), 116.9 (Ar-C), 122.2 (Ar-C), 128.7 (Ar-C), 132.5 
(C4); LRMS (ES+) m/z  = 236.20 [M+H]+; HRMS Calcd for C14H12N5 m/z = 236.0931 
[M+H]+, Found m/z = 236.0928 [M+H]+. 
Note: Not all carbon atoms visible 
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1-(2,4,6-Trichloropyrimidin-5-yl)ethanol (158) 
 
A solution of 2,4,6-trichloropyrimidine-5-carbaldehyde (144) (100 mg, 0.47 mmol) 
was made in anhydrous THF (1 mL). The reaction vessel was capped and flushed 
with nitrogen then cooled to 0 oC. Methyl magnesium bromide (3M in diethylether) 
(173 μL, 0.52 mmol) was added dropwise and the resulting yellow solution was 
stirred (0 oC, 30 min) then allowed to warm (RT, 30 min). Water (2 mL) was added 
followed by EtOAc (30 mL). A fine white precipitate formed which was removed by 
filtering through Celite. The filtrate was washed with brine (3 x 30 mL), dried 
(MgSO4) then dry loaded onto silica and purified by MPLC on silica (3:7 
EtOAc/petrol) resulting in the title compound (158) as a white crystalline solid (80 
mg, 0.35 mmol, 74%). 
Rf = 0.35 (3:7 EtOAc/petrol); m.p. 148-149 
oC; UV λmax (EtOH/nm) 267; IR ѵmax/cm
-
1: 3432 (br, OH), 2990, 2931, 2715, 2476, 2405, 2360, 2238, 1896, 1515, 1454; 1H 
NMR (500 MHz, DMSO-d6) δ 1.46 (3H, d, J = 6.8 Hz, CH3), 5.28 (1H, dq, J = 4.2, 6.8 
and 13.6, ArCHOHCH3), 5.67 (1H, d, J = 4.1, OH); LRMS (ES+) m/z = 227.0 [M+H]
+
. 
 
Note: HRMS and 13C NMR unsuccessful due to compound degradation 
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1-(2,4,6-Trichloropyrimidin-5-yl)ethanone (159) 
 
A solution of 1-(2,4,6-trichloropyrimidin-5-yl)ethanol (158) (60 mg, 0.26 mmol) was 
made in anhydrous DCM (2.5 mL). The flask was flushed with nitrogen and a 
solution of Dess-Martin periodinane (130 mg, 0.31 mmol) in anhydrous DCM (3.5 
mL) was added dropwise with stirring. The mixture was stirred (RT, 2 h) after which a 
white suspension had formed. Ether (10 mL) was added and resulting solution was 
washed with NaOH(aq) (1.3M) (2 x 2.5 ml) and water (2 x 10 mL). The organic 
solution was dried (MgSO4) then dry loaded onto silica and purified by MPLC on 
silica (3:7 EtOAc/petrol) to give compound (159) as a white crystalline solid (53 mg, 
0.23 mmol, 89%). 
Rf = 0.35 (3:7 EtOAc/petrol); m.p. 76-79 
oC; UV λmax (EtOH/nm) 225; IR ѵmax/cm
-1: 
2362, 2337, 1713 (CO), 1541, 1497; 1H NMR (500 MHz, CDCl3) δ 2.63 (3H, s, CH3); 
LRMS (ES+) m/z = 224.9 [M+H]+.  
 
Note: HRMS and 13C NMR unsuccessful due to compound degradation 
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4,6-Dichloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (160) 
 
1-(2,4,6-trichloropyrimidin-5-yl)ethanone (159) (475 mg, 2.10 mmol) was dissolved in 
MeOH (15 mL) and cooled to -15 oC. A solution of hydrazine hydrate (105 μL, 2.17 
mmol) in MeOH (5 mL) at -15 oC was added dropwise followed by a solution of 
triethylamine (316 μL, 2.10 mmol) in MeOH (5 mL) at -15 oC. The reaction mixture 
was stirred (-15 oC, 6 h) then warmed to RT. The solvent was removed in vacuo and 
the crude product was redissolved in EtOAc (50 mL). The resulting solution was 
washed with water (3 x 50 mL), dried (MgSO4) and dry loaded onto silica. The crude 
product was purified by MPLC on silica (3:7 EtOAc/petrol) followed by C18 reverse 
phase MPLC (3:7 MeOH (0.1% HCOOH)/Water (0.1% HCOOH)) to give the title 
compound (160) as a yellow crystalline solid (192 mg, 0.95 mmol, 45%). 
Rf = 0.45 (3:7 EtOAc/petrol); m.p. 80-82 
oC; UV λmax (EtOH/nm) 203.1; IR ѵmax/cm
-1: 
3118, 3085, 3047, 2996, 2963, 2901, 2866, 2816, 2778, 2693, 2027, 1980, 1608, 
1556; 1H NMR (500 MHz, DMSO-d6) δ 3.30 (3H, s, CH3), 14.23 (1H, br s, NH 
pyrazolopyrimidine); 13C NMR (125 MHz, CDCl3) δ 14.1 (Ar-CH3), 111.1 (Ar-C), 144.3 
(Ar-C), 156.1 (Ar-C), 156.7 (Ar-C), 157.1 (Ar-C); LRMS (ES+) m/z = 203.1 [M+H]+. 
Note: HRMS unsuccessful due to compound degradation. 
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4,6-Dichloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d] 
pyrimidine (161) 
 
To a solution of 4,6-dichloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (160) (190 mg, 
0.94 mmol) in EtOAc (20 mL) was added (Rac)-camphor sulfonic acid (8.0 mg, 3.4 x 
10-2 mmol). The reaction mixture was heated to 60 oC at which point 3,4-dihydro-2H-
pyran (128 µL, 1.41 mmol) was added. The reaction mixture was heated (60 oC, 18 
h) then cooled to RT and washed with NaHCO3(aq) (40 mL). EtOAc (20 mL) was 
added and the resulting organic solution was washed with brine (40 mL) and water 
(2 x 40 mL) then dried (Na2SO4) and dry loaded onto silica. The title compound (161) 
was purified by MPLC on silica (15:85 EtOAc/petrol) as a white crystalline solid (290 
mg, 0.94 mmol, >99%). 
Rf = 0.34 (15:85 EtOAc/petrol); m.p. 106-108 
oC; UV λmax (EtOH/nm) 220; IR 
ѵmax/cm
-1: 2955, 2863, 2159, 1977, 1915, 1584, 1541, 1507, 1458; 1H NMR (500 
MHz, CDCl3) δ 1.59-2.16 (6H, m, 3 x CH2), 2.71 (3H, s, CH3), 3.79 (1H, m, CH), 
4.09-4.16 (1H, m, CH), 5.93 (1H, dd, J = 2.5 and 9.7, CH); LRMS (ES+) m/z = 287.1 
[M+H]+; 13C NMR (125 MHz, DMSO-d6) δ 13.1 (CH3), 22.9 (CH2), 25.1 (CH2), 28.9 
(CH2) 105.1 (CH); HRMS Calcd for C11H13Cl2N4O m/z = 287.0461 [M+H]
+, Found 
m/z = 287.0466 [M+H]+. 
 
Note: not all carbon atoms visible 
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6-Chloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-
pyrazolo[3,4-d]pyrimidine (162) 
 
A flask was charged with 4,6-dichloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-
pyrazolo[3,4-d]pyrimidine (161) (50 mg, 0.17 mmol), copper(I) iodide (0.7 mg, 3.48 x 
10-3 mmol) and Pd(PPh3)2Cl2 (2.5 mg, 3.48 x 10
-3 mmol). THF (1 mL) was added 
followed by triisopropylsilyl acetylene (44 μL, 0.19 mmol) and triethylamine (66 μL, 
0.44 mmol). The vessel was capped and degassed (15 min, N2) then shielded from 
light and stirred (RT, 18 h). The reaction mixture was filtered through Celite, dried 
(MgSO4) and dry loaded onto silica then purified by MPLC (1:9 EtOAc/petrol) to give 
the title compound (162) as a colourless oil (73 mg, 0.74 mmol, >99%). 
Rf = 0.40 (15:85 EtOAc/petrol); UV λmax (EtOH/nm) 223; IR ѵmax/cm
-1: 2944, 2893, 
2865, 1557, 1508, 1461, 1377; 1H NMR (500 MHz CDCl3) δ 1.14-1.24 (21H, m, 
CH2CH3), 1.59-2.60 (6H, m, 3 x CH2), 2.73 (3H, s, CH3), 3.79 (1H, m, CH), 4.12 (1H, 
m, CH), 5.93 (1H, dd, J = 10.7 and 2.4, CH); 13C NMR (125 MHz, DMSO-d6) δ 11.1 
(Si(CH(CH3)2)3), 13.7 (CH3), 18.9 (Si(CH(CH3)2)3), 23.1 (CH2), 25.1 (CH2), 28.7 
(CH2), 70.1 (OCH2) 105.1 (CH); HRMS Calcd for C22H34ClN4OSi m/z = 433.2185 
[M+H]+, Found m/z = 433.2185 [M+H]+. 
 
Note: not all carbon atoms visible 
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6-Chloro-3-methyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine 
(163) 
 
To a solution of 6-chloro-3-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-((triisopropylsilyl) 
ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (162) (73 mg, 0.17 mmol) in 2-propanol (540 
μL) was added TFA (268 μL, 3.48 mmol) and water (268 μL). The reaction mixture 
was heated (100 oC, 18 h) then diluted with NaHCO3(aq) (15 mL). The aqueous 
mixture was extracted with DCM (2 x 15 mL). The combined organic layers were 
washed with water (2 x 15 mL) and dried (phase separator). The crude product was 
dry loaded onto NH silica and purified by NH MPLC on silica (5:95 MeOH/DCM) to 
give the title compound (163) as a white solid (28 mg, 5.4 x 10-2 mmol, 48%). 
Rf = 0.23 (NH silica 5:95 MeOH/DCM); m.p. 126-127 
oC; UV λmax (EtOH/nm) 220; IR 
ѵmax/cm
-1: 3196, 3115, 2945, 2927, 2893, 2867, 2804, 2276, 2160, 2045, 2019, 
1682, 1600, 1558; 1H NMR (500 MHz, CDCl3) δ 1.10-1.28 (21H, m, CH2CH3), 2.75 
(3H, s, CH3), 10.40 (1H, br s, NH pyrazolopyrimidine); HRMS Calcd for C17H26ClN4Si 
m/z = 349.1610 [M+H]+, Found m/z = 349.1610 [M+H]+. 
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3-Methyl-N-phenyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-
amine (164) 
 
The title compound was prepared following general procedure E using: 6-chloro-3-
methyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine (163) (110 mg, 0.32 
mmol), aniline (86 μL, 0.95 mmol) and TFA (62 µL, 0.80 mmol) in TFE (6 mL). The 
crude product was dry loaded onto silica and purified by MPLC on silica (15:85 
EtOAc/petrol) to give (164) as a light yellow solid (90 mg, 0.23 mmol, 73%). 
Rf = 0.44 (5:95 MeOH/DCM); m.p. 147-149 
oC; UV λmax (EtOH/nm) 272; IR ѵmax/cm
-
1: 3277, 3205, 3127, 3031, 2942, 2891, 2865, 2772, 2732, 2686, 2120, 2100, 1885, 
1853, 1696, 1595, 1570, 1528; 1H NMR (500 MHz, CDCl3) δ 1.09-1.30 (21H, m, 
CH2CH3), 2.66 (3H, s, CH3), 7.07 (1H, tt, J = 7.3 and 1.1 Hz, C
1-H), 7.35 (2H, dd, J = 
8.5 and 7.7 Hz, C2-H), 7.36 (1H, br s, ArNHAr), 7.66 (1H, d, J = 8.5 Hz, C3-H) 9.72 
(1H, br s, NH pyrazolopyrimidine); 13C NMR (125 MHz, CDCl3) δ 10.8 
((Si(CH(CH3)2)3), 13.2 (Ar-CH3), 18.4 ((Si(CH(CH3)2)3), 95.1 (C≡C-Si), 101.3 (Ar-C) 
110.1 (C≡C), 117.9 (Ar-C) 120.2 (Ar-C), 122.8 (Ar-C), 129.6 (Ar-C), 139.8 (Ar-C), 
147.2 (Ar-C), 149.8 (Ar-C), 160.6 (Ar-C); HRMS Calcd for C23H32N5Si m/z = 
406.2421 [M+H]+, Found m/z = 406.2417 [M+H]+. 
Note: not all carbon atoms were visible 
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4-Ethynyl-3-methyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine (165) 
 
The title compound was prepared following general procedure A using: 3-methyl-N-
phenyl-4-((triisopropylsilyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (164) (224 
mg, 0.6 mmol) and TBAF (1 M in THF) (903 µL, 0.90 mmol) in THF (30 mL). The 
crude product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title 
compound (165) as a yellow solid (73 mg, 0.29 mmol, 49%). 
Rf = 0.36 (5:95 MeOH/DCM); m.p. 230 
oC (dec.); UV λmax (EtOH/nm) 270; IR 
ѵmax/cm
-1: 3278, 3207, 3091, 3049, 2989, 2926, 2855, 2804, 2251, 2211, 2160, 
2123, 2037, 1975, 1720, 1598, 1575, 1548; 1H NMR (500 MHz, DMSO-d6) δ 2.53 
(3H, s, CH3), 4.97 (1H, s, ethynyl CH), 6.97 (1H, tt, J = 7.4 and 1.0 Hz, C
1-H), 7.30 
(2H, app. t, J = 7.4 Hz, C2-H), 7.81 (2H, d, J = 7.6 Hz, C3-H); LRMS (ES+) m/z = 
250.1 [M+H]+; HRMS Calcd for C14H12N5 m/z = 250.1087 [M+H]
+, Found m/z = 
250.1087 [M+H]+. 
 
 
 
 
 
 
 
 
 
 
Chapter Ten 
 
250 
6-Chloro-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine (171)232,301,302 
 
A suspension of 4-chloroaniline (10.35 g, 0.081 mol) in water (75 mL) was cooled to 
0 oC. HCl(aq) (12 M) (22.5 mL, 0.27 mol) was added dropwise with stirring until the 
mixture had fully dissolved. A solution of NaNO2 (5.66 g, 0.082 mol) in water (75 mL) 
was then added via a dropping funnel over a 30 min period to give a solution of 4-
chlorobenzene diazonium chloride which was kept at 0 oC until required.  
4-Chloro-2,6-diaminopyrimidine  (10.60 g, 0.073 mol) was dissolved in a mixture of 
water (365 mL) and glacial AcOH (365 mL, 6.38 mol). The mixture was stirred until 
all of the 4-chloro-2,6-diaminopyrimidine had dissolved (~30 min) at which point 
NaOAc (147 g, 1.79 mol) was added. The cooled solution of 4-chlorobenzene 
diazonium chloride synthesised previously was then added dropwise with stirring 
(RT, 30 min). The resulting bright yellow solution was stirred (RT, 18 h) resulting in a 
yellow precipitate. The precipitate was collected via Buchner filtration then washed 
with water (50 mL) and dried under vacuum to give compound (171) as a yellow 
solid (16.0 g, 0.057 mol, 78%). The filtrate was cooled to 5 oC overnight resulting in a 
further 3.5 g of the desired product (171), which gave a total yield of 19.5 g, 0.069 
mol, 95%.  
Rf = 0.34 (5:95 MeOH/DCM); m.p. 280 
oC (dec.) (Lit m.p. > 230 oC (dec.)); UV λmax 
(EtOH/nm) 379; IR ѵmax/cm
-1: 3406, 3288, 3136, 2801, 2657, 2430, 2218, 2195, 
2170, 2122, 4886, 1647, 1622, 1564, 1517; 1H NMR (500 MHz, DMSO-d6) δ 7.32 
and 7.53 (2H, 2 x br s, NH2 a), 7.58 (2H, d, J = 8.8 Hz, C
1-H), 7.83 (2H, d, J = 8.8 
Hz, C2-H), 8.19 and 9.25 (2H, 2 x br s, NH2 b). 
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6-Chloropyrimidine-2,4,5-triamine (172)232,302 
 
A suspension of 6-chloro-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine (171) 
(9.45 g, 33.5 mmol) in THF (100 mL) was cooled to 0 oC. Glacial acetic acid (15 mL) 
was added and the reaction vessel was placed under nitrogen. Zinc powder (4.73 g) 
was added in portions with stirring (0 oC, 15 min). The reaction mixture was warmed 
to (RT, 15 min) resulting in consumption of the starting material (171) (LC-MS). The 
reaction mixture was filtered through Celite and the resulting red filtrate dry loaded 
onto silica. The crude product was purified by MPLC on silica (5:95 MeOH/DCM) to 
give the title compound (172) as an off-white crystalline solid (5.93 g, 30.2 mmol, 
90%).  
Rf = 0.36 (5:95 MeOH/DCM); m.p. 225-227 
oC (Lit m.p. 226-227 oC); UV λmax 
(EtOH/nm) 219; IR ѵmax/cm
-1: 3365, 3267, 3169, 3123, 3084, 1626, 1579, 1540, 
1449; 1H NMR (500 MHz, DMSO-d6) δ 3.89 (2H, br s, NH2), 5.51 (2H, br s, NH2), 
6.35 (2H, br s, NH2). 
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7-Chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (173)302 
 
A solution of 6-chloropyrimidine-2,4,5-triamine (172) (500 mg, 3.13 mmol) in a 
mixture of water (45 ml) and glacial AcOH (9.4 mL, 164 mmol) was cooled to 0 oC. A 
solution of NaNO2 (238 mg, 3.45 mmol) in water (5 mL) was then added dropwise 
with stirring over a period of 15 minutes.  The mixture was stirred (0 oC, 1 h) after 
which an orange precipitate had formed. The precipitate was collected by filtration 
and washed with water (15 ml) then dissolved in EtOH (30 mL). The solvent was 
removed in vacuo and the crude product was redissolved in EtOAC (30 mL). The 
resulting solution was washed with brine (3 x 30 mL) and dried (MgSO4). The solvent 
was removed to give title compound (173) as a yellow solid (360 mg, 2.12 mmol, 
68%). 
Rf = 0.35 (1:9 MeOH/DCM); m.p. 185 
oC (dec.); UV λmax (EtOH/nm) 219; IR 
ѵmax/cm
-1: 3424, 3386, 3307, 3200, 2954, 2829, 2752, 1659, 1614, 1563, 1508; 1H 
NMR (500 MHz, DMSO-d6) δ 7.40 (2H, br s, NH2), 15.82 (1H, br s, NH 
triazolopyrimidine).  
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tert-Butyl 5-amino-7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-carboxylate 
(174) 
 
A solution 5-amino-7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine (173) in anhydrous 
THF (100 ml) was cooled to -10 oC.  Di-tert-butyl dicarbonate (2.7 g, 12.4 mmol) was 
then added in one portion followed by 4-dimethylaminopyridine (72 mg, 0.59 mmol). 
The reaction mixture was stirred under nitrogen (6h, RT) resulting in consumption of 
the starting material. The solvent was removed in vacuo and the crude product was 
redissolved in EtOAc (50 mL). The organic solution was washed with water (3 x 50 
mL), dried (Na2SO4) and dry loaded onto silica. The title compound (174) was 
purified by silica based MPCL (5:95 MeOH/DCM) and obtained as an off-white solid 
(2.37 g, 8.7 mmol, 74%). 
Rf = 0.52 (5:95 MeOH/DCM; m.p. 234 
oC (dec.); UV λmax (EtOH/nm) 250.5 and 
313.0; IR ѵmax/cm
-1: 3496, 3314, 3124, 2988, 1767, 1678, 1617, 1557; 1H NMR (500 
MHz, DMSO-d6) δ 1.75 (9H, s, 
tBu), 4.58 (2H, br s, NH2); 
Note: HRMS and 13C NMR unsuccessful due to compound degradation 
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tert-Butyl 5-amino-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d] 
pyrimidine-3-carboxylate (179) 
 
To a solution of tert-butyl 5-amino-7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-
carboxylate (174) (2.37 g, 8.7 mmol) in anhydrous THF (30 mL) was added 
triisopropylsilyl acetylene (2.53 mL, 11.0 mmol), copper(I) iodide (66 mg, 0.35 mmol) 
and PdCl2(PPh3)2 (244 mg, 0.35 mmol) sequentially. Diisopropylethylamine (3.79 
mL, 21.8 mmol) was then added and the reaction mixture was degassed (N2, 30 
min). The reaction mixture was stirred (18h, RT) then filtered through Celite. The 
crude product was dry loaded onto silica and purified by MPLC (2:3 EtOAc/petrol) to 
give the title compound (179) as a yellow oil (2.92 g, 7.01 mmol, 80%).  
Rf = 0.46 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 260.0; IR ѵmax/cm
-1: 3513, 3303, 
3204, 2944, 2866, 2337, 1765, 1624, 1586, 1561; 1H NMR (500 MHz, CDCl3) δ 1.17-
1.21 (21H, m, CH3CH2), 1.72 (9H, s, 
tBu), 5.92 (2H, br s, NH2); 
13C NMR (125 MHz, 
CDCl3) δ 11.2 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 28.0 ((CH3)3), 87.5 
(OC(CH3)3), 99.3 (C≡C-Si), 106.6 (C≡C-Si), 132.4 (Ar-C), 146.0 (Ar-C), 146.2 (Ar-C), 
152.4 (Ar-C), 163.2 (NCOO); HRMS Calcd for C20H33N6O2Si m/z = 417.2429 [M+H]
+, 
Found m/z = 417.2426 [M+H]+. 
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7-((Triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (175) 
 
A solution of tert-butyl 5-amino-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-
d]pyrimidine-3-carboxylate (179) (2.92 g, 7.01 mmol) in TFE (150 mL) was heated 
(1h, 80 oC). The solvent was removed and the crude product was redissolved in 
DCM (50 mL) then dry loaded onto isolute. The crude product was purified by MPLC 
on silica (1:9 MeOH/DCM) to give the title compound (175) as a yellow oil (2.1 g, 6.6 
mmol, 95%). 
Rf = 0.66 (1:9 MeOH/DCM); UV λmax (EtOH/nm) 223.5 and 249.5; IR ѵmax/cm
-1: 
3745, 3314, 2945, 2866, 2364, 2160, 2035, 1937, 1607, 1564; 1H NMR (500 MHz, 
CDCl3) δ 1.10-1.28 (21H, m, SiCH and CH3), 5.98 (2H, br s, NH2), 14.22 (1H, br s, 
NH triazolopyrimidine); 13C NMR (125 MHz, CDCl3) δ 11.2 ((Si(CH(CH3)2)3), 18.6 
((Si(CH(CH3)2)3), 99.7 (C≡C-Si), 106.1 (C≡C-Si), 131.6 (Ar-C), 146.1 (Ar-C), 152.6 
(Ar-C), 161.8 (Ar-C); HRMS Calcd for C15H25N6Si m/z = 317.1904 [M+H]
+, Found m/z 
= 317.1909 [M+H]+. 
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2-(3-((7-((Triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl) 
amino)phenyl) acetamide (292) 
 
 
i) Synthesis of 5-chloro-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d] 
pyrimidine 
LiCl (134 mg, 3.16 mmol) was added to anhydrous dimethylacetamide (5 mL) and 
heated until a solution was made. The solution was cooled to 0 oC and 7-
((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (175) (250 mg, 
0.79 mmol) was added followed by isoamyl nitrite (160 µL, 1.19 mmol) and SOCl2 
(63 µL, 0.87 mmol). The reaction mixture was stirred (0 oC, 1 h) then allowed to 
warm (RT, 18 h). NaHCO3(aq) (15 mL) was added and the resulting aqueous mixture 
was extracted with EtOAc (3 x 15 mL). The organic layers were pooled, washed with 
brine (2 x 30 mL) then dried (Na2SO4). The solvent was removed to give the crude 
product as a brown oil (122 mg, 0.36 mmol, 46 %) which was used without further 
purification. 
ii) Synthesis of2-(3-((7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-
yl) amino)phenyl) acetamide 
The title compound was prepared following general procedure E using 5-chloro-7-
((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (122 mg, 0.36 mmol) 
prepared in i), 2-(3-aminophenyl)acetamide (290) (109 mg, 0.73 mmol) and TFA (70 
µL, 0.91 mmol) in TFE (3 mL). The crude product was dry loaded onto isolute and 
purified by MPLC on silica (1:9 MeOH/DCM) followed by C18 reverse phase MPLC 
(9:1 MeOH(0.1% HCOOH)/H2O (0.1% HCOOH)) to give the title compound (292) as 
a yellow oil (27 mg, 6.01 x 10-2 mmol, 16%). 
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Rf = 0.44 (1:9 MeOH/DCM); UV λmax (EtOH/nm) 272.0; IR ѵmax/cm
-1: 2942, 2865, 
2364, 2335, 1660, 1597, 1540, 1487, 1449;9 1H NMR (500 MHz, CDCl3) δ 1.15-1.21 
(21H, m, SiCH and CH3), 3.65 (2H, s, CH2), 5.96 (1H, br s, NH Amide), 6.56 (1H, br 
s, ArNHAr), 6.98 (1H, d, J = 7.7 Hz, C2-H), 7.20-7.30 (2H, m, C1-H and C3-H), 7.75 
(1H, br s, NH triazolopyrimidine), 7.93 (1H, s, C4-H), 14.4 (1H, br s, NH Amide); 13C 
NMR (125 MHz, CDCl3) δ 11.2 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 29.7 (CH2), 
99.8 (C≡C-Si), 105.4 (C≡C-Si), 119.4 (Ar-C), 121.1 (Ar-C), 124.6 (Ar-C), 129.6 (Ar-
C), 135.5 (Ar-C), 139.1 (Ar-C), 141.9 (Ar-C),  158.6 (Ar-C), 175.0 (H2NCOCH2); 
HRMS calcd for C23H32N7OS [M+H]
+ 450.2359, Found 450.2424. 
 
2-(3-((7-Ethynyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)amino)phenyl)acetamide 
(232) 
 
The title compound was prepared following general procedure A using: 7-
((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (292) (25 mg, 
5.6 x 10-2 mmol) and TBAF (1 M in THF) (83 µL, 8.3 x 10-2 mmol) in THF (3 mL). The 
crude product was purified by MPLC on silica (1:9 MeOH/DCM) to give the title 
compound (232) as a yellow solid (12 mg, 4.1 x 10-2 mmol, 74%). 
Rf = 0.24 (1:9 MeOH/DCM); m.p. 118 
oC (dec.); UV λmax (EtOH/nm) 268.0; IR 
ѵmax/cm
-1: 2959, 2367, 2341, 2333, 2113 (ethynyl), 1655, 1601, 1558, 1493, 1451, 
1371; 1H NMR (500 MHz, DMSO-d6) δ 3.36 (2H, s, CH2), 5.14 (1H, s, CH ethynyl), 
6.87 (1H, br s, NH), 6.96 (1H, d, J = 7.4 Hz, C2-H), 7.25 (1H, dd, J = 8.2 and 7.6, C3-
H), 7.43 (1H, br s, NH triazole), 7.58 (1H, s,  C1-H), 7.74 (1H, d, J = 8.4 Hz, C4-H), 
10.17 (1H, br s, NH Amide), 16.09 (1H, br s, NH Amide); 13C NMR (125 MHz, 
DMSO-d6) δ 66.3 (CH2), 78.3 (C≡C), 89.7 (C≡C), 117.9 (Ar-C), 120.5 (Ar-C), 123.8 
(Ar-C), 128.3 (Ar-C), 136.8 (Ar-C), 140.0 (Ar-C), 172.0 (H2NCOCH2);  HRMS calcd 
for C14H12N7O [M+H]
+ 294.1098,  Found  294.1100. 
Note: not all carbon atoms were visible 
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4,6-Dichloro-N-phenyl-1,3,5-triazin-2-amine (184)235 
 
To a cooled (0 oC) solution of cyanuric chloride (1 g, 5.4 mmol) in anhydrous THF 
(15 mL) was added K2CO3 (1.5 g, 0.11 mmol).  A solution of aniline (494 µL, 5.4 
mmol) in anhydrous THF (5 mL) was then added dropwise with stirring. The reaction 
mixture was stirred at 0 oC (30 min) then allowed to warm (RT, 1 h). The solvent was 
removed in vacuo and the crude product was redissolved in DCM (10 mL) then 
filtered and dry loaded on silica. The title compound (184) was purified by MPLC on 
silica (1:9 EtOAc/petrol) as a white crystalline solid (960 mg, 4.0 mmol, 73%). 
Rf = 0.40 (1:9 EtOAc/petrol; m.p. 115-116 
oC (Lit 136-138 oC); 1H NMR (500 MHz, 
CDCl3) δ 7.23 (1H, tt, C
3-H, J = 7.3 and 1.1 Hz) 7.41 (2H, app. t, J = 7.4 Hz, C2-H), 
7.49 (1H, br s, ArNHAr), 7.54 (2H, d, J = 8.4 Hz, C1-H); LRMS (ES+) m/z = 241.0 
[M+H]+. 
 
4-Chloro-N-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-amine (185) 
 
To a solution of 4,6-dichloro-N-phenyl-1,3,5-triazin-2-amine (184) (2.58 g, 10.7 
mmol) in anhydrous THF (30 mL) was added triisopropylsilyl acetylene (2.51 mL, 
11.2 mmol), copper(I) iodide (82 mg, 0.43 mmol) and PdCl2(PPh3)2 (300 mg, 0.43 
mmol) sequentially. Diisopropylethylamine (4.65 mL, 26.7 mmol) was then added 
and the reaction mixture was degassed (N2, 30 min). The reaction mixture was 
stirred (18h, RT) then filtered through Celite. The crude product was dry loaded onto 
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Isolute and purified by MPLC on silica (1:9 EtOAc/petrol)  to give compound (185) a 
colourless oil (2.64 g, 6.9 mmol, 64%). 
Rf = 0.59 (1:9 EtOAc/petrol); UV λmax (EtOH/nm) 276.0; IR ѵmax/cm
-1: 3260, 3203, 
3157, 3111, 2944, 2893, 2866, 2170, 1608, 1566, 1516, 1494;  1H NMR (500 MHz, 
CDCl3) δ 1.12-1.26 (21H, m, SiCH and CH3), 7.17 (1H, tt,  J = 7.2 and 1.1 Hz, C
3-H) 
7.38 (2H, app. t, J = 7.6 Hz, C2-H), 7.46 (1H, br s, ArNHAr), 7.56 (2H, d, J = 8.4 Hz, 
C1-H); 13C NMR (125 MHz, CDCl3) δ 17.8 ((Si(CH(CH3)2)3), 18.8 ((Si(CH(CH3)2)3), 
121.2 (Ar-C), 130.1 (Ar-C), 164.3 (Ar-C), 171.5 (Ar-C); HRMS Calcd for C20H28ClN4Si 
m/z = 387.1772 [M+H]+, Found m/z = 387.177 [M+H]+. 
Note: not all carbon atoms were visible 
 
N2-Methyl-N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine 
(186) 
 
The title compound was prepared following general procedure B using: 4-chloro-N-
phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-amine (185) (20 mg, 0.052 mmol) 
and methylamine (2 M in THF) (77 µL, 0.16 mmol) in THF (1 mL). The crude product 
was purified by MPLC on silica (1:4 EtOAc/petrol) to give the title compound (186) as 
a colourless oil (19 mg, 0.05 mmol, 96%). 
Rf = 0.36 (1:4 EtOAc/petrol); UV λmax (EtOH/nm) 269.0; IR ѵmax/cm
-1: 3261, 2942, 
2892, 2867, 2356, 1937, 1621, 1527, 1496, 1449, 1423; 1H NMR (500 MHz, CDCl3) 
δ 1.12-1.19 (21H, m, SiCH and CH3), 3.02 (3H, d, J = 4.7 Hz, NHCH3),  5.23 and 
5.61 (1H, br s, ArNHCH3 rotamers), 7.07 (1H, tt, J = 7.0 and 1.0 Hz, C
3-H), 7.19 (1H, 
br s, ArNHAr), 7.32 (2H, app. t, J = 7.6 Hz, C2-H), 7.54 and 7.63 (2H, d, J = 7.9 Hz, 
C1-H); 13C NMR (125 MHz, CDCl3) δ 11.3 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 
27.9 (NHCH3), 60.3 (C≡C-Si), 91.1 (C≡C-Si), 120.0 (Ar-C), 123.3 (Ar-C), 128.9 (Ar-
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C), 138.4 (Ar-C), 158.7 (Ar-C), 163.8 (Ar-C), 166.1 (Ar-C); HRMS Calcd for 
C21H32N5Si m/z = 382.2421 [M+H]
+, Found m/z = 382.2416 [M+H]+. 
 
N2-Ethyl-N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (187) 
 
The title compound was prepared following general procedure B using: 4-chloro-N-
phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-amine (185) (130 mg, 0.34 mmol) 
and ethylamine (2 M in THF) (513 µL, 1.03 mmol) in THF (4 mL). The crude product 
was purified by MPLC on silica (1:4 EtOAc/petrol) to give the title compound (187) as 
a colourless oil (110 mg, 0.28 mmol, 81%). 
Rf = 0.56 (1:4 EtOAc/petrol); UV λmax (EtOH/nm) 271.0; IR ѵmax/cm
-1: 3262, 3112, 
2943, 2893, 2866, 2127, 2097, 1615, 1520;  1H NMR (500 MHz, CDCl3) δ 1.12-1.19 
(21H, m, SiCH and CH3), 1.25 (3H, m, CH3), 3.48 (2H, m, NHCH2),  5.22 and 5.54 
(1H, br s, ArNHCH2 rotamers), 7.06 (1H, tt, J = 7.0 and 1.1 Hz, C
3-H), 7.12 (1H, br s, 
ArNHAr), 7.32 (2H, app. t, J = 7.8 Hz, C2-H), 7.54 and 7.61 (1H, d, J = 7.9 Hz, C1-H); 
13C NMR (125 MHz, CDCl3) δ 11.3 ((Si(CH(CH3)2)3), 14.8 (CH3), 19.4 
((Si(CH(CH3)2)3), 36.3 (NHCH2CH3), 60.8 (C≡C-Si), 91.3 (C≡C-Si), 120.4 (Ar-C), 
123.8 (Ar-C), 128.9 (Ar-C), 139.0 (Ar-C), 159.3 (Ar-C), 164.3 (Ar-C), 165.6 (Ar-C); 
HRMS Calcd for C22H34N5Si m/z = 396.2578 [M+H]
+, Found m/z = 396.2571 [M+H]+.  
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N2-(4-Methoxybenzyl)-N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-
diamine (188) 
 
The title compound was prepared following general procedure B using: 4-chloro-N-
phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazin-2-amine (185) (342 mg, 0.89 mmol) 
and 4-methoxybenzylamine (345 µL, 2.56 mmol) in THF (10 mL). The crude product 
was purified by MPLC on silica (1:9 EtOAc/petrol) to give the title (188) compound as 
a colourless oil (370 mg, 0.76 mmol, 86%). 
Rf = 0.27 (1:9 EtOAc/petrol); UV λmax (EtOH/nm) 278.0; IR ѵmax/cm
-1: 3342, 3259, 
3107, 2911, 2848, 2851, 2119, 2068, 1604;  1H NMR (500 MHz, DMSO-d6) δ 1.07-
1.13 (21H, m, SiCH and CH3), 3.71 and 3.72 (3H, s, OCH3 rotamers), 4.41 and 4.42 
(2H, d, J = 6.3 Hz, NHCH2 Ar rotamers), 7.61 (2H, d, J = 8.7 Hz, C
4-H), 6.97 (1H, tt, J 
= 7.3 and 1.1 Hz, C3-H), 7.20-7.28 (4H, m, C2-H and C5-H) 7.62 and 7.78 (2H, d, J = 
8.7 Hz, C1-H); 13C NMR (125 MHz, DMSO-d6) δ 10.5 ((Si(CH(CH3)2)3), 18.4 
((Si(CH(CH3)2)3), 55.0 (OCH3), 113.7 (Ar-C), 119.9 (Ar-C), 128.2 (Ar-C), 128.4 (Ar-
C), 158.2 (Ar-C); HRMS Calcd for C28H38N5OSi m/z = 488.2840 [M+H]
+, Found m/z = 
488.2835 [M+H]+. 
 
Note: not all carbon atoms were visible 
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6-Ethynyl-N2-methyl-N4-phenyl-1,3,5-triazine-2,4-diamine (92) 
 
The title compound was prepared following general procedure A using: N2-methyl-
N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (186) (114 mg, 0.30 
mmol) and TBAF (1 M in THF) (448 µL, 0.45 mmol) in THF (4 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(92) as an off-white solid (52 mg, 0.23 mmol, 77%). 
Rf = 0.32 (5:95 MeOH/DCM);  m.p. 188-190 
oC (dec.); UV λmax (EtOH/nm) 256.5; IR 
ѵmax/cm
-1: 3298, 3257, 3190, 3120, 3042, 2968, 2127 (ethynyl), 1639 (NH), 1612, 
1597, 1566, 1523, 1446, 802; 1H NMR (500 MHz, DMSO-d6) δ 2.79 and 2.83 (3H, d, 
J = 4.7 Hz, CH3 Rotamers), 4.20 and 4.24 (1H, s, CH ethynyl, rotamers), 6.98 and 
6.99 (1H, tt, J = 7.2 and 1.1 Hz, C3-H Rotamers), 7.29 and  7.27 (2H, app. t, J = 7.8 
Hz, C2-H rotamers), 7.55-7.67 (1H, br s, ArNHCH3), 7.68-7.79 (2H, m, C
1-H), 9.67 
and 9.78 (1H, br s, ArNHAr rotamers); 13C NMR (125 MHz, DMSO-d6) δ 27.2 (CH3), 
77.4 (C≡C-H), 119.9 (Ar-C), 122.4 (Ar-C), 128.5 (Ar-C), 139.4 (Ar-C), 157.6 (Ar-C), 
165.3 (Ar-C), 165.4 (Ar-C);  HRMS calcd for C12H12N5 [M+H]
+ 226.1087, Found 
226.1088. 
 
6-Ethynyl-N2-ethyl-N4-phenyl-1,3,5-triazine-2,4-diamine (93) 
 
The title compound was prepared following general procedure A using: N2-ethyl-N4-
phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (187) (110 mg, 0.28 
mmol) and TBAF (1 M in THF) (684 µL, 0.42 mmol) in THF (5 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(93) as a light orange solid (65 mg, 0.27 mmol, 98%). 
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Rf = 0.70 (5:95 MeOH/DCM);  m.p. 165-167 
oC (dec.); UV λmax (EtOH/nm) 257.0; IR 
ѵmax/cm
-1: 3261, 2975, 2612, 2325, 2306, 2119 (ethynyl), 1613, 1493, 1446; 1H NMR 
(500 MHz, DMSO-d6) δ 1.10 and 1.14 (3H, t, CH3, J = 7.3  rotamers), 3.24-3.35 (2H, 
m, NHCH2, rotamers), 4.19 and 4.23 (1H, s, CH ethynyl, rotamers), 7.02 (1H, dd, J = 
6.5 and 7.4, C3-H), 7.30 (2H, m, C2-H rotamers), 7.66-7.77 (2H, m, C1-H rotamers) 
7.83 (1H, br s, ArNHCH2) 9.67 and 9.77 (1H, br s, ArNHAr, rotamers); 
13C NMR (125 
MHz, DMSO-d6) δ 14.3 (CH3), 34.9 (CH2), 67.3 (C≡C-H), 77.4 (C≡C), 119.9 (Ar-C), 
122.3 (Ar-C), 128.6 (Ar-C), 139.5 (Ar-C), 158.0 (Ar-C), 164.8 (Ar-C);  HRMS calcd for 
C13H14N5 [M+H]
+ 240.1244, Found 240.1245. 
 
6-Ethynyl-N2-(4-methoxybenzyl)-N4-phenyl-1,3,5-triazine-2,4-diamine (94) 
 
The title compound was prepared following general procedure A using: N2-(4-
methoxybenzyl)-N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine 
(188) (125 mg, 0.26 mmol) and TBAF (1 M in THF) (385 µL, 0.39 mmol) in THF (10 
mL). The crude product was purified by MPLC on silica (5:95 MeOH/DCM) then C18 
reverse phase MPLC (8:2 MeCN(0.1% HCOOH)/H2O(0.1% HCOOH)) to give the 
title compound (94) as a dark red solid (55 mg, 0.17 mmol, 65%). 
Rf = 0.43 (5:95 MeOH/DCM);  m.p. 166-167 
oC; UV λmax (EtOH/nm) 257.5; IR 
ѵmax/cm
-1: 3269, 3001, 2906, 2836, 2343, 2118 (ethynyl), 2083, 1601, 1531, 1510, 
1494; 1H NMR (500 MHz, DMSO-d6) δ 3.73 and 3.74 (3H, s, OCH3, rotamers), 4.22 
and 4.25 (1H, s, CH ethynyl, rotamers), 4.42 (2H, d, J = 6.2 Hz, CH2), 6.89 (2H, d, J 
= 8.6, C4-H), 6.98 (H, dd, J = 7.75 and 7.25, C1-H)  7.20-7.30 (4H, m, C2-H and C5-
H), 7.61 and 7.75 (2H, d, J = 8.0 Hz, C3-H rotamers), 8.18 and 8.37 (1H, br s, 
ArNHCH2, rotamers), 9.76 (1H, br s, ArNHAr); 
13C NMR (125 MHz, DMSO-d6) δ 40.1 
(CH3), 55.0 (NHCH2Ar), 113.7 (Ar-C), 128.4 (Ar-C), 165.0 (Ar-C); LRMS (ES+) m/z = 
332.1 [M+H]+. 
Note: not all carbon atoms were visible 
Chapter Ten 
 
264 
N2-Phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (293) 
 
A solution of N2-(4-methoxybenzyl)-N4-phenyl-6-((triisopropylsilyl)ethynyl)-1,3,5-
triazine-2,4-diamine (188) (246 mg, 0.51 mmol) in TFA (5 mL) was heated to reflux 
(72 oC) for 18 h. The resulting green solution was allowed to cool to RT and water 
(10 mL) was added resulting in a green precipitate. The precipitate was collected by 
filtration, washed with water (2 x 20 mL) then dissolved in EtOAc (20 mL). The 
resulting solution was washed with saturated NaHCO3(aq) (20 mL) and water (2 x 20 
mL). The crude yellow product was dried (Na2SO4) the dry loaded onto silica and 
purified by MPLC (5:95 MeOH/DCM) to give the title compound (293) as a yellow oil 
(183 mg, 0.50 mmol, 99%). 
Rf = 0.34 (5:95 MeOH/DCM); IR ѵmax/cm
-1: 3499, 3292, 3155, 3107, 2943, 2890, 
2865, 1788, 1638, 1604, 1566, 1521, 1494; 1H NMR (500 MHz, CDCl3) δ 1.12-1.18 
(21H, m, SiCH and CH3), 5.57 (2H, br s, NH2), 7.09 (1H, dd, J = 7.3 and 7.6, C
3-H), 
7.32 (2H, dd, J = 7.6 and 8.3, C2-H), 7.54 (2H, d, J = 8.2 Hz, C1-H); 13C NMR (125 
MHz, CDCl3) δ 11.2 ((Si(CH(CH3)2)3), 18.6 ((Si(CH(CH3)2)3), 120.6 (Ar-C), 123.8 (Ar-
C), 128.9 (Ar-C), 137.9 (Ar-C), 164.2 (Ar-C), 166.8 (Ar-C); HRMS calcd for 
C20H30N5Si [M+H]
+ 368.2265, Found 368.2268. 
 
6-Ethynyl-N2-phenyl-1,3,5-triazine-2,4-diamine (91) 
 
The title compound was prepared following general procedure A using: N2-phenyl-
6-((triisopropylsilyl)ethynyl)-1,3,5-triazine-2,4-diamine (293) (90 mg, 0.25 mmol) and 
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TBAF (1 M in THF) (367 µL, 0.37 mmol) in THF (5 mL). The crude product was 
purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound (91) as an 
orange solid (50 mg, 0.24 mmol, 97%). 
Rf = 0.25 (5:95 MeOH/DCM);  m.p. 170 
oC (dec.); UV λmax (EtOH/nm) 255.5; IR 
ѵmax/cm
-1: 3478 (NH2), 3322, 3264, 2123 (ethynyl), 1638, 1603, 1546, 1532, 1497; 
1H 
NMR (500 MHz, DMSO-d6) δ 3.28 (2H, br s, NH2), 4.20 (1H, s, CH ethynyl), 6.99 
(1H, tt, J = 7.5 and 1.1 Hz, C3-H), 7.27 (2H, dd J = 7.6 and 8.4 Hz, C2-H), 7.73 (2H, 
d, J = 7.4 Hz, C1-H), 9.69 (1H, br s, ArNHAr); 13C NMR (125 MHz, DMSO-d6) δ 118.1 
(Ar-C), 120.0 (Ar-C), 122.4 (Ar-C), 128.4 (Ar-C), 139.4 (Ar-C); HRMS calcd for 
C11H10N5 [M+H]
+ 212.0931, Found 212.0931. 
Note: not all carbon atoms were visible 
 
Phenylguanidine nitrate (204)303 
 
To a solution of aniline (1.28 mL, 14 mmol) in ethanol (14 mL) was added cyanamide 
(677 mg, 16.1 mmol). HNO3 (69%) (1 mL, 14 mmol) was added to the reaction 
mixture dropwise with stirring and the resulting solution was heated to reflux (110 oC, 
3h) after which almost all of the aniline had been consumed (observed by TLC). The 
reaction mixture was cooled (0 oC) then poured into ether (150 mL) and stirred (20 
min, RT) resulting in a grey precipitate. The precipitate was removed by filtration and 
washed with ether (3 x 20 mL) to give the title compound (204) as a grey solid (2.17 
g, 10.9 mmol, 78%). 
m.p. 111-112 oC (Lit. 122 oC); 1H NMR (500 MHz, DMSO-d6) δ 7.24 (2H, d, J = 7.5 
Hz, C1-H), 7.29 (1H, tt, J = 7.4 and 1.1 Hz, C3-H), 7.37 (4H, br s, NH2 and NH2
+), 
7.45 (2H, app. t, J = 7.5 Hz, C2-H), 9.63 (1H, br s, ArNH). 
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6-Hydroxy-2-(phenylamino)pyrimidin-4(1H)-one (206)304 
 
To a solution of phenylguanidine nitrate (204) (5.2 g, 26.2 mmol) in anhydrous 
methanol (200 mL), was added diethyl malonate (4.38 mL, 28.9 mmol). Freshly 
prepared sodium methoxide in methanol (50 mL, 78.7 mmol) was added and the 
resulting solution was stirred overnight (18h, RT). The solvent was removed in vacuo 
and water was added (50 mL). The reaction mixture was acidified (pH 6) with HCl(aq) 
(2 M) to give a white precipitate, which was washed with cold water (10 mL) and 
ether (3 x 30 mL) to give the title compound (206) as a white solid (65 mg, 0.32 
mmol, 63%). 
Rf = 0.50 (2:8 MeOH/DCM); m.p. 224 
oC (dec.) (Lit >220); 1H NMR (500 MHz, 
DMSO-d6) δ 4.87 (1H, s, pyrimidine C
5-H), 7.03 (1H, dd, J =7.3 and 7.6, C3-H), 7.31 
(2H, dd, J = 7.6 and 8.5, C2-H), 7.62 (2H, d, J = 7.7 Hz, C1-H), 8.79 (1H, s, OH), 
10.18 (1H, br s, ArNHAr) 10.80 (1H, s, pyrimidine NH). LRMS (ES+) m/z = 204.1 
[M+H]+. 
 
4,6-Dichloro-N-phenylpyrimidin-2-amine (207)304 
 
A suspension of 6-hydroxy-2-(phenylamino)pyrimidin-4(1H)-one (206) (500 mg, 2.46 
mmol) in POCl3 (2.25 mL, 24.6 mmol) was stirred (RT, 30 min). The reaction mixture 
was heated using microwave irradiation (20 min, 140 oC) to give a dark orange 
solution, which was quenched over ice water (50 mL). The mixture was cooled (0 oC) 
and neutralised (NaOH), then extracted with EtOAc (30 mL). The organic layer was 
then washed with water (3 x 30 mL), dried (MgSO4) then dry loaded onto silica and 
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purified by MPLC (3:7 DCM/petrol) to give the title compound (207) as a white solid 
(464 mg, 1.93 mmol, 79%). 
Rf = 0.58 (3:7 DCM/petrol); m.p. 112-113 
oC (Lit 112.5); 1H NMR (500 MHz, CDCl3) δ 
7.11 (1H, dd, J = 7.4 and 7.7, C3-H), 7.27 (1H, br s, ArNHAr), 7.36 (2H, dd, J = 7.6 
and 8.2, C2-H) 7.57 (2H, d, J = 8.0, C1-H), LRMS (ES+) m/z = 240.0 [M+H]+. 
 
6-Chloro-N4-methyl-N2-phenylpyrimidine-2,4-diamine (208) 
 
The title compound was prepared following general procedure C using: 4,6-
dichloro-N-phenylpyrimidin-2-amine (207) (200 mg, 0.83 mmol), KHCO3 (100 mg, 1.0 
mmol) and methylamine (2 M in THF) (833 µL, 1.67 mmol) in THF (3 mL). The crude 
product was purified by MPLC on silica (3:7 EtOAc/petrol) to give the title compound 
(208) as a white solid (166 mg, 0.71 mmol, 85%). 
Rf = 0.20 (15:85 EtOAc/petrol); m.p. 120-121 
oC; UV λmax (EtOH/nm) 237.0 and 
268.5; IR ѵmax/cm
-1: 3240, 3182, 3108, 3099, 1583, 1524, 1497; 1H NMR (500 MHz, 
CDCl3) δ 3.00 (3H, s, NHCH3), 4.98 (1H, br s, ArNHCH3), 5.89 (1H, s, pyrimidine 
CH), 7.03 (2H, dd and s, J = 7.2 and 7.5, C3-H and ArNHAr), 7.31 (2H, dd, J = 7.5 
and 8.6, C2-H), 7.58 (2H, d, J = 7.9 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 28.5 
(CH3), 119.4 (Ar-C), 122.7 (Ar-C), 128.8 (Ar-C); HRMS calcd for C11H12ClN4 [M+H]
+ 
235.0745, Found 235.0743. 
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6-Chloro-N4-ethyl-N2-phenylpyrimidine-2,4-diamine (209) 
 
The title compound was prepared following general procedure C using: 4,6-
dichloro-N-phenylpyrimidin-2-amine (207) (200 mg, 0.83 mmol), KHCO3 (100 mg, 1.0 
mmol) and ethylamine (2 M in THF) (833 µL, 1.67 mmol) in THF (3 mL). The crude 
product was purified by MPLC on silica (3:7 EtOAc/petrol) to give the title compound 
(209) as a white solid (182 mg, 0.73 mmol, 88%). 
Rf = 0.53 (3:7 EtOAc/petrol); m.p. 102-103 
oC; UV λmax (EtOH/nm) 240.0 and 268.0; 
IR ѵmax/cm
-1: 3254, 3197, 3114, 3043, 2978, 2873, 2367, 1585, 1523, 1497; 1H NMR 
(500 MHz, CDCl3) δ 1.25 (3H, t, J = 7.3 Hz, CH3), 3.35 (2H, ap. s, CH2) 4.97 (1H, br 
s, ArNHCH2), 5.85 (1H, s, pyrimidine CH), 7.01 (1H, dd, J = 7.3 and 7.6, C
3-H), 7.04 
(1H, br s, ArNHAr) , 7.30 (2H, dd, J = 7.4 and 8.5, C2-H), 7.56 (2H, d, J = 8.0 Hz, C1-
H); 13C NMR (125 MHz, CDCl3) δ 14.6 (CH3), 36.5 (NHCH2CH3), 119.3 (Ar-C), 122.5 
(Ar-C), 128.8 (Ar-C), 139.4 (Ar-C), 159.2 (Ar-C), 163.9 (Ar-C); HRMS calcd for 
C12H14ClN4 [M+H]
+ 249.0902, Found 249.0900. 
 
6-Chloro-N4-(4-methoxybenzyl)-N2-phenylpyrimidine-2,4-diamine (210) 
 
The title compound was prepared following general procedure C using: 4,6-
dichloro-N-phenylpyrimidin-2-amine (207) (200 mg, 0.83 mmol), KHCO3 (100 mg, 1.0 
mmol) and 4-methoxybenzylamine (216 µL, 1.67 mmol) in THF (3 mL). The crude 
product was purified by MPLC on silica (3:7 EtOAc/petrol) to give the title compound 
(210) as a colourless oil (285 mg, 0.83 mmol, >99%). 
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Rf = 0.55 (3:7 EtOAc/petrol); UV λmax (EtOH/nm) 239.5 and 269.5; IR ѵmax/cm
-1: 
3402, 3285, 3200, 3060, 2957, 2908, 2853, 1574, 1510, 1442; 1H NMR (500 MHz, 
CDCl3) δ 3.80 (3H, s, CH3), 4.46 (2H, s, CH2), 5.89 (1H, s, pyrimidine CH), 6.89 (2H, 
d, J = 8.7 Hz, C4-H), 7.01 (1H, dd, J = 7.0 and 7.8, C3-H), 7.06 (1H, br s, ArNHAr), 
7.24 (2H, d, J = 8.7 Hz, C5-H), 7.28 (2H, dd, J = 7.6 and 8.5, C2-H), 7.53 (2H, d, J = 
8.2 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 45.3 (NHCH2Ar), 55.4 (OCH3), 114.4 
(Ar-C), 119.4 (Ar-C), 122.6 (Ar-C), 128.8 (Ar-C), 139.3 (Ar-C), 159.2 (Ar-C), 163.8 
(Ar-C). HRMS calcd for C18H18ClN4O [M+H]
+ 341.1164, Found 341.1170. 
 
6-((tert-Butyldimethylsilyl)ethynyl)-N4-methyl-N2-phenylpyrimidine-2,4-diamine 
(211) 
 
The title compound was prepared following general procedure D using: 6-chloro-N4-
methyl-N2-phenylpyrimidine-2,4-diamine (208) (83 mg, 0.36 mmol), tert-
butyldimethylsilyl acetylene boronic acid pinacol ester (142 mg, 0.53 mmol), Cs2CO3 
(174 mg, 0.53 mmol) and Pd(PPh3)4 (41 mg, 0.036 mmol) in dioxane (4 mL). The title 
compound (211) was purified by MPLC on silica (3:7 EtOAc/petrol) to give the final 
product as a white crystalline solid (97 mg, 0.29 mmol, 81%). 
Rf = 0.14 (3:7 EtOAc/petrol); m.p. 162-163 
oC; UV λmax (EtOH/nm) 235.0 and 269.5; 
IR ѵmax/cm
-1: 3253, 3196, 3117, 3061, 2948, 2927, 2884, 2854, 2360, 2343, 1603, 
1585, 1531; 1H NMR (500 MHz, CDCl3) δ 0.20 (6H, s, 2 x SiCH3), 1.00 (9H, s, Si
tBu), 
2.97 (3H, d, J = 5.0 Hz, NHCH3),  4.85 (1H, br s, ArNHCH3), 6.02 (1H, s, pyrimidine 
CH), 6.98 (2H, dd and s, J = 7.2 and 7.5, C3-H and ArNHAr), 7.28 (2H, dd, J = 7.4 
and 8.7, C2-H), 7.59 (2H, d, J = 8.9 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ -4.75 
(Si(CH3)2C), 16.7 (SiC(CH3)3), 26.2 (CH3), 103.7 (C≡C-Si), 119.0 (Ar-C), 122.1 (Ar-
C), 128.8 (Ar-C), 140.1 (Ar-C), 159.8 (Ar-C), 164.0 (Ar-C); HRMS calcd for 
C19H27N4Si [M+H]
+ 339.1999, Found 339.1997. 
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6-((tert-Butyldimethylsilyl)ethynyl)-N4-ethyl-N2-phenylpyrimidine-2,4-diamine 
(212) 
 
The title compound was prepared following general procedure D using: 6-chloro-N4-
ethyl-N2-phenylpyrimidine-2,4-diamine (209) (91 mg, 0.37 mmol), tert-
butyldimethylsilyl acetylene boronic acid pinacol ester (147 mg, 0.55 mmol), Cs2CO3 
(180 mg, 0.55 mmol) and Pd(PPh3)4 (41 mg, 0.037 mmol) in dioxane (4 mL). The title 
compound (212) was purified by MPLC on silica (3:7 EtOAc/petrol) to give the final 
product as a white crystalline solid (69 mg, 0.20 mmol, 53%). 
Rf = 0.63 (3:7 EtOAc/petrol); m.p. 145-146 
oC; UV λmax (EtOH/nm) 236.0 and 269.5; 
IR ѵmax/cm
-1: 3408, 3335, 3265, 3196, 3123, 3058, 2952, 2928, 2883, 2856, 1606, 
1581, 1535; 1H NMR (500 MHz, CDCl3) δ 0.20 (6H, s, 2 x SiCH3), 1.00 (9H, s, Si
tBu), 
1.26 (3H, t, J = 7.2 Hz, CH2CH3) 3.39 (2H, br s, NHCH2CH3),  4.78 (1H, br s, 
ArNHCH3), 6.02 (1H, s, pyrimidine CH), 6.98 (2H, dd and s, J = 7.0 and 7.6, C
3-H 
and ArNHAr), 7.28 (2H, dd, J = 7.4 and 8.4, C2-H), 7.57 (2H, d, J = 7.6 Hz, C1-H); 
13C NMR (125 MHz, CDCl3) δ -4.6 (Si(CH3)2C), 14.9 (SiC(CH3)3), 16.9 (CH3), 26.3 
(NHCH2CH3), 103.7 (C≡C-Si), 119.1 (Ar-C), 122.1 (Ar-C), 128.9 (Ar-C), 140.0 (Ar-C), 
159.8 (Ar-C), 163.1 (Ar-C); HRMS calcd for C20H29N4Si [M+H]
+ 353.2156, Found 
353.2153. 
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6-((tert-Butyldimethylsilyl)ethynyl)-N4-(4-methoxybenzyl)-N2-phenylpyrimidine-
2,4-diamine (213) 
 
The title compound was prepared following general procedure D using: 6-chloro-N4-
(4-methoxybenzyl)-N2-phenylpyrimidine-2,4-diamine (210) (248 mg, 0.73 mmol), tert-
butyldimethylsilyl acetylene boronic acid pinacol ester (291 mg, 1.09 mmol), Cs2CO3 
(355 mg, 1.09 mmol) and Pd(PPh3)4 (84 mg, 0.073 mmol) in dioxane (15 mL). The 
title compound (213) was purified by MPLC on silica (3:7 EtOAc/petrol) to give the 
final product as a yellow oil (305 mg, 0.69 mmol, 94%). 
Rf = 0.25 (15:75 EtOAc/petrol); UV λmax (EtOH/nm) 235.0 and 272.0; IR ѵmax/cm
-1: 
3400, 3265, 3192, 3120, 3036, 2951, 2927, 2896, 2855, 2361, 2341, 1604, 1578, 
1536; 1H NMR (500 MHz, CDCl3) δ 0.19 (6H, s, 2 x SiCH3), 1.00 (9H, s, Si
tBu), 3.81 
(3H, s, CH3), 4.50 (2H, s, CH2), 5.04 (1H, br s, ArNHCH2), 6.05 (1H, s, pyrimidine 
CH), 6.89 (2H, d, J = 8.7 Hz, C4-H), 6.97 (1H, dd, J = 7.0 and 7.6, C3-H), 7.02 (1H, br 
s, ArNHAr), 7.21-7.29 (4H, m, C5-H and C2-H), 7.55 (2H, d, J = 7.89 Hz, C1-H); 13C 
NMR (125 MHz, CDCl3) δ -4.5 (Si(CH3)2C), 16.9 (SiC(CH3)3), 26.6 (OCH3), 55.8 
(NHCH2Ar), 114.5 (Ar-C), 119.6 (Ar-C), 122.5 (Ar-C), 128.8 (Ar-C), 129.0 (Ar-C), 
139.9 (Ar-C), 159.2 (Ar-C), 159.7 (Ar-C), 163.2 (Ar-C); HRMS calcd for C26H33N4OSi 
[M+H]+ 445.2418, Found 445.2410. 
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6-((tert-Butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine (220) 
 
A solution of 6-((tert-butyldimethylsilyl)ethynyl)-N4-(4-methoxybenzyl)-N2-phenyl 
pyrimidine-2,4-diamine (213) (50 mg, 0.11 mmol) in TFA (1 mL) was heated (18 h, 
75 oC). The reaction mixture was carefully added to sat. NaHCO3(aq) (30 mL) and 
extracted with EtOAc (20 mL). The organic layer was removed and washed with 
water (3 x 30 mL) then dried (Na2SO4) and dry loaded onto silica. The title compound 
(220) was purified by MPLC on silica (2:3 EtOAc/petrol) to give a yellow solid (34 
mg, 0.10 mmol, 91 %). 
Rf = 0.54 (2:3 EtOAc/petrol); m.p. 146-147 
oC; UV λmax (EtOH/nm) 225.0 and 268.5; 
IR ѵmax/cm
-1: 3420, 3284, 3121, 3062, 2950, 2928, 2887, 2856, 1598, 1576, 1538; 1H 
NMR (500 MHz, CDCl3) δ 0.20 (6H, s, 2 x SiCH3), 1.00 (9H, s, Si
tBu), 4.77 (2H, br s, 
NH2),  4.85 (1H, br s, ArNHCH3), 6.10 (1H, s, pyrimidine CH), 7.00 (2H, dd, J = 7.3 
and 7.6, C3-H), 7.05 (1H, br s, ArNHAr), 7.29 (2H, dd, J = 7.3 and 8.7, C2-H), 7.56 
(2H, d, J = 7.7 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ -4.8 (Si(CH3)2C), 16.9 
(SiC(CH3)3), 100.0 (C≡C-Si), 119.3 (Ar-C), 122.3 (Ar-C), 128.8 (Ar-C), 139.6 (Ar-C), 
163.5 (Ar-C). HRMS calcd for C18H25N4Si [M+H]
+ 325.1843, Found 325.1841. 
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5-Bromo-6-((tert-butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine 
(222) 
 
A solution of 6-((tert-butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine 
(220) (100 mg, 0.31 mmol) in anhydrous MeCN (10 mL) was cooled to 0 oC. N-
bromosuccinimide (58 mg, 0.32 mmol) was added in one portion and the reaction 
mixture was stirred until no starting material remained (0 oC, 45 min). The solvent 
was removed in vacuo and the crude product was redissolved in EtOAc (10 mL) and 
dry loaded onto isolute HM-N. The title compound (222) was purified by C18 reverse 
phase MPLC (8:2 MeCN (0.1% HCOOH)/H2O (0.1% HCOOH) as a white crystalline 
solid (84 mg, 0.21 mmol, 68%). 
Rf = 0.38 (1:4 EtOAc/petrol); m.p 158-159 
oC; UV λmax (EtOH/nm) 272.5; IR ѵmax/cm
-
1: 3482, 3422, 3294, 3175, 3055, 3018, 2949, 2927, 2884, 2855, 1622, 1597, 1526; 
1H NMR (500 MHz, CDCl3) δ 0.23 (6H, s, CH3), 1.03 (9H, s, tBu), 5.32 (2H, br s, 
ArNH2), 6.98 (1H, br s, ArNHAr), 7.02 (1H, tt, J = 7.3 and 1.1 Hz, C
3-H), 7.30 (2H, 
app. t, J = 7.5 Hz, C2-H), 7.51 (2H, d, J = 7.7 Hz, C1-H); 13C NMR (125 MHz, CDCl3) 
δ -5.0 (Si(CH3)2), 26.1 (SiC(CH3)3), 20.8 (C-CH3), 92.3 (C≡C-Si), 101.4 (C≡C), 119.1 
(Ar-C), 120.5 (Ar-C), 122.3 (Ar-C), 128.5 (Ar-C) 131.5 (Ar-C); HRMS calcd for 
C18H24BrN4Si [M+H]
+ 403.0948, Found 403.0945. 
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6-((tert-Butyldimethylsilyl)ethynyl)-5-chloro-N2-phenylpyrimidine-2,4-diamine 
(221) 
 
A biotage microwave vessel was charged with 6-((tert-butyldimethylsilyl)ethynyl)-N2-
phenylpyrimidine-2,4-diamine (220) (100 mg, 0.31 mmol). Anhydrous MeCN (10 mL) 
and N-chlorosuccinimide (43 mg, 0.32 mmol) were added and the reaction mixture 
was heated using microwave irradiation (100 oC, 25 min). The solvent was removed 
in vacuo and the crude product was redissolved in EtOAc (10 mL) and dry loaded 
onto silica. The title compound (221) was purified by MPLC on silica (1:4 
EtOAc/petrol) as a yellow crystalline solid (84 mg, 0.21 mmol, 87%). 
Rf = 0.44 (1:4 EtOAc/petrol); m.p. 149-150 
oC; UV λmax (EtOH/nm) 272.0; IR 
ѵmax/cm
-1:  3247, 3423, 3290, 3165, 2950, 2928, 2856, 2362, 2343, 2362, 2343, 
1629, 1599, 1567, 1535; 1H NMR (500 MHz, CDCl3) δ 0.23 (6H, s, CH3), 1.03 (9H, s, 
tBu), 5.25 (2H, br s, ArNH2), 6.94 (1H, br s, ArNHAr), 7.01 (1H, tt, J = 7.4 and 1.1 Hz, 
C3-H), 7.30 (2H, app. t, J = 7.4 Hz, C2-H), 7.52 (2H, d, J = 7.7 Hz, C1-H); 13C NMR 
(125 MHz, CDCl3) δ -4.9 (Si(CH3)2), 26.1 (SiC(CH3)3), 100.0 (C≡C-Si), 101.7 (C≡C-
Si), 108.7 (Ar-C), 119.3 (Ar-C), 122.5 (Ar-C), 128.9 (Ar-C), 139.4 (Ar-C), 146.8 (Ar-
C), 157.3 (Ar-C), 159.6 (Ar-C); HRMS calcd for C18H24ClN4Si [M+H]
+ 359.1453, 
Found 359.1451. 
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6-Ethynyl-N4-methyl-N2-phenylpyrimidine-2,4-diamine (96) 
 
The title compound was prepared following general procedure A using: 6-((tert-
butyldimethylsilyl)ethynyl)-N4-methyl-N2-phenylpyrimidine-2,4-diamine (211) (50 mg, 
0.13 mmol) and TBAF (1 M in THF) (140 µL, 0.14 mmol) in THF (15 mL). The crude 
product was purified by MPLC on silica (2:3 EtOAc/petrol) to give the title compound 
(96) as a brown solid (28 mg, 0.13 mmol, 91 %). 
Rf = 0.22 (1:2 EtOAc/petrol);  m.p. 80.0-81.0 
oC; UV λmax (EtOH/nm) 269.0; IR 
ѵmax/cm
-1:  3247, 2366, 2153, 1975, 1589, 1528, 1497, 1441, 1389; 1H NMR (500 
MHz, CDCl3) δ 2.98 (3H, d, J = 3.8 Hz, CH3), 3.09 (1H, s, CH ethynyl), 4.85 (1H, br s, 
ArNHCH3) 6.05 (1H, s, pyrimidine CH), 6.92 (1H, br s, ArNHAr), 6.99 (1H, tt, J = 7.4 
and 1.2, C3-H), 7.29 (2H, dd, J = 7.6 and 7.3 Hz, C2-H), 7.60 (2H, d, J = 7.9 Hz, C1-
H); 13C NMR (125 MHz, CDCl3) δ 28.3 (CH3), 77.5 (C≡C-H), 82.0 (C≡C), 119.1 (Ar-
C), 122.1 (Ar-C), 128.8 (Ar-C), 139.9 (Ar-C), 148.3 (Ar-C), 163.8 (Ar-C), 171.3 (Ar-
C); HRMS calcd for C13H13N4 [M+H]
+ 225.1135, Found 225.1130. 
 
N4-Ethyl-6-ethynyl-N2-phenylpyrimidine-2,4-diamine (67) 
 
The title compound was prepared following general procedure A using: 6-((tert-
butyldimethylsilyl)ethynyl)-N4-ethyl-N2-phenylpyrimidine-2,4-diamine (212) (60 mg, 
0.17 mmol) and TBAF (1 M in THF) (190 µL, 0.19 mmol) in THF (15 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(67) as an off-white solid (26 mg, 0.11 mmol, 64%). 
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Rf = 0.66 (5:95 MeOH/DCM);  m.p. 96.5-97.8 
oC; UV λmax (EtOH/nm) 269; IR 
ѵmax/cm
-1: 3258, 2968, 2356, 2118, 1797, 1575, 1526, 1497, 1410, 1346; 1H NMR 
(500 MHz, CDCl3) δ 1.27 (3H, t, J = 7.3 Hz, CH3), 3.09 (1H, s, CH ethynyl), 3.39 (2H, 
m, ArCH2CH3),  4.81 (1H, br s, ArNHCH2), 6.03 (1H, s, pyrimidine CH), 6.95 (1H, br 
s, ArNHAr), 6.98 (1H, tt, J = 7.3 and 1.1 Hz, C3-H), 7.29 (2H, app. t, J = 7.6 Hz, C2-
H), 7.58 (2H, d, J = 7.6 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 14.7 (CH3), 36.3 
(NHCH2CH3), 77.6 (C≡C-H), 119.1 (Ar-C), 122.1 (Ar-C), 128.8 (Ar-C), 139.8 (Ar-C), 
148.8 (Ar-C), 162.8 (Ar-C); HRMS calcd for C14H15N4 [M+H]
+ 239.1291, Found 
239.1287. 
 
6-Ethynyl-N4-(4-methoxybenzyl)-N2-phenylpyrimidine-2,4-diamine (98) 
 
The title compound was prepared following general procedure A using: 6-((tert-
butyldimethylsilyl)ethynyl)-N4-(4-methoxybenzyl)-N2-phenylpyrimidine-2,4-diamine 
(213) (50 mg, 0.11 mmol) and TBAF (1 M in THF) (120 µL, 0.12 mmol) in THF (15 
mL). The crude product was purified by MPLC on silica (2:3 EtOAc/petrol) to give the 
title (98) compound as a brown oil (25 mg, 7.6 x 10-2 mmol, 67%). 
Rf = 0.35 (2:3 EtOAc/petrol); UV λmax (EtOH/nm) 270.5; IR ѵmax/cm
-1: 3406, 3282, 
2835, 2351, 2114, 1790, 1580, 1536, 1511, 1494, 1456, 1441; 1H NMR (500 MHz, 
CDCl3) δ 3.09 (1H, s, CH ethynyl), 3.80 (3H, s, CH3), 4.51 (2H, s, CH2), 5.11 (1H, br 
s, ArNHCH2), 6.06 (1H, s, pyrimidine CH), 6.89 (2H, d, J = 8.8 Hz, C
4-H), 7.01 (1H, 
tt, J = 7.3 and 1.1, C3-H), 6.99 (1H, br s, ArNHAr), 7.25 (2H, d, J = 8.8 Hz, C5-H), 
7.28 (2H, app. t, J = 7.6 C2-H), 7.55 (2H, d, J = 8.7 Hz, C1-H); 13C NMR (125 MHz, 
CDCl3) δ 45.0 (NHCH2Ar), 55.6 (OCH3), 77.6 (C≡C-H), 81.9 (C≡C), 114.2 (Ar-C), 
119.2 (Ar-C), 122.1 (Ar-C), 128.8 (Ar-C), 128.9 (Ar-C), 139.7 (Ar-C), 159.2 (Ar-C), 
159.8 (Ar-C), 162.8 (Ar-C); HRMS calcd for C20H19N4O [M+H]
+ 331.1553, Found 
331.1557. 
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6-Ethynyl-N2-phenylpyrimidine-2,4-diamine (95) 
 
The title compound was prepared following general procedure A using: 6-((tert-
butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine (220) (75 mg, 0.23 
mmol) and TBAF (1 M in THF) (250 µL, 0.25 mmol) in THF (20 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(95) as a yellow oil (38 mg, 0.18 mmol, 78%). 
Rf = 0.31 (5:95 MeOH/DCM); UV λmax (EtOH/nm) 267.5; IR ѵmax/cm
-1: 2676, 2337, 
2118, 1687, 1615, 1528, 1495, 1403, 1358, 1232, 1173; 1H NMR (500 MHz, CDCl3) 
δ 3.12 (1H, s, CH ethynyl), 4.81 (2H, br s, ArNH2) 6.13 (1H, s, pyrimidine CH), 6.97 
(1H, br s, ArNHAr), 7.01 (1H, tt, J = 7.4 and 1.0 Hz, C3-H), 7.30 (2H, app. t, J = 7.4 
Hz, C2-H), 7.57 (2H, d, J = 7.4 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 78.1 (C≡C-
H), 81.6 (C≡C), 100.0 (Ar-C), 119.4 (Ar-C), 122.4 (Ar-C), 128.8 (Ar-C), 139.5 (Ar-C), 
149.0 (Ar-C), 159.6 (Ar-C), 163.6 (Ar-C); HRMS calcd for C12H11N4 [M+H]
+ 211.0978, 
Found 211.0979. 
 
5-Bromo-6-ethynyl-N2-phenylpyrimidine-2,4-diamine (100) 
 
The title compound was prepared following general procedure A using: 5-bromo-6-
((tert-butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine (222) (70 mg, 0.17 
mmol) and TBAF (1 M in THF) (190 µL, 0.19 mmol) in THF (15 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(100) as a white solid (48 mg, 0.16 mmol, 95%). 
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Rf = 0.64 (5:95 MeOH/DCM); m.p 160.9-162.7 
oC; UV λmax (EtOH/nm) 271.5; IR 
ѵmax/cm
-1: 3479, 3447, 3401, 3274, 2178, 2033, 1977, 1631, 1596, 1561, 1520; 1H 
NMR (500 MHz, CDCl3) δ 3.36 (1H, s, CH ethynyl), 5.27 (2H, br s, ArNH2), 6.87 (1H, 
br s, ArNHAr), 6.96 (1H, tt, J = 7.4 and 1.0 Hz, C3-H), 7.24 (2H, app. t, J = 7.6 Hz, 
C2-H), 7.45 (2H, d, J = 7.7 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 80.3 (C≡C-H), 
82.9 (C≡C), 95.4 (Ar-C), 119.5 (Ar-C), 122.7 (Ar-C), 128.9 (Ar-C), 139.2 (Ar-C), 
148.4 (Ar-C), 158.1 (Ar-C), 160.5 (Ar-C); HRMS calcd for C12H10BrN4 [M+H]
+ 
289.0083, Found 289.0089. 
 
5-Chloro-6-ethynyl-N2-phenylpyrimidine-2,4-diamine (99) 
 
The title compound was prepared following general procedure A using: 5-chloro-6-
((tert-butyldimethylsilyl)ethynyl)-N2-phenylpyrimidine-2,4-diamine (221) (64 mg, 0.18 
mmol) and TBAF (1 M in THF) (196 µL, 0.20 mmol) in THF (10 mL). The crude 
product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound 
(99) as an off-white solid (37 mg, 0.15 mmol, 85%). 
Rf = 0.68 (5:95 MeOH/DCM); m.p 96.5-97.8 
oC; UV λmax (EtOH/nm) 270.0; IR 
ѵmax/cm
-1: 3486, 3449, 3397, 3274, 3057, 2121, 1632, 1595, 1564, 1523; 1H NMR 
(500 MHz, CDCl3) δ 3.45 (1H, s, CH ethynyl), 5.29 (2H, br s, ArNH2), 6.93 (1H, br s, 
ArNHAr), 6.96 (1H, tt, J = 7.4 and 1.1 Hz, C3-H), 7.31 (2H, app. t, J = 7.6 Hz, C2-H), 
7.52 (2H, d, J = 7.7 Hz, C1-H); 13C NMR (125 MHz, CDCl3) δ 78.8 (C≡C-H), 83.6 
(C≡C), 119.4 (Ar-C), 122.7 (Ar-C), 128.7 (Ar-C), 139.2 (Ar-C), 146.1 (Ar-C), 157.3 
(Ar-C), 159.6 (Ar-C), 162.8 (Ar-C); HRMS calcd for C12H10ClN4 [M+H]
+ 245.0589, 
Found 245.0592. 
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7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (257) 
 
To a solution of NaH (60% in mineral oil) in anhydrous DMSO (10 mL) was added 
cyclohexylmethanol (4.34 mL, 35.3 mmol) under nitrogen. The resulting mixture was 
stirred until no further gas was evolved (45 min) then added to a separate solution of 
7-chloro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (173) (1.50 g, 8.82 mmol) in 
anhydrous DMSO (10 mL). The reaction mixture was stirred under nitrogen (RT, 
18h)  then added to water (100 mL). The aqueous solution was neutralised (AcOH) 
and stirred for a further hour resulting in a light orange precipitate. The precipitate 
was filtered then washed with water (50 mL) then ether (2 x 30 mL) and dried under 
vacuum to give (257) as a light orange solid (1.52 g, 6.14 mmol, 70%).  
m.p. 214-216 oC; UV λmax (EtOH/nm) 285.0; IR ѵmax/cm
-1: 3494, 3378, 2925, 2780, 
2651, 2362, 2329, 2115, 2085, 2013, 1906, 1628, 1608, 1578, 1488; 1H NMR (500 
MHz, DMSO-d6) δ 1.03-1.89 (11H, m, cyclohexyl), 4.30 (2H, d, J = 6.5, OCH2), 6.91 
(2H, br s, NH2), 15.28 (1H, br s, NH triazolopyrimidine); 
13C NMR (125 MHz, DMSO-
d6) δ 25.1 (CH2), 25.9 (CH2), 29.1 (CH2), 36.6 (CH), 71.2 (CH2), 162.2 (Ar-C);  HRMS 
calcd for C11H17N6O [M+H]
+
  249.1458, Found 249.1461. 
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4-((7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)amino) 
benzenesulfonamide (253) 
 
i) Synthesis of 5-chloro-7-(cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
LiCl (34 mg, 0.80 mmol) was added to anhydrous dimethylacetamide (500 µL), which 
was heated until all LiCl had dissolved. The solution was cooled (0 oC) and 7-
(cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (257) (50 mg, 0.20 
mmol) was added followed by isoamyl nitrite (61 µL, 0.30 mmol) and SOCl2 (16 µL, 
0.22 mmol). The reaction mixture was stirred (0 oC, 1 h) then allowed to warm (RT, 
18 h). NaHCO3(aq) (15 mL) was added and the resulting aqueous mixture was 
extracted with EtOAc (3 x 15 mL). The organic layers were pooled, washed with 
brine (2 x 30 mL) then dried (Na2SO4). The solvent was removed to give the crude 
product as a brown oil (54 mg, 0.20 mmol, >99 %) which was used without further 
purification. 
ii) Synthesis of 4-((7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-
yl)amino) benzenesulfonamide 
The title compound was prepared following general procedure E using crude 5-
chloro-7-(cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (54 mg, 0.20 mmol), 
sulfanilamide (69 mg, 0.40 mmol) and TFA (78 µL, 1.00 mmol) in TFE (1 mL). The 
crude product was dry loaded onto isolute HM-N and purified by MPLC on silica (3:7 
EtOAc/petrol) followed by C18 reverse phase MPLC (8:2 MeOH(0.1% HCOOH)/H2O 
(0.1% HCOOH)) to give the title compound (253) as a  white solid (28 mg, 6.9 x 10-2 
mmol, 35%). 
Rf = 0.18 (7:3 EtOAc/petrol), m.p. 217-219 
oC; UV λmax (EtOH/nm) 310.0; IR 
ѵmax/cm
-1: 3254, 3121, 2924, 2851, 2363, 2342, 2199, 2140, 1992, 19118, 1700, 
1582, 1534, 1492, 1447; 1H NMR (500 MHz, DMSO-d6) δ 1.04-1.92 (11H, m, 
Cyclohexyl), 4.36 (2H, d, J = 6.8 Hz, OCH2), 7.18 (2H, br s, SO2NH2), 7.72 (2H, d, J 
= 8.8 Hz, C2-H), 7.98 (1H, br s, CH triazolopyrimidine), 7.99 (2H, d, J = 9.0 Hz, C1-
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H), 9.92 (1H, br s, ArNHAr) 13.34 (1H, br s, NH triazolopyrimidine); 13C NMR (125 
MHz, DMSO-d6) δ 25.1 (CH2), 29.1 (CH2), 35.9 (CH), 118.0 (Ar-C), 126.4 (Ar-C);  
HRMS calcd for C17H22N7O3S [M+H]
+
  404.1499, Found 404.1500. 
Note: not all carbon atoms were visible 
 
2-Amino-4,6-dichloropyrimidine-5-carbaldehyde (285)305,306  
 
POCl3 (33 mL, 0.37 mmol) was cooled in an ice bath (0 
oC) and placed under 
nitrogen. To this Anhydrous DMF (3.44 mL, 0.44 mmol) was added dropwise with 
stirring over 30 min. 2-Amino-4.6-dihydroxy pyrimidine was then added in portions 
and the resulting mixture was allowed to warm to RT. The reaction mixture was 
heated (110 oC, 5 h) after which no starting material remained (LC-MS). The 
resulting brown oil was cooled to RT and the POCl3 was removed in vacuo until the 
total volume was reduced to approximately 20%. The residual POCl3 was neutralised 
by gradual addition to ice water (300 mL) resulting in a yellow precipitate which was 
filtered, washed with water (3 x 50 mL) and dried under vacuum to give the title 
compound (285) as a yellow solid (4.18 g, 0.22 mmol, 59%) which was sufficiently 
pure for use in the next reaction. 
m.p. 300 oC (dec.) (Lit 208-224 oC); 1H-NMR (DMSO-d6) δ 8.55 (2H, br s, NH2), 
10.08 (1H, s, CHO); LRMS (ES-) m/z = 190 [M+H]- 
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4-Chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (286)307 
 
A solution of 2-amino-4,6-dichloropyrimidine-5-carbaldehyde (285) (500 mg, 2.6 
mmol) in a 3:1 mixture of THF/Water (11 mL) was heated to 50 oC. Hydrazine 
hydrate (252 µL, 5.2 mmol) in water (3.3 mL) was added resulting in a yellow 
precipitate. The reaction mixture was cooled to RT and poured into ice-water (12 
mL). The volume of solvent was reduced in vacuo resulting in further precipitation. 
The resulting solid was collected by filtration and washed with cold acetone (15 mL) 
to give the title compound (286) as a yellow solid (220 mg, 13.6 mmol, 50%).  
m.p. 201 oC (dec.) (Lit. 210 oC (dec.)); 1H-NMR (DMSO-d6) δ 8.50 (1H, br s, NH2), 
10.06 (1H, s, CH pyrazolopyrimidine), 11.55 (1H, br s, NH pyrazolopyrimidine), 
LRMS (ES+) m/z = 170.0 [M+H]+. 
 
4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (256) 
 
NaH (60% in mineral oil) was added to a solution of cyclohexylmethanol (364 µL, 3.0 
mmol) in anhydrous DMSO (1 mL). The mixture was stirred until no further gas was 
evolved (RT, 1 h). The resulting solution was added dropwise with stirring, to 4-
chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (286) (125 mg, 0.74 mmol) dissolved in 
anhydrous DMSO (1 mL). The reaction mixture was heated (100 oC, 30 min) then 
allowed to cool and added to water (25 mL) which was then neutralised (AcOH) 
resulting in a yellow precipitate. The precipitate was filtered and washed with water 
(10 mL) followed by ether (2 x 10 mL). The crude product was purified by MPLC on 
silica (1:9 MeOH/DCM) to give the title compound (287) as an off-white crystalline 
solid (68 mg, 0.28 mmol, 37%). 
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Rf = 0.70 (1:9 MeOH/DCM), m.p. 193-195 
oC; UV λmax (EtOH/nm) 275.5; IR 
ѵmax/cm
-1: 3498, 3353, 3232, 3121, 2960, 2921, 2851, 2750, 2667, 2158, 2038, 
1902, 1794, 1633, 1578, 1497 ,1469, 1441; 1H NMR (500 MHz, DMSO-d6) δ 0.98-
1.82 (11H, m, cyclohexyl), 4.21 (2H, d, J = 6.5, OCH2), 6.55 (2H, br s, NH2), 7.77 
(1H, s, CH pyrazolopyrimidine), 12.78 (1H, br s, NH pyrazolopyrimidine); 13C NMR 
(125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.1 (CH2), 36.7 (CH), 70.5 (CH2), 
95.4 (Ar-C), 131.6 (Ar-C), 158.9 (Ar-C), 162.0 (Ar-C), 163.4 (Ar-C);  HRMS calcd for 
C12H18N5O [M+H]
+
  248.1506, Found 248.1508. 
 
6-Chloro-4-(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (287) 
 
LiCl (69 mg,1.62 mmol) was added to anhydrous dimethylacetamide (1 mL), which 
was heated until the LiCl had fully dissolved. The solution was cooled to 0 oC and 4-
(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (286) (100 mg, 0.40 
mmol) was added, followed by isoamyl nitrite (123 µL, 0.61 mmol) and SOCl2 (32 µL, 
0.45mmol). The reaction mixture was stirred (RT, 18 h) then diluted with EtOAc (45 
mL). The resulting solution was washed with NaHCO3(aq) (45 mL) and brine (2 x 45 
mL)  then dried (Na2SO4) and dry loaded onto silica. The crude product was purified 
by MPLC (5:95 MeOH/DCM) to give the title compound (287) as a yellow solid (65 
mg, 0.24 mmol, 60%). 
Rf = 0.32 (5:95 MeOH/DCM), m.p. 152-153 
oC; UV λmax (EtOH/nm) 252.5; IR 
ѵmax/cm
-1: 3148, 2922, 2851, 1677, 1579, 1443; 1H NMR (500 MHz,CDCl3) δ 0.96-
1.95 (11H, m, cyclohexyl), 4.39 (2H, d, J = 6.0 Hz, OCH2), 8.09 (1H, s, C
1-H), 11.19 
(1H, br s, NH pyrazolopyrimidine); 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 
(CH2), 29.1 (CH2), 36.7 (CH), 70.5 (CH2O), 95.4 (Ar-C), 131.6 (C
1-H), 158.9 (Ar-C), 
162.0 (Ar-C), 163.4 (Ar-C); HRMS calcd for C12H16ClN4O [M+H]
+
  267.1007, Found 
267.1012. 
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4-((4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6yl)amino)benzene 
sulfonamide (252) 
 
The title compound was prepared following general procedure E using: 6-chloro-4-
(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (287) (42 mg, 0.18 mmol), 
sulfanilamide (62 mg, 0.36 mmol) and TFA (69 µL, 0.90 mmol) in TFE (1 mL). The 
crude product was purified by MPLC on silica (7:3 EtOAc/petrol) followed by C18 
reverse phase MPLC (8:2 MeOH(0.1% HCOOH)/H2O (0.1% HCOOH)) to give the 
title compound (252) as a  white solid (20 mg, 5.0 x 10-2 mmol, 28%). 
Rf = 0.21 (7:3 EtOAc/petrol), m.p. 268-269 
oC; UV λmax (EtOH/nm) 304.5; IR 
ѵmax/cm
-1: 3367, 3333, 3269, 2922, 2853, 2162, 2012, 1691, 1658, 1624, 1583, 
1551, 1524; 1H NMR (500 MHz, DMSO-d6) δ 1.04-1.92 (11H, m, Cyclohexyl), 4.36 
(2H, d, J = 6.8 Hz, OCH2), 7.18 (2H, br s, SO2NH2), 7.72 (2H, d, J = 8.8 Hz, C
2-H), 
7.98 (1H, br s, C3-H), 7.99 (2H, d, J = 9.0 Hz, C1-H), 9.92 (1H, br s, ArNHAr) 13.34 
(1H, br s, NH Pyrazolopyrimidine); 13C NMR (125 MHz, DMSO-d6) δ 25.4 (CH2), 26.5 
(CH2), 29.5 (CH2), 37.1 (CH), 71.5 (CH2) 118.6 (Ar-C), 136.6 (Ar-C), 144.0 (Ar-C);  
HRMS calcd for C18H23N6O3S [M+H]
+
  403.1547, Found 403.1547. 
Note: not all carbon atoms were visible 
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2-Amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (264)221 
 
HCl(aq) (2 M) (450 µL, 0.91 mmol) was added to a mixture of bromoacetaldehyde 
diethyl acetal (596 µL, 4.0 mmol) and water (1.75 mL). The resulting biphasic mixture 
rapidly stirred with heating until a solution was formed (90 oC, 30 min), which was 
cooled to RT and NaOAc (338 mg, 4.12 mmol) was added. In a separate flask a 
suspension of 2,6-diamino-4-pyrimidinone (500 mg, 4.0 mmol) in water (3.75 mL) 
with NaOAc (175 mg, 2.13 mmol) was stirred at RT. The freshly prepared 
bromoacetaldehyde solution was added in a single portion and the reaction mixture 
was heated (80 oC, 3 h). The reaction mixture was cooled to 0 oC for 90 min resulting 
in an off-white precipitate. The precipitate was filtered and washed with cold water (5 
mL) then acetone (2 x 10 mL) to give the title compound (264) as a light brown solid 
(376 mg, 2.5 mmol).  
m.p. 325 oC (dec.) (Lit >230 oC (dec.)); 1H NMR (500 MHz, DMSO-d6) δ 5.88 (2H, br 
s, NH2), 6.17 (1H, d, J = 2.1 Hz, C
1-H), 6.60 (1H, d, J = 2.1 Hz, C2-H), 10.19 (1H, br 
s, NH pyrrolopyrimidine), 10.94 (1H, br s, NHCO); LRMS (ES+) m/z = 151.1 [M+H]+. 
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4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine (265)221 
 
A suspension of 2-amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (264) (1.34 g, 8.9 
mmol) in POCl3 (8.15 mL, 89 mmol) was stirred (RT, 30 min). The reaction mixture 
was then heated to reflux (110 oC, 4h). The volume of POCl3 was reduced in vacuo 
to approximately 20%.  The remaining POCl3 was quenched over ice water (50 mL) 
then neutralised (NaHCO3(aq)). The resulting solution was filtered through Celite then 
extracted with EtOAc (3 x 300 mL) to give the title compound (264) as a yellow solid 
(660 mg, 3.9 mmol, 44%). 
m.p. 225 oC (dec.) (Lit 215-217 oC); 1H NMR (500 MHz, DMSO-d6) δ 6.24 (1H, d, J = 
2.1 Hz, C1-H), 6.46 (2H, br s, NH2), 7.08 (1H, d, J = 2.1 Hz, C
2-H), 11.44 (1H, br s, 
NH pyrrolopyrimidine); LRMS (ES+) m/z = 169.0 [M+H]+. 
 
4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (255) 
 
Cyclohexyl methanol (438 µL, 3.6 mmol) was added dropwise under nitrogen to a 
mixture of NaH (60% in mineral oil) in anhydrous DMSO (1 mL). The resulting 
mixture was stirred until no further gas was evolved (45 min). A separate solution of 
4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine (254) (150 mg, 0.89 mmol) in anhydrous 
DMSO (1 mL) was prepared to which the freshly prepared cyclohexyl methoxide was 
added dropwise under nitrogen. The reaction mixture was heated using microwave 
irradiation (170 oC, 5 h), cooled to RT then added to water (20 mL). The aqueous 
mixture was neutralised (AcOH) then extracted with EtOAc (50 mL) before filtration 
of the resulting emulsion through Celite to give a biphasic mixture. The organic layer 
was removed and the aqueous layer was further extracted with EtOAc (2 x 30 mL). 
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The organic layers were pooled and dried (Na2SO4) then dry loaded onto silica. The 
title compound (255) was purified by MPLC on silica (1:9 MeOH/DCM) followed by 
C18 reverse phase MPLC (8:2 MeOH (0.1% HCOOH)/ Water (0.1% HCOOH) as a 
white crystalline solid (37 mg, 0.15 mmol, 17%).  
Rf = 0.55 (1:9 MeOH/DCM); m.p. 216.3-217.3 
oC; UV λmax (EtOH/nm) 221; IR 
ѵmax/cm
-1: 3494, 3362, 3117, 2922, 2851, 2164, 2045, 1968, 1617, 1585, 1499, 
1478; 1H NMR (500 MHz, DMSO-d6) 0.98-1.83 (11H, m, cyclohexyl), 4.15 (2H, d, J = 
6.5, OCH2), 5.91 (2H, br s, NH2), 6.17 (1H, dd, J = 1.9 and 3.5, C
1-H), 6.79 (1H, dd, 
J = 2.2 and 3.5, C2-H), 10.97 (1H, br s, NH pyrrolopyrimidine); 13C NMR (125 MHz, 
DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.3 (CH2), 36.8 (CH), 69.9 (CH2O), 96.9 (C
1-
H), 97.9 (Ar-C), 119.1 (C2-H), 155.0 (Ar-C), 159.3 (Ar-C), 162.7 (Ar-C); HRMS calcd 
for C13H19N4O  [M+H]
+ 247.1553, Found 247.1556. 
 
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-
amine (279) 
 
A solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine (255) (100 mg, 0.59 mmol) 
in anhydrous MeCN (3 mL) was cooled to -30 oC. NaH (60% in mineral oil, 26 mg, 
0.65 mmol) was added and the reaction mixture was stirred under nitrogen (45 min). 
2-(Trimethylsilyl)ethoxymethyl chloride (SEM-Cl) (90%, 122 µL, 0.62 mmol) was 
added drop-wise and the reaction mixture was stirred for a further 60 min then 
allowed to warm to (RT, 2 h). Water (20 mL) was added and the resulting solution 
was extracted with EtOAc (20 mL). The organic layer was then washed with brine (3 
x 20 mL), dried (Na2SO4) then dry loaded onto silica. The title compound (279) was 
purified by MPLC on silica (15:85 EtOAc/petrol) as a yellow solid (130 mg, 0.44 
mmol, 74%). 
Rf = 0.41 (15:85 EtOAc/petrol); m.p. 63-64 
oC; UV λmax (EtOH/nm) 234.0 and 317.5; 
IR ѵmax/cm
-1: 3423, 3318, 3212, 3096, 2952, 1631, 1608, 1546, 1493; 1H NMR (500 
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MHz, CDCl3) δ -0.04 (9H, s, CH3), 0.91 (2H, t, J = 8.0 Hz, CH2Si), 3.81 (2H, t, J = 8.3 
Hz, OCH2), 4.96 (2H, br s, NH2), 5.44 (2H, s, ArCH2), 6.43 (1H, d, J = 3.7 Hz, C
1-H), 
6.99 (1H, d, J = 3.7 Hz, C2-H); 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 19.2 
(CH2CH2Si), 67.7 (OCH2CH2), 74.3 (NCH2O), 102.2 (C
5H), 112.2 (Ar-C), 127.0 
(C6H), 154.2 (Ar-C), 155.6 (Ar-C), 160.2 (Ar-C); HRMS calcd for C12H20ClN4OSi 
[M+H]+  299.1089, Found 299.1090. 
 
4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-amine (280) 
 
NaH (60% in mineral oil, 121 mg, 3.03 mmol) was added under nitrogen to a solution 
of cyclohexylmethanol (496 µL, 4.03 mmol) in anhydrous THF (5 mL). The resulting 
mixture was stirred (RT, 45 min) until no further gas was evolved then added 
dropwise to a solution of 4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-amine (279) (300 mg, 1.01 mmol) in THF (10 mL). The reaction was 
stirred (RT, 72 h) then the volume of solvent was reduced in vacuo to approximately 
2 mL. The resulting solution was added to HCl(aq) (1 M) (50 mL) which was then 
extracted with DCM (25 mL) and washed with NaHCO3(aq) (50 mL) and brine (50 
mL). The organic layer was dried (phase separator) then dry loaded onto silica. The 
title compound (280) was purified by MPLC on silica (15:85 EtOAc/petrol) as a 
yellow solid (296 mg, 0.79 mmol, 78%). 
Rf = 0.17 (15:85 EtOAc/petrol); m.p. 88-90 
oC; UV λmax (EtOH/nm) 223.0, 260.0 and 
286.5; IR ѵmax/cm
-1: 3346, 3222, 2926, 2852, 1647, 1602; 1H NMR (500 MHz, CDCl3) 
δ -0.05 (9H, s, CH3), 0.91 (2H, t, J = 8.3 Hz, CH2Si), 1.01-1.91 (11H, m cyclohexyl), 
3.51 (2H, t, J = 8.3 Hz, OCH2CH2), 4.21 (2H, d, J = 6.5 Hz, OCH2CH), 4.68 (2H, br s, 
NH2), 5.41 (2H, s, ArCH2), 6.40 (1H, d, J = 3.7 Hz, C
1-H), 6.82 (1H, d, J = 3.7 Hz, C2-
H); 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 19.2 (CH2CH2Si), 27.2 (CH2), 
28.0 (CH2), 31.3 (CH2), 38.8 (CH), 67.4 (OCH2CH2), 72.6 (CH2), 74.1 (NCH2O), 
101.2 (C5H), 123.6 (C6H), 160.6 (Ar-C), 165.4 (Ar-C); HRMS calcd for C19H33N4O2Si 
[M+H]+  377.2367, Found 377.2367. 
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2-Chloro-4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-
pyrrolo[2,3-d]pyrimidine (281) 
 
4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d] 
pyrimidin-2-amine (280) (100 mg, 0.27 mmol) was added to a solution of LiCl in THF 
(0.5M, 2.13 mL, 1.1 mmol). The reaction mixture was cooled to 0 oC then isoamyl 
nitrite (81 µL, 0.40 mmol) and SOCl2 (21.3 µL, 0.29 mmol) were added 
simultaneously. The resulting solution was stirred (RT, 5 h) then added to NH4Cl(aq) 
(30 mL). The aqueous mixture was extracted with EtOAc (30 mL) and the organic 
layer was washed with water (3 x 30 mL), dried (Na2SO4) and dry loaded onto silica. 
The crude product was purified by MPLC (15:85 EtOAc/petrol) to give the title 
compound (281) as a colourless oil (60 mg, 0.15 mmol, 56%). 
Rf = 0.45 (15:85 EtOAc/Petrol); UV λmax (EtOH/nm) 270; IR ѵmax/cm
-1 2924, 2852, 
1750, 1661, 1588, 1558, 1506; 1H NMR (500 MHz, DMSO-d6) δ -0.09 (9H, s, CH3), 
0.82 (2H, t, J = 8.1 Hz, CH2Si), 0.95-1.89 (11H, m cyclohexyl), 3.50 (2H, t, J = 8.1 
Hz, OCH2CH2), 4.28 (2H, d, J = 6.0 Hz, OCH2CH), 5.52 (2H, s, ArCH2), 6.61 (1H, d, 
J = 3.6 Hz, C1-H), 7.55 (1H, d, J = 3.5 Hz, C2-H); 13C NMR (125 MHz, DMSO-d6) δ 
0.0 (Si(CH3)3), 18.5 (CH2CH2Si), 26.6 (CH2), 30.5 (CH2) 31.8 (CH2), 38.8 (CH), 67.1 
(OCH2CH2), 73.3 (CH2), 74.2 (NCH2O), 100.4 (C
5H), 126.4 (C6H), 129.7 (Ar-C); 
HRMS calcd for C19H31ClN3O2Si [M+H]
+
  396.1869, Found 396.1872. 
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4-((4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-yl)amino)benzenesulfonamide (282) 
 
To a solution of 2-chloro-4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-
7H-pyrrolo[2,3-d]pyrimidine (281) (50 mg, 0.13 mmol) in anhydrous MeCN (2 mL) 
was added sulfanilamide (24 mg, 0.14 mmol), anhydrous K2CO3 (35 mg, 0.25 mmol), 
Pd2(dba)3 (3 mg, 5.0 x 10
-3 mmol) and XPhos (2.4 mg,  5.0 x 10-3 mmol). The 
reaction mixture was degassed (N2, 30 min) and heated (80 
oC, 2 h) then cooled to 
RT and filtered (Celite). The resulting solution was diluted with EtOAc (20 mL) and 
washed sequentially with HCl(aq) (1 M) (20 mL), NaHCO3 (20 mL) and brine (30 mL) 
then  dried (Na2SO4) and dry loaded onto silica. The title compound (282) was 
purified by MPLC (1:1 EtOAc/petrol) as a yellow oil (33 mg, 6.2 x 10-2 mmol, 49%). 
Rf = 0.63 (1:1 EtOAc/petrol); UV λmax (EtOH/nm) 269; IR ѵmax/cm
-1 3644, 3342, 
2924, 2853, 1586, 1528, 1488; 1H NMR (500 MHz,CDCl3) δ -0.08 (9H, s, Si(CH3)3), 
0.88-0.95 (2H, t, J = 8.36 Hz, CH2Si) 1.04 - 1.93 (11H, m, cyclohexyl), 3.56 (2H, t, J 
= 3.4 Hz, O-CH2CH2Si) 4.29 (2H, d, J = 6.5 Hz, OCH2), 4.72 (2H, br s,NH2), 5.52 
(2H, s, Ar-CH2-O), 6.49 (1H, d, J = 3.5 Hz, C
3-H), 6.96 (1H, d, J = 3.6 Hz, C4-H), 7.20 
(1H, br s, Ar-NH-Ar), 7.87 (4H, ap s, C1/2-H); 13C NMR (125 MHz, CDCl3) δ 0.0 
(SiCH3), 15.6 (CH2Si), 27.2 (CH2), 27.9 (CH2), 31.3 (CH2), 38.8 (CH), 67.8 (CH2), 
73.2 (CH2), 74.5 (CH2), 101.5 (Ar-C), 101.9 (Ar-C), 118.8 (Ar-C), 125.0 (Ar-C), 129.3 
(Ar-C), 146.2 (Ar-C); HRMS calcd for C25H38N5O4SSi [M+H]
+
  532.2408, Found 
532.2406.  
Note: Not all carbon atoms visible 
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4-((4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino) 
benzenesulfonamide (251) 
 
A solution of 4-((4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-
pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzenesulfonamide (282) (40 mg. 7.5 x 10-2 
mmol) in TFA (1.5 mL) was heated to reflux (75 oC, 5 min). The resulting green 
solution was neutralised over NaHCO3(aq) (30 mL) then extracted with EtOAc (2 x 30 
mL). The combined organic layers were dried (Na2SO4) and the solvent was 
removed to give the hemiaminal as a yellow solid (22.5 mg, 5.2 x 10-2 mmol). MeCN 
(4 mL) and water (4 mL) were added and the pH was adjusted to 10 with aqueous 
ammonia (32%). The reaction mixture was stirred (1 h, RT) and the solvent was 
removed. The crude product was redissolved in EtOAc (20 mL), dried (Na2CO3) and 
dry loaded onto silica. The title compound (251) was purified by MPLC on silica (3:7 
petrol/EtOAc) as a white solid (12 mg, 3.0 x 10 -2 mmol, 40%). 
Rf = 0.39 (3:7 petrol/EtOAc); m.p. 251.2-252.0 
oC; UV λmax (EtOH/nm) 312.0; IR 
ѵmax/cm
-1: 3374, 3322, 2058, 2924, 2856, 2012, 1615, 1595, 1579; 1H NMR (500 
MHz, DMSO-d6) δ 1.07-1.95 (11H, m, cyclohexyl), 4.31 (2H, d, J = 6.3 Hz, OCH2), 
6.34 (1H, d, J = 2.1 Hz, C3-H), 7.05 (1H, d, J = 2.2 Hz, C4-H), 7.13 (2H, br s, 
SO2NH2), 7.68 (2H, d, J = 8.9 Hz, C
2-H) 7.99 (2H, d, J = 8.8 Hz, C1-H), 9.57 (1H, br 
s, ArNHAr), 11.54 (1H, br s, NH).; 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 
(CH2), 29.3 (CH2), 36.8 (CH), 70.6 (CH2), 98.2 (C
5H), 116.9 (Ar-C), 126.4 (C6H), 
134.9 (Ar-C), 144.6 (Ar-C), 146.4 (Ar-C), 153.6 (Ar-C), 154.4 (Ar-C), 162.4 (Ar-C); 
HRMS calcd for C19H24N5O3S [M+H]
+
  402.1594, Found 402.1596. 
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N-Phenyl-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-
amine (176) 
 
i) Preparation of 5-chloro-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d] 
pyrimidine 
A solution of trimethylsilyl chloride (100 µL, 0.79 mmol) in anhydrous DCM (4 mL) 
was cooled (0 oC) and placed under nitrogen. In a separate flask a solution of 
benzyltriethylammonium nitrite (294) (170 mg, 0.71 mmol) in anhydrous DCM (2 mL) 
was cooled (0 oC) and placed under nitrogen. The solution of (294) was added 
dropwise with stirring to the trimethylsilyl chloride solution at 0 oC.  The resulting 
mixture was stirred (0 oC, 15 min) at which point a cooled (0 oC) solution of 7-
(triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (175) (50 mg, 
0.16 mmol) in anhydrous DCM (2 mL) was introduced dropwise with stirring. The 
reaction mixture was stirred (0 oC, 30 min) then warmed to RT (30 min). The 
resulting solution was washed with NaHCO3(aq) (4 x 20 mL), dried (phase separator) 
and the solvent was removed under vacuum (20 oC) to give the crude product as a 
dark orange oil (59 mg, 0.18 mmol, 112%) which was used without any further 
purification.  
 
ii) N-Phenyl-7-((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine 
(105) 
The crude product from i) was dissolved in a 1 M solution of aniline in DMSO (500 
µL, 0.50 mmol) and heated (70 oC, 96 h). The resulting solution was poured into 1 M 
HCl(aq) (30 mL) which was extracted with EtOAc (2 x 20 mL). The organic layers 
were combined and washed with 1 M HCl(aq) (3 x 30 mL), NaHCO3(aq) (30 mL) and 
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brine (30 mL) then dried (MgSO4). The crude product was purified via preparative 
TLC (5:95 MeOH/DCM) to give (176) as a yellow oil (48 mg, 0.12 mmol, 81%).  
Rf = 0.31 (5:95 MeOH/DCM); UV λmax (EtOH/nm) 274.0; IR ѵmax/cm
-1: 3294, 3209, 
3112, 2943, 2865, 1585, 1564, 1516; 1H NMR (500 MHz, CDCl3) δ 1.12-1.32 (21H, 
m, CH2CH3), 7.08-7.15 (1H, m, C
1-H), 7.35 (2H, app. t, J = 7.6 Hz, C2-H), 7.63 (2H, 
d, J = 7.6 Hz, C3-H), 7.73 (1H, br s, ArNHAr), 13.07 (1H, br s, NH triazolopyrimidine); 
13C NMR (125 MHz, CDCl3) δ 11.3 (Si(CH(CH3)2)3), 18.6 (Si(CH(CH3)2)3), 99.7 (C≡C-
Si), 105.7 (C≡C), 120.3 (Ar-C), 121.0 (Ar-C), 124.1 (Ar-C), 129.1 (Ar-C), 138.3 (Ar-
C), 145.5 (Ar-C), 152.2 (Ar-C), 158.9 (Ar-C); HRMS calcd for C21H29N6Si [M+H]
+
  
393.2217 Found 393.2219. 
 
7-Ethynyl-N-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (90) 
 
The title compound was prepared following general procedure A using: N-phenyl-7-
((triisopropylsilyl)ethynyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (176) (40 mg, 
0.1 mmol) and TBAF (1 M in THF) (112 µL, 1.1 mmol) in THF (4 mL) at 0 oC. The 
crude product was purified by MPLC on silica (5:95 MeOH/DCM) to give the title 
compound (90) as a yellow solid (22 mg, 9.5 x 10-2 mmol, 92%). 
 
Rf = 0.17 (5:95 MeOH/DCM); m.p. 130 
oC (dec); UV λmax (EtOH/nm) 265.0; IR 
ѵmax/cm
-1: 3303, 3283, 3206, 3144, 3097, 2793, 2121, 1596, 1572, 1553; 1H NMR 
(300 MHz, DMSO-d6) δ 5.19 (1H, s, CH ethynyl), 7.03 (1H, tt, J = 7.2 and 1.1 Hz, C
1-
H), 7.34 (2H, app. t, J = 7.4 Hz, C2-H), 7.81 (2H, d, J = 8.6 Hz, C3-H), 10.29 (1H, br 
s, ArNHAr), 16.11 (1H, br s, NH triazolopyrimidne); 13C NMR (125 MHz, DMSO-d6) δ 
77.8 (C≡C-H), 89.6 (C≡C), 119.4 (Ar-C), 122.4 (Ar-C), 128.6 (Ar-C), 139.6 (Ar-C); 
HRMS calcd for C12H9N6 [M+H]
+
 237.0883 Found 237.0886. 
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2-Benzyl-1H-purin-6(9H)-one (81)289,308 
 
A solution of 5-amino-4-imidazole carboxamide hydrochloride (500 mg, 3.1 mmol) 
was prepared in 2:1 mixture of DMF/pyridine (24 mL). Phenylacetic acid (419 mg, 
3.1 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (590 mg, 
3.1 mmol) and DMAP (376 mg, 3.1 mmol) were added and the mixture was heated 
(70 oC, 18 h). The solvent was removed in vacuo and NaOH(aq) (2 M) (25 mL) was 
added. The reaction mixture was heated to reflux (100 oC, 1 h) then cooled (0-5 oC) 
and neutralised with 2 M HCl(aq) resulting in a white precipitate. The precipitate was 
filtered, washed with water (3 x 15 mL) and ether (3 x 15 mL) then dried overnight in 
a vacuum oven to give (81) as an off-white solid (512 mg, 2.3 mmol, 73%). 
1H NMR (300 MHz, DMSO-d6) δ 3.94 (2H, s, CH2), 7.21-7.35 (5H, m, C
1-3-H), 8.04 
(1H, s, C4-H), 12.34 (1H, br s, N9-H), 13.18 (1H, Br s, N1-H); LRMS (ES+) m/z = 
227.1 [M+H]+. 
 
2-Benzyl-6-chloro-9H-purine (82)196 
 
To DMF (anhydrous) (2.6 mL) cooled to 0 oC was added thionyl chloride (2.4 mL, 33 
mmol) dropwise with stirring. The resulting mixture was stirred for 15 minutes at 0 oC 
and kept at this temperature until required. In a separate flask a suspension of (81) 
(1.5 g, 6.6 mmol) in chloroform (30 mL) was prepared. The suspension was heated 
to reflux and the previously prepared DMF solution was introduced dropwise. The 
reaction mixture was maintained at reflux (2 h) resulting in a red precipitate. The 
solvent was removed in vacuo and the precipitate was dissolved by adding EtOAc 
(50 mL) and NaHCO3(aq) (50 mL). The biphasic mixture was filtered and the organic 
layer was removed. The remaining aqueous layer was extracted with EtOAc (2 x 50 
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mL) and the organic layers were combined, dried (Na2SO4). and dry loaded onto 
silica. The title compound (82) was purified by MPLC on silica (EtOAc) as a light 
yellow solid (1.2 g, 4.9 mmol, 74%). 
Rf = 0.38 (EtOAc); 
1H NMR (300 MHz, DMSO-d6) δ 4.34 (2H, s, CH2), 7.11-7.35 (5H, 
m, C1-3-H), 8.19 (1H, s, C4-H), 13.24 (1H, br s, N9-H); LRMS (ES+) m/z = 245.1 
[M+H]+ 
 
tert-Butyl 2-benzyl-6-chloro-9H-purine-9-carboxylate (83) 
 
To a solution of (82) (1.15 g, 4.7 mmol) in DCM (anhydrous) (50 mL) was added di-
tert-butyl dicarbonate (1.08 g, 4.9 mmol) and DMAP (29 mg, 0.24 mmol). The 
reaction mixture was stirred (RT, 1 h) after which no starting material remained 
(observed by LC-MS). The crude product was dry loaded onto silica and purified by 
MPLC (3:7 EtOAc/petrol) to give (83) as a colourless oil (1.23 g, 3.6 mmol, 76%). 
Rf = 0.51 (3:7 EtOAc/petrol); UV λmax (EtOH/nm) 254; IR ѵmax/cm
-1 2981, 2934, 
1754, 1595, 1552, 1495; 1H NMR (500 MHz, DMSO-d6) δ 1.61 (9H, s, C(CH3)3), 4.30 
(2H, s, ArCH2Ar), 7.18-7.39 (5H, m, C
1-3-H), 8.89 (1H, s, C4-H); 13C NMR (125 MHz, 
DMSO-d6) δ 27.4 (C(CH3)), 44.5 (CH2), 86.3 (CCH3), 126.5 (Ar-C), 128.4 (Ar-C), 
129.0 (Ar-C), 130.0 (Ar-C), 137.9 (Ar-C), 138.4 (Ar-C), 145.6 (Ar-C), 151.6 (Ar-C), 
164.8 (Ar-C);  HRMS calcd for C17H18ClN4O2 [M+H]
+
 345.1113 Found 345.1118. 
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tert-Butyl 2-benzyl-6-((triisopropylsilyl)ethynyl)-9H-purine-9-carboxylate (82) 
 
To a solution of tert-butyl 2-benzyl-6-chloro-9H-purine-9-carboxylate (83) (1.23 g, 
3.57 mmol) in anhydrous THF (15 mL) was added (triisopropylsilyl)acetylene (897 
µL, 4.00 mmol). Pd(PPh3)2Cl2 (100 mg, 0.14 mmol) and copper iodide (27 mg, 0.14 
mmol) were then added followed by triethylamine (1.24 mL, 8.93 mmol). The 
reaction vessel was stoppered with a septum then degassed (N2, 20 min) and 
shielded from light. The reaction mixture was stirred (RT, 18 h) then filtered over a 
pad of Celite and purified by silica based MPLC (1:9 EtOAc/petrol) resulting in the 
title compound (84) as a colourless oil (1.45 g, 2.95 mmol, 83%). 
 
Rf = 0.37 (1:9 EtOAc/Petrol); UV λmax (EtOH/nm) 261; IR ѵmax/cm
-1 2941, 2864, 
1756, 1573, 1495; 1H NMR (500 MHz, DMSO-d6) δ 1.05-1.24 (21H, m, 
Si(CH(CH3)2)3), 1.61 (9H, s, C(CH3)3), 4.29 (2H, s, ArCH2Ar), 7.16-7.39 (5H, m, C
1-3-
H), 8.86 (1H, s, C4-H); 13C NMR (125 MHz, DMSO-d6) δ 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 27.5 (C(CH3)), 45.0 (CH2), 86.3 (CCH3), 100.9 (C≡C-Si), 126.3 
(C≡C), 128.3 (Ar-C), 129.1 (Ar-C), 133.6 (Ar-C), 138.3 (Ar-C), 140.1 (Ar-C), 145.7 
(Ar-C), 145.8 (Ar-C), 151.5 (Ar-C), 164.8 (Ar-C); HRMS calcd for C28H39N4O2Si 
[M+H]+ 491.2837 Found 491.2831. 
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2-Benzyl-6-((triisopropylsilyl)ethynyl)-9H-purine (85) 
 
A solution of tert-butyl 2-benzyl-6-((triisopropylsilyl)ethynyl)-9H-purine-9-carboxylate 
(84) (1.45 g, 2.95 mmol) in TFE (50 mL) was heated (2h, 80 oC). The solvent was 
removed and the crude product was redissolved in DCM (50 mL) then dry loaded 
onto silica. The crude product was purified by MPLC on silica (1:1 EtOAc/petrol) to 
give the title compound (85) as a white solid (1.05 g, 2.69 mmol, 91%). 
Rf = 0.02 (2:3 EtOAc/Petrol); m.p. 189 
oC; UV λmax (EtOH/nm) 272; IR ѵmax/cm
-1 
3031, 2941, 2864, 1573, 1462; 1H NMR (500 MHz, DMSO-d6) δ 1.01-1.22 (21H, m, 
Si(CH(CH3)2)3), 4.26 (2H, s, ArCH2Ar), 7.15-7.36 (5H, m, C
1-3-H), 8.54 (1H, s, C4-H), 
13.5 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 44.8 (CH2), 99.2 (C≡C-Si), 126.2 (C≡C), 128.3 (Ar-C), 129.0 (Ar-C), 
138.3 (Ar-C), 162.9 (Ar-C); HRMS calcd for C23H31N4Si [M+H]
+
 391.2313 Found 
391.2318. 
 
Note: not all carbon atoms visible 
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2-Benzyl-6-ethynyl-9H-purine (56) 
 
The title compound was prepared following general procedure A using: 2-Benzyl-6-
((triisopropylsilyl)ethynyl)-9H-purine (86) (500 mg, 1.28 mmol) and TBAF (1 M in 
THF (1.41 mL, 1.41 mmol) in THF (40 mL). The crude product was purified by MPLC 
on silica (1:9 MeOH/DCM) to give the title compound (56) as a light yellow solid (295 
mg, 1.26 mmol, 98%). 
Rf = 0.23 (1:9 MeOH/DCM); m.p. 179.1 
oC (dec.); UV λmax (EtOH/nm) 217.5 and 
294.0; IR ѵmax/cm
-1 3142, 3113, 3057, 2993, 2968, 2833, 2795, 2717, 2100, 1606, 
1576; 1H NMR (500 MHz, DMSO-d6) δ 4.25 (2H, s, CH2), 4.94 (1H, s, CH ethynyl), 
7.14-7.35 (5H, m, C1-3-H), 8.58 (1H, s, C4-H), 13.60 (1H, br s, NH); 13C NMR (125 
MHz, DMSO-d6) δ 44.9 (CH2), 78.9 (C≡C-H), 88.1 (C≡C), 126.2 (Ar-C), 128.3 (Ar-C), 
129.0 (Ar-C), 138.9  (Ar-C), 162.9 (Ar-C); HRMS calcd for C14H11N4 [M+H]
+
 235.0978 
Found 235.098. 
 
N-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (66) 
 
To a solution of 2-fluoro-6-((triisopropylsilyl)ethynyl)-9H-purine (65) (100 mg, 0.31 
mmol) in anhydrous toluene (2 mL) was added N-methylaniline (68 µL, 0.63 mmol) 
and TFA (61 µL, 0.79 mmol). The reaction mixture was heated (160 oC, 4 h) using 
microwave irradiation resulting in consumption of the starting material (65) (observed 
by LC-MS). The solvent was removed and the crude product was redissolved in 
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EtOAc (15 mL) and dry loaded onto silica. The title compound (66) was purified by 
MPLC on silica (5:95 MeoH/DCM) as a yellow oil (85 mg, 0.21 mmol, 67%).  
Rf = 0.41 (5:95 MeOH/DCM); UV λmax (EtOH/nm) 278.0; IR ѵmax/cm
-1 2945, 2864, 
1594, 1566, 1493; 1H NMR (500 MHz, DMSO-d6) δ 1.07-1.21 (21H, m, 
Si(CH(CH3)2)3), 3.48 (3H, s, N-CH3), 7.13 – 7.24 (1H, m, C
1-H), 7.32-7.46 (4H, m, 
C2/3-H), 8.16 (1H, s, C4-H)  12.95 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 
10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 97.7 (C≡C-Si), 102.4 (C≡C), 125.0 (Ar-
C), 126.3 (Ar-C), 128.6 (Ar-C), 128.8 (Ar-C), 139.2 (Ar-C), 142.7 (Ar-C), 146.0 (Ar-
C), 154.3 (Ar-C), 158.1 (Ar-C); LRMS (ES+) m/z = 406.2 [M+H]+. 
Note: N-CH3 carbon NMR peak obscured by DMSO 
 
6-Ethynyl-N-methyl-N-phenyl-9H-purin-2-amine (54) 
 
The title compound was prepared following general procedure A using: N-Methyl-
N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (66) (64 mg, 0.16 mmol) and 
TBAF (1 M in THF (174 µL, 0.174 mmol) in THF (6 mL). The crude product was 
purified by MPLC on silica (5:95 MeOH/DCM) to give the title compound (54) as a 
yellow solid (14 mg, 5.62 x10-2 mmol, 36%). 
Rf = 0.32 (5:95 MeOH/DCM); m.p. 249.3 
oC; UV λmax (EtOH/nm) 227 and 254; IR 
ѵmax/cm
-1 3262, 3091, 3019, 2918, 2848, 2795, 2727, 2112, 1622, 1597; 1H NMR 
(500 MHz, DMSO-d6) 3.46 (3H, s, CH3), 4.75 (1H, s, CH ethynyl), 7.20 (1H, tt, J = 
7.4 and 1.2 Hz, C1-H), 7.35 (2H, d, J = 7.4 Hz, C3-H), 7.39 (2H, app. t, J = 7.4 Hz, 
C2-H), 8.20 (1H, s, C4-H); 13C NMR (125 MHz, DMSO-d6) 39.3 (CH3), 86.8 (C≡C-H), 
125.0 (Ar-C), 126.4 (Ar-C), 128.9 (Ar-C), 146.0 (Ar-C), 158.2 (Ar-C); HRMS calcd for 
C14H12N5 [M+H]
+
 250.1087 Found 250.1089. 
Note: not all carbon atoms visible 
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6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine (70)219 
 
4-Methoxybenzylchloride (0.88 ml, 6.49 mmol) was added to a solution of 2-amino-6-
chloropurine (69) (1.00 g, 5.90 mmol) and K2CO3 (0.90 g, 6.49 mmol) in dry DMF (30 
ml). The reaction mixture was heated at 60 °C for 18 h before being cooled to RT 
and evaporated to dryness in vacuo. The resultant residue was purified by silica gel 
chromatography (19:1 DCM:MeOH) to give the target compound (70) as a pale 
yellow solid (1.47 g, 5.07 mmol, 86%). 
Rf = 0.29 (19:1 DCM:MeOH); m.p. 170-173 °C; UV λmax (EtOH/nm) 224, 310; IR 
ѵmax/cm
-1 3440, 3310, 3201, 3076, 2957, 2831, 1610, 1561, 1512; 1H NMR (500 
MHz, DMSO-d6) 3.70 (3H, s, OCH3), 5.19 (1.4 H, s, N
9-CH2), 5.46 (0.6 H, s, N
7-CH2), 
6.64 (0.6 H, s, C2-NH2 – N
7-PMB), 6.89 (2H, d, J = 8.8 Hz, Benzyl-H3/5), 6.93 (1.4 H, 
s, C2-NH2 – N
9-PMB), 7.12 (0.6 H, d, J = 8.8 Hz, N7-Benzyl-H2/6), 7.23 (1.4 H, d, J = 
8.8 Hz, N9-Benzyl-H2/6), 8.19 (0.7 H, s, C8-H – N9-PMB), 8.52 (0.3 H, s, C8-H – N7-
PMB); 13C NMR (125 MHz, DMSO-d6) 45.6 (N
9-CH2), 48.7 (N
7-CH2), 55.0 (N
7-
OCH3), 55.1 (N
9-OCH3), 114.1 (Ar-C), 123.2 (Ar-C), 127.9 (Ar-C), 128.1 (Ar-C), 
128.5 (Ar-C), 128.8 (Ar-C), 143.1 (Ar-C), 149.4 (Ar-C), 149.8 (Ar-C), 153.9 (Ar-C), 
158.8 (Ar-C), 158.9 (Ar-C), 159.9 (Ar-C), 160.0 (Ar-C), 164.4 (Ar-C); HRMS calcd. for 
C13H13ClN5O (ES+) m/z 290.0803 [M+H]
+ found 290.0808. 
Note: Greater number of 13C NMR signals than environments due to regioisomers. 
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9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (71)219  
 
6-Chloropurine intermediate (70) (0.50 g, 1.73 mmol), (triisopropylsilyl)acetylene 
(0.46 ml, 2.07 mmol), copper iodide (6 mg, 0.03 mmol), Pd(PPh3)2Cl2 (21 mg, 0.03 
mmol) and triethylamine (0.60 ml, 4.31 mmol) were dissolved in DMF (17 ml). The 
reaction mixture was degassed (20 min, N2) and shielded from light then stirred 
overnight (RT, 18 h). The crude product was filtered over a pad of Celite then dry 
loaded onto silica. Purification by chromatography on silica (1:1 petrol:EtOAc) gave 
the target compound (71) as a pale yellow solid (0.52 g, 1.19 mmol, 69%).  
Rf = 0.59 (1:1 petrol:EtOAc); m.p. 121-124 °C; UV λmax (EtOH/nm) 230, 344; IR 
ѵmax/cm
-1 3487, 3296, 3183, 2944, 2866, 1594, 1567, 1511; 1H NMR (500 MHz, 
DMSO-d6) 1.09-1.17 (21H, m, Si(CH(CH3)2)3), 3.72 (3H, s, -OCH3), 5.21 (2H, s, N
9-
CH2), 6.68 (2H, s, C
2-NH2), 6.90 (2H, d, J = 8.7 Hz, C
2-H), 7.23 (2H, d, J = 8.7 Hz, 
C1-H), 8.19 (1H, s, C3-H); 13C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 45.2 (N
9-CH2), 55.1 (-OCH3), 97.1 (C≡C-Si), 101.9 (C≡C-Si), 114.0 
(Ar-C), 127.9 (Ar-C), 128.6 (Ar-C), 128.8 (Ar-C), 140.3 (Ar-C), 143.4 (Ar-C), 153.7 
(Ar-C), 158.8 (Ar-C), 160.4 (Ar-C); HRMS calcd. for C24H34N5OSi (ES+) m/z 
436.2527 [M+H]+ found 436.2527. 
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2-Chloro-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (72) 
 
A solution of trimethylsilyl chloride (1.01 mL, 7.95 mmol) in anhydrous DCM (40 mL) 
was cooled (0 oC) and placed under nitrogen. In a separate flask a solution of 
benzyltriethylammonium nitrite (294) (1.70 g, 7.14 mmol) in anhydrous DCM (15 mL) 
was cooled (0 oC) and placed under nitrogen. The solution of (294) was then added 
dropwise with stirring to the trimethylsilyl chloride solution at 0 oC.  The resulting 
mixture was stirred (0 oC, 15 min) at which point a cooled (0 oC) solution of 9-(4-
methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (71) (690 mg, 1.59 
mmol) in anhydrous DCM (15 mL) was gradually added. The reaction mixture was 
stirred (0 oC, 30 min) then the ice bath was removed stirring was continued (RT, 30 
min). The resulting solution was washed with NaHCO3(aq) (3 x 70 mL), dried (phase 
separator) and purified by silica based MPCL (1:4 EtOAc/petrol) to give (72) as a 
colourless oil (518 mg, 1.14 mmol, 72%). 
 
Rf = 0.23 (1:4 EtOAc/petrol); UV λmax (EtOH/nm) 254.1; IR ѵmax/cm
-1 2943, 2865, 
1568, 1514; 1H NMR (500 MHz, DMSO-d6) δ 1.07-1.23 (21H, m, Si(CH(CH3)2)3), 
3.72 (3H, s, OCH3), 5.39 (2H, s, ArCH2Ar) 6.91 (2H, d, J = 8.6 Hz, C
2-H), 7.30 (2H, 
d, J = 8.6 Hz, C1-H), 8.78 (1H, s, C3-H); 13C NMR (125 MHz, DMSO-d6) δ 10.5 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 46.3 (N
9-CH2), 55.1 (-OCH3), 100.2 (C≡C-Si), 
102.5 (C≡C), 114.1 (Ar-C), 127.7 (Ar-C), 129.2 (Ar-C), 134.1 (Ar-C), 140.5 (Ar-C), 
148.6 (Ar-C), 152.3 (Ar-C), 153.6 (Ar-C), 159.0 (Ar-C); HRMS calcd for 
C24H32ClN4OSi [M+H]
+
 455.2028 Found 455.2031. 
 
Chapter Ten 
 
303 
9-(4-Methoxybenzyl)-2-phenoxy-6-((triisopropylsilyl)ethynyl)-9H-purine (73) 
 
A vial was charged with phenol (129 mg, 1.37 mmol) and K3PO4 (484 mg, 2.28 
mmol). A solution of 2-chloro-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-
purine (72) (518 mg, 1.14 mmol)  in anhydrous toluene (6 mL) was then added 
followed by Pd(OAc)2 (5.1 mg, 2.28 x 10
-2 mmol) and XPhos (16.3 mg, 3.42 x 10-2 
mmol). The vial was capped and degassed (N2, 20 min) then heated (100 
oC, 1 h). 
The crude mixture was cooled and diluted with DCM (30 mL) and filtered through 
Celite. The resulting solution was washed with NaHCO3(aq) (3 x 30 mL), dried (phase 
separator) and dry loaded onto silica. The title compound (73) was purified by MPLC 
on silica (1:3 EtOAC/petrol) as a colourless oil (476 mg, 0.93 mmol, 82%).   
Rf = 0.25 (5:95 MeOH/DCM); UV λmax (EtOH/nm) 273.1; IR ѵmax/cm
-1 3068, 2943, 
2864, 1574, 1514, 1490; 1H NMR (500 MHz, CDCl3) 1.07-1.30 (21H, m, 
Si(CH(CH3)2)3), 3.79 (3H, s, OCH3), 5.12 (2H, s, N
9-CH2), 6.68 (2H, s, C
2-NH2), 6.81 
(2H, d, J = 8.8 Hz, C4-H), 7.15 (2H, d, J = 8.9 Hz, C5-H), 7.22-7.27 (3H, m, C1/3-H), 
7.38-7.46 (2H, m, C2-H), 7.91 (1H, s, C6-H); 13C NMR (125 MHz, DMSO-d6) 11.2 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 47.1 (N
9-CH2), 55.3 (OCH3), 100.6 (C≡C-Si), 
103.1 (C≡C-Si), 108.5 (Ar-C) 114.3 (Ar-C), 121.6 (Ar-C), 124.9 (Ar-C), 126.8 (Ar-C), 
129.3 (Ar-C), 129.8 (Ar-C), 132.0 (Ar-C), 143.0 (Ar-C), 144.3 (Ar-C), 153.5 (Ar-C), 
159.8 (Ar-C), 161.1 (Ar-C); HRMS calcd for C30H37N4O2Si [M+H]
+
 513.2680 Found 
513.2665. 
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2-Phenoxy-6-((triisopropylsilyl)ethynyl)-9H-purine (68) 
 
A solution of 9-(4-methoxybenzyl)-2-phenoxy-6-((triisopropylsilyl)ethynyl)-9H-purine 
(73) (476 mg, 0.93 mmol) in TFA (10 mL) was heated to reflux (75 oC, 3 h). The 
resulting red solution was neutralised over saturated NaHCO3(aq) (50 mL), which was 
then extracted with EtOAc (3 x 50 mL). The organic layers were pooled then dried 
(MgSO4) and dry loaded onto silica. The title compound (68) was purified by MPLC 
on silica (5:95 MeOH/DCM) as a yellow oil (360 mg, 9.2 mmol, 99%). 
Rf = 0.25 (5:95 MeOH/DCM); UV λmax (EtOH/nm) 254.0; IR ѵmax/cm
-1 3070, 2943, 
2865, 1575, 1497; 1H NMR (500 MHz,DMSO-d6) δ 1.05-1.26 (21H, m, 
(Si(CH(CH3)2)3), 7.15-7.52 (C
1-3-H), 8.46 (1H, C4-H); 13C NMR (125 MHz,CDCl3) δ 
10.6 (SiCH), 18.4 (CHCH3), 54.9 (Si-C≡C), 100.1 (C≡C), 121.4 (Ar-C), 124.9 (Ar-C), 
129.7 (Ar-C), 153.4 (Ar-C), 160.4 (Ar-C); HRMS calcd for C22H29N4OSi [M+H]
+
 
393.2105 Found 393.2106. 
 
Note: not all carbon atoms are visible 
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6-Ethynyl-2-phenoxy-9H-purine (55) 
 
 
The title compound was prepared following general procedure A using: 2-phenoxy-
6-((triisopropylsilyl)ethynyl)-9H-purine (68) (300 mg, 0.77 mmol) and TBAF (1 M in 
THF (842 µL, 0.84 mmol) in THF (30 mL). The crude product was purified by MPLC 
on silica (5:95 MeOH/DCM) to give the title compound (55) as a white solid (176 mg, 
0.75 mmol, 99%). 
Rf = 0.06 (5:95 MeOH/DCM); m.p. 193 
oC (dec.); UV λmax (EtOH/nm) 218; IR 
ѵmax/cm
-1 3232, 3072, 2775, 2562, 2488, 2110, 1613, 1577, 1491; 1H NMR (500 
MHz, DMSO-d6) δ 4.99 (1H, s, CH –ethynyl), 7.21 (2H, d, J = 8.5 Hz, C
3H), 7.25 (1H, 
tt, J = 7.2 Hz and 1.1 Hz, C1-H), 7.44 (2H, app. t, J = 8.4 Hz, C2-H), 8.51 (1H, s, C4-
H), 13.58 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ 88.9, 121.5, 124.9, 129.7, 
153.4, 160.4; HRMS calcd for C13H9N4O [M+H]
+
 237.0771 Found 237.0773. 
 
N-Benzyltriethylammonium nitrite (294)309 
 
To a solution of benzyltriethylammonium tetrafluoroborate (1.4 g, 5.0 mmol) in a 
mixture of water (7.5 mL) and ethanol (6 mL) was prepared. Potassium nitrite (426 
mg, 5.0 mmol) dissolved in water (0.5 mL) was added dropwise at RT and the 
resulting mixture was stirred overnight then filtered. The solvent was removed in 
vacuo and the resulting crude product was redissolved in DCM and further dried 
using a phase separator. The DCM was evaporated to give the title compound as an 
off-white crystalline solid (1.06 g, 4.5 mmol, 89%). 
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m.p. 137 oC (Lit 132.0-132.3), 1H NMR (500 MHz,DMSO-d6) δ 1.30 (9H, t, J = 7.2 
Hz, 3 x CH3), 3.16 (6H, q, J = 7.2 Hz, 3 x CH2), 4.48 (2H, s, ArCH2), 7.45-7.61 (5H, 
m, 5 x Ar-H); LRMS (ES+) m/z = 239.2 [M+H]+. 
 
4,6-Dichloro-2-(phenylamino)pyrimidine-5-carbaldehyde (228) 
 
To a flask containing DMF (190 µL, 2.46 mmol) cooled to 0 oC, was carefully added 
POCl3 (2.21 mL, 24.10 mmol) dropwise with stirring (10 min). The mixture was 
allowed to warm (RT, 30 min) after which 6-hydroxy-2-(phenylamino)pyrimidin-4(1H)-
one (73) (500 mg, 2.46 mmol) was added in portions. The resulting suspension was 
stirred (RT, 1 h), heated to reflux (110 oC, 3 h) then cooled to RT and quenched over 
rapidly stirred ice water. The pH was adjusted to 7 with solid NaHCO3 and the 
resulting aqueous mixture was extracted with DCM (2 x 100 mL). The organic layers 
were pooled, dried (phase separator) and dry loaded onto silica. The title compound 
was purified by MPLC on silica (3:7 EtOAc/petrol) as a light yellow solid (323 mg, 
1.21 mmol, 49%).  
Rf = 0.56 (3:7 EtOAc/petrol); m.p. 135 
oC; UV λmax (EtOH/nm) 232.3; IR ѵmax/cm
-1; 
1H NMR (500 MHz,CDCl3) δ 7.18-7.23 (1H, m, C
1-H), 7.40 (2H, app. t, J = 7.6 Hz, 
C2-H), 7.60 (2H, d, 7.6 Hz, C3-H), 7.72 (1H, br s, ArNHAr), 10.31 (1H, s, CHO); 13C 
NMR (125 MHz,CDCl3) δ 114.7 (Ar-C), 120.9 (Ar-C), 124.5 (Ar-C), 128.9 (Ar-C), 
137.5 (Ar-C), 157.7 (Ar-C), 185.0 (CHO); LRMS (ES+) m/z = 168.0 [M+H]+. 
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4-Chloro-6-((4-methoxybenzyl)amino)-2-(phenylamino)pyrimidine-5-
carbaldehyde (229) 
 
To a solution of 4,6-dichloro-2-(phenylamino)pyrimidine-5-carbaldehyde (122) (50 
mg, 0.19 mmol) in anhydrous DCM (5 mL) was added 4-methoxybenzylamine (25 
µL, 0.20 mmol) and DIPEA (34 µL, 0.20 mmol). The reaction mixture was stirred 
(RT, 1 h) after which no starting material remained (LC-MS). The crude product was 
dry loaded onto KP-NH silica and purified by KP-NH MPLC on silica (3:7 
EtOAc/petrol) to give the target compound as a white solid (59 mg, 0.16 mmol, 85%).   
Rf = 0.40 (3:7 EtOAc/petrol, KP-NH silica); m.p. 128 
oC; UV λmax (EtOH/nm) 249.1; 
IR ѵmax/cm
-1 3421, 3310, 3281, 3191, 2871, 2121, 1675 (CHO), 1611; 1H NMR (500 
MHz, DMSO-d6) δ 1.35 (3H, s, OCH3), 4.67 (2H, d, J = 5.9 Hz, NHCH2), 6.90 (2H, d, 
J = 8.6 Hz, C4-H), 6.99 – 7.09 (1H, m, C1-H), 7.19 – 7.39 (4H, m, C2/3-H) 7.65 (2H, d, 
J = 8.5 Hz, C5-H), 9.67 (1H, br s, ArNHCH2), 10.01 (1H, s, CHO), 10.40 (1H, br s, 
ArNHAr); 13C NMR (125 MHz,CDCl3) δ 42.1 (CH2), 56.1 (OCH3), 114.1 (Ar-C), 118.9 
(Ar-C), 122.2 (Ar-C), 129.1 (Ar-C), 130.5 (Ar-C), 189.1 (CHO); HRMS calcd for 
C19H18ClN4O2 [M+H]
+
 369.1118 Found 369.1110. 
 
Note: not all carbon atoms visible 
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4-((tert-Butyldimethylsilyl)ethynyl)-6-((4-methoxybenzyl)amino)-2-
(phenylamino)pyrimidine-5-carbaldehyde (230) 
 
The title compound was prepared following general procedure D using: 4-chloro-6-
((4-methoxybenzyl)amino)-2-(phenylamino)pyrimidine-5-carbaldehyde (123) (30 mg, 
8.15 x 10-2 mmol), tert-butyldimethylsilyl acetylene boronic acid pinacol ester (33 mg, 
0.12 mmol), Cs2CO3 (40 mg, 0.12 mmol) and Pd(PPh3)4 (9.4 mg, 8.15 x 10
-3 mmol) 
in dioxane (1 mL). The title compound (124) was purified by KP-NH MPLC on silica 
(1:4 EtOAc/petrol) to give the final product as a yellow oil (28 mg, 5.92 x 10-2 mmol, 
73%). 
Rf = 0.41 (1:4 EtOAc/petrol, KP-NH silica); UV λmax (EtOH/nm) 252.1; IR ѵmax/cm
-1 
3459, 3299, 3276, 3205, 2843, 2099, 1680 (CHO), 1603, 1571; 1H NMR (500 MHz, 
CDCl3) δ 0.23 (6H, Si(CH3)2), 1.00 (9H, C(CH3)3), 3.80 (3H, s, OCH3), 4.69 (2H, d, J 
= 6.9 Hz, C4-H), 7.06 (1H, tt, J = 7.4 and 1.3 Hz, C1-H), 7.25 (2H, d, J = 7.1 Hz, C5-
H)  7.29 (2H, app. t, J = 7.6 Hz, C2-H), 7.35 (1H, br s, ArNHAr), 7.54 (2H, d, J = 7.8 
Hz, C3-H) 9.40 (1H, br s, ArNHCH2), 10.21 (1H, s, CHO); 
13C NMR (125 MHz, 
CDCl3) δ -4.9 (SiC), 26.2 (SiC(CH3)3), 44.1 (NCH2Ar), 55.3 (OCH3), 102.3 (Ar-C), 
114.1 (Ar-C), 120.1 (Ar-C), 123.6 (Ar-C), 128.7 (Ar-C), 128.9 (Ar-C), 138.3 (Ar-C), 
159.0 (Ar-C), 189.9 (CHO); HRMS calcd for C27H33N4O2Si [M+H]
+
 473.2367 Found 
473.2361. 
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4-Amino-6-((tert-butyldimethylsilyl)ethynyl)-2-(phenylamino)pyrimidine-5-
carbaldehyde (226) 
 
A solution of 4-((tert-butyldimethylsilyl)ethynyl)-6-((4-methoxybenzyl)amino)-2-
(phenylamino)pyrimidine-5-carbaldehyde (124) (25 mg, 5.29 x 10-2 mmol) in TFA (1 
mL) was heated (80 oC, 1 h). The resulting solution was added dropwise to 
NaHCO3(aq) (30 mL) then extract with DCM (2 x 15 mL). The organic layers were 
pooled, dried (phase separator) and dry loaded onto silica. The title (125) compound 
was purified by MPLC on silica (3:7 EtOAc/Hexane) as a yellow oil (18 mg, 5.29 x 
10-2 mmol, 97%). 
Rf = 0.43 (3:7 EtOAc/petrol); UV λmax (EtOH/nm) 265.3; IR ѵmax/cm
-1
 3451, 3310, 
3279, 3211, 2839, 2117, 1701 (CHO), 1601, 1533; 1H NMR (500 MHz, CDCl3) δ 0.24 
(6H, Si(CH3)2), 1.01 (9H, C(CH3)3), 5.66 (1H, br s, N-H a) 7.11 (1H, tt, J = 7.3 Hz and 
1.1 Hz), 7.32 (1H, br s, ArNHAr), 7.34 (2H, app. t, J = 7.3 Hz, C2-H), 7.59 (2H, d, J = 
7.4 Hz), 8.65 (1H, br s, N-H b) 10.24 (1H, s, CHO); 13C NMR (125 MHz, CDCl3) δ -
4.8 (SiC), 26.3 (SiC(CH3)3), 96.3 (C≡C-Si), 113.9 (Ar-C), 121.1 (Ar-C), 122.4 (Ar-C), 
129.8 (Ar-C), 130.1 (Ar-C), 137.3 (Ar-C), 159.5 (Ar-C), 189.8 (CHO); HRMS calcd for 
C19H25N4OSi [M+H]
+
 353.1792 Found 353.1796. 
 
Note: not all carbon atoms visible. 
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4-Amino-6-ethynyl-2-(phenylamino)pyrimidine-5-carbaldehyde (101) 
 
The title compound was prepared following general procedure A using: 4-amino-6-
((tert-butyldimethylsilyl)ethynyl)-2-(phenylamino)pyrimidine-5-carbaldehyde (125) 
(115 mg, 0.33 mmol) and TBAF (1 M in THF) (360 µL, 0.36 mmol) in THF (23 mL). 
The crude product was purified by MPLC on silica (3:7 EtOAc/Hexane) to give the 
title compound (126) as a yellow crystalline solid (53 mg, 0.22 mmol, 68%). 
Rf = 0.48 (2:3 EtOAc/petrol); m.p. 185 
oC; UV λmax (EtOH/nm) 234.0, 286.5, 351.5; 
IR ѵmax/cm
-1 3483, 3307, 3283, 3212, 2859, 2112, 1646 (CHO), 1612, 1565, 1523; 
1H NMR (500 MHz, CDCl3) δ 3.48 (1H, s, C≡C-H), 5.71 (H, br s, C
4-NH a), 7.71 (1H, 
tt, J = 7.5 and 1.1 Hz, C3-H), 7.41 (2H, app. t, J = 7.6 Hz, C2-H), 7.58 (2H, d, J = 7.6 
Hz, 1-H), 7.58 (1H, br s, ArNHAr), 8.63 (1H, br s, C4-NH b), 10.20 (1H, s, CHO); 13C 
NMR (125 MHz, CDCl3) δ 77.9 (C≡C-H), 84.4 (C≡C), 120.5 (Ar-C), 124.1 (Ar-C), 
129.0 (Ar-C), 137.9 (Ar-C), 155.9 (Ar-C), 160.0 (Ar-C), 162.8 (Ar-C), 167.5 (Ar-C), 
189.6 (CHO). HRMS calcd. for C13H11N4O (ES+) m/z 239.0927 [M+H]
+ found 
239.0931. 
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7-Chloro-5-nitro-3H-imidazo[4,5-b]pyridine (258)297 
 
A solution of tert-butyl 7-chloro-5-nitro-3H-imidazo[4,5-b]pyridine-3-carboxylate (107) 
(500 mg, 1.67mmol) in TFE (50 mL) was heated to reflux (85 oC, 3 h) resulting in 
complete Boc deprotection (observed by LC-MS). The solvent was removed until ca. 
5 mL remained resulting precipitation of the product as an orange solid. The 
precipitate was filtered then washed with petrol (3 x 15 mL) then dried under vacuum 
to give (258) as an orange solid (322 mg, 1.63 mmol, 97%).  
m.p. 250 oC (Lit 249.5); 1H NMR (500 MHz, DMSO-d6) 8.40 (1H, s, C
1-H), 8.91 (1H, 
s, C2-H), 14.18 (1H, br s, NH); LRMS (ES+) m/z = 199.0 [M+H]+. 
 
7-Chloro-3H-imidazo[4,5-b]pyridin-5-amine (259)310 
 
7-Chloro-5-nitro-3H-imidazo[4,5-b]pyridine (258) (500 mg, 2.53 mmol) was dissolved 
in a mixture of absolute ethanol (15 mL), water (5 mL) and glacial AcOH (1.13 mL, 
19.7 mmol). Iron powder (310 mg, 5.56 mmol) was added in one portion with stirring 
and the reaction mixture was heated (80 oC, 3 h). The resulting dark brown solution 
was filtered through Celite and the solvent was removed. The crude product was 
redissolved in MeOH (25 mL) then dry loaded onto silica and purified via MPLC on 
silica (1:4 MeOH/DCM) to give (259) as a light yellow solid (370 mg, 2.20 mmol, 
87%), which was used immediately in the next reaction. 
Rf = 0.60 (1:4 MeOH/DCM); m.p. 228-231 oC (Lit 230 oC); 1H NMR (500 MHz, 
DMSO-d6) 6.80 (1H, d, C
1-H), 3.30 (2H, br s, NH2), 8.1 (1H, s, C
2-H), 8.9 (1H, br s, 
NH); 1H NMR (125 MHz, DMSO-d6) 109 (Ar-C), 150 (Ar-C); HRMS calcd for 
C6H6ClN4 [M+H]
+
 169.0276 Found 169.0274. 
Note: not all carbon atoms visible 
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7-Chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (260) 
 
7-Chloro-5-nitro-3H-imidazo[4,5-b]pyridine (259) (40 mg, 0.24 mmol) was dissolved 
in anhydrous DMF (1 mL). Anhydrous K2CO3 (36 mg, 0.26 mmol) was added 
followed by 4-methoxybenzyl chloride (34 µL, 0.25 mmol) with stirring. The reaction 
mixture was placed under nitrogen and heated (65 oC, 18 h). The solvent was 
evaporated to dryness and the crude product was redissolved in EtOAc (30 mL) then 
washed with brine (3 x 30 mL). The organic layer was dried (Na2SO4) then dry 
loaded onto silica and purified by MPLC on silica (2:3 EtOAc/petrol) to give (260) as 
a light yellow solid (29 mg, 0.10 mmol, 42 %). 
Rf = 0.21 (3:2 EtOAc/petrol); m.p. 105 oC; UV λmax (EtOH/nm) 311.0; IR ѵmax/cm
-1 
3431, 3312, 3198, 3022, 2940, 2798, 1571, 1513; 1H NMR (500 MHz DMSO-d6) 3.71 
(3H, s, OCH3), 5.22 (2H, s, Ar-CH2-Ar), 6.24 (2H, br s, NH2), 6.48 (1H, s, C
3-H), 6.88 
(2H, d, J = 8.7 Hz, C2-H), 7.23 (2H, d, J = 8.8 Hz, C1-H), 8.07 (1H, s, C4-H); 13C NMR 
(125 MHz DMSO-d6) 45.4 (Ar-CH2-Ar), 55.1 (OCH3), 103.8 (Ar-C), 114.0 (Ar-C), 
124.4 (Ar-C), 128.7 (Ar-C), 129.2 (Ar-C), 133.9 (Ar-C), 140.5 (Ar-C), 146.6 (Ar-C), 
157.4 (Ar-C), 158.7 (Ar-C); HRMS calcd for C14H14ClN4O [M+H]
+
 289.0851 Found 
289.0855.  
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7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine 
(261) 
 
To a solution of NaH (60% in mineral oil) (96 mg, 0.24 mmol) in anhydrous DMSO (1 
mL) was added cyclohexylmethanol (442 µL, 3.59 mmol). The flask was flushed with 
nitrogen and stirred until no further gas was evolved (ca. 30 min). In a separate flask 
a solution of 7-chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-amine (260) 
(172 mg, 0.60 mmol) in anhydrous DMSO (2 mL) was prepared and placed under 
nitrogen. The freshly prepared cyclohexylmethoxide solution was then introduced 
dropwise with stirring. The reaction mixture was heated by microwave irradiation 
(100 oC, 2 h) resulting in consumption of the starting material. The reaction mixture 
was added to water (50 mL) then extracted with ether (3 x 50 mL). The ether layers 
were combined then washed with water (4 x 50 mL) and brine (50 mL) then dried 
(MgSO4) and dry loaded onto isolute. The product (261) was purified via MPLC on 
silica (4:1 EtOAc/petrol) as a colourless oil (164 mg, 0.45 mmol, 75%). 
Rf = 0.47 (4:1 EtOAc/Petrol); UV λmax (EtOH/nm) 271.0; IR ѵmax/cm
-1 3311, 2954, 
2899, 2163, 1672, 1598, 1516; 1H NMR (500 MHz DMSO-d6) 0.90-1.87 (11H, m, 
cyclohexyl), 3.71 (3H, s, OCH3), 4.00 (2H, d, J = 6.7 Hz, OCH2), 5.17 (2H, br s, NH2), 
5.90 (1H, s, C3-H), 6.87 (2H, d, J = 8.7 Hz, C2-H), 7.20 (2H, d, J = 8.8 Hz, C1-H), 
7.82 (1H, s, C4-H); 13C NMR (125 MHz DMSO-d6) 25.2 (CH2), 26.0 (CH2), 29.1 
(CH2), 37.0 (CH), 45.0 (Ar-CH2), 55.1 (CH3), 73.3 (CH2), 87.5 (Ar-C), 113.9 (Ar-C), 
118.2 (Ar-C), 128.7 (Ar-C), 129.7 (Ar-C),  137.9 (Ar-C), 147.4 (Ar-C), 157.8 (Ar-C), 
158.5 (Ar-C), 158.6 (Ar-C); HRMS calcd for C21H27N4O2 [M+H]
+
 367.2129 Found 
367.2132. 
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7-(Cyclohexylmethoxy)-5-iodo-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine 
(262) 
 
To a solution of 7-(cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-
b]pyridin-5-amine (261) (112 mg, 0.31 mmol) in anhydrous THF (4 mL) was added 
diiodomethane (123 µL, 1.50 mmol) and CuI (59 mg, 0.31 mmol). Isoamyl nitrite (187 
µL, 0.92 mmol) was then introduced with stirring and the reaction mixture was 
heated to reflux (70 oC, 4 h). The dark brown solution was filtered through Celite and 
diluted with EtOAc (40 mL). The organic solution was washed with sodium 
thiosulfate solution (10% in H2O) (2 x 40 mL) and brine (40 mL) then dried (MgSO4) 
and dry loaded onto silica. The title compound (262) was purified by MPLC on silica 
(3:7 EtOAc/petrol) as a yellow oil (64 mg, 0.13 mmol, 44%). 
Rf = 0.19 (3:7 EtOAc/petrol); UV λmax (EtOH/nm) 262.0; IR ѵmax/cm
-1 3333, 2951, 
2891, 2122, 1672, 1584, 1521; 1H NMR (500 MHz DMSO-d6) 0.98-1.89 (11H, m, 
cyclohexyl), 3.71 (3H, s, OCH3), 4.19 (2H, d, J = 6.5 Hz, OCH2), 5.17 (2H, s, CH2), 
6.90 (2H, d, J = 8.7 Hz, C2-H), 7.18 (1H, s, C3-H), 7.26 (2H, d, J = 8.8 Hz, C1-H), 
8.31 (1H, s, C4-H); 13C NMR (125 MHz DMSO-d6) 25.1 (CH2), 25.9 (CH2), 28.9 
(CH2), 37.0 (CH), 45.8 (Ar-CH2), 55.1 (CH3), 74.4 (CH2), 112.0 (Ar-C), 112.7 (Ar-C), 
114.1 (Ar-C), 124.6 (Ar-C), 128.8 (Ar-C), 129.0 (Ar-C), 142.6 (Ar-C), 148.5 (Ar-C), 
157.0 (Ar-C), 158.8 (Ar-C); HRMS calcd for C21H25IN3O2 [M+H]
+
 478.0986 Found 
478.0980. 
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4-((7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-yl) 
amino)benzenesulfonamide (263) 
 
To a solution of 7-(cyclohexylmethoxy)-5-iodo-3-(4-methoxybenzyl)-3H-imidazo[4,5-
b]pyridine (262) (48 mg, 0.10 mmol) in anhydrous MeCN (2 mL) was added 
sulfanilamide (19 mg, 0.11 mmol), anhydrous K2CO3 (28 mg, 0.20 mmol), Pd2(dba)3 
(2.3 mg, 4.0 x 10-3 mmol) and XPhos (1.9 mg,  4.0 x 10-3 mmol). The reaction 
mixture was degassed (N2, 30 min) then heated (80 
oC, 2 h). The resulting solution 
was cooled to RT and filtered through Celite then diluted with EtOAc (20 mL). The 
organic solution was washed sequentially with HCl(aq) (1 M) (20 mL), NaHCO3 (20 
mL) and brine (30 mL) then  dried (Na2SO4) and dry loaded onto silica. The title 
compound (263) was purified by normal phase MPLC (7:3 EtOAc/petrol) followed by 
C18 reverse phase MPLC (3:7 water (0.1% HCOOH)/MeOH (0.1% HCOOH)) as a 
white solid (23 mg, 4.4 x 10-2 mmol, 43%). 
Rf = 0.59 (7:3 EtOAc/petrol); m.p. 142 oC; UV λmax (EtOH/nm) 257.0; IR ѵmax/cm
-1 
3329, 2933, 2874, 2158, 1662, 1588, 1501; 1H NMR (500 MHz, CDCl3) δ 1.00-1.97 
(11H, m, cyclohexyl), 3.79 (3H, s, OCH3), 4.01 (2H, d, J = 6.1 Hz, ), 4.76 (2H, br s, 
NH2), 5.28 (2H, s, OCH2), 6.17 (1H, s, C
3-H), 6.79 (1H, br s, ArNHAr), 6.88 (2H, d, J 
= 8.8 Hz, C5-H), 7.24 (2H, d, J = 8.7 Hz, C4-H), 7.61 (2H, J = 8.8 Hz, C1/2-H), 7.81 
(2H, J = 8.8 Hz, C1/2-H); 13C NMR (125 MHz,CDCl3) δ 25.7 (CH2), 26.4 (CH2), 29.8 
(CH2), 37.6 (CH2), 46.9 (CH), 55.4 (CH2), 74.8 (OCH3), 90.7 (OCH2), 114.3 (Ar-C), 
117.1 (Ar-C), 128.0 (Ar-C), 129.1 (Ar-C), 139.7 (Ar-C), 145.5 (Ar-C), 152.1 (Ar-C); 
HRMS calcd for C27H32N5O4S [M+H]
+
 522.2170 Found 522.2166. 
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4-((7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-yl)amino) 
benzenesulfonamide (250) 
 
A solution of 4-((7-(cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-
b]pyridin-5-yl)amino)benzenesulfonamide (263) (22 mg, 4.20 x 10-2 mmol) in TFA (1 
mL) was heated to reflux (75 oC, 2 h). The resulting solution was neutralised over 
saturated NaHCO3(aq) (25 mL), which was then extracted with EtOAc (3 x 30 mL). 
The organic layers were pooled then dried (MgSO4) and dry loaded onto silica. The 
title compound (250) was purified by preparative TLC (5:95 MeOH/DCM) as a white 
solid (16.7 mg, 4.18 x 10-2 mmol, 99%). 
Rf = 0.25 (5:95 MeOH/DCM); m.p. 165-166 oC; UV λmax (EtOH/nm) 274.7 and 
324.3; IR ѵmax/cm
-1 3332, 2925, 2852, 2164, 1677, 1583, 1500; 1H NMR (500 MHz, 
MeOD) δ 1.07-2.05 (11H, m, cyclohexyl), 4.03 (2H, d, J = 6.2 Hz, OCH2), 6.33 (1H, s, 
C3-H), 7.77 (2H, d, J = 8.9 Hz, C1/2-H), 7.92 (2H, d, J = 8.8 Hz, C1/2-H), 7.96 (1H, s, 
C4-H); 13C NMR (125 MHz,CDCl3) δ 26.9 (CH2), 27.6 (CH2), 30.8 (CH2), 38.9 (CH), 
74.9 (CH2O), 90.9 (Ar-C), 117.9 (Ar-C), 128.2 (Ar-C); HRMS calcd for C19H24N5O3S 
[M+H]+ 522.2170 Found 522.2166. 
 
 
 
 
 
 
 
 
Chapter Ten 
 
317 
7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-amine (254) 
 
A solution of 7-(cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-
amine (261) (35 mg, 9.55 x 10-2 mmol) in TFA (1 mL) was heated to reflux (75 oC, 2 
h). The resulting solution was neutralised over saturated NaHCO3(aq) (25 mL), which 
was then extracted with EtOAc (3 x 30 mL). The organic layers were pooled then 
dried (MgSO4) and dry loaded onto silica. The title compound (254) was purified by 
MPLC on silica (1:9 MeOH/DCM) as a white solid (16.5 mg, 6.69 x 10-2 mmol, 70%). 
Rf = 0.16 (1:9 MeOH/DCM); m.p. 99-102 oC; UV λmax (EtOH/nm) 244.7 and 292.9; 
IR ѵmax/cm
-1 3447, 3323, 3187, 2923, 2850, 2795, 2026, 1591, 1527; 1H NMR (500 
MHz,CDCl3) δ 1.03-2.00 (11H, m, cyclohexyl), 4.03 (2H, d, J = 6.1 Hz, OCH2), 4.37 
(1H, br s, NH2), 5.91 (1H, s, C6H), 7.77 (1H, s, C2H ), 9.89 (1H, br s, N3H);
 13C NMR 
(125 MHz,CDCl3) δ 25.7, 26.4, 29.8, 37.5, 74.4, 88.1, 157.3; HRMS calcd. for 
C13H19N4O (ES+) m/z 247.1553 [M+H]
+ found 247.1556. 
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Appendix 
i - Small-Molecule X-ray Crystallography Data 
Pyrrolopyrimidine 88 
Table 9.  Crystal data and structure refinement for 88. 
 
Identification code  88 
Chemical formula (moiety) C14H10N4 
Chemical formula (total) C14H10N4 
Formula weight  234.26 
Temperature  150(2) K 
Radiation, wavelength  CuK, 1.54178 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 12.1047(2) Å  = 90° 
 b = 10.0066(2) Å  = 99.405(2)° 
 c = 20.2146(3) Å  = 90° 
Cell volume 2415.62(7) Å
3
 
Z 8 
Calculated density  1.288 g/cm
3
 
Absorption coefficient  0.648 mm1 
F(000) 976 
Crystal colour and size colourless, 0.15  0.10  0.10 mm3 
Reflections for cell refinement 7206 ( range 2.2 to 66.6°) 
Data collection method Oxford Diffraction Gemini A Ultra 
diffractometer 
 thick-slice  scans 
 range for data collection 4.0 to 66.7° 
Index ranges h 14 to 12, k 11 to 11, l 23 to 22 
Completeness to  = 66.7° 99.3 %  
Reflections collected 14800 
Independent reflections 4243 (Rint = 0.0344) 
Reflections with F
2
>2 3455 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9090 and 0.9380 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0525, 0.2814 
Data / restraints / parameters 4243 / 0 / 350 
Final R indices [F
2
>2] R1 = 0.0327, wR2 = 0.0841 
R indices (all data) R1 = 0.0441, wR2 = 0.0897 
Goodness-of-fit on F
2
 1.016 
Extinction coefficient 0.00052(12) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.21 and 0.19 e Å3 
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Table 10.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for 88.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
 
N(1) 0.55869(9) 0.21161(12) 0.32823(6) 0.0279(3) 
N(2) 0.36752(9) 0.24152(11) 0.27626(5) 0.0271(3) 
N(3) 0.33890(9) 0.22219(11) 0.15554(5) 0.0271(3) 
N(4) 0.19114(10) 0.25928(13) 0.21068(6) 0.0330(3) 
N(5) 0.33497(9) 0.35539(12) 0.40850(6) 0.0298(3) 
N(6) 0.50721(9) 0.25982(11) 0.46393(5) 0.0268(3) 
N(7) 0.54830(9) 0.30908(11) 0.58187(5) 0.0259(2) 
N(8) 0.66868(10) 0.18164(13) 0.53265(6) 0.0306(3) 
C(1) 0.65830(11) 0.18643(14) 0.30585(7) 0.0303(3) 
C(2) 0.64157(11) 0.17757(14) 0.23799(7) 0.0294(3) 
C(3) 0.52424(11) 0.19870(13) 0.21631(6) 0.0258(3) 
C(4) 0.47608(11) 0.22002(13) 0.27463(6) 0.0247(3) 
C(5) 0.44830(11) 0.20033(13) 0.15651(6) 0.0252(3) 
C(6) 0.48575(11) 0.17392(14) 0.09356(6) 0.0276(3) 
C(7) 0.52235(13) 0.15161(16) 0.04396(7) 0.0364(3) 
C(8) 0.30339(11) 0.23972(13) 0.21537(6) 0.0266(3) 
C(9) 0.12930(11) 0.25469(15) 0.26438(6) 0.0286(3) 
C(10) 0.14785(12) 0.15757(17) 0.31415(7) 0.0390(4) 
C(11) 0.07957(14) 0.1526(2) 0.36267(8) 0.0490(4) 
C(12)  0.00847(14) 0.24150(19) 0.36157(8) 0.0459(4) 
C(13)  0.02709(13) 0.33695(17) 0.31220(8) 0.0409(4) 
C(14) 0.04228(12) 0.34454(16) 0.26390(7) 0.0341(3) 
C(15) 0.25314(12) 0.43618(15) 0.42796(7) 0.0324(3) 
C(16) 0.27880(11) 0.46597(14) 0.49416(7) 0.0301(3) 
C(17) 0.38241(11) 0.40014(13) 0.51816(6) 0.0260(3) 
C(18) 0.41410(11) 0.33247(13) 0.46281(6) 0.0250(3) 
C(19) 0.45495(11) 0.38327(13) 0.57853(6) 0.0255(3) 
C(20) 0.43078(11) 0.43714(14) 0.64071(7) 0.0291(3) 
C(21) 0.40967(13) 0.47734(16) 0.69217(8) 0.0385(4) 
C(22) 0.57029(11) 0.25259(13) 0.52473(6) 0.0250(3) 
C(23) 0.70220(11) 0.08893(13) 0.48764(6) 0.0258(3) 
C(24) 0.81568(11) 0.07509(14) 0.48601(7) 0.0301(3) 
C(25) 0.85354(12)  0.01941(15) 0.44498(7) 0.0356(3) 
C(26) 0.77832(13)  0.09951(15) 0.40386(7) 0.0366(3) 
C(27) 0.66517(12)  0.08581(14) 0.40540(7) 0.0325(3) 
C(28) 0.62649(11) 0.00584(14) 0.44740(6) 0.0286(3) 
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Table 11.   Bond lengths [Å] and angles [°] for 88. 
 
N(1)–H(1)  0.860(18) N(1)–C(1)  1.3785(19) 
N(1)–C(4)  1.3515(17) N(2)–C(4)  1.3374(17) 
N(2)–C(8)  1.3437(17) N(3)–C(5)  1.3392(17) 
N(3)–C(8)  1.3596(17) N(4)–H(4)  0.864(19) 
N(4)–C(8)  1.3607(18) N(4)–C(9)  1.4164(18) 
N(5)–H(5)  0.925(19) N(5)–C(15)  1.3846(19) 
N(5)–C(18)  1.3534(17) N(6)–C(18)  1.3383(17) 
N(6)–C(22)  1.3386(17) N(7)–C(19)  1.3444(17) 
N(7)–C(22)  1.3510(17) N(8)–H(8)  0.882(18) 
N(8)–C(22)  1.3733(17) N(8)–C(23)  1.4049(18) 
C(1)–H(1A)  0.950 C(1)–C(2)  1.356(2) 
C(2)–H(2A)  0.950 C(2)–C(3)  1.4318(19) 
C(3)–C(4)  1.4141(19) C(3)–C(5)  1.3941(18) 
C(5)–C(6)  1.4434(19) C(6)–C(7)  1.182(2) 
C(7)–H(7)  0.92(2) C(9)–C(10)  1.390(2) 
C(9)–C(14)  1.384(2) C(10)–H(10A)  0.950 
C(10)–C(11)  1.383(2) C(11)–H(11A)  0.950 
C(11)–C(12)  1.385(3) C(12)–H(12A)  0.950 
C(12)–C(13)  1.373(2) C(13)–H(13A)  0.950 
C(13)–C(14)  1.390(2) C(14)–H(14A)  0.950 
C(15)–H(15A)  0.950 C(15)–C(16)  1.357(2) 
C(16)–H(16A)  0.950 C(16)–C(17)  1.4294(19) 
C(17)–C(18)  1.4134(18) C(17)–C(19)  1.3924(18) 
C(19)–C(20)  1.4409(19) C(20)–C(21)  1.182(2) 
C(21)–H(21)  0.95(2) C(23)–C(24)  1.3864(19) 
C(23)–C(28)  1.3962(19) C(24)–H(24A)  0.950 
C(24)–C(25)  1.384(2) C(25)–H(25A)  0.950 
C(25)–C(26)  1.384(2) C(26)–H(26A)  0.950 
C(26)–C(27)  1.382(2) C(27)–H(27A)  0.950 
C(27)–C(28)  1.382(2) C(28)–H(28A)  0.950 
 
H(1)–N(1)–C(1) 127.5(11) H(1)–N(1)–C(4) 123.8(11) 
C(1)–N(1)–C(4) 108.70(11) C(4)–N(2)–C(8) 113.46(11) 
C(5)–N(3)–C(8) 117.62(10) H(4)–N(4)–C(8) 115.4(12) 
H(4)–N(4)–C(9) 115.1(12) C(8)–N(4)–C(9) 126.07(11) 
H(5)–N(5)–C(15) 126.7(11) H(5)–N(5)–C(18) 125.0(11) 
C(15)–N(5)–C(18) 108.23(11) C(18)–N(6)–C(22) 113.41(11) 
C(19)–N(7)–C(22) 118.01(11) H(8)–N(8)–C(22) 115.6(11) 
H(8)–N(8)–C(23) 116.4(11) C(22)–N(8)–C(23) 127.06(11) 
N(1)–C(1)–H(1A) 124.8 N(1)–C(1)–C(2) 110.47(12) 
H(1A)–C(1)–C(2) 124.8 C(1)–C(2)–H(2A) 127.0 
C(1)–C(2)–C(3) 106.06(12) H(2A)–C(2)–C(3) 127.0 
C(2)–C(3)–C(4) 106.89(11) C(2)–C(3)–C(5) 138.38(13) 
C(4)–C(3)–C(5) 114.70(12) N(1)–C(4)–N(2) 126.27(12) 
N(1)–C(4)–C(3) 107.88(11) N(2)–C(4)–C(3) 125.83(11) 
N(3)–C(5)–C(3) 121.67(12) N(3)–C(5)–C(6) 117.99(11) 
C(3)–C(5)–C(6) 120.32(12) C(5)–C(6)–C(7) 176.30(14) 
C(6)–C(7)–H(7) 178.4(12) N(2)–C(8)–N(3) 126.69(12) 
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N(2)–C(8)–N(4) 118.86(12) N(3)–C(8)–N(4) 114.44(11) 
N(4)–C(9)–C(10) 122.28(13) N(4)–C(9)–C(14) 118.07(12) 
C(10)–C(9)–C(14) 119.47(13) C(9)–C(10)–H(10A) 120.2 
C(9)–C(10)–C(11) 119.58(15) H(10A)–C(10)–C(11) 120.2 
C(10)–C(11)–H(11A) 119.6 C(10)–C(11)–C(12) 120.86(15) 
H(11A)–C(11)–C(12) 119.6 C(11)–C(12)–H(12A) 120.2 
C(11)–C(12)–C(13) 119.51(14) H(12A)–C(12)–C(13) 120.2 
C(12)–C(13)–H(13A) 119.9 C(12)–C(13)–C(14) 120.15(15) 
H(13A)–C(13)–C(14) 119.9 C(9)–C(14)–C(13) 120.40(14) 
C(9)–C(14)–H(14A) 119.8 C(13)–C(14)–H(14A) 119.8 
N(5)–C(15)–H(15A) 124.8 N(5)–C(15)–C(16) 110.46(12) 
H(15A)–C(15)–C(16) 124.8 C(15)–C(16)–H(16A) 126.9 
C(15)–C(16)–C(17) 106.27(12) H(16A)–C(16)–C(17) 126.9 
C(16)–C(17)–C(18) 106.79(11) C(16)–C(17)–C(19) 138.24(13) 
C(18)–C(17)–C(19) 114.95(12) N(5)–C(18)–N(6) 126.03(12) 
N(5)–C(18)–C(17) 108.26(11) N(6)–C(18)–C(17) 125.71(11) 
N(7)–C(19)–C(17) 121.02(12) N(7)–C(19)–C(20) 116.85(11) 
C(17)–C(19)–C(20) 122.03(12) C(19)–C(20)–C(21) 177.85(16) 
C(20)–C(21)–H(21) 179.4(13) N(6)–C(22)–N(7) 126.86(12) 
N(6)–C(22)–N(8) 119.25(12) N(7)–C(22)–N(8) 113.88(11) 
N(8)–C(23)–C(24) 118.27(12) N(8)–C(23)–C(28) 122.62(12) 
C(24)–C(23)–C(28) 119.03(13) C(23)–C(24)–H(24A) 119.7 
C(23)–C(24)–C(25) 120.59(13) H(24A)–C(24)–C(25) 119.7 
C(24)–C(25)–H(25A) 119.8 C(24)–C(25)–C(26) 120.38(13) 
H(25A)–C(25)–C(26) 119.8 C(25)–C(26)–H(26A) 120.5 
C(25)–C(26)–C(27) 119.09(14) H(26A)–C(26)–C(27) 120.5 
C(26)–C(27)–H(27A) 119.5 C(26)–C(27)–C(28) 121.07(13) 
H(27A)–C(27)–C(28) 119.5 C(23)–C(28)–C(27) 119.80(13) 
C(23)–C(28)–H(28A) 120.1 C(27)–C(28)–H(28A) 120.1 
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Table 12.   Anisotropic displacement parameters (Å
2
) for 88.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
N(1) 0.0273(6)  0.0354(7) 0.0202(6)  0.0015(5) 0.0013(5)  0.0014(5) 
N(2) 0.0257(6)  0.0334(6) 0.0215(5)  0.0002(4) 0.0015(4)   0.0005(5) 
N(3) 0.0267(6)  0.0331(6) 0.0210(5)   0.0009(4) 0.0029(4)   0.0023(5) 
N(4) 0.0242(6)  0.0555(8) 0.0186(6)   0.0016(5) 0.0009(5)   0.0009(5) 
N(5) 0.0283(6)  0.0367(7) 0.0231(6)  0.0000(5) 0.0002(5)  0.0040(5) 
N(6) 0.0251(6)  0.0331(6) 0.0214(5)   0.0001(4) 0.0012(4)  0.0007(5) 
N(7) 0.0235(5)  0.0319(6) 0.0221(5)   0.0017(4) 0.0033(4)   0.0010(5) 
N(8) 0.0250(6)  0.0433(7) 0.0218(6)   0.0063(5)  0.0014(5)  0.0052(5) 
C(1) 0.0249(7)  0.0350(8) 0.0294(7)  0.0052(6) 0.0000(5)  0.0026(6) 
C(2) 0.0262(7)  0.0338(7) 0.0284(7)  0.0037(6) 0.0055(5)  0.0032(6) 
C(3) 0.0275(7)  0.0252(7) 0.0247(6)  0.0022(5) 0.0046(5)   0.0017(5) 
C(4) 0.0260(7)  0.0247(7) 0.0224(6)  0.0013(5) 0.0013(5)   0.0014(5) 
C(5) 0.0268(7)  0.0256(7) 0.0232(6)  0.0006(5) 0.0041(5)   0.0028(5) 
C(6) 0.0262(7)  0.0295(7) 0.0264(7)  0.0010(5) 0.0023(5)   0.0025(5) 
C(7) 0.0390(8)  0.0438(9) 0.0279(8)   0.0015(6) 0.0098(7)  0.0010(7) 
C(8) 0.0261(7)  0.0312(7) 0.0222(6)   0.0001(5) 0.0027(5)   0.0019(5) 
C(9) 0.0228(7)  0.0412(8) 0.0211(6)   0.0022(6) 0.0012(5)   0.0057(6) 
C(10) 0.0292(7)  0.0498(9) 0.0373(8)  0.0113(7) 0.0037(6)  0.0010(7) 
C(11) 0.0386(9)  0.0709(12) 0.0374(8)  0.0211(8) 0.0056(7)   0.0053(8) 
C(12) 0.0380(9)  0.0713(12) 0.0313(8)  0.0006(8) 0.0138(7)   0.0088(8) 
C(13) 0.0343(8)  0.0478(9) 0.0427(9)   0.0065(7) 0.0127(7)  0.0003(7) 
C(14) 0.0301(7)  0.0407(8) 0.0312(7)  0.0025(6) 0.0042(6)   0.0001(6) 
C(15) 0.0261(7)  0.0366(8) 0.0329(7)  0.0040(6) 0.0005(6)  0.0052(6) 
C(16) 0.0274(7)  0.0308(7) 0.0326(7)  0.0011(6) 0.0063(6)  0.0029(6) 
C(17) 0.0257(7)  0.0262(7) 0.0267(6)  0.0010(5) 0.0066(5)   0.0026(5) 
C(18) 0.0244(6)  0.0279(7) 0.0221(6)  0.0019(5) 0.0024(5)   0.0020(5) 
C(19) 0.0250(6)  0.0270(7) 0.0247(6)   0.0007(5) 0.0048(5)   0.0042(5) 
C(20) 0.0275(7)  0.0304(7) 0.0294(7)   0.0003(6) 0.0044(6)   0.0011(6) 
C(21) 0.0457(9)  0.0392(9) 0.0324(8)   0.0078(7) 0.0121(7)   0.0027(7) 
C(22) 0.0236(6)  0.0297(7) 0.0212(6)   0.0008(5) 0.0021(5)   0.0008(5) 
C(23) 0.0285(7)  0.0287(7) 0.0197(6)  0.0038(5) 0.0026(5)  0.0037(5) 
C(24) 0.0281(7)  0.0319(7) 0.0287(7)   0.0019(6)  0.0002(5)  0.0018(6) 
C(25) 0.0280(7)  0.0395(8) 0.0391(8)   0.0026(6) 0.0048(6)  0.0078(6) 
C(26) 0.0427(8)  0.0315(8) 0.0351(7)   0.0052(6) 0.0048(6)  0.0094(6) 
C(27) 0.0388(8)  0.0261(7) 0.0308(7)  0.0007(6) 0.0000(6)   0.0018(6) 
C(28) 0.0272(7)  0.0309(7) 0.0276(7)  0.0054(5) 0.0040(5)   0.0004(6) 
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Table 13.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for 88. 
 
      x       y       z       U 
 
H(1) 0.5486(14) 0.2237(17) 0.3689(9) 0.038(4) 
H(4) 0.1524(15) 0.2462(17) 0.1714(9) 0.042(5) 
H(5) 0.3351(14) 0.3194(18) 0.3663(9) 0.043(5) 
H(8) 0.7205(15) 0.2076(17) 0.5660(9) 0.038(4) 
H(1A) 0.7288 0.1767 0.3340 0.036 
H(2A) 0.6965 0.1608 0.2104 0.035 
H(7) 0.5525(15) 0.1359(19) 0.0056(10) 0.051(5) 
H(10A) 0.2070 0.0950 0.3148 0.047 
H(11A) 0.0932 0.0875 0.3972 0.059 
H(12A)  0.0556 0.2364 0.3947 0.055 
H(13A)  0.0875 0.3979 0.3110 0.049 
H(14A) 0.0299 0.4118 0.2304 0.041 
H(15A) 0.1882 0.4665 0.3990 0.039 
H(16A) 0.2364 0.5198 0.5195 0.036 
H(21) 0.3921(17) 0.509(2) 0.7333(10) 0.063(6) 
H(24A) 0.8679 0.1309 0.5133 0.036 
H(25A) 0.9316  0.0293 0.4451 0.043 
H(26A) 0.8041  0.1630 0.3750 0.044 
H(27A) 0.6131  0.1403 0.3771 0.039 
H(28A) 0.5486 0.0123 0.4489 0.034 
 
Table 14.  Torsion angles [°] for 88. 
 
C(4)–N(1)–C(1)–C(2)  0.32(17) N(1)–C(1)–C(2)–C(3) 0.10(16) 
C(1)–C(2)–C(3)–C(4) 0.14(15) C(1)–C(2)–C(3)–C(5)  177.77(16) 
C(8)–N(2)–C(4)–N(1)  177.46(13) C(8)–N(2)–C(4)–C(3) 0.84(19) 
C(1)–N(1)–C(4)–N(2) 178.95(13) C(1)–N(1)–C(4)–C(3) 0.40(15) 
C(2)–C(3)–C(4)–N(1)  0.33(15) C(2)–C(3)–C(4)–N(2)  178.89(13) 
C(5)–C(3)–C(4)–N(1) 178.14(11) C(5)–C(3)–C(4)–N(2)  0.4(2) 
C(8)–N(3)–C(5)–C(3)  1.56(19) C(8)–N(3)–C(5)–C(6) 176.48(12) 
C(2)–C(3)–C(5)–N(3) 178.57(15) C(2)–C(3)–C(5)–C(6) 0.6(3) 
C(4)–C(3)–C(5)–N(3) 0.77(19) C(4)–C(3)–C(5)–C(6)  177.23(12) 
N(3)–C(5)–C(6)–C(7)  179(100) C(3)–C(5)–C(6)–C(7)  1(2) 
C(4)–N(2)–C(8)–N(3)  1.8(2) C(4)–N(2)–C(8)–N(4) 179.44(12) 
C(5)–N(3)–C(8)–N(2) 2.2(2) C(5)–N(3)–C(8)–N(4)  178.98(12) 
C(9)–N(4)–C(8)–N(2)  13.9(2) C(9)–N(4)–C(8)–N(3) 167.15(13) 
C(8)–N(4)–C(9)–C(10)  42.1(2) C(8)–N(4)–C(9)–C(14) 142.69(15) 
N(4)–C(9)–C(10)–C(11)  175.51(14) C(14)–C(9)–C(10)–C(11)  0.4(2) 
C(9)–C(10)–C(11)–C(12) 1.3(2) C(10)–C(11)–C(12)–C(13)  1.0(3) 
C(11)–C(12)–C(13)–C(14)  0.3(2) N(4)–C(9)–C(14)–C(13) 174.48(13) 
C(10)–C(9)–C(14)–C(13)  0.8(2) C(12)–C(13)–C(14)–C(9) 1.2(2) 
C(18)–N(5)–C(15)–C(16) 0.20(16) N(5)–C(15)–C(16)–C(17)  0.21(16) 
C(15)–C(16)–C(17)–C(18) 0.14(15) C(15)–C(16)–C(17)–C(19)  
177.94(16) 
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C(22)–N(6)–C(18)–N(5)  179.35(13) C(22)–N(6)–C(18)–C(17) 1.62(19) 
C(15)–N(5)–C(18)–N(6)  179.27(13) C(15)–N(5)–C(18)–C(17)  0.10(15) 
C(16)–C(17)–C(18)–N(5)  0.03(15) C(16)–C(17)–C(18)–N(6) 179.14(13) 
C(19)–C(17)–C(18)–N(5) 178.57(12) C(19)–C(17)–C(18)–N(6)  2.3(2) 
C(22)–N(7)–C(19)–C(17) 0.72(19) C(22)–N(7)–C(19)–C(20) 177.17(12) 
C(16)–C(17)–C(19)–N(7) 178.93(15) C(16)–C(17)–C(19)–C(20) 2.7(3) 
C(18)–C(17)–C(19)–N(7) 0.96(18) C(18)–C(17)–C(19)–C(20)  
175.30(12) 
N(7)–C(19)–C(20)–C(21)  79(4) C(17)–C(19)–C(20)–C(21) 98(4) 
C(18)–N(6)–C(22)–N(7) 0.4(2) C(18)–N(6)–C(22)–N(8)  179.56(12) 
C(19)–N(7)–C(22)–N(6)  1.5(2) C(19)–N(7)–C(22)–N(8) 178.41(11) 
C(23)–N(8)–C(22)–N(6)  15.3(2) C(23)–N(8)–C(22)–N(7) 164.79(13) 
C(22)–N(8)–C(23)–C(24) 149.77(14) C(22)–N(8)–C(23)–C(28)  33.7(2) 
N(8)–C(23)–C(24)–C(25) 176.81(13) C(28)–C(23)–C(24)–C(25) 0.2(2) 
C(23)–C(24)–C(25)–C(26) 1.4(2) C(24)–C(25)–C(26)–C(27)  1.4(2) 
C(25)–C(26)–C(27)–C(28)  0.3(2) C(26)–C(27)–C(28)–C(23) 1.9(2) 
N(8)–C(23)–C(28)–C(27)  178.28(12) C(24)–C(23)–C(28)–C(27)  1.79(19) 
 
 
Table 15.  Hydrogen bonds for 88 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N(1)–H(1)...N(6) 0.860(18) 2.094(19) 2.9504(17) 174(2) 
N(4)–H(4)...N(7A) 0.864(19) 2.103(19) 2.9609(16) 172(2) 
N(5)–H(5)...N(2) 0.925(19) 2.076(19) 2.9906(16) 169(1) 
N(8)–H(8)...N(3B) 0.882(18) 2.230(18) 3.1096(16) 175(1) 
 
Symmetry operations for equivalent atoms 
A   x1/2,y+1/2,z1/2      B   x+1/2,y+1/2,z+1/2    
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Pyrazolopyrimidine 154 
Table 16.  Crystal data and structure refinement for 154. 
 
Identification code  154 
Chemical formula (moiety) C19H20N6O2 
Chemical formula (total) C19H20N6O2 
Formula weight  364.41 
Temperature  150(2) K 
Radiation, wavelength  synchrotron, 0.68890 Å 
Crystal system, space group  monoclinic, P21/n 
Unit cell parameters a = 5.047(3) Å  = 90° 
 b = 13.893(7) Å  = 93.969(5)° 
 c = 25.912(14) Å  = 90° 
Cell volume 1812.5(17) Å
3
 
Z 4 
Calculated density  1.335 g/cm
3
 
Absorption coefficient  0.091 mm1 
F(000) 768 
Crystal colour and size colourless, 0.08  0.01  0.01 mm3 
Data collection method Rigaku 
 thick-slice  scans 
 range for data collection 1.6 to 27.6° 
Index ranges h 5 to 5, k 0 to 18, l 0 to 34 
Completeness to  = 27.6° 90.4 %  
Reflections collected 5548 
Independent reflections 5549 (Rint = 0.0000) 
Reflections with F
2
>2 4298 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9927 and 0.9991 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.1010, 1.3440 
Data / restraints / parameters 5549 / 0 / 266 
Final R indices [F
2
>2] R1 = 0.0778, wR2 = 0.2029 
R indices (all data) R1 = 0.0999, wR2 = 0.2137 
Goodness-of-fit on F
2
 1.094 
Extinction coefficient 0.24(3) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.30 and 0.30 e Å3 
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Table 17.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for 154.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
 
O(1) 0.1328(4) 0.45373(15) 0.44024(7) 0.0322(5) 
O(2)  0.0732(10) 0.1939(4) 0.58266(17) 0.1213(16) 
N(1)  0.2858(6) 0.4457(2) 0.46261(10) 0.0379(7) 
N(2) 0.3895(5) 0.14392(18) 0.29956(9) 0.0321(6) 
N(3) 0.5400(5) 0.29129(15) 0.26879(8) 0.0279(5) 
N(4) 0.7695(6) 0.42374(17) 0.23138(10) 0.0354(7) 
N(5) 0.9667(6) 0.43618(17) 0.19810(10) 0.0383(7) 
N(6) 0.7058(5) 0.13632(16) 0.24211(8) 0.0292(6) 
C(1)  0.1011(6) 0.43187(18) 0.42930(10) 0.0271(6) 
C(2)  0.1880(6) 0.3876(2) 0.37763(10) 0.0312(7) 
C(3)  0.0825(6) 0.28633(19) 0.37365(10) 0.0303(7) 
C(4)  0.1910(7) 0.2127(2) 0.40094(12) 0.0412(8) 
C(5)  0.1035(8) 0.1189(2) 0.39499(13) 0.0469(9) 
C(6) 0.0895(7) 0.0992(2) 0.36180(12) 0.0402(8) 
C(7) 0.2032(6) 0.1723(2) 0.33422(10) 0.0312(7) 
C(8) 0.1172(6) 0.26711(19) 0.34027(9) 0.0277(6) 
C(9) 0.5484(6) 0.19527(18) 0.26966(10) 0.0276(6) 
C(10) 0.7156(6) 0.32959(18) 0.23858(10) 0.0278(6) 
C(11) 1.0356(7) 0.3499(2) 0.18329(11) 0.0358(7) 
C(12) 0.8858(6) 0.27861(19) 0.20769(10) 0.0311(7) 
C(13) 0.8685(6) 0.17799(19) 0.21072(10) 0.0285(6) 
C(14) 1.0262(6) 0.1174(2) 0.17963(11) 0.0335(7) 
C(15) 1.1482(7) 0.0721(2) 0.15135(13) 0.0428(8) 
C(16)  0.0295(15) 0.1257(4) 0.5448(3) 0.119(3) 
C(17) 0.2436(12) 0.1385(4) 0.5305(3) 0.0995(19) 
C(18) 0.2737(13) 0.2483(4) 0.5346(3) 0.108(2) 
C(19) 0.0641(13) 0.2781(4) 0.5689(2) 0.0946(17) 
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Table 18.   Bond lengths [Å] and angles [°] for 154. 
 
O(1)–C(1)  1.233(3) O(2)–C(16)  1.392(7) 
O(2)–C(19)  1.418(7) N(1)–H(1A)  0.93(4) 
N(1)–H(1B)  0.76(3) N(1)–C(1)  1.328(4) 
N(2)–H(2)  0.81(4) N(2)–C(7)  1.401(4) 
N(2)–C(9)  1.356(4) N(3)–C(9)  1.335(3) 
N(3)–C(10)  1.333(4) N(4)–H(4)  0.78(4) 
N(4)–N(5)  1.372(4) N(4)–C(10)  1.352(3) 
N(5)–C(11)  1.313(4) N(6)–C(9)  1.375(3) 
N(6)–C(13)  1.328(4) C(1)–C(2)  1.510(4) 
C(2)–H(2A)  0.990 C(2)–H(2B)  0.990 
C(2)–C(3)  1.511(4) C(3)–C(4)  1.378(4) 
C(3)–C(8)  1.399(4) C(4)–H(4A)  0.950 
C(4)–C(5)  1.388(4) C(5)–H(5A)  0.950 
C(5)–C(6)  1.371(4) C(6)–H(6A)  0.950 
C(6)–C(7)  1.389(4) C(7)–C(8)  1.399(4) 
C(8)–H(8A)  0.950 C(10)–C(12)  1.406(4) 
C(11)–H(11A)  0.950 C(11)–C(12)  1.420(4) 
C(12)–C(13)  1.403(4) C(13)–C(14)  1.442(4) 
C(14)–C(15)  1.172(4) C(15)–H(15)  0.99(4) 
C(16)–H(16A)  0.990 C(16)–H(16B)  0.990 
C(16)–C(17)  1.463(8) C(17)–H(17A)  0.990 
C(17)–H(17B)  0.990 C(17)–C(18)  1.536(8) 
C(18)–H(18A)  0.990 C(18)–H(18B)  0.990 
C(18)–C(19)  1.488(8) C(19)–H(19A)  0.990 
C(19)–H(19B)  0.990  
 
C(16)–O(2)–C(19) 106.3(5) H(1A)–N(1)–H(1B) 124(3) 
H(1A)–N(1)–C(1) 116(2) H(1B)–N(1)–C(1) 120(2) 
H(2)–N(2)–C(7) 113(2) H(2)–N(2)–C(9) 115(2) 
C(7)–N(2)–C(9) 131.9(2) C(9)–N(3)–C(10) 112.8(2) 
H(4)–N(4)–N(5) 116(3) H(4)–N(4)–C(10) 132(3) 
N(5)–N(4)–C(10) 111.7(2) N(4)–N(5)–C(11) 106.7(2) 
C(9)–N(6)–C(13) 117.5(2) O(1)–C(1)–N(1) 121.3(3) 
O(1)–C(1)–C(2) 121.3(2) N(1)–C(1)–C(2) 117.5(3) 
C(1)–C(2)–H(2A) 109.5 C(1)–C(2)–H(2B) 109.5 
C(1)–C(2)–C(3) 110.9(2) H(2A)–C(2)–H(2B) 108.0 
H(2A)–C(2)–C(3) 109.5 H(2B)–C(2)–C(3) 109.5 
C(2)–C(3)–C(4) 120.1(3) C(2)–C(3)–C(8) 119.5(2) 
C(4)–C(3)–C(8) 120.3(3) C(3)–C(4)–H(4A) 120.0 
C(3)–C(4)–C(5) 120.0(3) H(4A)–C(4)–C(5) 120.0 
C(4)–C(5)–H(5A) 119.9 C(4)–C(5)–C(6) 120.2(3) 
H(5A)–C(5)–C(6) 119.9 C(5)–C(6)–H(6A) 119.5 
C(5)–C(6)–C(7) 120.9(3) H(6A)–C(6)–C(7) 119.5 
N(2)–C(7)–C(6) 116.4(3) N(2)–C(7)–C(8) 124.3(3) 
C(6)–C(7)–C(8) 119.2(3) C(3)–C(8)–C(7) 119.4(2) 
C(3)–C(8)–H(8A) 120.3 C(7)–C(8)–H(8A) 120.3 
N(2)–C(9)–N(3) 121.1(3) N(2)–C(9)–N(6) 111.7(2) 
N(3)–C(9)–N(6) 127.3(3) N(3)–C(10)–N(4) 128.0(2) 
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N(3)–C(10)–C(12) 126.2(2) N(4)–C(10)–C(12) 105.8(2) 
N(5)–C(11)–H(11A) 124.9 N(5)–C(11)–C(12) 110.3(3) 
H(11A)–C(11)–C(12) 124.9 C(10)–C(12)–C(11) 105.5(2) 
C(10)–C(12)–C(13) 115.3(2) C(11)–C(12)–C(13) 139.1(3) 
N(6)–C(13)–C(12) 120.8(2) N(6)–C(13)–C(14) 118.4(2) 
C(12)–C(13)–C(14) 120.8(3) C(13)–C(14)–C(15) 175.2(3) 
C(14)–C(15)–H(15) 175(2) O(2)–C(16)–H(16A) 110.3 
O(2)–C(16)–H(16B) 110.3 O(2)–C(16)–C(17) 107.0(6) 
H(16A)–C(16)–H(16B) 108.6 H(16A)–C(16)–C(17) 110.3 
H(16B)–C(16)–C(17) 110.3 C(16)–C(17)–H(17A) 111.5 
C(16)–C(17)–H(17B) 111.5 C(16)–C(17)–C(18) 101.2(5) 
H(17A)–C(17)–H(17B) 109.3 H(17A)–C(17)–C(18) 111.5 
H(17B)–C(17)–C(18) 111.5 C(17)–C(18)–H(18A) 110.9 
C(17)–C(18)–H(18B) 110.9 C(17)–C(18)–C(19) 104.2(5) 
H(18A)–C(18)–H(18B) 108.9 H(18A)–C(18)–C(19) 110.9 
H(18B)–C(18)–C(19) 110.9 O(2)–C(19)–C(18) 107.5(5) 
O(2)–C(19)–H(19A) 110.2 O(2)–C(19)–H(19B) 110.2 
C(18)–C(19)–H(19A) 110.2 C(18)–C(19)–H(19B) 110.2 
H(19A)–C(19)–H(19B) 108.5  
 
 
Table 19.   Anisotropic displacement parameters (Å
2
) for 154.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
O(1) 0.0279(13)  0.0379(11) 0.0313(9)   0.0069(8) 0.0067(8)   0.0026(9) 
O(2) 0.134(4)  0.136(4) 0.098(3)  0.002(3) 0.035(3)   0.003(3) 
N(1) 0.0256(18)  0.0536(18) 0.0354(13)   0.0156(12) 0.0091(11)   0.0039(13) 
N(2) 0.0396(17)  0.0221(12) 0.0360(12)   0.0012(9) 0.0143(11)  0.0039(11) 
N(3) 0.0322(15)  0.0226(11) 0.0296(10)   0.0006(8) 0.0072(10)  0.0027(9) 
N(4) 0.0477(19)  0.0203(11) 0.0398(12)  0.0000(9) 0.0144(12)  0.0032(11) 
N(5) 0.0490(19)  0.0260(12) 0.0420(13)  0.0029(10) 0.0166(12)   0.0008(11) 
N(6) 0.0349(16)  0.0245(11) 0.0288(11)   0.0030(8) 0.0067(9)  0.0018(10) 
C(1) 0.0314(18)  0.0241(13) 0.0263(12)   0.0020(9) 0.0046(11)  0.0006(11) 
C(2) 0.0308(18)  0.0326(14) 0.0304(12)   0.0051(10) 0.0034(11)  0.0049(12) 
C(3) 0.0343(19)  0.0285(14) 0.0281(12)   0.0080(10) 0.0017(11)   0.0007(12) 
C(4) 0.050(2)  0.0386(17) 0.0371(14)   0.0048(12) 0.0200(14)  0.0007(15) 
C(5) 0.061(3)  0.0360(16) 0.0471(17)  0.0014(13) 0.0275(17)   0.0033(16) 
C(6) 0.052(2)  0.0276(14) 0.0425(15)  0.0001(12) 0.0165(15)  0.0013(14) 
C(7) 0.0336(19)  0.0299(14) 0.0308(13)   0.0034(10) 0.0072(12)  0.0017(12) 
C(8) 0.0305(18)  0.0257(13) 0.0273(12)   0.0035(9) 0.0037(11)   0.0024(11) 
C(9) 0.0347(18)  0.0201(12) 0.0282(12)   0.0019(9) 0.0039(11)  0.0009(11) 
C(10) 0.0335(18)  0.0222(12) 0.0277(12)   0.0006(9) 0.0028(11)  0.0024(11) 
C(11) 0.046(2)  0.0255(13) 0.0367(14)  0.0029(11) 0.0113(13)  0.0010(13) 
C(12) 0.040(2)  0.0257(13) 0.0283(12)   0.0016(10) 0.0072(12)   0.0007(12) 
C(13) 0.0339(18)  0.0239(13) 0.0278(12)   0.0041(9) 0.0032(11)  0.0015(11) 
C(14) 0.039(2)  0.0261(13) 0.0368(14)   0.0004(10) 0.0087(13)   0.0041(12) 
C(15) 0.047(2)  0.0380(17) 0.0451(16)   0.0083(13) 0.0178(15)  0.0017(15) 
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C(16) 0.148(7)  0.073(4) 0.142(6)  0.017(4) 0.066(5)  0.016(4) 
C(17) 0.092(5)  0.100(5) 0.109(4)   0.008(3) 0.021(4)  0.002(3) 
C(18) 0.097(5)  0.100(5) 0.128(5)  0.043(4) 0.007(4)   0.014(4) 
C(19) 0.103(5)  0.082(4) 0.097(4)   0.002(3)  0.002(4)   0.005(3) 
 
Table 20.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for 154. 
 
      x       y       z       U 
 
H(1A)  0.227(7) 0.473(2) 0.4941(15) 0.045(9) 
H(1B)  0.431(7) 0.434(2) 0.4550(12) 0.023(9) 
H(2) 0.418(7) 0.087(3) 0.3005(13) 0.043(10) 
H(4) 0.710(7) 0.471(3) 0.2426(15) 0.054(11) 
H(2A)  0.1223 0.4275 0.3495 0.037 
H(2B)  0.3844 0.3866 0.3733 0.037 
H(4A)  0.3255 0.2261 0.4238 0.049 
H(5A)  0.1776 0.0682 0.4140 0.056 
H(6A) 0.1462 0.0346 0.3576 0.048 
H(8A) 0.1939 0.3180 0.3219 0.033 
H(11A) 1.1668 0.3369 0.1596 0.043 
H(15) 1.262(8) 0.038(3) 0.1272(17) 0.070(12) 
H(16A)  0.1557 0.1353 0.5143 0.142 
H(16B)  0.0543 0.0599 0.5584 0.142 
H(17A) 0.2661 0.1155 0.4949 0.119 
H(17B) 0.3719 0.1050 0.5550 0.119 
H(18A) 0.4523 0.2660 0.5499 0.130 
H(18B) 0.2456 0.2788 0.5001 0.130 
H(19A) 0.1452 0.3100 0.6003 0.114 
H(19B)  0.0602 0.3238 0.5506 0.114 
 
Table 21.  Torsion angles [°] for 154. 
 
C(10)–N(4)–N(5)–C(11) 1.1(4) O(1)–C(1)–C(2)–C(3) 69.7(3) 
N(1)–C(1)–C(2)–C(3)  109.9(3) C(1)–C(2)–C(3)–C(4) 73.4(4) 
C(1)–C(2)–C(3)–C(8)  109.6(3) C(2)–C(3)–C(4)–C(5) 176.5(3) 
C(8)–C(3)–C(4)–C(5)  0.6(5) C(3)–C(4)–C(5)–C(6)  0.4(6) 
C(4)–C(5)–C(6)–C(7) 0.9(6) C(5)–C(6)–C(7)–N(2)  177.1(3) 
C(5)–C(6)–C(7)–C(8)  0.5(5) C(9)–N(2)–C(7)–C(6)  175.0(3) 
C(9)–N(2)–C(7)–C(8) 8.6(5) C(2)–C(3)–C(8)–C(7)  176.1(3) 
C(4)–C(3)–C(8)–C(7) 1.0(4) N(2)–C(7)–C(8)–C(3) 175.9(3) 
C(6)–C(7)–C(8)–C(3)  0.4(4) C(10)–N(3)–C(9)–N(2) 178.0(3) 
C(10)–N(3)–C(9)–N(6)  2.7(4) C(7)–N(2)–C(9)–N(3)  1.8(5) 
C(7)–N(2)–C(9)–N(6) 178.7(3) C(13)–N(6)–C(9)–N(2) 179.1(3) 
C(13)–N(6)–C(9)–N(3)  0.3(4) C(9)–N(3)–C(10)–N(4)  175.9(3) 
C(9)–N(3)–C(10)–C(12) 3.6(4) N(5)–N(4)–C(10)–N(3) 178.8(3) 
N(5)–N(4)–C(10)–C(12)  0.7(3) N(4)–N(5)–C(11)–C(12)  1.0(4) 
N(3)–C(10)–C(12)–C(11)  179.5(3) N(3)–C(10)–C(12)–C(13)  1.5(4) 
N(4)–C(10)–C(12)–C(11) 0.1(3) N(4)–C(10)–C(12)–C(13) 178.0(3) 
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N(5)–C(11)–C(12)–C(10) 0.6(4) N(5)–C(11)–C(12)–C(13)  176.5(4) 
C(9)–N(6)–C(13)–C(12) 2.6(4) C(9)–N(6)–C(13)–C(14)  177.1(3) 
C(10)–C(12)–C(13)–N(6)  1.8(4) C(10)–C(12)–C(13)–C(14) 177.9(3) 
C(11)–C(12)–C(13)–N(6) 175.2(3) C(11)–C(12)–C(13)–C(14)  5.1(6) 
N(6)–C(13)–C(14)–C(15) 131(4) C(12)–C(13)–C(14)–C(15)  49(4) 
C(19)–O(2)–C(16)–C(17) 37.1(7) O(2)–C(16)–C(17)–C(18)  35.8(7) 
C(16)–C(17)–C(18)–C(19) 21.1(7) C(16)–O(2)–C(19)–C(18)  21.9(7) 
C(17)–C(18)–C(19)–O(2)  0.5(7)  
 
 
Table 22.  Hydrogen bonds for 154 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N(1)–H(1A)...O(1A) 0.93(4) 2.01(4) 2.935(4) 173(3) 
N(1)–H(1B)...O(1B) 0.76(3) 2.22(3) 2.954(4) 160(3) 
N(2)–H(2)...N(5C) 0.81(4) 2.17(4) 2.976(4) 175(3) 
N(4)–H(4)...N(6D) 0.78(4) 2.36(4) 3.033(4) 144(4) 
 
Symmetry operations for equivalent atoms 
A   x,y+1,z+1      B   x1,y,z      C   x+3/2,y1/2,z+1/2        
D   x+3/2,y+1/2,z+1/2        
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Triazolopyrimidine 174 
Table 23.  Crystal data and structure refinement for 174. 
 
Identification code  174 
Chemical formula (moiety) C9H11ClN6O2 
Chemical formula (total) C9H11ClN6O2 
Formula weight  270.69 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/n1 
Unit cell parameters a = 9.9614(4) Å  = 90° 
 b = 10.7013(4) Å  = 94.166(3)° 
 c = 11.2291(4) Å  = 90° 
Cell volume 1193.86(8) Å
3
 
Z 4 
Calculated density  1.506 g/cm
3
 
Absorption coefficient  0.325 mm1 
F(000) 560 
Crystal colour and size colourless, 0.40  0.30  0.30 mm3 
Reflections for cell refinement 4154 ( range 2.8 to 28.3°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.8 to 28.4° 
Index ranges h 13 to 13, k 14 to 14, l 14 to 14 
Completeness to  = 25.0° 99.9 %  
Reflections collected 9462 
Independent reflections 2602 (Rint = 0.0242) 
Reflections with F
2
>2 2288 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.8809 and 0.9087 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0354, 0.5961 
Data / restraints / parameters 2602 / 0 / 175 
Final R indices [F
2
>2] R1 = 0.0328, wR2 = 0.0795 
R indices (all data) R1 = 0.0392, wR2 = 0.0840 
Goodness-of-fit on F
2
 1.066 
Extinction coefficient 0.0050(12) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.36 and 0.21 e Å3 
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Table 24.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for 174.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
 
N(1) 0.14545(13) 0.41830(12) 0.54332(11) 0.0250(3) 
N(2) 0.08966(13) 0.31408(12) 0.56801(11) 0.0242(3) 
N(3) 0.04581(12) 0.32162(11) 0.68288(10) 0.0192(3) 
N(4) 0.05862(12) 0.48183(11) 0.83823(10) 0.0182(3) 
C(5) 0.10482(14) 0.59974(13) 0.85164(12) 0.0191(3) 
N(5) 0.08970(16) 0.65617(13) 0.95514(12) 0.0270(3) 
Cl(7) 0.25655(4) 0.70625(4) 0.55984(3) 0.02827(13) 
C(7) 0.18186(14) 0.61857(13) 0.66548(13) 0.0196(3) 
N(6) 0.16551(12) 0.67025(11) 0.76816(11) 0.0209(3) 
C(8) 0.14073(14) 0.49645(14) 0.64038(13) 0.0194(3) 
C(9) 0.07827(14) 0.43650(13) 0.73077(12) 0.0169(3) 
C(10)  0.02808(14) 0.22429(13) 0.73440(13) 0.0194(3) 
O(11)  0.08992(12) 0.24572(10) 0.81920(10) 0.0292(3) 
O(12)  0.01518(11) 0.11982(9) 0.67679(9) 0.0230(2) 
C(13)  0.09201(16) 0.00726(14) 0.71490(14) 0.0236(3) 
C(14)  0.0389(2)  0.03077(17) 0.83870(16) 0.0366(4) 
C(15)  0.0588(2)  0.08972(16) 0.62429(18) 0.0444(5) 
C(16)  0.24037(18) 0.03588(17) 0.70672(19) 0.0401(5) 
 
Table 25.   Bond lengths [Å] and angles [°] for 174. 
 
N(1)–N(2)  1.2853(18) N(1)–C(8)  1.3773(19) 
N(2)–N(3)  1.3939(16) N(3)–C(9)  1.3710(18) 
N(3)–C(10)  1.4225(19) N(4)–C(5)  1.3477(19) 
N(4)–C(9)  1.3281(18) C(5)–N(5)  1.3280(19) 
C(5)–N(6)  1.3769(19) N(5)–H(5A)  0.82(2) 
N(5)–H(5B)  0.84(2) Cl(7)–C(7)  1.7232(14) 
C(7)–N(6)  1.2996(19) C(7)–C(8)  1.392(2) 
C(8)–C(9)  1.386(2) C(10)–O(11)  1.1933(18) 
C(10)–O(12)  1.3027(17) O(12)–C(13)  1.5058(17) 
C(13)–C(14)  1.507(2) C(13)–C(15)  1.507(2) 
C(13)–C(16)  1.506(2) C(14)–H(14A)  0.980 
C(14)–H(14B)  0.980 C(14)–H(14C)  0.980 
C(15)–H(15A)  0.980 C(15)–H(15B)  0.980 
C(15)–H(15C)  0.980 C(16)–H(16A)  0.980 
C(16)–H(16B)  0.980 C(16)–H(16C)  0.980 
 
N(2)–N(1)–C(8) 108.42(12) N(1)–N(2)–N(3) 108.59(11) 
N(2)–N(3)–C(9) 109.52(11) N(2)–N(3)–C(10) 122.69(11) 
C(9)–N(3)–C(10) 127.69(12) C(5)–N(4)–C(9) 111.83(12) 
N(4)–C(5)–N(5) 117.65(13) N(4)–C(5)–N(6) 126.88(13) 
N(5)–C(5)–N(6) 115.46(13) C(5)–N(5)–H(5A) 118.6(14) 
C(5)–N(5)–H(5B) 120.7(13) H(5A)–N(5)–H(5B) 119.7(19) 
Cl(7)–C(7)–N(6) 117.86(11) Cl(7)–C(7)–C(8) 120.47(11) 
N(6)–C(7)–C(8) 121.67(13) C(5)–N(6)–C(7) 117.41(12) 
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N(1)–C(8)–C(7) 134.73(14) N(1)–C(8)–C(9) 109.96(13) 
C(7)–C(8)–C(9) 115.30(13) N(3)–C(9)–N(4) 129.62(13) 
N(3)–C(9)–C(8) 103.50(12) N(4)–C(9)–C(8) 126.86(13) 
N(3)–C(10)–O(11) 119.75(13) N(3)–C(10)–O(12) 110.72(12) 
O(11)–C(10)–O(12) 129.53(14) C(10)–O(12)–C(13) 118.34(11) 
O(12)–C(13)–C(14) 109.07(12) O(12)–C(13)–C(15) 102.59(12) 
O(12)–C(13)–C(16) 109.69(13) C(14)–C(13)–C(15) 110.94(15) 
C(14)–C(13)–C(16) 112.85(15) C(15)–C(13)–C(16) 111.19(15) 
C(13)–C(14)–H(14A) 109.5 C(13)–C(14)–H(14B) 109.5 
C(13)–C(14)–H(14C) 109.5 H(14A)–C(14)–H(14B) 109.5 
H(14A)–C(14)–H(14C) 109.5 H(14B)–C(14)–H(14C) 109.5 
C(13)–C(15)–H(15A) 109.5 C(13)–C(15)–H(15B) 109.5 
C(13)–C(15)–H(15C) 109.5 H(15A)–C(15)–H(15B) 109.5 
H(15A)–C(15)–H(15C) 109.5 H(15B)–C(15)–H(15C) 109.5 
C(13)–C(16)–H(16A) 109.5 C(13)–C(16)–H(16B) 109.5 
C(13)–C(16)–H(16C) 109.5 H(16A)–C(16)–H(16B) 109.5 
H(16A)–C(16)–H(16C) 109.5 H(16B)–C(16)–H(16C) 109.5 
 
 
Table 26.   Anisotropic displacement parameters (Å
2
) for 174.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
N(1) 0.0311(7)  0.0232(7) 0.0216(6)   0.0041(5) 0.0068(5)   0.0039(6) 
N(2) 0.0306(7)  0.0231(6) 0.0200(6)   0.0053(5) 0.0082(5)   0.0028(5) 
N(3) 0.0235(6)  0.0167(6) 0.0178(6)   0.0041(5) 0.0045(5)   0.0017(5) 
N(4) 0.0206(6)  0.0160(6) 0.0181(6)   0.0021(5) 0.0020(5)  0.0004(5) 
C(5) 0.0213(7)  0.0174(7) 0.0186(7)   0.0016(6) 0.0005(5)  0.0006(6) 
N(5) 0.0435(9)  0.0181(7) 0.0201(7)   0.0047(6) 0.0067(6)   0.0075(6) 
Cl(7) 0.0344(2)  0.0250(2) 0.0267(2)  0.00194(15) 0.01042(16)   
0.00649(16) 
C(7) 0.0186(7)  0.0191(7) 0.0210(7)  0.0024(6) 0.0018(5)   0.0009(6) 
N(6) 0.0234(6)  0.0183(6) 0.0210(6)   0.0009(5) 0.0025(5)   0.0014(5) 
C(8) 0.0199(7)  0.0198(7) 0.0188(7)   0.0016(6) 0.0025(5)  0.0001(6) 
C(9) 0.0155(6)  0.0154(7) 0.0195(7)   0.0017(5) 0.0005(5)  0.0009(5) 
C(10) 0.0202(7)  0.0175(7) 0.0204(7)   0.0034(6) 0.0006(5)   0.0013(6) 
O(11) 0.0370(6)  0.0238(6) 0.0287(6)   0.0092(5) 0.0148(5)   0.0074(5) 
O(12) 0.0308(6)  0.0159(5) 0.0232(5)   0.0049(4) 0.0093(4)   0.0041(4) 
C(13) 0.0304(8)  0.0166(7) 0.0243(8)   0.0020(6) 0.0065(6)   0.0074(6) 
C(14) 0.0470(11)  0.0289(9) 0.0331(9)  0.0078(7)  0.0016(8)   0.0072(8) 
C(15) 0.0736(14)  0.0204(8) 0.0425(11)   0.0102(8) 0.0274(10)   0.0121(9) 
C(16) 0.0289(9)  0.0314(10) 0.0592(12)   0.0016(9)  0.0021(8)   0.0096(7) 
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Table 27.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for 174. 
 
      x       y       z       U 
 
H(14A)  0.0617 0.0336 0.8960 0.055 
H(14B) 0.0591  0.0402 0.8409 0.055 
H(14C)  0.0796  0.1104 0.8597 0.055 
H(15A)  0.0934  0.0626 0.5445 0.067 
H(15B)  0.1005  0.1695 0.6436 0.067 
H(15C) 0.0390  0.1002 0.6258 0.067 
H(16A)  0.2664 0.0736 0.6289 0.060 
H(16B)  0.2601 0.0943 0.7704 0.060 
H(16C)  0.2912  0.0416 0.7155 0.060 
H(5A) 0.126(2) 0.724(2) 0.9676(17) 0.033(5) 
H(5B) 0.0566(19) 0.6176(18) 1.0116(17) 0.029(5) 
 
Table 28.  Torsion angles [°] for 174. 
 
C(8)–N(1)–N(2)–N(3) 0.34(16) N(1)–N(2)–N(3)–C(9)  0.69(16) 
N(1)–N(2)–N(3)–C(10) 175.86(13) C(9)–N(4)–C(5)–N(5) 179.27(13) 
C(9)–N(4)–C(5)–N(6) 0.2(2) Cl(7)–C(7)–N(6)–C(5) 179.53(10) 
C(8)–C(7)–N(6)–C(5)  0.4(2) N(4)–C(5)–N(6)–C(7)  0.7(2) 
N(5)–C(5)–N(6)–C(7)  179.80(13) N(2)–N(1)–C(8)–C(7)  178.77(16) 
N(2)–N(1)–C(8)–C(9) 0.12(17) Cl(7)–C(7)–C(8)–N(1) 0.7(2) 
Cl(7)–C(7)–C(8)–C(9)  178.11(11) N(6)–C(7)–C(8)–N(1)  179.32(16) 
N(6)–C(7)–C(8)–C(9) 1.8(2) C(5)–N(4)–C(9)–N(3)  179.91(14) 
C(5)–N(4)–C(9)–C(8) 1.5(2) N(2)–N(3)–C(9)–N(4)  178.10(14) 
N(2)–N(3)–C(9)–C(8) 0.72(15) C(10)–N(3)–C(9)–N(4) 5.6(2) 
C(10)–N(3)–C(9)–C(8)  175.61(13) N(1)–C(8)–C(9)–N(3)  0.52(16) 
N(1)–C(8)–C(9)–N(4) 178.34(13) C(7)–C(8)–C(9)–N(3) 178.61(12) 
C(7)–C(8)–C(9)–N(4)  2.5(2) N(2)–N(3)–C(10)–O(11)  162.33(14) 
N(2)–N(3)–C(10)–O(12) 17.84(19) C(9)–N(3)–C(10)–O(11) 13.6(2) 
C(9)–N(3)–C(10)–O(12)  166.26(13) N(3)–C(10)–O(12)–C(13)  177.08(11) 
O(11)–C(10)–O(12)–C(13) 3.1(2) C(10)–O(12)–C(13)–C(14)  65.81(17) 
C(10)–O(12)–C(13)–C(15) 176.50(14) C(10)–O(12)–C(13)–C(16) 58.25(17) 
 
 
Table 29.  Hydrogen bonds for 174 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N(5)–H(5B)...N(4A) 0.84(2) 2.36(2) 3.2009(19) 174(2) 
 
Symmetry operations for equivalent atoms 
A   x,y+1,z+2        
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5-Formylpyrimidine 101 
Table 30.  Crystal data and structure refinement for 101. 
 
Identification code  101 
Chemical formula (moiety) C13H10N4O 
Chemical formula (total) C13H10N4O 
Formula weight  238.25 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 4.6755(3) Å  = 90° 
 b = 24.8238(17) Å  = 94.831(6)° 
 c = 9.8280(7) Å  = 90° 
Cell volume 1136.62(13) Å
3
 
Z 4 
Calculated density  1.392 g/cm
3
 
Absorption coefficient  0.094 mm1 
F(000) 496 
Crystal colour and size colourless, 0.30  0.20  0.10 mm3 
Reflections for cell refinement 1894 ( range 3.2 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.2 to 28.5° 
Index ranges h 5 to 6, k 28 to 32, l 13 to 11 
Completeness to  = 25.0° 99.9 %  
Reflections collected 5145 
Independent reflections 2363 (Rint = 0.0210) 
Reflections with F
2
>2 1894 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9724 and 0.9907 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0436, 0.2327 
Data / restraints / parameters 2363 / 0 / 217 
Final R indices [F
2
>2] R1 = 0.0389, wR2 = 0.0909 
R indices (all data) R1 = 0.0524, wR2 = 0.0991 
Goodness-of-fit on F
2
 1.040 
Extinction coefficient 0.0055(14) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.25 and 0.19 e Å3 
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Table 31.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for 101.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
 
O 0.2051(2) 0.83340(4) 0.51056(10) 0.0312(3) 
N(1) 0.2006(3) 0.72288(5) 0.49977(12) 0.0244(3) 
N(2) 0.4917(2) 0.68462(4) 0.35331(10) 0.0215(3) 
N(3) 0.7834(2) 0.73801(4) 0.21340(11) 0.0199(3) 
N(4) 0.7969(2) 0.64658(4) 0.20629(11) 0.0225(3) 
C(1) 0.3839(3) 0.83054(5) 0.42645(13) 0.0246(3) 
C(2) 0.4827(3) 0.78171(5) 0.36851(12) 0.0197(3) 
C(3) 0.3897(3) 0.72952(5) 0.40782(12) 0.0197(3) 
C(4) 0.6825(3) 0.69067(5) 0.26186(12) 0.0193(3) 
C(5) 0.6792(3) 0.78202(5) 0.26818(12) 0.0190(3) 
C(6) 0.7762(3) 0.83275(5) 0.21558(13) 0.0229(3) 
C(7) 0.8535(4) 0.87392(6) 0.17104(17) 0.0369(4) 
C(8) 0.7275(3) 0.59162(5) 0.22095(13) 0.0217(3) 
C(9) 0.9131(8) 0.55568(12) 0.1711(4) 0.0269(8) 
C(10) 0.8592(9) 0.50093(12) 0.1769(4) 0.0331(9) 
C(9A) 0.7582(8) 0.55736(12) 0.1072(3) 0.0258(8) 
C(10A) 0.6997(8) 0.50271(12) 0.1156(4) 0.0293(8) 
C(11) 0.6176(3) 0.48165(6) 0.23479(15) 0.0303(3) 
C(12) 0.4330(8) 0.51843(12) 0.2835(4) 0.0292(8) 
C(13) 0.4833(8) 0.57360(11) 0.2787(3) 0.0265(8) 
C(12A) 0.5862(9) 0.51431(12) 0.3461(4) 0.0316(9) 
C(13A) 0.6419(8) 0.56931(12) 0.3384(3) 0.0283(8) 
 
Table 32.   Bond lengths [Å] and angles [°] for 101. 
 
O–C(1)  1.2263(17) N(1)–H(1A)  0.892(19) 
N(1)–H(1B)  0.874(18) N(1)–C(3)  1.3266(18) 
N(2)–C(3)  1.3416(17) N(2)–C(4)  1.3270(17) 
N(3)–C(4)  1.3670(16) N(3)–C(5)  1.3285(16) 
N(4)–H(4)  0.907(16) N(4)–C(4)  1.3534(16) 
N(4)–C(8)  1.4126(17) C(1)–H(1C)  0.950 
C(1)–C(2)  1.4321(18) C(2)–C(3)  1.4301(18) 
C(2)–C(5)  1.4033(19) C(5)–C(6)  1.4483(18) 
C(6)–C(7)  1.180(2) C(7)–H(7)  0.93(2) 
C(8)–C(9)  1.364(3) C(8)–C(9A)  1.421(3) 
C(8)–C(13)  1.391(3) C(8)–C(13A)  1.370(3) 
C(9)–H(9A)  0.950 C(9)–C(10)  1.384(4) 
C(10)–H(10A)  0.950 C(10)–C(11)  1.391(4) 
C(9A)–H(9AA)  0.950 C(9A)–C(10A)  1.388(4) 
C(10A)–H(10B)  0.950 C(10A)–C(11)  1.367(4) 
C(11)–H(11)  0.950 C(11)–C(12)  1.370(4) 
C(11)–C(12A)  1.379(4) C(12)–H(12A)  0.950 
C(12)–C(13)  1.391(4) C(13)–H(13A)  0.950 
C(12A)–H(12B)  0.950 C(12A)–C(13A)  1.393(4) 
C(13A)–H(13B)  0.950  
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H(1A)–N(1)–H(1B) 121.8(16) H(1A)–N(1)–C(3) 121.6(12) 
H(1B)–N(1)–C(3) 116.6(11) C(3)–N(2)–C(4) 117.28(11) 
C(4)–N(3)–C(5) 114.63(11) H(4)–N(4)–C(4) 114.7(10) 
H(4)–N(4)–C(8) 115.5(10) C(4)–N(4)–C(8) 129.62(12) 
O–C(1)–H(1C) 117.3 O–C(1)–C(2) 125.32(13) 
H(1C)–C(1)–C(2) 117.3 C(1)–C(2)–C(3) 122.93(12) 
C(1)–C(2)–C(5) 121.80(12) C(3)–C(2)–C(5) 115.26(11) 
N(1)–C(3)–N(2) 116.64(12) N(1)–C(3)–C(2) 122.13(12) 
N(2)–C(3)–C(2) 121.23(12) N(2)–C(4)–N(3) 127.21(12) 
N(2)–C(4)–N(4) 119.54(11) N(3)–C(4)–N(4) 113.25(11) 
N(3)–C(5)–C(2) 124.36(11) N(3)–C(5)–C(6) 115.71(11) 
C(2)–C(5)–C(6) 119.92(11) C(5)–C(6)–C(7) 179.12(15) 
C(6)–C(7)–H(7) 179.0(12) N(4)–C(8)–C(9) 115.87(16) 
N(4)–C(8)–C(9A) 117.28(15) N(4)–C(8)–C(13) 123.78(16) 
N(4)–C(8)–C(13A) 124.22(16) C(9)–C(8)–C(9A) 38.45(15) 
C(9)–C(8)–C(13) 120.3(2) C(9)–C(8)–C(13A) 106.1(2) 
C(9A)–C(8)–C(13) 105.62(19) C(9A)–C(8)–C(13A) 118.5(2) 
C(13)–C(8)–C(13A) 38.56(16) C(8)–C(9)–H(9A) 119.9 
C(8)–C(9)–C(10) 120.2(3) H(9A)–C(9)–C(10) 119.9 
C(9)–C(10)–H(10A) 119.6 C(9)–C(10)–C(11) 120.8(3) 
H(10A)–C(10)–C(11) 119.6 C(8)–C(9A)–H(9AA) 119.8 
C(8)–C(9A)–C(10A) 120.3(2) H(9AA)–C(9A)–C(10A) 119.8 
C(9A)–C(10A)–H(10B) 120.1 C(9A)–C(10A)–C(11) 119.7(3) 
H(10B)–C(10A)–C(11) 120.1 C(10)–C(11)–C(10A) 38.93(16) 
C(10)–C(11)–H(11) 121.0 C(10)–C(11)–C(12) 118.1(2) 
C(10)–C(11)–C(12A) 105.4(2) C(10A)–C(11)–H(11) 119.3 
C(10A)–C(11)–C(12) 106.0(2) C(10A)–C(11)–C(12A) 120.7(2) 
H(11)–C(11)–C(12) 121.0 H(11)–C(11)–C(12A) 120.0 
C(12)–C(11)–C(12A) 38.65(16) C(11)–C(12)–H(12A) 119.0 
C(11)–C(12)–C(13) 122.1(3) H(12A)–C(12)–C(13) 119.0 
C(8)–C(13)–C(12) 118.5(3) C(8)–C(13)–H(13A) 120.7 
C(12)–C(13)–H(13A) 120.7 C(11)–C(12A)–H(12B) 120.0 
C(11)–C(12A)–C(13A) 120.0(3) H(12B)–C(12A)–C(13A) 120.0 
C(8)–C(13A)–C(12A) 120.7(3) C(8)–C(13A)–H(13B) 119.6 
C(12A)–C(13A)–H(13B) 119.6  
 
 
Table 33.   Anisotropic displacement parameters (Å
2
) for 101.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
O 0.0311(6)  0.0352(6) 0.0290(5)   0.0038(4) 0.0124(4)  0.0029(5) 
N(1) 0.0238(6)  0.0263(6) 0.0242(6)  0.0010(5) 0.0087(5)   0.0010(5) 
N(2) 0.0207(6)  0.0231(6) 0.0213(5)  0.0009(4) 0.0053(5)   0.0022(5) 
N(3) 0.0180(6)  0.0202(6) 0.0218(5)  0.0010(4) 0.0040(4)  0.0002(4) 
N(4) 0.0208(6)  0.0199(6) 0.0281(6)  0.0009(5) 0.0105(5)   0.0005(5) 
C(1) 0.0268(7)  0.0246(7) 0.0229(6)  0.0007(5) 0.0058(6)  0.0005(6) 
C(2) 0.0184(7)  0.0223(7) 0.0183(6)  0.0007(5) 0.0007(5)  0.0002(5) 
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C(3) 0.0163(6)  0.0249(7) 0.0177(6)  0.0007(5) 0.0006(5)   0.0002(5) 
C(4) 0.0170(6)  0.0213(6) 0.0195(6)  0.0009(5) 0.0007(5)   0.0011(5) 
C(5) 0.0159(6)  0.0219(7) 0.0189(6)  0.0011(5)  0.0002(5)   0.0001(5) 
C(6) 0.0212(7)  0.0231(7) 0.0255(7)   0.0030(6) 0.0069(6)  0.0018(6) 
C(7) 0.0410(9)  0.0227(8) 0.0498(9)  0.0017(7) 0.0212(8)   0.0005(7) 
C(8) 0.0195(7)  0.0205(6) 0.0252(6)  0.0014(5) 0.0030(5)  0.0003(5) 
C(9) 0.0227(18)  0.0243(15) 0.0350(17)  0.0004(13) 0.0105(16)   0.0011(13) 
C(10) 0.032(2)  0.0228(15) 0.045(2)   0.0052(14) 0.0097(18)  0.0046(14) 
C(9A) 0.0252(19)  0.0283(15) 0.0249(15)  0.0017(12) 0.0083(15)  0.0032(13) 
C(10A) 0.028(2)  0.0254(15) 0.0349(17)   0.0067(13) 0.0052(16)  0.0021(13) 
C(11) 0.0316(8)  0.0192(7) 0.0405(8)  0.0006(6) 0.0058(7)   0.0021(6) 
C(12) 0.0305(19)  0.0272(16) 0.0310(17)  0.0027(13) 0.0088(16)   0.0077(14) 
C(13) 0.0253(18)  0.0224(14) 0.0330(17)   0.0013(13) 0.0094(15)   0.0014(13) 
C(12A) 0.037(2)  0.0263(16) 0.0324(17)  0.0063(13) 0.0089(17)   0.0025(14) 
C(13A) 0.032(2)  0.0275(16) 0.0265(15)   0.0012(12) 0.0054(15)   0.0001(14) 
 
Table 34.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for 101. 
 
      x       y       z       U 
 
H(1A) 0.123(4) 0.7509(7) 0.5399(18) 0.042(5) 
H(1B) 0.159(4) 0.6897(7) 0.5201(16) 0.037(5) 
H(4) 0.928(3) 0.6538(6) 0.1459(15) 0.030(4) 
H(1C) 0.4634 0.8634 0.3974 0.029 
H(7) 0.916(4) 0.9061(8) 0.1349(18) 0.056(5) 
H(9A) 1.0800 0.5683 0.1323 0.032 
H(10A) 0.9886 0.4762 0.1410 0.040 
H(9AA) 0.8190 0.5719 0.0251 0.031 
H(10B) 0.7167 0.4800 0.0388 0.035 
H(11) 0.5818 0.4441 0.2404 0.036 
H(12A) 0.2653 0.5059 0.3216 0.035 
H(13A) 0.3538 0.5984 0.3141 0.032 
H(12B) 0.5266 0.4993 0.4280 0.038 
H(13B) 0.6202 0.5916 0.4154 0.034 
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Table 35.  Torsion angles [°] for 101. 
 
O–C(1)–C(2)–C(3)  2.8(2) O–C(1)–C(2)–C(5) 177.19(13) 
C(4)–N(2)–C(3)–N(1)  179.56(11) C(4)–N(2)–C(3)–C(2) 0.16(17) 
C(1)–C(2)–C(3)–N(1) 1.1(2) C(1)–C(2)–C(3)–N(2)  178.58(11) 
C(5)–C(2)–C(3)–N(1)  178.83(11) C(5)–C(2)–C(3)–N(2) 1.48(17) 
C(3)–N(2)–C(4)–N(3)  1.82(19) C(3)–N(2)–C(4)–N(4) 178.44(11) 
C(8)–N(4)–C(4)–N(2) 6.2(2) C(8)–N(4)–C(4)–N(3)  173.53(11) 
C(5)–N(3)–C(4)–N(2) 1.55(18) C(5)–N(3)–C(4)–N(4)  178.69(10) 
C(4)–N(3)–C(5)–C(2) 0.40(18) C(4)–N(3)–C(5)–C(6)  178.21(10) 
C(1)–C(2)–C(5)–N(3) 178.27(11) C(1)–C(2)–C(5)–C(6)  3.17(18) 
C(3)–C(2)–C(5)–N(3)  1.78(18) C(3)–C(2)–C(5)–C(6) 176.77(11) 
N(3)–C(5)–C(6)–C(7) 64(10) C(2)–C(5)–C(6)–C(7)  115(10) 
C(4)–N(4)–C(8)–C(9)  169.1(2) C(4)–N(4)–C(8)–C(9A) 147.7(2) 
C(4)–N(4)–C(8)–C(13) 12.5(3) C(4)–N(4)–C(8)–C(13A)  34.5(3) 
N(4)–C(8)–C(9)–C(10)  178.1(3) C(9A)–C(8)–C(9)–C(10)  76.0(4) 
C(13)–C(8)–C(9)–C(10) 0.4(4) C(13A)–C(8)–C(9)–C(10) 39.7(4) 
C(8)–C(9)–C(10)–C(11)  0.7(5) N(4)–C(8)–C(9A)–C(10A) 178.6(3) 
C(9)–C(8)–C(9A)–C(10A) 80.5(4) C(13)–C(8)–C(9A)–C(10A)  38.9(4) 
C(13A)–C(8)–C(9A)–C(10A) 0.6(4) C(8)–C(9A)–C(10A)–C(11)  1.3(5) 
C(9A)–C(10A)–C(11)–C(10)  74.5(4) C(9A)–C(10A)–C(11)–C(12) 40.6(4) 
C(9A)–C(10A)–C(11)–C(12A) 1.4(4) C(9)–C(10)–C(11)–C(10A) 81.7(4) 
C(9)–C(10)–C(11)–C(12) 1.1(4) C(9)–C(10)–C(11)–C(12A)  38.5(4) 
C(10)–C(11)–C(12)–C(13)  1.2(4) C(10A)–C(11)–C(12)–C(13)  41.3(4) 
C(12A)–C(11)–C(12)–C(13) 78.3(4) N(4)–C(8)–C(13)–C(12) 177.9(2) 
C(9)–C(8)–C(13)–C(12)  0.4(4) C(9A)–C(8)–C(13)–C(12) 38.5(4) 
C(13A)–C(8)–C(13)–C(12)  77.9(4) C(11)–C(12)–C(13)–C(8) 0.8(5) 
C(10)–C(11)–C(12A)–C(13A) 38.4(4) C(10A)–C(11)–C(12A)–C(13A)  
0.8(5) 
C(12)–C(11)–C(12A)–C(13A)  77.5(4) N(4)–C(8)–C(13A)–C(12A)  177.9(3) 
C(9)–C(8)–C(13A)–C(12A)  39.6(4) C(9A)–C(8)–C(13A)–C(12A) 0.0(4) 
C(13)–C(8)–C(13A)–C(12A) 79.1(4) C(11)–C(12A)–C(13A)–C(8) 0.1(5) 
 
 
Table 36.  Hydrogen bonds for 101 [Å and °]. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
 
N(4)–H(4)...OA 0.907(16) 1.959(17) 2.8647(15) 177(1) 
N(1)–H(1A)...O 0.892(19) 2.108(18) 2.7456(17) 128(1) 
N(1)–H(1A)...N(3B) 0.892(19) 2.441(19) 3.1378(17) 135(1) 
 
Symmetry operations for equivalent atoms 
A   x+1,y+3/2,z1/2      B   x1,y+3/2,z+1/2        
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ii - 1H-qNMR Experimental Data  
2-Benzylpurine 52 – 0.30 mole equivalents of DABCO 
Experiment 1 (R2 = 0.9832; k' = 5.0 × 10-4 s-1; t½ = 1386 s) 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment 2 (R2 = 0.9203; k' = 4.9 × 10-4 s-1; t½ = 1415 s) 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment 3 (R2 = 0.9564; k' = 4.8 × 10-4 s-1; t½ = 1444 s) 
 
 
 
 
 
 
 
 
 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 52 ] (mM) ln[ 52 ] 
975 0.6539 3.92 -5.54 
1575 0.4082 2.45 -6.01 
2175 0.2874 1.72 -6.36 
2775 0.2053 1.23 -6.70 
3375 0.1554 0.93 -6.98 
3975 0.1257 0.75 -7.19 
4575 0.0751 0.45 -7.70 
5175 0.0779 0.47 -7.67 
5775 0.0568 0.34 -7.98 
6375 0.0407 0.24 -8.32 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 52 ] (mM) ln[ 52 ] 
1044 0.4157 2.49 -5.99 
1644 0.2658 1.59 -6.44 
2244 0.1960 1.18 -6.75 
2844 0.1475 0.89 -7.03 
3444 0.1278 0.77 -7.17 
4044 0.0684 0.41 -7.80 
4644 0.0594 0.36 -7.94 
5244 0.0550 0.33 -8.02 
5844 0.0690 0.41 -7.79 
6444 0.0412 0.25 -8.31 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 52 ] (mM) ln[ 52 ] 
984 0.6446 3.87 -5.56 
1584 0.4950 2.97 -5.82 
2184 0.3238 1.94 -6.24 
2784 0.2476 1.49 -6.51 
3384 0.1926 1.16 -6.76 
3984 0.1740 1.04 -6.86 
4584 0.0951 0.57 -7.47 
5184 0.0545 0.33 -8.03 
5784 0.0696 0.42 -7.78 
6384 0.0590 0.35 -7.95 
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2-Methylanilinopurine 54 – 0.30 mole equivalents of DABCO 
Experiment 1 (R2 = 0.9895; k' = 1.5 × 10-4 s-1; t½ = 4621 s) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment 2 (R2 = 0.8869; k' = 1.3 × 10-4 s-1; t½ = 5332 s) 
 
 
 
 
 
 
 
 
 
 
 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 54 ] (mM) ln[ 54 ] 
985 0.7330 4.40 -5.43 
1585 0.7319 4.39 -5.43 
2185 0.6414 3.85 -5.56 
2785 0.6102 3.66 -5.61 
3385 0.5033 3.02 -5.80 
3985 0.4996 3.00 -5.81 
4585 0.4504 2.70 -5.91 
5185 0.3983 2.39 -6.04 
5785 0.3596 2.16 -6.14 
6385 0.3045 1.83 -6.31 
6985 0.3103 1.86 -6.29 
7585 0.2755 1.65 -6.41 
8185 0.2779 1.67 -6.40 
8785 0.2379 1.43 -6.55 
9385 0.2043 1.23 -6.70 
9985 0.1928 1.16 -6.76 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 54 ] (mM) ln[ 54 ] 
985 0.6333 3.80 -5.57 
1585 0.5270 3.16 -5.76 
2185 0.4887 2.93 -5.83 
2785 0.4304 2.58 -5.96 
3385 0.4084 2.45 -6.01 
3985 0.3432 2.06 -6.19 
4585 0.3058 1.83 -6.30 
5185 0.2785 1.67 -6.39 
5785 0.2431 1.46 -6.53 
6385 0.2618 1.57 -6.46 
6985 0.2014 1.21 -6.72 
7585 0.2414 1.45 -6.54 
8185 0.2089 1.25 -6.68 
8785 0.1726 1.04 -6.87 
9385 0.2015 1.21 -6.72 
9985 0.2287 1.37 -6.59 
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Experiment 3 (R2 = 0.9141; k' = 1.3 × 10-4 s-1; t½ = 5332 s) 
 
 
 
 
 
 
 
 
 
 
Pyrrolopyrimidine 88 – 0.30 mole equivalents of DABCO 
Experiment 1 (R2 = 0.9939; k' = 3.1 × 10-5 s-1; t½ = 22360 s) 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 54 ] (mM) ln[ 54 ] 
846 0.8411 5.05 -5.29 
1446 0.7693 4.62 -5.38 
2046 0.7014 4.21 -5.47 
2646 0.5982 3.59 -5.63 
3246 0.5317 3.19 -5.75 
3846 0.5016 3.01 -5.81 
4446 0.4156 2.49 -5.99 
5046 0.4217 2.53 -5.98 
5646 0.3869 2.32 -6.07 
6246 0.5035 3.02 -5.80 
6846 0.4199 2.52 -5.98 
7446 0.3640 2.18 -6.13 
8046 0.3166 1.90 -6.27 
8646 0.2949 1.77 -6.34 
9246 0.2160 1.30 -6.65 
9846 0.2214 1.33 -6.62 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 88 ] (mM) ln[ 88 ] 
972 0.9908 5.94 -5.13 
1572 0.9701 5.82 -5.15 
2172 0.9453 5.67 -5.17 
2772 0.9280 5.57 -5.19 
3372 0.9107 5.46 -5.21 
3972 0.8912 5.35 -5.23 
4572 0.8787 5.27 -5.25 
5172 0.8495 5.10 -5.28 
5772 0.8397 5.04 -5.29 
6372 0.8224 4.93 -5.31 
6972 0.8089 4.85 -5.33 
7572 0.7980 4.79 -5.34 
8172 0.7935 4.76 -5.35 
8772 0.7777 4.67 -5.37 
9372 0.7448 4.47 -5.41 
9972 0.7528 4.52 -5.40 
10572 0.7517 4.51 -5.40 
11172 0.7365 4.42 -5.42 
11772 0.6941 4.16 -5.48 
12372 0.6890 4.13 -5.49 
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Experiment 2 (R2 = 0.9187; k' = 3.0 × 10-5 s-1; t½ = 23105 s) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12972 0.6691 4.01 -5.52 
13572 0.6689 4.01 -5.52 
14172 0.6429 3.86 -5.56 
14772 0.6357 3.81 -5.57 
15372 0.6155 3.69 -5.60 
15972 0.6115 3.67 -5.61 
16572 0.6114 3.67 -5.61 
17172 0.6044 3.63 -5.62 
17772 0.5715 3.43 -5.68 
18372 0.5644 3.39 -5.69 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 88 ] (mM) ln[ 88 ] 
990 0.8023 4.81 -5.34 
1590 0.7438 4.46 -5.41 
2190 0.6481 3.89 -5.55 
2790 0.6703 4.02 -5.52 
3390 0.6830 4.10 -5.50 
3990 0.6534 3.92 -5.54 
4590 0.6292 3.78 -5.58 
5190 0.6545 3.93 -5.54 
5790 0.6009 3.61 -5.63 
6390 0.6236 3.74 -5.59 
6990 0.5573 3.34 -5.70 
7590 0.6311 3.79 -5.58 
8190 0.5776 3.47 -5.66 
8790 0.5744 3.45 -5.67 
9390 0.5439 3.26 -5.72 
9990 0.5820 3.49 -5.66 
10590 0.5225 3.14 -5.77 
11190 0.5528 3.32 -5.71 
11790 0.5310 3.19 -5.75 
12390 0.5521 3.31 -5.71 
12990 0.4827 2.90 -5.84 
13590 0.4993 3.00 -5.81 
14190 0.4853 2.91 -5.84 
14790 0.4507 2.70 -5.91 
15390 0.4950 2.97 -5.82 
15990 0.4684 2.81 -5.87 
16590 0.4602 2.76 -5.89 
17190 0.4687 2.81 -5.87 
17790 0.4109 2.47 -6.01 
18390 0.4527 2.72 -5.91 
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Experiment 3 (R2 = 0.9951; k' = 2.8 × 10-5 s-1; t½ = 24755 s) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 88 ] (mM) ln[ 88 ] 
978 0.8463 5.08 -5.28 
1578 0.8432 5.06 -5.29 
2178 0.8180 4.91 -5.32 
2778 0.8001 4.80 -5.34 
3378 0.7953 4.77 -5.35 
3978 0.7747 4.65 -5.37 
4578 0.7537 4.52 -5.40 
5178 0.7448 4.47 -5.41 
5778 0.7352 4.41 -5.42 
6378 0.7300 4.38 -5.43 
6978 0.7176 4.31 -5.45 
7578 0.6965 4.18 -5.48 
8178 0.6842 4.11 -5.50 
8778 0.6994 4.20 -5.47 
9378 0.6655 3.99 -5.52 
9978 0.6490 3.89 -5.55 
10578 0.6428 3.86 -5.56 
11178 0.6399 3.84 -5.56 
11778 0.6304 3.78 -5.58 
12378 0.6205 3.72 -5.59 
12978 0.6147 3.69 -5.60 
13578 0.5821 3.49 -5.66 
14178 0.5841 3.50 -5.65 
14778 0.5659 3.40 -5.69 
15378 0.5610 3.37 -5.69 
15978 0.5545 3.33 -5.71 
16578 0.5391 3.23 -5.73 
17178 0.5362 3.22 -5.74 
17778 0.5316 3.19 -5.75 
18378 0.5173 3.10 -5.78 
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Pyrazolopyrimidine 89 – 0.03 mole equivalents of DABCO 
Experiment 1 (R2 = 0.9408; k' = 5.7 × 10-4 s-1; t½ = 1218 s) 
 
 
 
 
 
 
 
 
Experiment 2 (R2 = 0.9937; k' = 5.3 × 10-4 s-1; t½ = 1310 s) 
 
 
 
 
 
 
 
 
 
 
 
 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 89 ] (mM) ln[ 89 ] 
1044 0.4709 2.83 -5.87 
1644 0.3177 1.91 -6.26 
2244 0.2076 1.25 -6.69 
2844 0.1357 0.81 -7.11 
3444 0.0999 0.60 -7.42 
4044 0.0663 0.40 -7.83 
4644 0.0382 0.23 -8.38 
5244 0.0244 0.15 -8.83 
5844 0.0128 0.08 -9.47 
6444 0.0199 0.12 -9.03 
7044 0.0169 0.10 -9.20 
7644 0.0145 0.09 -9.35 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 89 ] (mM) ln[ 89 ] 
858 0.5965 3.58 -5.64 
1458 0.4416 2.65 -5.93 
2058 0.3520 2.11 -6.16 
2658 0.2331 1.40 -6.57 
3258 0.1594 0.96 -6.95 
3858 0.1134 0.68 -7.29 
4458 0.0769 0.46 -7.68 
5058 0.0571 0.34 -7.98 
5658 0.0451 0.27 -8.21 
6258 0.0309 0.19 -8.59 
6858 0.0265 0.16 -8.75 
7458 0.0211 0.13 -8.97 
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Triazolopyrimidine 90 – 0.03 mole equivalents of DABCO 
Experiment 1 (R2 = 0.9524; k' = 16.5 × 10-4 s-1; t½ = 420 s) 
 
 
 
 
 
 
 
Experiment 2 (R2 = 0.8291; k' = 16.6 × 10-4 s-1; t½ = 418 s) 
 
 
 
 
 
 
 
Experiment 3 (R2 = 0.8882; k' = 19.0 × 10-4 s-1; t½ = 401 s) 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 90 ] (mM) ln[ 90 ] 
564 0.5923 3.55 -5.64 
744 0.4565 2.74 -5.90 
924 0.3316 1.99 -6.22 
1104 0.2354 1.41 -6.56 
1284 0.1540 0.92 -6.99 
1464 0.1265 0.76 -7.18 
1644 0.0886 0.53 -7.54 
1824 0.0448 0.27 -8.22 
2004 0.0698 0.42 -7.78 
2184 0.0480 0.29 -8.15 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 90 ] (mM) ln[ 90 ] 
552 0.5931 3.56 -5.64 
732 0.4095 2.46 -6.01 
912 0.2756 1.65 -6.40 
1092 0.1630 0.98 -6.93 
1272 0.0590 0.35 -7.95 
1452 0.0608 0.36 -7.92 
1632 0.0456 0.27 -8.20 
1812 0.0543 0.33 -8.03 
1992 0.0538 0.32 -8.04 
2172 0.0452 0.27 -8.21 
Time (s) 
Integration of Ethynyl C-H  
(Baseline Corrected) 
[ 90 ] (mM) ln[ 90 ] 
528 0.6458 3.87 -5.55 
708 0.4391 2.63 -5.94 
888 0.2840 1.70 -6.37 
1068 0.1689 1.01 -6.89 
1248 0.1139 0.68 -7.29 
1428 0.0731 0.44 -7.73 
1608 0.0513 0.31 -8.09 
1788 0.0482 0.29 -8.15 
1620 0.0361 0.22 -8.44 
2148 0.0473 0.28 -8.17 
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